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Abstract 
Improved understanding of normal human ageing will provide important insights into major risk 
factors for many age-related diseases. Using the progeroid disease Werner syndrome (WS) as a 
model for accelerated ageing, this project aimed to investigate how modulation of protein 
function in the p38α stress-signalling kinase cascade could affect ageing on the cellular level. 
New rapid routes towards p38α and MK2 inhibitors have been developed to evaluate their use 
as chemical probes to investigate the mechanisms of cellular ageing. The p38α inhibitor 
RO3201195 has been synthesized and used as a probe to corroborate previously published 
evidence that inhibition of the p38α protein kinase reverses the aged morphology of WS 
fibroblasts.1 
A new route for the synthesis of the MK2 inhibitor PF-3644022 was developed, exploring new 
methods for building the heterocyclic scaffold through a number of retrosynthetic strategies. 
Microwave-assisted organic synthesis was used extensively as a tool towards halogenated 
benzothiophenes2 and fused quinoline systems, and in rapid Suzuki-Miyaura coupling and 
Buchwald-Hartwig N-arylation chemistry.3 This MK2 inhibitor can now be used as a readily 
accessible probe to further investigate the role of kinases downstream of p38α and the role of 
MK2 in the premature ageing of WS cells. 
The final part of the project focussed on the potential of a known p38α inhibitor, BIRB 796, in 
the development of new chemical probes. BIRB 796 binds allosterically outside of the ATP-
binding pocket of p38α MAPK, which drives a conformational change of the kinase into an 
inactive form. Using rapid synthetic methods towards pyrazole and urea formation, the 
selectivity elements of the inhibitor were reviewed and a new library of analogues was 
synthesized. Upon testing against a small panel of kinases, it was found that through small 
changes the inhibitor potency for p38α could be dramatically altered, and binding affinity for 
alternative kinases could be selectively enhanced.  
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1. Introduction 
1.1. Ageing. 
Strehler and Mildvan defined ageing as an inherent process that is progressive, intrinsic, 
degenerative and universal.4,5 Although it is possible to age in relatively good health, unhealthy 
ageing increases the probability of developing a range of age-related morbidities, including 
cancers, Alzheimer’s and Parkinson’s disease, and a much impaired lifestyle.6 By increasing 
understanding of the underlying causes of ageing, it is hoped that the process can be modulated 
to increase the human health span, as well as the human life span. 
Biological studies of ageing have been defined by Faragher et al. as “roughly akin to the study of 
the consequences of wear and tear”, as with age comes a reduced ability of an organism to 
handle stresses that younger organisms may be able to survive.5  
There are many theories of how and why ageing occurs, though one of the most prolific models 
is the cellular senescence hypothesis. This model proposes that the progressive accumulation of 
senescent cells over time results in the development of the aged phenotype. Indeed, the build-
up of senescent cells in aged individuals has been linked to the development of cancers and age-
related conditions.7   
Replicative senescence occurs when a cell has reached its set capacity for division, as determined 
by telomere erosion and controlled by tumour suppressor genes. Cells with short telomeres are 
potentially oncogenic and to prevent replication of these high risk cells they are put into a stable, 
non-dividing senescent state.7 In younger individuals this programmed senescence prevents the 
growth of malignant tumours, while in aged individuals the accumulation of senescent cells has 
been proposed to contribute to inflammatory conditions and cancer progression. Senescent 
cells are known to secrete pro-inflammatory and growth factors, and so Lockett et al. have 
postulated that these factors alter the immediate microenvironment to promote oncogenic 
mutations.7  
Although it is likely that there is a broad spectrum of mechanisms which contribute to the normal 
aged phenotype,8 in order to better understand the ageing process, premature ageing diseases 
classed as progeroid syndromes have been widely studied. These disorders are phenocopies of 
normal ageing, exhibiting many of the same characteristics of normally aged individuals.9 
Dependent upon the syndrome studied, individuals may not exhibit all of the clinical 
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characteristics generally associated with normal ageing. It is the segmented nature of these 
syndromes that allow them to be analyzed and studied in a tractable manner.10 
 
1.2. Werner syndrome. 
Werner syndrome (WS) is a rare genome instability and segmental progeroid disorder in which 
individuals exhibit the premature on-set of age-related conditions between the ages of 15 and 
30, and a shortened median life span.11 The prominent features of this age-related phenotype 
include short stature, skin atrophy, cataracts, greying hair and hair loss, in addition to a number 
of age-related inflammatory disorders including type II diabetes, osteoporosis and  
atherosclerosis.8,12,13 This “stunning mimicry” of normal human ageing has led to WS being used 
extensively as a model to investigate the mechanisms of normal human ageing.14 
 
On a cellular level, the dermal fibroblasts of WS patients show an extremely reduced replicative 
life span, resembling those of elderly individuals who have aged normally.14,15 Though the 
segmented nature of WS is evident in a lack of degradation of the central nervous system (CNS), 
and limited damage to T-cells and the immune system compared to normally aged 
individuals.5,9,12 
WS is caused by a genetic mutation of a member of the RecQ helicase family (WRN).13 In normal 
cells, this gene helps regulate DNA replication, recombination and prevents the collapse of 
replication forks.16 WS cells deficient in this gene experience interrupted and illegitimate 
recombination events and frequent DNA replication ‘fork stalling’.16,17 These events cause 
significant genomic stress and contribute to the reduced replicative lifespan of WS fibroblasts.9  
Figure 1: WS case at 48 years. General aged appearance, with loss of and greying hair.11 
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Senescent WS fibroblasts resemble normal cells that have undergone stress-induced premature 
senescence (SIPS).14,18 They exhibit elevated levels of the stress-associated p38 mitogen-
activated protein kinase (MAPK) and an enlarged morphology due to prominent F-actin stress 
fibres.14,18,19  
In order to investigate the role of p38 MAPK on the stressed morphology of WS cells, Davis et 
al. treated primary WS fibroblasts with the p38α/β inhibitor SB203580 (1).14,18,19 The group 
found that upon treatment with 1 the aged morphology of the WS fibroblasts was reversed. The 
treated cells exhibited an extended replicative lifespan, a 20% increase in growth rate compared 
to DMSO controls, and a morphology resembling that of a normal young cell, with a dramatic 
reduction in stress fibre production.  
 
Figure 2 illustrates the F-actin stress fibre visualization completed by Davis et al. It can be 
observed that for normal young cells, treatment with 1 had no effect on the extent of F-actin 
stress fibres or growth rate. Though for the WS cells (AC03141), after treatment there was a 
dramatic reduction in F-actin stress fibres and a significant change in the morphology of the 
cells.14  
These results supported a p38-mediated SIPS-like mechanism contributing to the aged 
morphology and accelerated senescence of WS cells. However, the p38 MAPK inhibitor 
SB203580 (1) is prone to off-target effects, and so it could have been the case that other kinases 
Figure 2: Visualization of F-actin stress-fibre production in normal (MRC5) and WS (AG03141) cells with p38 
inhibitor SB203580 (1), with population doublings (PD) indicated.14 
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were responsible for the reversal of the aged morphology.18 In order to understand more about 
the role of p38 and other MAPKs in the premature ageing phenotype, a number of p38 inhibitors 
have been used as probes in WS cells. 
 
1.3. P38 MAPK inhibitors. 
Protein kinases are enzymes which modify the functional properties of proteins through 
covalent phosphorylation, mediated by the co-enzyme adenosine triphosphate (ATP).20 These 
kinases mediate signalling cascades in all eukaryotic cells to relay signals from extracellular 
stimuli to the nucleus and regulate most aspects of normal cellular function including protein 
synthesis, gene transcription and cell death.20,21 
The binding of ATP is essential to protein kinase function and so when the first protein kinase 
modulators were designed the ATP binding pocket was a prime target. Though this site is highly 
druggable, due to the existence of over five hundred protein kinases in the human kinome and 
the high degree of conserved structural domains, the design of selective kinase inhibitors can be 
a prodigious challenge.20,22 
 
1.3.1. The p38 MAPK cascade. 
MAPK signalling cascades are extremely widespread across all eukaryotic cells, with the p38-
mediated pathway one of many which responds to different extracellular stimuli. Stimuli can 
range from hormones and growth factors, to inflammatory cytokines like tumor necrosis factor-
α (TNF-α) and interleukin-β (IL-β), to environmental stresses including osmotic shock, radiation 
and heat.21,23   
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Figure 3 illustrates the main stress-signalling pathway of interest in this project. MAPKs are the 
“middle-men” in the signalling cascade.24 After receptor stimulation at the plasma membrane 
of the cell an MAP kinase kinase kinase (MAPKKK) is activated and phosphorylates a downstream 
MAP kinase kinase (MAPKK). For p38α the upstream MAPKKs are MKK3 or MKK6. P38 MAPK 
exists in four isoforms, with each eliciting a different immunological response. For instance, 
p38α and p38β, once activated, can bind to kinase targets like MAPK activated protein kinase 2 
(MAPKAPK-2, MK2), or translocate to the nucleus to activate other targets and promote 
immunological responses.24 It should be noted there are many other targets downstream of the 
p38 MAPKs, and there is a significant amount of cross-talk that can occur between kinases in 
different inflammatory pathways.24  
The p38 MAPK stress-signalling cascade is activated by extracellular stimuli including stress, 
heat, and the pro-inflammatory cytokines TNF-α and IL-β.25,26 P38α MAPK is believed to be the 
primary member of the p38 MAPK family responsible for the regulation of inflammation,27 with 
expression controlling regulation of the actin-cytoskeleton through heat shock protein HSP27, 
and production of pro-inflammatory cytokines TNF-α and IL-β.23  
Figure 3: MAPK signalling cascade. Extracellular stimuli activate responses through mitogen activated protein 
kinases through phosphorylation, travelling downstream via p38 MAPK to elicit immunological responses. 
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Hence, over-activation of p38α can result in a potential feedback loop to exacerbate 
inflammatory diseases mediated by these pro-inflammatory cytokines, including rheumatoid 
arthritis (RA), Crohn’s disease and inflammatory bowel disease (IBD).24,25 As a result, p38 
inhibitors have been studied extensively as potential anti-inflammatory agents, though the 
design of efficacious p38 inhibitors has encountered problems including severe off-target and 
cytotoxic side-effects.28 
 
1.3.2. SB203580, the first p38 inhibitor. 
The pyridinylimidazole class of anti-inflammatory drugs were initially designed as dual 
cyclooxygenase (COX) and 5-lipoxygenase inhibitors, and were found to inhibit biosynthesis of 
the pro-inflammatory cytokine interleukin-1 (IL-1).29,30 Gallagher et al. at SmithKline Beecham 
expanded the pharmacophore of SK&F 86002 (2) using a structure-activity relationship (SAR) 
study to develop SB203580 (1).  
They hypothesized that the 4-pyridinyl group was essential for inhibition of IL-1 biosynthesis, 
and they found incorporation of a para-sulfoxide substituted phenyl group at the imidazole C-2 
enhanced potency, and good pharmacokinetics were maintained through the 4-fluorophenyl 
group.29 Further studies identified 1 as an ATP-competitive inhibitor which binds selectively to 
p38α and p38β MAPKs, resulting in IL-1 biosynthesis inhibition by blocking the p38 MAPK 
cascade.27,31–33 
 
X-ray co-crystallization studies of ATP (3) with p38 identified the key binding interactions of the 
hinge region-ATP binding pocket of p38 (see Figure 5). Hydrogen bonding in the hinge region 
with the ATP adenosine ring was identified as essential for binding, allowing the correct 
orientation of the phosphate group to mediate phosphorylation of the kinase.10,34  
Figure 4: Gallagher et al.'s SAR led investigation to improve inhibitory activity towards IL-1 biosynthesis.29 
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X-ray co-crystallization of 1 with p38α identified the 4-fluorophenyl group occupied a 
hydrophobic pocket that was vacant in the ATP-p38 complex (see Figures 5 and 6). Through 
occupation of that space, the entropy of binding was positively affected, with the expulsion of 
solvent from the pocket. X-ray co-crystallization also confirmed Gallagher et al.’s hypothesis of 
the importance of the 4-pyridinyl group to conduct essential hydrogen bonding with the p38α 
hinge region akin to ATP (see Figure 6).29,31,35 
 
The aged morphology of WS cells was successfully reverted when treated with p38α inhibitor 1, 
with the lifespan and growth rate of the WS fibroblasts increased to within normal ranges.14 
Unfortunately, 1 has been found to have significant cross-kinase activity, exhibiting potencies 
Figure 6: P38 MAPK inhibitor SB203580 (1) bound to the hinge region of p38, illustrating occupation of the 
hydrophobic pocket and phosphate binding region, and essential hydrogen bonding with hinge region.10 
Figure 5: ATP bound to unphosphorylated p38 MAPK, illustrating key adenosine hydrogen bonding interactions in 
hinge region and an unoccupied hydrophobic pocket.10 
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similar to that with p38α/β when bound to the stress-related c-Jun kinases (JNKs), casein kinase 
1 (CK1) and growth related kinase cRaf1.18,28 Hence, these off-target interactions have hampered 
efforts to delineate the specific physiological role of the p38α kinase in inflammatory conditions 
and WS.32 Additionally, 1 has been found to exhibit a significant toxicity profile, thereby limiting 
its use in vivo.20 
This lack of specificity and the resultant toxicity have been traits common to many p38 
inhibitors.28,36 In recent years some very selective p38 inhibitors have been designed exploring 
a variety of different pharmacophores;37 a selection of these will now be discussed with regards 
to their selectivity and binding modes with p38. Additionally, a number of p38 inhibitors have 
been used to probe the role of p38 in the premature aged phenotype of WS fibroblasts; a 
selection of these studies will also be discussed where pertinent. 
 
1.3.2. The biaryl imidazole pharmacophore. 
Since the development of SB203580 (1) there have been a number of iterations of p38 inhibitors 
designed, some of which were developed using the SAR of the pyridinylimidazole 
pharmacophore and others that have been identified through hits in high-throughput screening 
(HTS) programmes.  
Goldstein et al. at Roche sought to enhance the inherent potency of the SmithKline Beecham 
(SB/SKB) biarylimidazole pharmacophore 2 by adapting the known SAR to an alternative 
scaffold.38 X-ray co-crystallization studies had identified the imidazole N-lone pair of 2 as an 
important hydrogen bond acceptor (HBA), interacting with a lysine residue in the p38 ATP-
binding pocket.35 This interaction was postulated to stabilize the molecule in the binding pocket 
to enable further ligand-kinase interactions. 
The group at Roche proposed that exchange of the imidazole ring for an azaindole would 
increase the intrinsic potency of the inhibitor through incorporation of a more basic nitrogen 
whilst retaining a similar structural geometry. Hence, 4-azaindole 4 was designed and found to 
be a potent inhibitor of p38α, with an IC50 value in the low nanomolar range (see Figure 7).  
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Alkylation of the indole group to give 5 increased compound bioavailability.38 Unfortunately, 4 
and 5 both exhibited high rates of oxidative metabolism at the pyridine ring, and so a metabolic 
shunt was installed α- to the pyridinyl nitrogen to give RO3206145 (6). The chiral (2-
hydroxypropyl)amine group also helped to enhance bioavailability, inhibitor potency and 
endowed reasonable selectivity for p38α against a panel of related kinases.38  
The spatial arrangement of the aryl rings fused to the indole ring in 6 accurately simulated the 
arrangement in biarylimidazole 1, facilitating the same interactions with the p38 hinge region. 
Another potent p38α inhibitor, which was very closely modelled on this pharmacophore, though 
based on a 6-membered heterocyclic core, is the Palau Pharma pyrazolopyridine UR-13756 (7).39 
 
A potent p38α MAPK inhibitor in cellular assays and with favourable pharmacokinetic 
properties, 7 also demonstrated a much improved kinase selectivity profile over SB203580 (1), 
with selectivity for the p38α isoform over p38β.40,41 The inhibitory activity of 7 was confirmed 
Figure 7: Compounds studied by Goldstein et al. in the design of p38 inhibitors based upon 4-azaindoles.38 
Figure 8: P38α inhibitors adopting a similar binding motif to SB203580 (1): UR-13756 (7),40 and alternative HBAs, 2-
aminobenzimidazole (8) and benzotriazole (9). 42,43 
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by Bagley et al. in telomere immortalised human cells and WS cells.40 Treatment of WS cells with 
7 resulted in inhibition of the p38 signalling pathway, with much reduced levels of 
phosphorylated MK2 (p-MK2) and phosphorylated HSP27 (p-HSP27) observed through Western 
blotting.40 Though it has been noted by Davis et al. that the effect on the growth rate of WStert 
cellsi was much less pronounced than upon treatment with SB203580 (1), with only a 10% 
increase observed at maximal concentrations.18 
Other p38 inhibitors designed using the established SAR of SB203580 (1) include 2-
aminobenzimidazole 8 and benzotriazole 9, in which the pyridinyl ring has been exchanged for 
an alternative HBA (see Figure 8).42,43 The change in motif in 8 required the flexible hinge of the 
p38 ATP binding pocket to undergo a slight shift, to allow room for the larger size of the 
aminobenzimidazole compared to a 4-pyridinyl, which was confirmed by X-ray co-crystallization 
of 8 with p38α.42 These studies also confirmed the imine nitrogen to act as a HBA with the p38α 
hinge methionine residue, and that the isopropyl sulfonyl was exposed to a small lipophilic 
pocket not occupied by ATP or by 1. A similar movement and hydrogen bonding interaction with 
the hinge region was confirmed through X-ray co-crystallization of benzotriazole 9 with p38α.43 
Alternative pharmacophores to the classic pyridinylimidazole have been sought with the aim to 
improve kinase selectivity through new and interesting ATP-competitive binding motifs.44  
  
                                                          
i WStert cells: WS cells immortalised by ectopic expression of telomerase. 
Figure 9: RO3201195 (10) bound into the ATP-hinge region of p38α, with key binding interactions indicated between 
the hinge region of the ATP pocket and the exo-cyclic amine and benzoyl carbonyl group.45 
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The ATP-competitive 4-benzoyl-5-pyrazole p38α/β inhibitor RO3201195 (10) was developed by 
Goldstein et al. at Roche from an initial HTS hit. Through X-ray co-crystallization with 
unphosphorylated p38α, 10 was found to exhibit a unique binding mode through an exo-cyclic 
amine to a threonine residue (Thr 106) in the hinge region (see Figure 9).45 Only 20% of kinases 
exhibit a threonine at this position in the hinge, and so it was hypothesized this interaction could 
convey improved selectivity. Additionally the 4-benzoyl carbonyl oxygen was identified as a 
methionine residue HBA. The diol chain was found to be exposed to solvent, a modification 
which was found to dramatically improve the pharmacokinetics of the compound (see Chapter 
2 for more detail).  
The high selectivity of 10 towards p38α highlighted this compound as a prime candidate for 
testing in WS cells to explore the role of p38 in premature cellular ageing. One aspect of this 
project will describe the development of a rapid synthesis of this molecule for testing in WS cells 
(see Chapter 2). 
 
1.3.3. Extending the scope. 
 
In an effort to reduce the promiscuity of imidazole based p38 inhibitor scaffolds, many groups 
sought to uncover alternative chemotypes with potency for p38. One such alternative 
pharmacophore was benzophenone; for example EO-1428 (11), designed by Leo 
Figure 10: Alternative p38 inhibitor chemotypes: benzophenone EO-1428 (11), cyclic lactam VX-745 (12) and 
piperazine Scio 469 (13). 
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Pharmaceuticals for the treatment of inflammatory skin conditions. The carbonyl group was 
postulated to act as a HBA with the hinge methionine, akin to 10, and the ortho-toluene ring 
occupied a hydrophobic pocket.46 The fused lactam VX-745 (12), disclosed by Vertex 
Pharmaceuticals in 1999, has been postulated to conduct a similar carbonyl-methionine 
hydrogen bonding interaction, with the difluorophenyl group occupying the same hydrophobic 
pocket as the 4-fluorophenyl group of SB203580 (1).44,47  
With potent inhibition of p38α and 1000-fold selectivity over related kinases JNK and MK2, 12 
was investigated by Bagley et al. for its effect on WS cells.48 They found 12 inhibited p38α activity 
in normal cells and WStert cells with no inhibition of the related JNK kinases.48 Davis et al. 
observed that 12 exhibited a similar effect on the growth rate of WStert cells as UR-13756 (7), 
with treatment causing an increase in the growth rate (approximatly 10%) that was much less 
pronounced than treatment with SB203580 (1). Trials of both of these compounds have since 
been discontinued.46  
Another potent chemotype which follows a linear binding mode was developed by Scio Inc. 
based upon a 2,5-trans-dimethyl-substituted piperazine, Scio 469 (13). Molecular modelling 
suggested that the benzoyl amide acted as a HBA with the methionine hinge residue and the 4-
fluorophenyl ring occupied a deep hydrophobic pocket.44 However, despite progressing to phase 
2 clinical trials, 13 was also discontinued as it was found to not be as effective as other 
treatments for RA.37 
Many of these inhibitors act by binding in multiple ‘selectivity hotspots’ in or near the ATP hinge 
region,37 endowing them with enhanced potency compared to ATP. 
 
One method that has been adopted widely to improve kinase selectivity has been the 
introduction of non-ATP-competitive, or type 2 inhibitors. For example, Boehringer Ingelheim’s 
Figure 11: Type 2 p38 inhibitors developed by Boehringer Ingelheim.49–51 
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high potency p38α inhibitor BIRB 796 (14) was developed from an initial HTS hit (15) and was 
identified through X-ray co-crystallization studies to occupy an allosteric binding pocket outside 
of the ATP binding site (for more information on binding mode see Chapter 4).49–51 
Lead optimization of 14 resulted in installation of a chain-linked morpholino group, which was 
found to improve the potency of the inhibitor by reaching around to act as a HBA with the hinge 
region methionine residue.49  
Treatment of WStert cells with BIRB 796 (14) by Bagley et al. was found to fully inhibit p38α 
activation and phosphorylation.52 Davis et al. also noted that upon treatment, the growth rate 
of WS cells was increased by 30%, an improved rate compared to treatment with SB203580 (1).18 
The group postulated that this improved activity over 1 was potentially due to the inhibitor 
binding both allosterically and in the ATP-pocket, to block p38 activity and activation. 
The unique binding mode of the N,N’-diaryl urea pharmacophore 14 has sparked a lot of interest 
in its application as a potent and selective method of binding.53,54 Part of this project will focus 
on exploring the potential of repurposing this pharmacophore to target alternative kinases and 
the development of new chemical probes to investigate MAPK stress-signalling pathways (see 
Chapter 4). 
 
1.3.4. Outlook for p38 inhibitors. 
For the development of therapeutics, despite the promise of p38 inhibitors for the modulation 
and treatment of inflammatory disorders, it has been surmised by a number of experts in the 
field that “the era of optimism surrounding the use of p38 MAPK inhibition for the treatment of 
RA is over”.26  
Due to the promiscuity of many p38 inhibitors initially hailed as ‘specific’, for the probing of the 
p38 MAPK stress-signalling pathways, Bain et al. have suggested testing inhibitors in parallel.32 
For instance, use of two inhibitors such as SB203580 (1) and BIRB 796 (14) which do not overlap 
in their off-target activities can be used to extrapolate data on the only overlapping interaction: 
p38α.32 This will be discussed with regards to the role of p38α in the premature aged phenotype 
of WS fibroblasts in further detail in Chapter 2. 
Severe physiological side effects have been a major contributor to the failure of many of the p38 
inhibitors that have entered clinical trials.55 It has been suggested that targeting p38 may not be 
the optimal strategy as p38 is an important checkpoint kinase, controlling feedback loops in the 
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inflammatory cascade, and plays a key role in other important immune system responses.56 
Hence, inhibition of p38 could interrupt or hyperactivate these other pathways, resulting in 
unwanted physiological side effects.55,56  
The significance of the p38 MAPK cascade in the modulation and regulation of inflammatory 
diseases is undeniable, and so alternative targets upstream and downstream of p38 have been 
suggested as alternative therapies.22,36 
 
1.4. MAPKAP kinase 2 (MK2) inhibitors. 
MAPK activated protein kinase 2 (MK2) is a downstream target of p38α, which once 
phosphorylated activates the heat shock protein HSP27 to regulate and stabilize the actin 
cytoskeleton and production of F-actin stress fibres (see Figure 3).57 These stress fibres are a 
prominent feature of senescent WS cells, resulting in an engorged morphology to resemble a 
normal cell that has undergone SIPS. Hence MK2 has been implicated as a key kinase in the 
stress-signalling cascade contributing to the aged phenotype of WS cells.10  
The viability of MK2 as a target in vivo is supported by the fact that MK2 knockout mice possess 
a normal healthy phenotype, exhibiting a significant reduction in TNF-α levels,58 while the 
removal of the p38α gene is lethal to growing embryos.22,59 Cells lacking MK2 also exhibit a 
significant reduction in levels of p38, implying that MK2 has a stabilizing effect on p38, though 
the exact mechanism for this stabilization is not clear.58 Additionally, the MK2/HSP27 pathway 
has been implicated to play a key role in remodelling and cell migration during cancer cell 
invasion and metastasis, hence modulation of this pathway could help in the development of 
anticancer therapies.55  
From this evidence, MK2 has presented itself as a prime candidate for inhibition in the 
development of anti-inflammatory agents, for the treatment of p38 MAPK mediated conditions, 
and as a target to probe the stressed and aged phenotype of WS fibroblasts.3,60 
 
1.4.1. Type 1 MK2 inhibitors. 
The majority of existing MK2 inhibitors belong to the type 1, ATP-competitive inhibitor class.55 
The ATP binding site of MK2 is characterized by a narrow and deep groove, resulting from the 
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closed conformation of the kinase. Figure 12 illustrates how adenosine diphosphate (ADP, 16) 
binds into the MK2 ATP binding site.55,61  
 
The hinge region of MK2 is defined by a Glu139, Cys140, Leu141 and Asp142 residue sequence, 
with the Glu139 and Leu141 residues forming hydrogen bonds with the adenine residue of ADP. 
There is a methionine gatekeeper residue which closes off the ATP binding pocket, reducing its 
size compared to other kinases.55 As a result, planar compounds tend to be better tolerated, 
although improving kinase selectivity is complicated as a consequence.55 Additionally, the MK2 
ATP-binding site is structurally very similar to a number of other kinases, including MK3 and 
MK5, further complicating the design of selective inhibitors. 
 
Aminocyanopyridines were one of the first chemotypes discovered as potent and selective MK2 
inhibitors.22 Anderson et al. at Pfizer identified the initial benzopyranopyridine scaffold 17 
Figure 13: Anderson et al.’s development of an aminocyanopyridine class of ATP-competitive MK2 inhibitors.62 
Figure 12: MK2 hinge region bound to ADP (16) indicating the hinge region, gatekeeper residue, sugar pocket and 
phosphate binding region.55,61  
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through HTS and optimized the structure to reduce potential toxicity of the malononitrile moiety 
on the pyran ring.62 Potency was increased through installation of the 7- and 8-hydroxy groups 
(18). It was inferred that these groups were involved in hydrogen bonding with the ATP binding 
pocket, as alkylation resulted in a severe loss in potency. 18 was found to be active in rat models 
in vivo, reducing TNF-α production. Subsequently Davis et al. established that this compound 
inhibited the MK2/HSP27 stress-signalling pathway in normal cells, but found that treatment of 
WStert cells with 18 gave inconclusive results (see Chapter 3).63 
Anderson et al. at Pfizer also identified pyrrolopyridine 19 as an inhibitor of MK2 through HTS.59 
Working from data generated from the X-ray co-crystal structure of ATP bound to MK2, the 
group carried out docking studies to provide a rationale for improving the SAR of 19. It was found 
that substitution at the pyridine 2-position (20) improved potency for MK2 over the 
unsubstituted pyridine 19. Further exploration led to the discovery of an extremely potent 3-
quinoline derivative 21. However it was found that 21 still demonstrated some cross-kinase 
activity with MK3 and MK5, which have very similar amino acid sequences and larger hinge 
regions which are able to accommodate the pyridine-2-substitutent. 
 
X-ray co-crystallization studies of 21 with MK2 identified that the pyridinyl nitrogen acts as a 
HBA with the hinge leucine NH and that the lactam ring forms two hydrogen bonds with the 
lysine and aspartic acid residues of the phosphate region of MK2 (see Figure 15).59 The group 
also identified close Van der Waals interactions between 20 and the gatekeeper methionine 
residue.64 Davis et al. used pyrrolopyridine 21 to probe the role of MK2 in WS cells, although 
inconclusive results were again obtained (see Chapter 3).60  
Figure 14: Hit to lead identification of pyrrolopyridine based MK2 inhibitors designed by Anderson et al. at Pfizer.59 
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Many of the key binding regions established using the pharmacophore of Anderson’s 
pyrrolopyridine MK2 inhibitor 21 have become ubiquitous to type 1 MK2 inhibitors. For instance, 
Velcicky et al. adopted a ‘scaffold-hopping’ strategy from analogues of 20 and 21 to develop the 
3-aminopyrazole MK2 inhibitor 22.65  
 
The group aimed to exchange the pyrrole of 21 for a phenyl ring, and so proposed a five-
membered heterocyclic HBA to maintain the same spatial arrangement between the binding 
sites. A 3-aminopyrazole scaffold was found to improve kinase activity over a simple pyrazole 
group, and extension of the 1H-aryl group revealed a new selectivity element. Using X-ray co-
crystallization studies the group discovered that when a 1-(1H-indol-6-yl)pyrazole was installed 
(22), a conformational rearrangement occurred through an additional hydrogen bonding 
Figure 15: Pyrrolopyridine MK2 inhibitor 21 complexed with the MK2 ATP-binding site showing hydrogen bonding 
between the pyridine moiety and Leu141 in the hinge region, and interaction with the phosphate binding region.59 
Scheme 1: Velcicky's ‘scaffold-hopping’ strategy for the development of novel 3-aminopyrazole MK2 inhibitors 
(22).65 
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interaction of the indole. This conformational shift exposed a new hydrophobic pocket behind 
the hinge region of the kinase, endowing 22 with an enhanced selectivity for MK2 over other 
similar kinases.65 
 
The β-carboline and benzothiophene MK2 inhibitors 23,66 24 and 25 developed by Pfizer also 
shared a number of binding traits with the pyrrolopyridine pharmacophore. β-Carboline 23 was 
developed before the crystal structure of MK2 was available,66 though with comparison with 
benzothiophene analogues 24 and 25, the key binding interactions can be inferred.67,68 The 
methoxy groups of 23 and 24, and the pyridine ring of 25 act as HBAs with the hinge leucine 
residue, while the carboxylic acid of 23 and the fused lactam rings of 24 and 25 interact with the 
phosphate binding region. 
Fused heterocyclic benzo[b]thiophene based MK2 inhibitor PF-3644022 (25) is a highly potent 
inhibitor for MK2, with a nanomolar IC50, good projected ADME characteristics and high 
selectivity for MK2 against a panel of two hundred kinases.69 It was proposed that this new 
pharmacophore would be an interesting compound to test in WS cells to probe the role of MK2 
on the aged phenotype of WS fibroblasts. Thus, the main thrust of this report will discuss efforts 
to develop a new total synthesis of the fused heterocyclic benzo[b]thiophene based MK2 
inhibitor PF-3644022 (25), ready for testing in WS cells. The development of new methods of 
heterocycle synthesis will be discussed, and the benefits of microwave-dielectric heating 
techniques for the development of a more efficient synthetic route will be explored (see Chapter 
3).  
 
1.4.3. Type 2 MK2 inhibitors. 
The high affinity of MK2 for ATP and high concentrations of ATP in vivo tend to result in a poor 
biochemical efficiency (BE) for type 1 MK2 inhibitors. Additionally, given the significant similarity 
Figure 16: β-Carboline and benzo[b]thiophene based MK2 inhibitors designed by Pfizer with similar 
pharmacophoric properties.66–68 
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between the ATP-binding pocket of MK2 and a number of other kinases, the design of efficacious 
type 2, non-ATP-competitive inhibitors has been proposed as a route to more selective and 
potent therapeutics.55,70 A limited number of type 2, non-ATP-competitive MK2 inhibitors have 
been designed, with the most extensive studies completed by Merck.  
Huang et al. at Merck identified the furan-2-carboxamide scaffold (26) as a potential non-ATP-
competitive MK2 inhibitor using an affinity selection-mass spectrometry (AS-MS)-based HTS 
method using an automated ligand identification system (ALIS). This method exposes the target 
biomolecule to a library of compounds, and then uses size-exclusion chromatography to 
separate out the unbound ligands and compounds, with subsequent analysis of complexes 
conducted using reverse-phase liquid chromatography-mass spectrometry (RP-LCMS) and 
electrospray ionization (ESI) mass spectrometry.55 
Initial hit compound 26 exhibited good pharmacokinetic and ADME characteristics and the non-
ATP-competitive binding mode was confirmed through NMR spectroscopic and enzymatic 
studies. Lead optimization was undertaken to improve cell potency and pharmacokinetic 
properties. 
 
It was found that functionalization of the secondary amide NH dramatically influenced 
compound potency, with installation of a pyridine ring (27) resulting in a compound with high 
selectivity against a panel of 150 kinases, a good toxicity profile and favourable 
pharmacokinetics in rat models.70 Compound 27 was also found to inhibit pro-inflammatory 
cytokine production in a concentration-dependent manner in human cells. 
It was proposed by the group that the increased potency from 26 to 27 was due to an 
energetically-favoured conformational change from the linear (Z) to the bent (E) conformer.71 
Figure 17: Merck's hit to lead identification of non-ATP-competitive MK2 inhibitors. From initial hit 25 to the 
development of tricyclic lactams 27 and 28.70,71 
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The group proposed that through constraining the geometry of the amide the potency of the 
compound should benefit. The synthesis of tricyclic lactam 28, supported this theory, with a 
significant increase in inhibitor efficiency and single digit nanomolar IC50 values.  
 
1.4.4. Outlook for MK2 inhibitors.  
A variety of pharmacophores have been explored in the development of ATP-competitive MK2 
inhibitors,22 although the majority have been found to suffer from poor solubility, low cell 
permeability and low cell potency due to the high levels of ATP. As such, efforts to improve the 
pharmacokinetics and binding potency of these compounds is still a priority.55 
The development of non-ATP-competitive MK2 inhibitors has been embraced as a potential 
route for the development of more viable therapeutic candidates. Studies into optimizing these 
compounds are still ongoing. 
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1.5. Project aims. 
This project aims to explore the development of new methods for the synthesis of a number of 
heterocyclic targets and their use as chemical probes to investigate the p38 stress-signalling 
cascade and its role in the modulation of the aged phenotype of WS cells. Its findings will be 
described in three sections. 
Firstly, a rapid synthetic route towards the p38α inhibitor RO3201195 (10) will be described. The 
aim of this investigation was to develop an improved total synthesis towards the pyrazole based 
inhibitor, adopting new chemical methods towards key bond-forming reactions and improving 
on methods published in the literature. Once synthesized, the compound was tested in WS cells, 
the results of which will be described in detail. 
Secondly, efforts to develop a new total synthesis of the MK2 inhibitor PF-3644022 (25) will be 
discussed. A number of different retrosynthetic strategies will be discussed, exploring a variety 
of heterocycle forming reactions and alternative disconnective routes to those described in the 
literature. The use of MK2 inhibitors as probes in WS cells will then be reflected upon, including 
the application of 25. 
Lastly, the pharmacophore of the p38α inhibitor BIRB 796 (14) will be probed for its potential 
towards drug repurposing. The unique binding mode of the N,N’-diaryl urea will be explored to 
target alternative kinases for the development of new, selective chemical probes to investigate 
the MAPK signalling cascade. 
 
 
 
  
22 
 
1.6. Methods and techniques. 
Throughout the course of this synthetic organic project a number of different chemical and 
synthetic methods and techniques were adopted. The most prevalent will now be discussed. 
 
1.6.1. Microwave-assisted organic synthesis (MAOS). 
Over the past two and a half decades, microwave-assisted synthesis has been recognized within 
mainstream organic chemistry as a clean and efficient way of achieving fast, high-yielding 
transformations.72 With the development of new instruments offering a greater degree of 
control, microwave-assisted synthesis has emerged as one of the most convenient and practical 
methods for conducting organic synthesis in industry and academia.73 
 
Microwave dielectric heating is promoted by two mechanisms as a consequence of the rapidly 
oscillating electric field component of electromagnetic radiation. When a polar molecule is 
subjected to an external electric field, dipolar polarization occurs and the molecule rotates as it 
attempts to align with the undulating field (see Figure 18). The frequency of radiation 
determines how quickly the molecule rotates. However, if the frequency is too high the molecule 
will not have enough time to adjust and rotate and will remain stationary.  
The energy window of microwave radiation lies at a frequency that is low enough to allow a 
polar molecule to start rotation into alignment, but not too low to allow full alignment before 
the phase of the wave changes. This creates phase differences which cause friction and collisions 
between the molecules in solution and loss of energy as heat.  
The addition of ions to solution can increase the rapidity of heating through a conductive 
mechanism. Ions rapidly align with the oscillating electric field and travel swiftly through the 
Figure 18: Effects of a rapidly oscillating electric field on molecules in solution, showing rotation of polar molecules 
and rapid movement of charged particles to align with the changing field. 
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solution to collide with other molecules (see Figure 18), converting kinetic energy into heat 
energy. Hence, the addition of ions to a non-polar solvent will enable the solution to be heated 
using microwave energy.  
Through a combination of these mechanisms rapid temperature gradients can be achieved. The 
use of sealed vessels allows solvents to be heated above their atmospheric boiling point and this 
creates energy profiles which are not easy to safely reproduce by conventional means.  
Microwave technology has been embraced as a reliable, efficient technique to accelerate drug 
design and discovery. Readily-adaptable from small to large scale, it is widely utilized in research 
and development with applications in metal-mediated reactions, combinatorial and library 
synthesis, solid-phase synthesis, and multi-component tandem reactions.72,74  
MAOS was adopted throughout this project as a means to facilitate rapid and efficient synthetic 
procedures, with specific applications to heterocyclic synthesis and metal-mediated reactions. 
 
1.6.2. Heterocycles. 
Heterocycles are ubiquitous in drugs and natural products, often acting as scaffolds from which 
further functionalization and diversification can be cultivated, and that are able to conduct 
electronic and hydrogen bonding interactions with biological targets.  
The most prominent heterocyclic scaffolds which appear throughout this project will now be 
discussed, including their synthesis, reactivity and applications in medicinal chemistry and other 
industries. 
 
1.6.2.1. Azoles. 
Clean, simple and efficient routes towards 5-membered heterocycles of the azole class, 
including pyrazoles (1,2-azole), imidazoles (1,3-azole) and oxygen containing oxazoles and 
isoxazoles, are highly desirable in medicinal chemistry and drug discovery as they can act as 
highly substituted scaffolds, while reducing lipophilicity compared to carbon-based scaffolds.75  
The incorporation of heteroatoms can facilitate numerous additional interactions with amino 
acid residues of proteins and kinases through hydrogen bonding and Van der Waals interactions. 
However, it is notable that pyrazoles do not exist in nature due to an inability of living organisms 
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to form N-N bonds.76 A selection of pyrazole and imidazole containing p38 MAPK inhibitors have 
already been discussed (see Chapter 1.3.1) including SB203580 (1), and the pyrazolopyridine 
UR-135756 (7). Figure 19 illustrates some examples of current drugs and agrochemicals which 
contain azoles.  
 
Celebrex is a pyrazole-containing COX-2 inhibitor and anti-inflammatory drug. Sildenafil and 
Vardenafil contain a pyrazole and imidazole respectively, and are both phosphodiesterase type 
5 (PDE5) inhibitors and vasodilators used in the treatment of male erectile dysfunction (ED).77  
The agrochemicals Fipronil and Prochloraz also contain azoles. Fipronil is an insecticide which 
acts through blocking the chloride ion channel of the γ-aminobutyric acid (GABA) receptor, and 
has a particular toxicity towards insects compared to vertebrates due to higher GABA receptor 
sensitivity in that species.78 Prochloraz is a fungicide which operates through inhibition of a  
Figure 19: Examples of azoles in pharmaceuticals and agrochemicals. 
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cytochrome P450-dependent pathway which is essential for building the cell membrane of 
fungi.79 The binding relies upon association of the imidazole to the iron core of cytochrome P450, 
but it is not very specific and affects a number of other P450-dependent pathways. Reports have 
advised that use of Prochloraz be reduced, as it has been found to exhibit endocrine disruptive 
effects in animals and humans, leading to disruptions in hormone levels during fetal 
development.79,80  
 
1.6.2.1.1. Synthetic routes towards functionalized pyrazoles.  
 
There are many routes for the synthesis of pyrazoles, of which the most widely used is the 
condensation of 1,3-dicarbonyl compounds and hydrazines to give di- or tri-substituted 
pyrazoles.81 The bis-nucleophilic hydrazine is able to react with each carbonyl in turn, with 
unsymmetrical dicarbonyl compounds potentially giving a mixture of regioisomers unless the 
reaction is carefully controlled (Scheme 2a).82 The reaction of an α,β-unsaturated aldehyde or 
ketone with hydrazine provides an alternative approach, giving an intermediate which must be 
oxidized in order to generate the poly-substituted pyrazole (Scheme 2b).83,84 Another method 
of synthesis is via the 1,3-dipolar cycloaddition of an alkyne or alkene with a diazoalkane or 
nitrilimine, which on tautomerization gives the desired pyrazole (Scheme 2c).85 Synthetic 
methods for the synthesis of 3,5-disubsituted pyrazoles will be discussed later in Chapter 4.1.2. 
Scheme 2: Different disconnective strategies towards pyrazoles. 
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The aminopyrazole scaffold is prominent in pharmaceutical agents and agrochemicals, with 5-
aminopyrazoles representing a useful building block in drug design as well as demonstrating 
significant biological activity.76,86 Examples of 5-aminopyrazoles of biological significance include 
the GABA inhibitor pesticide Fipronil (see Figure 19);78 the lymphocyte-specific protein kinase 
p56lck inhibitor 29,87 and the human neuropeptide Y5 (NPY5) receptor antagonist 30.88  
 
5-Aminopyrazoles can be synthesized by the condensation of β-ketonitriles and hydrazines.76 
This route was adopted by Regan et al. in the synthesis of the 1,3-disubstituted-5-aminopyrazole 
BIRB 796 (14) and by Goldstein et al. towards the 1,4-disubstituted-5-aminopyrazole RO3201195 
(10) (see Scheme 3, and Chapter 4.3 and Chapter 2.2).50  
 
Starting from a β-ketonitrile starting material, Goldstein et al. accessed different substitution 
patterns on the 5-aminopyrazole through β-ketonitrile homologation using N,N’-
diphenylformamidine. The aminoacylonitrile 32 preferentially underwent cyclocondensation 
Figure 20: Examples of 5-aminopyrazole-containing pharmaceutical agents.87,88 
Scheme 3: Methods for the synthesis of two differently substituted 5-aminopyrazoles in the preparation of p38α 
MAPK inhibitors from β-ketonitriles. Reaction conditions: i) H2NNHR2; ii) N,N’-diphenylformamidine. 
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with the hydrazine to change the pyrazole ring substitution pattern from a 3- to 4-substituted-
5-aminopyrazole, 31 and 33 respectively.  
Daniels et al. adopted a similar homologation approach to synthesize 5-aminopyrazole 
intermediates (35) in the preparation of pyrazolo[1,5-a]pyrimidines (36) and pyrazolo[3,4-
b]pyrimidines as new lead compounds for cancer and neuroscience programmes (see Scheme 
4).89  
 
Their method of homologation started from arylacetonitrile 34 and used N,N-
dimethylformamide dimethyl acetal (DMFDMA) as a single carbon unit donor.90 Daniels et al. 
adopted microwave-assisted dielectric heating to facilitate a more efficient synthesis of 5-
amino-4-arylpyrazole 35. Doing so they were able to reduce reaction times from over 72 h to 
just 20 minutes, and increased their yields from 55-75% to 88% over two steps in one pot.89 Acid-
mediated thermal cyclocondensation with malondialdehyde gave pyrazolopyrimidine product 
36. 
Another popular method for the synthesis of 4-substituted-5-aminopyrazoles starts from 
unsaturated malononitriles which can be reacted with hydrazine to give 4-cyano-5-
aminopyrazoles 37 (see Scheme 5).91,92  
 
Bagley et al. explored this route by reacting ethoxymethylenemalononitrile with 
monosubstituted alkyl and aryl hydrazines and synthesized 1-substituted-4-cyano-5-
aminopyrazole 37 with total regiocontrol.93 These pyrazole derivatives have found use as 
Scheme 4: Microwave-mediated synthesis of pyrazolo[1,5-a]pyrimidine 36 from 4-aryl-5-aminopyrazole 35. Reaction 
conditions: i) DMFDMA, PhCF3, MW 150 °C, 10 min; ii) N2H4, MW 140 °C, 10 min, 85%; iii) malondialdehyde, 5% 
AcOH/EtOH, MW 150-170 °C, 10 min, 85-98%.89  
Scheme 5: Synthesis of 1-substituted-4-cyano-5-aminopyrazoles synthesis. Reaction conditions: i) H2NNHR1, EtOH, 
Δ.93 
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potential purine antagonists,91,93 and as building blocks towards A2A adenosine antagonists (see 
Figure 21).94  
 
 
1.6.2.2. Pyridines. 
The prevalence of pyridine in nature, medicinal chemistry and industry is undeniable. Pyridine-
containing natural products include vitamins B6 (pyridoxine) and B3 (nicotinic acid) which are 
essential nutrients for human life. Nicotinamide adenine dinucleotide phosphate (NADP) is an 
essential co-enzyme in the body which mediates redox reactions and is derived from vitamin B3 
(see Figure 22).95,96  
 
In a survey conducted by Roughley and Jordan and published in 2008, 90% of all heterocycle-
forming reactions carried out in medicinal chemistry generated N-containing rings, with pyridine 
Figure 21: 1-Substituted-4-cyano-5-aminopyrazoles 37 are building blocks for the synthesis of purine 
antagonists91 and A2A adenosine antagonists.94 
Figure 22: Natural pyridine-containing compounds: vitamin B3, vitamin B6 and NADP. 
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constituting almost 25% of all heteroaromatic compounds.97 A few examples of pyridine-
containing pharmaceutical agents and drug candidates are detailed in Figure 23, including the 
antibiotic isoniazid (38), a prodrug used to treat tuberculosis. Activated by oxidation in the 
bacterium, the mechanism of action of this agent is postulated to operate through a nitric oxide 
radical.98 Further examples include the highly-bioavailable 2-pyridinemethylamine based 5-HT1A 
receptor agonist 39, an antidepressant that can travel across the blood-brain barrier and bind 
to 5-HT receptors and activate them,99 and the A3 adenosine receptor antagonist 40, which is an 
anti-inflammatory and anti-asthmatic that binds to and blocks adenosine receptors.100 
 
 
1.6.2.2.1. Synthesis of pyridines. 
Pyridine was originally isolated from a number of sources, including by-products of bone 
pyrolysis, via condensation of various aldehydes and ketones with ammonia,96 and for a long 
time directly from coal tar.81 With increasing understanding of their biological and practical 
applications, many new methods of pyridine synthesis have been discovered starting from 
simple materials.  
Depending upon the complexity of the target molecule there are numerous different 
disconnective routes available for the synthesis of pyridines. The classical [5+1] condensation 
reaction of ammonia and a 1,5-dicarbonyl compound gives 1,4-dihydropyridines, which can be 
oxidized to the corresponding pyridine. 1,5-Dicarbonyl compounds can be accessed by a number 
of routes, including via Michael addition of enolates and enones, or by ozonolysis of 
Figure 23: Examples of pyridine-containing pharmaceutical agents and drug candidates: Isoniazid (38), a 2-
pyridinemethylamine based 5-HT1A receptor agonist (39) and an A3 adenosine receptor antagonist (40). 
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cyclopentenes (see Scheme 6a  and 6b respectively). Through the use of hydroxylamine the final 
oxidation step can be avoided, giving the aromatic pyridine on elimination of water. 
 
The Hantzsch dihydropyridine synthesis adopts a [2+2+1+1] connective strategy.96 Classically 
two equivalents of a 1,3-dicarbonyl are condensed with one equivalent of an aldehyde and 
ammonia, with oxidation subsequent to cyclization affording the symmetrical pyridine (see 
Scheme 7). Mechanistically, the precise sequence of condensations is not explicitly known, 
though it is likely to be dependent upon the reagents used. 
 
Unsymmetrical pyridines can be formed by condensing ammonia and a 1,3-dicarbonyl 
compound to form an intermediate β-ketoenamine, and then reacting with an aldehyde and 
another 1,3-dicarbonyl compound. Oxidation to the dihydropyridine can be conducted using 
nitric acid, ceric ammonium nitrate, manganese dioxide or iodine with KOH.81 
The Hantzsch pyridine synthesis is commonly used for the synthesis of pentasubstituted 
pyridines. For instance, towards the A3 antagonist 40. Li et al. condensed a β-aminoester with a 
functionalized aldehyde and β-ketothioester to give the 1,4-dihydropyridine intermediate, 
Scheme 6: [5+1] Connective strategies for the synthesis of 2,6-disubstituted pyridines. a) Michael addition of an 
α,β-unsaturated ketone and a methyl ketone under basic conditions. Subsequent condensation with ammonia gives 
2,6-disubstituted pyridines. b) Ozonolysis of cyclopentene, condensation with ammonia, and subsequent oxidation. 
Scheme 7: Hantzsch dihydropyiridine synthesis. Condensation with loss of three equivalents of water to give the 
dihydropyiridine. Oxidation gives the final tetrasubstituted pyridine. 
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which was oxidized using tetrachloroquinone to afford pentasubstituted pyridine 41 (see 
Scheme 8).100 It was found that potency of the antagonist could be increased through a more 
conformationally constrained system. Hence 41 was deprotected and subjected to 
intramolecular transesterification using sodium thiomethoxide to afford 40 in high yield.100 
 
Pyridines can also be synthesized through [3+3] connective routes, for instance from the 
reaction of 1,3-dicarbonyl compounds and 3-aminoenones or 3-aminoacrylates (see Scheme 
9).81 
 
 The Guareschi synthesis is a variation on this route wherein a 3-aminocrotonitrile undergoes 
cyclocondensation with an ethoxyenone (42) via Michael addition to give the 6-ethoxycarbonyl-
3-cyanopyridine (43) (see Scheme 9).81,96 
 
Scheme 8: Synthesis of A3 adenosine receptor antagonist 40. Reaction conditions: i) EtOH, 80 °C, 24 h; ii) 
tetrachloroquinone, THF, Δ, overnight; iii) NaSMe, MeOH, RT, 30 min, 98%.100 
Scheme 10: [3+3] Guareschi pyridine synthesis: Reaction conditions: i) K2CO3, 73%.96 
Scheme 9: Pyridine [3+3] connective synthesis from 1,3-dicarbonyl compounds and 3-aminoenones or acrylates. 
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Through use of cyanoacetamide, 3-cyano-2-pyridones can be synthesised directly (see Scheme 
11). Claisen condensation of ethyl formate and a methyl ketone gives the stable enolate 44. 
Proton exchange can then occur in situ on treatment with cyanoacetamide, to facilitate the 
intermolecular aldol reaction.101,102 Intramolecular condensation and loss of water then affords 
the final 3-cyano-2-pyridone 45.  
 
2-Pyridones can tautomerize to 2-hydroxypyridines, but the amide tends to predominate due to 
the strong C=O bond.101 Pyridones can be useful intermediates in synthesis. Alkylation will 
readily occur at oxygen and conversion to the corresponding 2-chloropyridine can be carried out 
by reaction with phosphorous oxychloride (POCl3).101 
 
1.6.2.2.2. Reactions of pyridines. 
The reactivity of pyridine is very different from its carbocyclic analogue benzene. Exchange of a 
methine unit for nitrogen introduces a permanent dipole on the heterocycle and a new sp2 
hybridized lone pair in the plane of the ring.81 
 
The lone pair of the pyridine nitrogen makes the ring slightly basic, with pKaH 5.2 in water. It acts 
similarly to a tertiary amine and is open to attack by external electrophiles, resulting in formation 
Scheme 12: Resonance stabilization of protonated dimethylaminopyridine (DMAP). 
Scheme 11: Synthesis of Pyridones. Reaction conditions: i) HCO2Et, NaOMe.102 
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of the pyridinium cation.81 The basicity of the nitrogen lone pair can be tuned through the 
substituents on the ring, with electron-donating groups (EDG) increasing basicity, and the α- and 
γ-positions having a more pronounced effect. For example, 4-dimethylaminopyridine (DMAP) is 
a strongly basic analogue of pyridine, due to further resonance stabilization of the pyridinium 
cation (see Scheme 12), and is used commonly in synthetic organic reactions. 
Reactions that can occur at the nitrogen include nitration, oxidation, acylation and alkylation. 
Oxidation of pyridines to the pyridine N-oxide using mCPBA or peroxides can be used as a 
method to augment reactivity, enhancing the electrophilicity or nucleophilicity of the α- and γ-
positons. This contrasting effect can be viewed as being due to inductive withdrawal of electron 
density by the nitronium cation, or donation of electron density from the oxy anion (see Scheme 
13).81 For instance, alkylation and protonation of pyridine N-oxides will occur initially at the 
oxygen, thereby amplifying electrophilicity of the pyridinium ring at the α- and γ-positions.81 
 
Pyridine N-oxides can undergo nucleophilic attack through addition-elimination on 
functionalization of the oxide. For instance, reaction with POCl3 will result in formation of the 2-
chloropyridine. The oxide initially reacts with the oxophilic phosphorous to enhance 
electrophilicity of the α-position. Nucleophilic attack by a chloride anion is then proposed to 
occur, with elimination giving the rearomatized pyridine ring (see Scheme 14).103  
Chlorination will also tend to occur at the γ-position, with a 7:3 ratio of 2- and 4-chloropyridine 
products.103 However, Jung et al. found that through the use of stoichiometric amounts of NEt3, 
elimination of the more acidic proton at C-2 was promoted, and that chlorination could be 
carried out almost selectively at the α-position (90% yield, 99.2% selectively).103 The same 
method can be used with acetic anhydride to give the 2-acetoxypyridine.81 
Scheme 13: Pyridine N-oxide cannonical forms explain the increased reactivity on the ring towards attacking 
electrophiles and nucleophiles.81 
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Electrophilic substitution of pyridines at carbon occurs less readily than for benzene in part due 
to preliminary formation of a pyridinium cation. Through the use of bulky alkyl groups at the α-
carbons, electrophilic attack at nitrogen can be disfavoured, promoting electrophilic aromatic 
substitution (EAS) at the β-carbons.81 
Nucleophilic substitution on to the pyridine ring is much more favourable due to the electron-
deficient nature of the ring. For instance, pyridine amination can be carried out through the 
Chichibabin reaction. Using sodium amide the reaction is believed to occur through formation 
of an anionic intermediate (46). Hydride transfer to the amine product 47 eliminates hydrogen 
gas to give the aminopyridine conjugate base 48 and the 2-aminopyridine 47 on aqueous work-
up (see Scheme 15).   
 
Pyridines are extremely versatile intermediates in organic synthesis and exhibit a variety of 
interesting biological activities. Their fused analogues tend to demonstrate similar reactivities 
and are similarly important, biologically, with one major class being quinolines. 
 
  
Scheme 14: Chlorination of pyridine N-oxide using POCl3 and triethylamine base.103 
Scheme 15: Chichibabin amination of pyridines. Reaction conditions: i) NaNH2, PhNMe2, 100 °C, 75%.81 
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1.6.2.3. Quinolines. 
Highly regioselective methods for the synthesis of quinolines are desirable as, much like 
pyridines, quinoline derivatives elicit a range of biological responses and are present in natural 
and synthetic products.104,105  
 
For instance, the antimalarial agent chloroquine (49) is a quinoline-containing drug that was 
designed in the 1940s. It is believed to act by binding to DNA in blood, which is then ingested by 
the malaria parasite to inhibit its digestive pathway.106 Numerous natural quinoline and 
quinolinone alkaloids have been isolated from plants, animals and microbes and have been 
found to exhibit very interesting biological properties, including the anti-HIV activity of extracts 
from Evodia roxburghiana which contain quinoline-2-ones buchapine (50) and 51.107 
 
1.6.2.3.1. Synthesis of quinolines. 
Synthesis of quinolines or quinolones can be conducted through a number of different 
disconnective strategies, though most adopt anilines as the nitrogen containing component. The 
reactions tend to occur either through an initial C-N bond forming reaction between aniline and 
a 4-carbon synthon before cyclization onto the benzene ring, or reaction with a 2-carbon unit 
through C-C bond formation to an aniline ortho-substituent.  
The Friedländer quinoline synthesis is an example of the latter route, proceeding through a [4+2] 
cyclocondensation of an ortho-acyl-arylamine and a ketone or aldehyde (with an α-methylene 
group) to give substituted quinolines (see Scheme 16). The choice of conditions is very important 
for this reaction when using unsymmetrical ketones, as the orientation of condensation is highly 
dependent upon the enol or enolate that is formed.  
Figure 24: Quinoline containing drugs and natural products. Antimalarial chloroquine (49), and anti-HIV agents 
buchapine (50) and quinolin-2-one 51.105,107 
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For example, in Scheme 16 the acid-mediated reaction of an α-methyl ketone results in a 2,3,4-
trisubstituted quinoline. Though the mechanism of the Friedlander has not been defined 
explicitly,108 this reaction could either occur through an initial intermolecular aldol condensation 
or via a Schiff base formation. On the other hand, the base-mediated reaction affords the 2,4-
disubsituted quinoline through deprotonation of the terminal α-proton of the α-methyl ketone, 
with subsequent aldol cyclocondensation.  
Most other methods of quinoline synthesis using anilines tend to proceed through a [3+3] 
connective route. The Coombes quinoline synthesis adopts the traditional 1,3-dicarbonyl 
coupling partner to give 2,4-disubstituted quinolines (see Scheme 17). The reaction proceeds 
through initial condensation to form the β-ketoenamine (52), which can cyclize under acidic 
conditions via an EAS mechanism. 
 
Scheme 16: Friedländer quinoline synthesis, a [4+2] cyclocondensation. Reaction conditions: i) conc. H2SO4 (cat.), 
AcOH, Δ; ii) aq. KOH, EtOH, 0 °C.81 
Scheme 17: Coombes quinoline synthesis, an acid-mediated [3+3] cyclocondensation of anilines and 1,3-
dicarbonyl compounds. 
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A related method that gives 2-quinolones directly is the Knorr-carbostyril synthesis.109,110 Initial 
formation of a β-keto acid anilide 53 can be conducted using traditional amide bond forming 
reaction conditions with a carboxylic acid or acid chloride.111 Elevated temperatures or strongly 
acidic conditions promote EAS to afford the 2-quinolone 54 (see Scheme 18).81 
 
The Skraup is a classic method for the synthesis of quinolines, traditionally carried out as a 
“witch’s brew” combining aniline, glycerol, an acid and an oxidizing agent in one pot.101,112,113 
This traditional method tended to suffer from poor reproducibility, and hence in modern 
laboratories more reliable, step-wise routes have been adopted.101  
 
Analysis of the mechanism revealed that dehydration of glycerol occurred in the Skraup reaction 
to give acrolein, which undergoes conjugate addition with the aniline. Acidic cyclization and 
subsequent oxidation affords the aromatic product.114 The Skraup reaction is an ideal route to 
quinolines which are unsubstituted on the heteroaromatic ring (see Scheme 19).81  
The Doebner-von Miller reaction follows a similar mechanistic course. The substitution pattern 
obtained from the Doebner-von Miller was used as evidence that the mechanism of the Skraup 
occurs by Michael addition of the aniline, rather than formation of a Schiff base (see Scheme 
19).81 Though, mechanistic studies conducted by Eisch and Dluzniewski have suggested that 
Schiff base formation does indeed occur first and that rearrangement proceeds in situ through 
a bimolecular intermediate diazetidinium ion 55 to give 2-quinoline 56 (see Scheme 20).114 
Scheme 18: Knorr-carbostyril synthesis of 2-quinolones under acidic conditions. Reaction conditions: i) Coupling 
reagents; ii) conc. H2SO4.110 
Scheme 19: Michael addition of α,β-unsaturated carbonyls onto aniline. Skraup reaction when R1 = R2 = H. Doebner-
von Miller when R1 = akyl or aryl, R2 = H, alkyl, aryl. 
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The Doebner quinoline synthesis is another slight variation on this route, adopting a multi-
component reaction (MCR) to enable access to a more diverse array of potential products. 
Traditionally carried out using an aniline, aldehyde and pyruvic acid to give the quinoline-4-
carboxylic acid 57; decarboxylation then affords the 2-substituted quinoline 58 (see Scheme 
21).115,116 
 
Mechanistically, the reaction could occur through initial condensation of the aniline and 
aldehyde or the aldehyde and pyruvic acid, depending upon which is more kinetically favoured. 
A common variant of the reaction is to pre-form the Schiff base intermediate before addition of 
the second carbonyl derivative.117 For instance, in 2006 Wang et al. reported the synthesis of 
Scheme 21: Doebner multi-component quinoline synthesis via quinoline-4-carboxylic acid. 
Scheme 20: Eisch and Dluzniewski proposed bimolecular mechanism for the Doebner-von Miller quinoline 
synthesis.114 
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2,3-disubstituted quinolines in a mild and efficient one pot-procedure from the reaction of an 
aniline Schiff base with aliphatic aldehydes (see Scheme 22). 118  
 
The group found catalytic amounts of a Lewis acid were essential for the reaction to proceed, 
and deemed molecular iodine as the most efficient catalyst for the reaction. They proposed the 
reaction to proceed through Lewis acid-mediated activation of the Schiff base and aldehyde, 
with a fast aldol-type addition of the enol tautomer to the Schiff base. Subsequent Friedel-Crafts 
cyclization onto the ring would then afford the 1,2-dihydroquinoline which oxidized in air to give 
the disubstituted quinoline (see Scheme 23). 
 
The group of Xiang-Shan Wang et al. extended this method further, exploring the use of ketones 
in addition to aldehydes, and developed a Lewis acid-mediated MCR towards benzo[f]quinolines 
and benzo(naphtho)quinolines.119–122 The one-pot process reacted naphthalene-2-amines and 
aromatic aldehydes to give the Schiff base, which combined with an enolizable ketone as a two-
carbon unit (see Scheme 24). 
Scheme 22: Wang et al.'s synthesis of substituted quinolines. Reaction conditions: i) I2 (1 mol%), benzene, Δ, 0.5 h, 
79%.118 
Scheme 23: Proposed mechanistic course for iodine-mediated quinoline formation, with tautomerization and 
activation of the reactive partners.118 
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A number of different variations on the original scaffold were explored, with cyclic ketones used 
to synthesize benzo[f]cyclopenta[c]quinoline and benzo[f]cyclododeca[c]-quinoline derivatives, 
of interest for their biological and pharmaceutical properties.121 However, when exploring the 
utility of vinyl ethers, rather than generating the expected 1-butoxy-1,2,3,4-tetrahydro-3-
arylquinoline derivative 59 using n-butyl vinyl ether (n-BVE), it was found that re-aromatization 
and elimination of butanol occurred to give the 3-substituted arylbenzo[f]quinoline 60 (see 
Scheme 25).123 This method offers a mild, efficient and regioselective route towards fused α-
substituted quinolines. 
 
 
 
 
  
Scheme 24: Wang et al.'s MCR for the synthesis of naphthoquinolines. Reaction conditions: i) I2 (5 mol%), THF, 
Δ, 89%.120 
Scheme 25: Wang et al.'s synthesis of 2-substituted benzo[f]quinolines (50). Reaction conditions: i) ArCHO (1 equiv.), 
I1 (10 mol%), THF, Δ, 8-12 h.123  
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1.6.2.3.2. Reactions of quinolines.  
Quinolines have a very similar reactivity to pyridines, with primary reaction of electrophiles 
occurring at the nitrogen lone pair, reducing reactivity towards EAS. For this reason, electrophilic 
attack tends to occur on the carbocyclic ring (see Figure 25).  
Nucleophilic attack tends to occur at the 2-positon of quinolines, with analogous reactivity to 
pyridines. For instance, alkylation using aryl or alkyl lithium reagents gives the 1,2-
dihydroquinoline N-lithio salt (61), which on oxidation gives the corresponding 2-alkyl- or 2-
arylquinoline derivative (62) (see Scheme 26).81 
 
Similarly, Chichibabin amination occurs with quinolines using potassium or sodium amide. At 
temperatures higher than −45 °C rearrangement of the 2-amine adduct to the more stable 4-
amine will occur. Either adduct can be isolated through oxidative trapping (see Scheme 27).81,124  
 
Figure 25: Major points of reactivity for quinoline rings. 
Scheme 26: Synthesis of 2-arylquinolines (62) using an aryllithium reagent. Reaction conditions: i) ArLi; ii) H2O; iii) 
PhNO2.81 
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Oxidative amination can be promoted at other positions on the fused ring system if a nitro group 
is present to promote a vicarious nucleophilic substitution.125–127 The electron-withdrawing nitro 
group enhances electrophilicity of the ortho-positions, analogous to the electron-withdrawing 
action of a pyridine N-oxide or quinoline N-oxide (see Scheme 28). Oxidation to the quinoline 
can be mediated by the nitroquinoline or air.128 
 
Hydroxylation of quinoline to give the 2-quinolone or ‘carbostyril’ can be conducted by heating 
to high temperatures in the presence of KOH (see Scheme 29). Quinolones exhibit similar 
reactivity to pyridones, and so can be converted to the chloroquinoline on treatment with POCl3 
or phosphorous pentachloride (PCl5). Chlorinated quinolines can be used to direct nucleophilic 
substitution, with displacement of the halide as a good leaving group, or to facilitate metal-
mediated coupling reactions. 
 
 
 
 
 
 
Scheme 27: Chichibabin amination of quinolines. Reaction conditions: i) KNH2, NH3 (liq.), −66 °C; ii) KMnO4.124 
Scheme 28: Vicarious nucleophilic substitution mediated by nitro-substituents on quinoline. 
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For instance, in the synthesis of chloroquine (49), designed by Surrey and Hammer in 1946, 
chlorination of a quinolone was essential to install a directing group for nucleophilic substitution. 
Condensation of diethyl oxalpropionate and 3-chloroaniline (63) was used to construct the 
quinoline framework, with cyclization to the 4-quinolone at elevated temperatures.129 Base-
mediated saponification and subsequent decarboxylation gave the 7-substituted-4-quinolone 
64, which was chlorinated using POCl3. The chlorine was then used as a leaving group for SNAr 
using  a primary amine to give chloroquine (49) (see Scheme 30). 
 
Anderson et al. adopted the quinoline motif in their design of PF-3644022 (25) in order to take 
advantage of the structural rigidity of the aromatic ring system, as well as the nitrogen lone pair 
as a HBA for hinge binding in the ATP-pocket of MK2.68 
 
Scheme 30: Synthesis of chloroquine (49). Reaction conditions: i) Diethyl oxalpropionate, AcOH, 40 °C; ii) 250 °C; iii) 
aq. KOH, EtOH, then 270 °C; iv) POCl3, Δ; v) H2NCH(Me)(CH2)3NEt3, 180 °C.81,129 
Scheme 29: Hydoxylation of quinoline to 2-quinolone and subsequent chlorination. Reaction conditions: i) KOH, 
NaOH, 240 °C; ii) H2O; iii) POCl3, heat.81 
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1.6.2.4. Benzo[b]thiophenes. 
 
Benzo[b]thiophenes are naturally-occurring heterocycles that can be isolated from petroleum 
deposits and as complex glycoside derivatives from the roots of the Chinese Echinops grijissi 
plant.2,130 They are sulfur analogues of the nitrogen containing indole and oxygen containing 
benzo[b]furan (see Figure 26). They possess interesting π-delocalization properties due to the 
larger bonding radius of sulfur compared to the Group 2 heteroatoms nitrogen and oxygen, and 
the intermediate electronegativity of sulfur compared to those two heteroatoms. Due to these 
properties, benzo[b]thiophenes have been explored extensively in the development of organic 
semi-conductors.131–133  
Benzo[b]thiophenes have found widespread application as privileged structures and building 
blocks in drug discovery. The fused ring system has been shown to exhibit a range of biological 
activities including anti-fungal, anti-bacterial and anti-inflammatory effects.134 Additionally, 
incorporation of the benzo[b]thiophene scaffold has been demonstrated by Romagnoli et al. to 
improve the pharmacokinetics (PK) of tubulin polymerization inhibitors, and to enhance 
solubility and activity compared to hydrocarbon analogues.135  
 
Benzo[b]thiophenes can be found in a number of clinical agents including Raloxifene, a selective 
estrogen receptor modulator (SERM) used in the treatment and prevention of breast cancer and 
osteoporosis;136,137 and Zileuton, a 5-lipoxygenase inhibitor used in the prevention and 
Figure 27: Examples of benzo[b]thiophenes in clinical agents. Raloxifene, and Zileuton.137,139 
Figure 26: Benzo[b]fused heterocylic aromatic rings. 
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treatment of chronic asthma by modulating production of leukotrienes, which can trigger 
contractions of the smooth muscle lining of the bronchioles (see Figure 27).138,139 
In the design of novel kinase inhibitors, in addition to the benzo[b]thiophene scaffold present in 
MK2 inhibitor PF3644022 (25), benzo[b]thiophenes have also been explored as inhibitors for 
LIM kinases and PIM kinases.  
 
LIM kinases mediate regulation of the actin-cytoskeleton and have been postulated to play a 
role in determining the metastatic potential of tumour cells. Baell et al. used HTS to identify 3-
aminothieno[2,3-b]pyridine-2-carboxamide (65) as a potent inhibitor of LIMK1, and were able 
to develop the tricyclic LIMK-1 inhibitor 66 via an SAR-based lead investigation.140  
The PIM kinase family (Pim-1, Pim-2 and Pim-3) have been found to be overexpressed in a variety 
of malignancies and lymphomas, inferring a role for these kinases in tumorigenesis. Tao et al. 
proposed that simultaneous targeting of all PIM kinases may offer an alternative, superior 
cancer therapy.141 Benzo[b]thiophene based scaffold 67 was identified as a potential inhibitor 
through HTS, and lead optimization generated biaryl phenol 68 which exhibited a low nanomolar 
potency for all PIM kinases, a high bioavailability and excellent kinase selectivity (see Figure 
28).141 
There is a continued interest in the development of novel strategies towards the synthesis of 
benzo[b]thiophenes and their functionalized derivatives.2,142 The reactivity of 
benzo[b]thiophenes is somewhat reduced in comparison with many other heteroaromatic 
Figure 28: LIM kinase and PIM kinase benzo[b]thiophene-based scaffolds, from initial HTS hit to optimized kinase 
inhibitor.140,141 
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scaffolds, and so functionality tends to be installed during cyclization of the fused 
heteroaromatic ring. 
1.6.2.4.1. Synthesis of benzo[b]thiophenes. 
More traditional methods of synthesis follow routes very similar to those adopted for pyridine 
and quinoline synthesis, for instance, via intramolecular cyclocondensation of a 2-
arylthioaldehyde, ketone or acid onto a benzene ring (see Scheme 31).  
 
This method does not always control regioselectivity in the synthesis of benzo-substituted 
benzo[b]thiophenes. For instance, the acid mediated reaction of 2-arylthioketone 69 resulted in 
a 2:1 ratio of the 2,3,4- and 2,3,6-trisubstituted benzo[b]thiophenes 70 and 71, respectively  (see 
Scheme 32). Aoyama et al. carried out this reaction using solid-supported reagents to facilitate 
a one-pot base/acid-mediated reaction.143 With almost complete conversion to the 
benzo[b]thiophene products, this method offered an alternative to stepwise formation and 
isolation of reaction intermediates.  
 
In order to circumvent regioselectivity problems, the strategic use of substituents can help direct 
cyclization on to the ring. For instance, Higa and Krubsack developed a regioselective route 
Scheme 32: Solid-supported reagent-mediated benzo[b]thiophene formation from 3-methylthiophenol. Reaction 
conditions: i) Na2CO3-SiO2, PPA-SiO2, PhCl, 135 °C, 6 h, 95%.143 
Scheme 31: General reaction scheme for synthesis of benzo[b]thiophenes from 2-arylthioketones, aldehydes, or 
acids.81 
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towards 5-functionalized benzo[b]thiophenes via “electrocyclization” of meta-substituted 
cinnamic acids using thionyl chloride (SOCl2) and base.144 Using a meta-electron-donating group 
(EDG), Higa and Krubsack found that cyclization was directed to the para-position, to afford the 
3-chloro-5-substituted benzo[b]thiophene-2-acid chloride (see Scheme 33), whereas a meta-
directing electron-withdrawing group (EWG), such as a nitro group, was found to deactivate the 
ring and give a mixture of cyclization products. 
 
This method of benzo[b]thiophene formation was adopted by Anderson et al. at Pfizer for the 
synthesis of their initial benzo[b]thiophene MK2 inhibitor hit compound 24 (see Figure 16). Key 
intermediate 72 was synthesized from 3-methoxycinnamic acid and SOCl2 and then esterified to 
give methyl carboxylate 72 (see Scheme 33).67 
In order to circumvent regioselectivity problems, alternative methods have been explored. One 
such method is the base-mediated intramolecular aldol condensation of ortho-arylthioacetic 
acids or esters (see Scheme 34).145 Synthesis of the cyclization precursor 74 can be conducted 
by thioglycolate displacement of a halogen or nitro group ortho to a carbonyl moiety. Fluoro and 
nitro groups exhibit a faster rate of reaction, usually augmented by the electron-withdrawing α-
carbonyl group.146,147  
 
For example, Lee et al. synthesized dihalogenated benzaldehyde cyclization precursor 73 by 
ortho-deprotonation using lithium diisopropylamide (LDA), followed by treatment with 
dimethylformamide (DMF). The fluoride was then preferential displaced under base-mediated 
Scheme 34: Lee et al.'s methyl 4-iodobenzo[b]thiophene-2-carboxylate synthesis. Reaction conditions: i) LDA, THF, 
−78 °C then DMF, 60-95%; ii) Methyl thioglycolate, K2CO3, DMF, 65-95%.145 
Scheme 33: Higa and Krubsack's benzo[b]thiophene formation from meta-substituted cinnamic acids, adopted by 
Anderson et al. Reaction conditions: i) SOCl2, pyridine, 140 °C;144 ii) MeOH.67 
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reaction conditions with methyl thioglycolate to afford 75 after intramolecular aldol 
condensation of 74 (see Scheme 34).145 
For 3-halo-2-substituted benzo[b]thiophene synthesis, only a limited number of routes are 
available. The 5-endo-dig halocyclization of ortho-alkynyl thioethers is a regioselective and 
efficient route, though it suffers the disadvantage of necessitating installation of the alkyne 
moiety, usually by a metal-mediated method.131,148–150 Intramolecular attack by sulfur onto the 
alkyne can be promoted by halogen-containing electrophiles, such as iodine, bromine or N-
bromosuccinimide (NBS), to give the desired 3-halogenated benzo[b]thiophene (see Scheme 
35). 
 
Flynn et al. adopted this halocyclization route using molecular iodine as the electrophile to 
synthesize a library of 3-iodo-2-arylbenzo[b]thiophenes (77) in the development of novel tubulin 
binding agents (see Scheme 35).149 The group synthesized their alkyne precursors (76) via 
palladium-mediated coupling of the relevant phenylacetylene-zinc adduct and aryliodide, with 
subsequent cyclization affording the corresponding benzo[b]thiophene in high yield.  
 
1.6.2.4.2. Reactions of benzo[b]thiophenes. 
The regioselectivity of reaction of benzo[b]thiophenes with electrophiles is not as explicit as for 
many other heteroaromatic and fused systems. Reaction still generally occurs on the more 
electron-dense heteroaromatic ring, but depending upon the substituents, the C2 and C3 
positions can exhibit almost the same reactivity.2,81,151–153 
It has been calculated by Martinez et al. using density functional theory (DFT) that the most 
reactive sites on a benzo[b]thiophene ring towards electrophilic attack should theoretically be 
sulfur and carbon-3, though the products of attack on sulfur are rarely seen due to their 
instability.154 These studies complement general experimental evidence of reactivity.155–157 
However it is important to note that Martinez et al.’s calculations were conducted on an 
unsubstituted model. 
Scheme 35: Flynn et al.'s halocyclization to give 2,3-disubstituted benzo[b]thiophenes. Reaction conditions: i) 
Phenylacetylene, 2 n-BuLi, THF, then ZnCl2, Pd(PPh3)2Cl2, 95%; ii) I2, CH2Cl2, 98%. Ar = para-methoxyphenol.149  
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Sulfur in benzo[b]thiophene is very nucleophilic, and its lone pair will readily react with 
electrophilic alkylating agents in solution to form benzothiophenium salts.81 Additionally, 
oxidation of the sulfur centre can be effected to give the 1,1-dioxide 78, which can act as a 
dienophile, for example, with cyclopentadiene as illustrated in Scheme 36.158  
 
For reactions on carbon, bromination of unsubstituted benzo[b]thiophenes will preferentially 
occur at the 3-position under controlled conditions, though the yields are moderate. Therefore 
it can be more efficient to synthesize the 2,3-dibromobenzo[b]thiophene (79) followed by 
regioselective bromine-metal exchange and hydrolysis at the 2-position in order to access 3-
bromothiophene (80) (see Scheme 37).81,159 This method was adopted by Heynderickx et al. for 
the synthesis of 2- and 3-arylbenzo[b]thiophenes via Suzuki-Miyaura cross-coupling.159 The 
group found that 2,3-dibromobenzo[b]thiophene preferentially coupled at the 2-position under 
Suzuki conditions. Therefore to selectively couple at the 3-position the group removed the 2-
bromo substituent before coupling. 
 
For 2-substituted benzo[b]thiophenes, the heteroaryl ring can be activated towards EAS at the 
3-position. For example, Martin-Smith and Reid conducted a number of bromination studies on 
benzo[b]thiophenes in the 1950s and found that benzo[b]thiophene-2-carboxylic acids were 
Scheme 37: Heynderickx et al. selective bromination route for directed Suzuki-Miyaura coupling. Reaction 
conditions: i) Br2, CHCl3, RT, 18 h, 93%. ii) BuLi, Et2O, −78 °C, 20 min, then −20 °C for 1 h, then aq. NH4Cl; iii) ArB(OH)2, 
Pd(PPh3)4, aq. Na2CO3, DME-EtOH, Δ, 63-95%.159 
Scheme 36: 1,1-Dioxide formation and cycloaddition with cyclopentadiene. Reaction conditions: i) H2O2, AcOH, 95 
°C, 76%; ii) cyclopentadiene, xylene, 180 °C, 56%.81,158 
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deactivated towards electrophilic attack at the 3-position, but that reactivity was reinstated 
upon formation of the conjugate base.152 
This method was adapted by Mbere et al. in their synthesis of prospective anti-bacterial agents 
based upon benzo[b]thiophene-2-carboxamides.160 Regioselective bromination of 
benzo[b]thiophene-2-carboxylic acid 81 at the 3-position was facilitated by in situ conjugate 
base formation and reaction with molecular bromine, with subsequent esterification affording 
the methyl ester 82 (see Scheme 38). 
 
With regards to reactions involving the carbocyclic ring of a benzo[b]thiophenes, it is generally 
necessary to install an activating group onto the benzene ring to direct the attack. Bordwell and 
Stange conducted a number of studies in 1955 into the relative reactivity of differently 5-
substituted benzo[b]thiophenes towards nitration and bromination.161 They proposed that EAS 
would preferentially occur at the 4-position, as the transition state to prepare this intermediate 
(83) maintained stabilizing aromaticity in the thieno ring. The transition state from EAS at the 6-
position would provide a less stabilized conjugated triene intermediate (84) (see Scheme 39). 
 
Using 5-hydroxy, 5-acetoxy, 5-acetamido and 5-aminobenzo[b]thiophenes, Bordwell and Stange 
found that mononitration predominantly afforded the 4-nitro product. Under bromination 
conditions, 5-hydroxy, 5-acetamido and 5-aminobenzo[b]thiophene gave the 4-bromides, 
Scheme 38: Mbere et al.'s benzo[b]thiophene bromination. Reaction conditions: i) AcOH, NaOAc, then Br2, 55 °C, 
49%; ii) MeOH, H2SO4, 97%.160 
Scheme 39: Bordwell and Stange's explanation of EAS at the 4- and 6-positions of a 5-hydroxybenzothiophene.161 
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whereas 5-acetoxybenzo[b]thiophene afforded 5-acetoxy-3-bromobenzo[b]thiophene (see 
Scheme 40). Hence, Bordwell and Stange concluded that the acetoxy group was not strongly 
activating enough to promote bromination on the benzene ring over the heteroaryl ring.161 
 
These studies have been supported more recently through DFT studies completed by Wu et al. 
to investigate what appeared to be an “abnormal” bromination reaction of 5-diarylamino-2-
methylbenzo[b]thiophene (85). The group had expected the reaction to afford the 3-bromo-5-
diarylaminobenzo[b]thiophene, but found the reaction gave the 4-bromo analogue 86 with very 
high regiocontrol (see Scheme 41). 
 
The group conducted a number of DFT calculations and generated an electrostatic potential map 
of 85. This map inferred a significantly higher concentration of electron-density at the 4-position 
compared to the 3-position of the aromatic ring due to activation by the electron-donating 
diarylamine. In order to verify their theory, bromination was induced at the 3-position through 
installation of an EWG at the 5-position. Indeed, it was found that when 5-oxadiazole analogue 
87 was brominated under similar conditions, only the 3-bromobenzo[b]thiophene 88 was 
produced.  
Scheme 41: Wu et al.'s "abnormal" bromination pattern. Reaction conditions: i) NBS, CH2Cl2, −15 °C to −20 °C; ii) Br2, 
Fe, CHCl3, Δ.374 
Scheme 40: Bromination experiments completed by Bordwell and Stange. Reaction conditions: i) Br2, AcOH, H2O, 
100°C.161 
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These studies confirmed that, even though the carbocyclic ring of benzo[b]thiophenes might be 
considered to have a lower overall charge density, it can be activated towards EAS through the 
use of strategic functionalization. The required activating or deactivating substituents can 
usually be installed during initial heterocyclization and so careful consideration of the sequence 
of reaction steps must be considered in approaches towards any complex benzo[b]thiophene-
based scaffold. 
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1.6.3. Strategic bond forming reactions. 
In addition to heterocycle forming reactions and general oxidation, reduction and functional 
group interconversions, there are a number of key carbon-carbon and carbon-heteroatom bond 
forming reactions which have been adopted throughout the course of this project to facilitate 
the synthesis and connection of core scaffold molecules. These include amide bond formation, 
and metal-mediated Suzuki-Miyaura cross-coupling, the Mizoroki-Heck reaction and Buchwald-
Hartwig N-arylation. Each of these reactions will now be discussed in turn for their relevance 
and applicability as tools in organic synthesis. 
 
1.6.3.1. Amide bond forming reactions.  
The amide bond is an essential building block for life, linking the framework of all peptides and 
proteins in the human body. Protein synthesis occurs in the human body through the 
condensation reaction of α-amino acids and peptides. The reaction is mediated by numerous 
macromolecules in order to translate predetermined sequences of amino acids from genes in 
DNA to the new peptide on a single molecule scale.162  
The condensation reaction of amines and carboxylic acids to form amide bonds is 
thermodynamically disfavoured, with formation of the carboxylate salt being much more 
energetically favourable in solution (see Scheme 42). Hence, the body employs enzymes to 
mediate formation of a more reactive amino ester from one of the α-amino acid coupling 
partners. This will then condense with the N-terminus of another α-amino acid in a much less 
energetically demanding macromolecule-mediated process.162  
 
Amide bonds are ubiquitous in medicinal chemistry, present in approximately two thirds of drug 
candidates (as of 2006),163 and a quarter of all pharmaceuticals on the market.164,165 Therefore it 
is unsurprising that, in a survey conducted by Roughley and Jordan in 2008, amide bond forming 
reactions constituted at least 70% of acylation reactions in medicinal chemistry.97 Polymers 
Scheme 42: Thermodynamically favoured salt formation from the combination of two α-amino acids. 
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based upon the strong amide bond have also found extensive use in synthetics such as nylons 
and Kevlar, as adhesives in wound healing, and as drug delivery systems.166,167  
 
1.6.3.1.1. Coupling reagents. 
Medicinal chemists have faced many challenges regarding amide bond forming reactions for the 
synthesis of polypeptide chains and small molecules. Although the condensation reaction of a 
carboxylic acid and an amine can be conducted directly, very high temperatures are required 
and that could denature other functionalities in the molecule. In order to facilitate milder 
reaction conditions and overcome the substantial energy barriers, a plethora of technologies 
and methods have been designed.162,164,168,169  
‘Coupling reagents’ are widely used as stand-alone reagents to activate carboxylic acids, 
transforming them into mixed anhydrides, active esters or carbonic anhydrides. This activation 
lowers the energetic barrier towards subsequent nucleophilic substitution. Coupling reagents 
can be used for general small molecule synthesis and in parallel, peptide and library synthesis.  
The choice of coupling reagent is very important and is dependent upon the reaction substrates. 
For instance, in a library-based synthesis, the coupling reagent must enable the reaction to run 
under mild enough conditions to limit side-reactions and racemization, but activating enough 
for a wide range of amines.169 Additionally, for peptide coupling of α-amino acids, maintaining 
absolute stereochemistry of the peptide chain is paramount, and the choice of coupling reagent 
is vital when trying to reduce epimerization of asymmetric carbons. 
Carbodiimides were the first broadly-used coupling reagents, with the use of N,N’-
dicyclohexylcarbodiimide (DCC, 89) pioneered by Sheehan and Hess in 1955. An improvement 
over the moisture-sensitive mixed anhydride methods of the time, the reaction could be carried 
Figure 29: Kevlar, a synthetic polymer with high strength. 
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out in aqueous solvents, and the insoluble urea condensation side product could be removed 
relatively easily.170  
 
Unfortunately, epimerization of the activated O-acyl urea (90) was a prevalent issue associated 
with this method, and prominent side products included the N-acyl urea derivative and the 
carboxylic acid anhydride (see Scheme 43). However, thereafter the anhydride could undergo 
further reaction with the amine to afford the required amide product. 
In an effort to reduce epimerization and increase reactivity, in 1970 König and Geiger introduced 
additives to the amide coupling reaction mixture.171 Addition of 1-hydroxyl-1H-benzotriazole 
(HOBt, 91) and a non-nucleophilic base such as diisopropylethylamine (DIEA) to a DCC activated 
α-amino acid coupling was found to react in situ with the O-acyl urea to form a more activated 
ester (see Scheme 44). This in situ transformation resulted in improved yields and reduced levels 
of epimerization compared to the same reaction carried out with just DCC. It was believed that, 
in addition to improving the electrophilicity of the ester, the benzotriazole ring stabilized the 
approach of the nucleophilic amine in solution through hydrogen bonding.169 
Scheme 43: O-Terminal activation of a carboxylic acid using DCC (89) and subsequent coupling with a primary amine 
to give an amide, with potential side and by-products.169 
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Since these first innovations, various alternative carbodiimides and benzotriazole reagents have 
been designed to improve reaction efficiency. For example, the urea side products formed from 
reactions with diisopropylcarbodiimide (DIC) and DCC can be difficult to remove, and so more 
soluble unsymmetrical and cationic carbodiimides were designed (see Figure 30), including 
phenyl isopropyl carbodiimide (PIC) and 1-ethyl-3-(3-dimethyl aminopropyl)carbodiimide (EDC 
or EDCI), and the hydrochloride salts of these compounds.169  
 
Hydroxy-7-azabenzotriazole (HOAt, 92) was designed as an alternative to HOBt, and has been 
largely found to be a more efficient coupling reagent. This is believed to be due to additional 
chelation of the approaching amine with the pyridinyl ring (see Scheme 45). 172  
Scheme 44: HOBt (91) as an additive in peptide coupling α-amino acids with DCC, forming a more activated ester 
for attack by an external amine. 
Scheme 45: HOAt (92), a coupling reagent with enhanced chelation of the pyridinyl ring with the nucleophilic amine. 
Figure 30: Examples of carbodiimide reagents: diisopropylcarbodiimide (DIC), phenyl isopropyl carbodiimide (PIC) 
and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI)  
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In the development of more economical coupling reactions, a number of onium salts based upon 
the 1H-benzotriazole units HOBt and HOAt have been developed which are able to mediate 
amide bond formation without the need for an additional carbodiimide reagent. Figure 31 
illustrates some examples, with HATU (93), the most commonly used onium coupling reagent,173 
and the phosphonium salts AOP and BOP, based upon HOAt and HOBt respectively, which are 
used less often nowadays due to toxic side products. 
 
Amide bond formation mediated by these salts occurs through nucleophilic attack by the 
carboxylate on the guanidinium salt, with expulsion of the HOAt conjugate base 94. This then 
attacks the ester to give the O-acyl intermediate, which reacts with the amine coupling partner 
(see Scheme 46). 
 
For the coupling of two sterically hindered amino acids, El-Faham et al. found that aminium and 
phosphonium salts (HBTU, HATU, AOP and BOP) in the presence of DIEA base were more 
effective activators than DCC in the presence of HOAt.174 However it should be noted that 1-
hydroxybenzotriazole compounds have been noted for their potentially explosive properties, 
with a relatively high sensitivity to friction and sparks.175 
Figure 31: Onium salts of 1H-benzotriazoles used as coupling reagents. 
Scheme 46: Activation of carboxylic acid for amide bond formation using onium salt HATU (93).169 
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There have been many efforts to design new 1H-benzotriazole coupling reagents with improved 
reactivity and stability; however, comparison tends to reveal little improvement over those 
reagents already available.169 One example that has exhibited somewhat improved 
characteristics is COMU (96), a member of a new class of uronium coupling reagents which has 
a less-hazardous reaction profile and an enhanced reactivity.176 
 
El-Faham et al. had previously demonstrated that acidic oxime Oxyma (95) could be used as an 
alternative coupling reagent, with high activity and low racemization in peptide formation.177 
The uronium salt COMU (96) was developed to incorporate the oxyma residue as a leaving 
group, reminiscent of the mechanism of action of the onium salt HATU (93).176 COMU (96) has 
been found to be more stable than HATU (93) and its derivatives, and exhibits enhanced polarity, 
solubility and reactivity endowed through incorporation of the morpholino group.169,178,179 
The use of carbodiimides and 1H-benzotriazole, or their oxonium salt derivatives, is potentially 
the most prevalent method for amide bond formation and peptide coupling. However there are 
many other alternative ‘coupling reagents’, as well as alternative methods for amide bond 
formation.162,169 
 
1.6.3.1.2. Alternative coupling reagents. 
Acid chloride formation is one of the easiest methods of carboxylic acid activation, formed 
through reaction of a carboxylic acid and thionyl chloride (SOCl2), oxalyl chloride ((COCl)2) or 
POCl3.162 However, these reagents are limited in their practicality due to formation of HCl as a 
by-product, limiting N-protecting group strategies, and the propensity of acid chlorides towards 
hydrolysis and racemization under basic conditions. 
Figure 32: Alternative coupling reagents Oxyma (95) and uronium salt COMU (96).176 
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Formation of mixed anhydrides is a popular method of carboxylic acid activation. For instance, 
EEDQ (97) generates the reactive carbonic anhydride of the carboxylic acid. The reaction occurs 
through deprotonation of the acid by the highly basic ethoxy moiety on EEDQ, with anhydride 
formation then driven by re-aromatization of the quinoline (see Scheme 47). This anhydride 
then reacts rapidly in solution with external nucleophiles, limiting the extent of side reactions 
and potential epimerization.169,180,181  
There are many other coupling routes available,162,164,169 including the use of chloroformate to 
activate the carboxylic acid, Staudinger ligation and native chemical ligation, although the latter 
route employs thioester intermediates, limiting reaction applicability to amino acids and 
peptides containing terminal cysteines or thiol-functionalized serine or threonine residues.  
 
1.6.3.1.3. Protecting group strategies. 
Most of the coupling reagents discussed have been considered with respect to the reaction of 
amino acids in forming new peptide bonds. However, it is imperative when reacting amino acids 
that appropriate protecting group strategies be adopted. 
For solution phase synthesis, there must be two orthogonal protecting groups employed for the 
NH2 (N-terminus) and CO2H (C-terminus), which can be removed under different, mild conditions 
to enable selective modification of the requisite end of the peptide. Common C-terminus 
protecting groups include benzyl or tert-butyl esters, the latter formed through reaction of the 
carboxylic acid and isobutene under acidic conditions.  
Scheme 47: Mechanism for amide bond formation using carbonic anhydride EEDQ (97).162 
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This protecting group is stable under basic conditions as the bulky group prevents attack by 
nucleophiles in solution. Under acidic conditions the protonated carboxyl group will collapse to 
give the stabilized tert-butyl cation, which is quickly hydrolyzed in solution, and the deprotected 
acid (see Scheme 48).101 
Popular N-terminus protecting groups for peptide synthesis include the acid labile Boc (tert-
butyloxycarbonyl) group and the base labile Fmoc group. The Boc group is a carbamate derived 
protecting group, formed through reaction of the amine with the anhydride Boc2O. Deprotection 
occurs under acidic conditions, with loss of the tert-butyl cation collapsing to the volatile 
isobutene and decarboxylation giving the free amine (see Scheme 49).  
 
Fmoc (fluorenylmethyloxycarbonyl) is formed through reaction of Fmoc chloride and the free 
amine. Deprotection is usually carried out through deprotonation of the highly acidic proton on 
the fluorenyl ring system using a tertiary amine like piperidine, to produce a 14-electron anionic 
aromatic group (see Scheme 50). Fmoc protection is a popular strategy in peptide synthesis as 
most C-terminal protecting group strategies adopted are acid labile.162 
Scheme 48: C-terminal protecting group strategies using tert-butyl esters.101 
Scheme 49: N-terminal acid protecting group strategy with the acid-labile Boc-group. 
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1.6.3.1.4. Applications and advances: Solid phase peptide synthesis. 
Despite innovations in protecting group strategies and coupling reagents, solution phase 
peptide synthesis can be problematic for the synthesis of long chain peptides. This is due to 
problems of purification and solubility with increasing chain length. Solid phase peptide 
synthesis (SPPS) was introduced by Merrifield to circumvent these problems.182  
 
By mounting the nascent peptide chain covalently onto a solid support a step-wise process of 
coupling, washing, deprotection and cycle repetition can be conducted to build-up a peptide 
before cleavage from the resin (see Scheme 51). Protecting group strategies are paramount to 
this process, as the bond to the solid support must be stable to all reaction conditions, and the 
deprotection must be mild enough to not disrupt the stereochemical purity of the product. 
Scheme 50: N-terminal protecting group strategies with the Fmoc group. 
Scheme 51: Example SPPS using acid labile Wang resin and base labile Fmoc N-protection strategy. 
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For example, Wang resins are hydroxybenzyl-based resins (see Scheme 51, 98) which are base 
stable and bind to the C-terminus of an amino acid.183 SPPS using these resins can therefore be 
conducted in collaboration with a base labile N-protecting group, such as Fmoc. The completed 
peptide chain can then be selectively cleaved using trifluoroacetic acid (TFA), mindful of side 
chain stability and protecting group strategies that may still be employed. 
Amide bond forming reactions were used in this project as an essential tool in approaches 
towards the fused heterocyclic core of PF-3644022 (25) and its advanced intermediates (see 
Chapter 3). 
 
1.6.3.2. Metal-mediated cross-coupling.  
Metal-mediated cross-coupling reactions have become an essential item in the synthetic organic 
chemist’s ‘toolbox’, facilitating bond formations that may otherwise be severely energetically 
disfavoured.101 Early reports were documented at the end of the 19th century, with copper, 
organo-alkali-metals and organo-magnesium to mediate homocoupling reactions. Examples 
include seminal work by Glaser and Ullmann into the homocoupling of arylacetylenes,184,185 and 
the development of nucleophilic Grignard reagents.186 Over the following century, the reactive 
scope was extended to the selective formation of carbon-carbon bonds between different 
fragments, encompassing all hybridization states of carbon, the incorporation of heteroatoms, 
and the use of catalytic amounts of metals. 
Huge advances have been made in the field over the past 40 years, with ground-breaking work 
completed by Heck, Negishi and Suzuki in the 1970s earning them the Nobel prize in Chemistry 
in 2010 for their discoveries and development of the field of C-C bond construction.186,187 Their 
work led to major advances in the use of the group 10 metals in cross-coupling and 
catalysis.97,186–189 Palladium (Pd) has emerged to dominate the field as the choice metal catalyst 
and as a ”jack of all trades” for carbon-carbon bond forming reactions; offering enhanced 
chemo- and regioselectivity, high tolerance for a wide range of functional groups, and the ability 
to modulate reactivity through the use of ligands.101,186 
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The general catalytic cycle for a palladium-mediated cross-coupling reaction proceeds through 
four principle steps: catalyst activation, oxidative addition, transmetalation and reductive 
elimination (see Scheme 52). 
 
Palladium catalysts tend to require an activation step to form the unsaturated Pd(0) catalyst. 
Hence, saturated Pd(0) and Pd(II) complexes, like Pd(PPh3)4 and Pd(OAc)2, must undergo a loss 
or exchange of ligands, or react with nucleophiles in solution.101,190 Unsaturated Pd(0) is then 
able to activate C-X bonds through an oxidative addition step to form Pd(II) organopalladium 
complexes. The Pd(II) square-planar complex can then undergo transient cis- to trans-
isomerization to form the most thermodynamically stable complex. Organometallic reagents 
(pre-formed, or formed in situ) can then undergo a slow transmetalation step, with transfer of 
the organic component to the palladium centre and loss of a metal halide. To enable reductive 
elimination the palladium complex usually needs to isomerize back into the cis-configuration, a 
step which can be slow and energetically demanding. Once the two organic ligands are arranged 
in the cis-configuration, reductive elimination of the ligands as the coupled product regenerates 
the zerovalent Pd(0) active catalyst to facilitate the next cycle. 
Scheme 52: General catalytic cycle for palladium mediated cross-coupling.  
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The organometallic component that undergoes transmetalation can be based upon zinc, tin, 
silicon, magnesium, aluminium or boron. The RX component can be a halide or pseudo-halide, 
and the organic ligand must not have a β-hydrogen, as this can decompose via β-hydride 
elimination with palladium. Some examples of palladium-catalyzed reactions are illustrated in 
Scheme 53.  
 
The catalytic cycles for the Heck and Sonogashira reactions occur via slightly different pathways 
than the one illustrated in Scheme 52. Sonogashira coupling occurs via formation of an 
organometallic species in situ, through reaction of a terminal alkyne with a copper halide co-
catalyst and base in solution.101 The Heck reaction has an additional π-coordination and 
migratory insertion step which will now be discussed in more detail.  
 
  
Scheme 53: A few examples of palladium-catalyzed cross-coupling reactions. 
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1.6.3.2.1. The Mizoroki-Heck reaction. 
The Mizoroki-Heck reaction (here on referred to as the Heck reaction) is a widely explored and 
flexible method of C-C bond formation between two sp2 hybridized carbon centres, usually for 
the coupling of aryl (or vinyl) halides or pseudo-halides and activated alkenes in the presence of 
a base (see Scheme 54).190–192  
 
The reaction is quite accommodating in its requirements, though an optimal system has yet to 
be devized, with reaction conditions often referred to as a catalyst ‘cocktail’.193–195 For example, 
reactions have been conducted successfully under anhydrous conditions,196 in the presence of 
water197 and in water-organic mixtures.190,197 The source and amount of palladium required for 
catalytic activity has been widely discussed, including the role of palladium nanoparticles and 
homeopathic palladium.198,199 The use of ligands has been widely explored, initially used to 
extend reactivity beyond just iodides and to help maintain stereochemistry,200 and an extensive 
variety of phosphine and N-heterocyclic carbene (NHC) based ligands have been described in 
the literature,196,201–204 in addition to a number of ligand-free systems.205   
 
1.6.3.2.1.1. Catalytic cycles for ligated and ligandless systems. 
 
The classical mechanism of the Heck coupling reaction is similar to that illustrated in Scheme 52, 
though with an additional migratory insertion step of the alkene (see Scheme 55). Transient π-
Scheme 54: General reaction scheme for Mizoroki-Heck coupling. 
Scheme 55: Additional steps of the Heck catalytic cycle. A: Migratory insertion. B: β-Hydride elimination. C: Base-
assisted reductive elimination. 
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complexation of the alkene is proposed to occur with the organopalladium(II) complex, with syn- 
migratory insertion into the palladium-carbon bond (step A).200 The saturated chain must then 
rotate to enable β-hydride elimination (step B). The most stable transition state is usually the 
one in which the R groups eclipse the smallest group possible, leading to predominantly trans-
alkene products (see Scheme 56). Finally, base-assisted reductive elimination of HX returns the 
active Pd(0) catalyst (step C).  
 
Numerous studies have been conducted since the initial publication of the Heck reaction, and it 
has been found that the mechanism is much more complex than initially thought.206 An 
alternative mechanism postulated by Amatore and Jutand occurs via an anionic catalytic species, 
and has been proposed to be applicable to most ligated, homogeneous systems (see Scheme 
57).207,208  
Scheme 57: Amatore and Jutand’s postulated mechanism for palladium-mediated catalysis via an anionic palladium 
complex.207  
Scheme 56: Illustrative mechanism of how the syn-addition and syn-elimination steps of the palladium complex 
determine the stereochemistry of the product alkene. 
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Based upon a catalytic system involving use of triphenylphosphine (PPh3) and Pd(OAc)2, they 
proposed formation of an anionic 16-electron palladium species (99) as the active catalyst. 
Oxidative addition with RX forms a transient pentacoordinated aryl Pd(II) anionic complex 100, 
which eliminates the additional halide anion to give the neutral species. Coordination and 
migratory insertion of the electron-rich alkene can then occur following the traditional steps of 
the mechanism (see Scheme 57), and reaction of the Pd(II) complex with base in solution re-
generates the anionic Pd(0) catalyst.203,209  
The most popular ligand-free Heck reaction was developed by Jeffery, operating under generally 
milder, phase-transfer conditions.210,211 Classical Jeffery conditions are usually run at or near 
room temperature, using an excess of base, with a palladium(0) catalyst (for example, Pd(OAc)2) 
and a phase-transfer agent such as tetrabutylammonium chloride or bromide (TBAC and TBAB, 
respectively).210 Even Jeffery’s conditions tend to involve a catalyst ‘cocktail’, with yields highly 
dependent upon changes in the choice and concentration of phase-transfer agent, the choice of 
base, and the presence of water, which can be detrimental or beneficial dependent upon the 
system.211  
 
Generation of the active palladium species from Pd(OAc)2 in a ligand-free system is believed to 
occur through a sacrificial alkene and base-mediated mechanism, to produce Pd(0) in solution 
(see Scheme 58).206 Evidence has been found to support the agglomeration of Pd(0) atoms into 
nanoparticles or colloids, which are stabilized by bulky ammonium cations under Jeffery 
conditions.205  
It has been proposed that subsequent catalysis then occurs on the surface of the nanoparticles 
akin to a heterogeneous catalyst system,198,212 or through solubilization of the palladium clusters 
and oxidative addition with RX to form organopalladium intermediates RPdX or RPdX32- which 
then enter the catalytic cycle.205 
The use of quaternary ammonium salts as additives has also been found to be beneficial for a 
number of ligated systems, with proposed roles including as a source of additional anions in 
Scheme 58: Generation of the active Pd(0) catalyst in ligand-free Heck reactions.206 
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solution to act as promotors, in the stabilization of un-ligated Pd(0) in solution, or as phase-
transfer agents for reactions mediated by solid salts (solid-liquid) or aqueous solvents (liquid-
liquid).190,203 Indeed, Amatore et al. proposed that the presence of bulky cations in solution could 
help to regenerate and stabilize the active anionic species 99 and 100.208 
 
1.6.3.2.1.2. Regioselectivity. 
Regioselectivity of the Heck reaction is determined during the migratory insertion step of the 
alkene into the palladium-carbon bond, as the aryl (or alkenyl) group undergoes a β-shift from 
the palladium centre to the alkene to form the new C-C bond. Usually a concerted step, 
migration tends to be directed by steric factors of the alkene, with the aryl group moving to the 
least substituted and often more electron-deficient carbon.213,214 In the case of electron-rich 
alkenes, like enol ethers, migration of the aryl group tends to be directed to the more electron-
deficient α-position. However, this is dependent on the electronics of the palladium complex 
and migrating group, as an electron-poor aryl group will favour migration to the electron-rich β-
position of the alkene (see Scheme 59).194,215  
 
Additionally, electronic effects of the palladium complex have been studied to explore their 
influence on regioselectivity. For instance, von Schenck et al. conducted a number of studies 
into the use of neutral and anionic palladium complexes with symmetrical and unsymmetrical 
ligand systems and found that, through tuning the electronics of the catalyst, migratory insertion 
could be directed to alter the regioselectivity of the reaction.216  
 
Scheme 59: Changes in regioselectivity with the use of enol ethers. Substituting at the α- or β-position depending 
on the electron density of the aromatic ring.  
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1.6.3.2.1.3. Heck coupling of α,β-disubstituted alkenes. 
α,β-Disubstituted alkenes are much less reactive towards Heck coupling than their 
monosubstituted or 1,1-disubstituted counterparts.196 However, there are a number of 
examples of electron poor α,β-disubstituted alkenes that have been coupled successfully in Heck 
reactions, including cinnamates and crotonates,194,217 alkoxypropenes,215 methyl 3-
methoxyacrylates,201 and 3-subsituted acrylonitriles.218  
 
Masllorens et al. conducted Heck coupling between 3-subsituted acrylonitriles and aryl iodides 
under Jeffery’s conditions with total control of regioselectivity; to substitute at the β-position, 
and with complete stereocontrol giving the (E)-isomer.218 Electron-rich and electron-poor aryl 
iodides both coupled at the β-position, and trans- to the nitrile group, though more electron-
poor aryl iodides required longer reaction times (see Scheme 60). 
The versatility of the Heck reaction using α,β-disubstituted alkenes has been explored as a route 
towards the synthesis of quinolone and coumarin derivatives. Heck et al. developed a one pot 
method, coupling α,β-disubstituted malonates with 2-iodoanilines in an effort to promote 
cyclization to the heterocycle in situ.217 Use of monosubstituted alkenes, including acrylic acid 
and methyl acrylate, returned only the (E)-alkene (101) after coupling with 2-bromo and 2-
iodoaniline. It was concluded that β-hydride elimination of these derivatives must occur at a 
faster rate than the desired cyclization (see Scheme 61). 
Scheme 60: Masllorens et al.’s stereoselective synthesis of 3,3-disubsituted acrylonitriles using Heck coupling. 
Reaction conditions: i) Pd(OAc)2, KOAc, nBu4NBr, DMF, 80-100 °C, 2-3 days.218 
Scheme 61: Heck et al.'s attempted 2-quinolone formation via Heck coupling of a monosubstituted alkene and a 2-
bromoaniline. Reaction conditions: i) Pd[P(o-tolyl)3]2; ii) acrylic acid, base; iii) P(o-tol)3, Et3N.217 
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It was hypothesized that use of a 1,2-disubstituted alkene, specifically the (Z)-isomer of an 
acrylate derivative (103), would couple with iodide 102 and possess the correct stereochemistry 
for cyclization to occur. It was also proposed that conducting the reaction in the absence of any 
additional triarylphosphine should help slow the final β-elimination step, thus enabling the 
desired cyclization to occur (see Scheme 62). Heck et al. did experience some problems with 
isomerization of intermediates, but achieved yields of up to 72% of their desired 2-quinolone 
104 using this one step procedure. 
  
The utility of this Heck-mediated synthetic route towards quinolones has since been 
demonstrated in the total synthesis of Tipifarnib, a potent and orally-bioavailable inhibitor for 
farnesyl protein transferase,219 and in the synthesis of Semaxanib (106), a tyrosine-kinase 
inhibitor and cancer therapeutic (see Scheme 63). A tandem Horner-Wadsworth-Emmons 
(HWE)/Heck process,  provided alkene 105 which was then subjected to an intramolecular Heck 
reaction to form the 3-methylidene-oxindole 106, Semaxanib.220 
Scheme 63: Synthesis of Semaxanib (106), via a tandem HWE and Heck reaction.220 
Scheme 62: Heck et al. one pot synthesis of 2-quinolones using 2-iodoanilines and (Z)-3-substituted acrylates. 
Reaction conditions: i) Pd(OAc)2, Et3N, MeCN 100 °C.217 
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Given the adaptability and flexibility of the Heck reaction,190 it presented itself as a prime 
method to be explored in this project for the total synthesis of RO3201195 (10), specifically for 
the preparation of benzoylacetonitrile intermediate 107 (see Scheme 64). 
 
1.6.3.2.2. Suzuki-Miyaura cross-coupling. 
The Suzuki-Miyaura reaction (hereon referred to as the Suzuki or Suzuki-coupling reaction) is 
one of the most prolific cross-coupling reactions, observed in approximately 40% of C-C bond 
forming reactions in medicinal chemistry,97 and earnt Suzuki a share of the Chemistry Nobel 
prize in 2010.187,221 Suzuki reactions can be more generally classified as the coupling of an 
organoborane and an organic electrophile, usually an organohalide or triflate, in the presence 
of a base (see Scheme 65 for examples). Over the course of this project, Suzuki coupling was 
relied upon as an efficient and reliable method for the formation of biaryl linkages. 
 
 
Scheme 64: Retrosynthetic strategy for Heck coupling towards benzoylacetonitriles. 
Scheme 65: Prototypical Suzuki coupling reactions. Reaction conditions: i) Palladium catalyst and base. 
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1.6.3.2.2.1. The catalytic cycle. 
Suzuki et al. first reported their coupling method in 1979, for the stereoselective synthesis of 
(E)-arylalkenes222 and (E)-aryldienes.223 The desired 1-alkenylborane was synthesized through 
hydroboration of the relevant alkyne, and coupled with aryl halides, haloalkynes or haloalkenes 
in the presence of base and catalytic tetrakis(triphenylphosphine)palladium (Pd(PPh3)4) (see 
Scheme 66). The reaction scope was quickly extended to the synthesis of symmetrical and 
unsymmetrical biaryls via palladium catalyzed coupling of arylboronic acids and esters with aryl 
halides in the early 1980s.224 
 
Suzuki coupling occurs through the traditional catalytic cycle detailed in Scheme 52 (Section 
1.6.3.2). Activation of the catalyst affords an unsaturated Pd(0) complex, with oxidative addition 
of the organic halide, transmetalation of the organoboron reagent and reductive elimination 
affording the coupled product.225,226 
Suzuki coupling offers several advantages over other C-C bond forming reactions, including high 
functional group tolerance, mild reaction conditions, ease of removal of side products and 
amenability towards aqueous and heterogeneous reaction conditions.221 These features are 
almost entirely due to the chemical nature of the organoboron coupling partner.225,227   
Stability of organoboron reagents can be attributed to the small dipole moment of the carbon-
boron bond and low nucleophilicity of the organic component. Since the conception of Suzuki 
coupling, a plethora of new organoborane reagents have been designed with improved stability 
and reactivity, to facilitate cleaner, more efficient and selective reactions.228  
The presence of a base in Suzuki reactions is paramount to activation of the organoboron, 
though there have been abundant discussions over its precise role.225,229 One theory is that the 
base coordinates with Lewis acidic boron to create a four coordinate ‘ate’ complex, to increase 
the nucleophilicity of the carbon component and facilitate transmetalation onto the Pd(II) 
complex (the “boronate pathway”, see Scheme 67a). 225,228,230 
Scheme 66: Suzuki's first published reactions using the “Suzuki” coupling system. Reaction conditions: i) Bis(1,2-
dimethylpropyl)borane; ii) Pd(PPh3)4, base. 
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An alternative pathway has been proposed to occur via ligand exchange of the anionic base and 
halide on the Pd(II) complex. This forms a new hydroxy-, alkoxy- or acetopalladium(II) active 
complex. The oxo-palladium(II) complex then acts as a Lewis base to coordinate with the 
oxophilic organoboron and promote transmetalation (the “oxo-palladium” pathway, see 
Scheme 67b).225,226,228 Studies by Suzuki and Miyaura support this second mechanism of 
reaction, with transmetalation found to occur readily under neutral conditions between 
organoboron reagents and alkoxypalladium(II) complexes, for example, formed from oxidative 
addition of epoxybutenes,231 propargyl carbonates,226,232 allylic acetates and phenoxides.233,234   
In early studies the most common catalytic systems used in Suzuki coupling were Pd(PPh3)4, 
PdCl2(PPh3)2 and Pd(OAc)2, the latter with the addition of phosphine ligands.226 In order to carry 
out the catalytic cycle it is necessary for the catalyst to undergo activation to form an 
unsaturated Pd(0) species, which was generally facilitated by ligand dissociation or reaction in 
solution with an additional ligand, nucleophile or base, as discussed in Section 1.6.3.2.  
Miyaura claimed that, in some cases, the choice of a suitable base was more important than the 
choice of the catalyst.229 Nonetheless, some of the great advances that have been achieved in 
extending the scope of Suzuki coupling can be attributed to improvements in the stability and 
reactivity of metal catalysts and the use of supportive ligands. For instance, the use of bulky, 
linked bisphosphines, chiral phosphines, and N-heterocylic carbene ligands have led to advances 
including reactions with aryl chlorides, hindered substrates and asymmetric reactions, in 
addition to conducting reactions at a lower temperature and with lower catalyst loadings (for 
more information on ligands, see Chapter 1.6.3.2.3).235–237 
 
Scheme 67: Potential reaction pathways for base-mediated Suzuki-Miyaura coupling: a) The boronate pathway; b) 
The oxo-palladium pathway. 
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1.6.3.2.2.2. Applications in medicinal chemistry. 
The extent of the applications of Suzuki coupling in pharmaceutical, agrochemical and 
engineering industries is widespread.221 For example, Danishefsky et al. adopted Suzuki coupling 
for the formation of a Z-trisubstituted alkene (110) in their total synthesis of the natural product 
(−)-epothilone B (111), a compound of interest due to its antifungal and cytotoxic properties.238  
 
Boron alkyl 108 was generated via hydroboronation of the relevant alkene with 9-
borabicyclo[3.3.1]nonane (9-BBN) and reacted with vinyl iodide 109, synthesized via a complex 
Wittig reaction. Using [Pd(dppf)2] (dppf = 1,1’-bis(diphenylphosphino)ferrocene) with Cs2CO3 
and AsPh3 in water and DMF, Suzuki coupling was conducted in high yield (77%) at room 
temperature to generate exclusively the (Z)-alkene 110 (see Scheme 68). Further 
functionalization and macroaldolization followed, with deprotection of the hydroxyl groups and 
chemoselective epoxidation affording (−)-epothilone B (111).  
Suzuki coupling has also been used successfully to synthesize a number of MK2 inhibitors.3 For 
instance, Velcicky et al. used Suzuki coupling extensively in the synthesis of pyrrolopyridine MK2 
inhibitor 22 (see Chapter 1.4.1).65 Bagley et al. proposed this chemotype as a prime candidate 
to investigate the role of MK2 in WS cells.3 However, when conducting their own synthesis of 
22, problems were encountered when conducting the halogenation of intermediates for the 
Suzuki coupling step. Therefore, the group synthesized the simplified target 112, which 
maintained the majority of pharmacophoric traits important for binding in MK2 (see Scheme 
69).  
 
 
Scheme 68: Danishefsky et al.'s Suzuki-mediated synthesis of (-)-epothilone B (111). Reaction conditions: i) 
Pd(dppf), Cs2CO3, Ph3As, H2O, DMF, RT, 77%.238  
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Suzuki coupling was adopted to install the pyrazole 4-aryl substituent onto the ring, using aryl 
boronic acid 113. Adopting microwave-assisted dielectric heating, the coupled product 112 was 
obtained in reasonable yield (54%) after heating at 150 °C for 2 h in aqueous solvent (see Scheme 
69). WS cells grown in the presence of 112 were found to have a slightly extended life-span 
compared to controls, though only very low levels of MK2 inhibition was noted, making it 
difficult to draw significant conclusions about the role of MK2 from these results.3 
 
1.6.3.2.3. Buchwald-Hartwig N-Arylation. 
Before the advent of palladium-mediated N-arylation, methods available for aryl-nitrogen bond 
formation were very limited and generally required quite harsh conditions. Suitable methods 
include, for instance, copper-mediated nucleophilic displacement reactions of aryl halides using 
various nitrogen nucleophiles,239 strongly acidic nitration and subsequent reduction to the 
aniline, and radical nucleophilic aromatic substitution (SRN1) using alkali metals and ammonia, 
which could return a mixture of products through benzyne formation.240  
 
 
 
Scheme 69: Bagley et al.'s Suzuki-mediated synthesis of aminopyrazole MK2 inhibitor analogue 112. Reaction 
conditions: i) NaOEt, EtOH, MW 150 °C, 2 h, 85%; ii) NBS, THF, MW 150 °C 2 h, 77%; iii) 113, PdCl2(PPh3)2, K2CO3, i-
PrOH, H2O, MW 150 °C, 2 h, 54%.3 
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1.6.3.2.3.1. Palladium-mediated N-arylation and catalytic cycle. 
 
In the development of milder, functional group tolerant and regiospecific reactions, palladium 
was explored as a catalyst and reaction mediator in the mid-1980s. Boger and Panek published 
an intramolecular palladium(0) mediated aryl C-N bond formation in 1984 in the synthesis of the 
natural product lavendamycin (114).241 They used super-stoichiometric amounts of Pd(PPh3)4 in 
THF to effect 5-membered cyclization of a linked aryl amine and aryl bromide (see Scheme 70). 
They proposed formation of a 6-membered σ-bonded palladacycle intermediate. 
Only one year before, in 1983 Migita et al. published a study using catalytic amounts of 
PdCl2[P(o-tolyl)3]2 to mediate aryl C-N bond formation.242 Using aryl bromides and diethylamino-
tributyltin as coupling partners, the group screened a number of palladium complexes and found 
that catalytic amounts of PdCl2[P(o-tolyl)3]2 returned much higher yields of the coupled product 
than when Pd(PPh3)4 or PdCl2(PPh3)2 were used (see Scheme 71). 
 
In 1994, Buchwald and Hartwig both separately published work extending the scope of this 
coupling reaction. Hartwig recognized the similarity between the work of Migita and Stille, using 
tin-based reagents to mediate C-N and C-C bond formation, respectively.243 The group 
Scheme 70: Boger and Panek's Pd(0)-mediated aryl C-N bond formation in the synthesis of lavendamycin (114). 
Reaction conditions: i) Pd(PPh3)4 (1.5 equiv.) , THF, 80 °C, 21 h, 84%.241 
Scheme 71: Migita's original N-arylation reaction from 1984. Reaction conditions: i) PdCl2[P(o-tolyl)3]2 (1 mol%), 
toluene, Ar, 100 °C, 3 h, 33-79%.242 
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conducted work to identify the key intermediates of the reaction and the oxidation state of the 
active palladium species to elucidate the mechanistic aspects of the reaction.  
The group isolated the Pd(II) dimer complex [PdArBr(P(o-tolyl)3)]2, formed after oxidative 
addition of ArBr onto the monophosphine Pd0[P(o-tolyl)3] active complex. In this primary 
publication, it was proposed that transmetalation could occur onto either the monomer or dimer 
of this complex,243 with later studies confirming reductive elimination to occur via a three-
coordinate monomeric species to give the coupled arylamine (see Scheme 72).244 
 
Concurrently, Buchwald et al. extended the scope of Migita et al.’s work by developing a method 
for the transamination of tributyltin amines. They recognized that aminostannes tended to be 
unstable, and proposed that an in situ transamination reaction would enable access to a wider 
variety of substrates.245  
 
Heating together an aminostannane derived from a highly volatile amine (such as diethylamino-
tributyltin) with a free amine that possessed a higher boiling point in toluene resulted in 
exchange of the amino groups, with the more volatile amine removed by purging the vessel with 
argon. Immediate palladium-mediated N-arylation could then be conducted. This method 
enabled access to a much wider variety of amine coupling partners, including primary and 
secondary alkyl and aryl amines (see Scheme 73).  
Scheme 72: Hartwig's original proposed reaction pathway for N-arylation. L = P(o-tolyl)3.243 
Scheme 73: Buchwald et al.'s transamination and palladium-mediated arylamine formation.245 
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Buchwald et al. also confirmed that use of alternative ligands such as PPh3, dppf and linked 
diphosphine PPh2(CH2)3PPh2 instead of Migita’s original ligand of choice, P(o-tolyl)3, gave inferior 
results. It was also confirmed that more electron-poor aryl bromides reacted faster in the 
oxidative addition step, and that the sterics and electronics of the aminostannane were very 
important in determining intrinsic reactivity. For instance, larger aminostannanes derived from 
n-hexylamine and N-methylcyclooctylamine did not react under the conditions tested. This was 
presumed to be due to the steric bulk of the P(o-tolyl)3 ligands obstructing ligand exchange.245  
Despite the importance of these transamination reactions for extending the scope of C-N 
coupling reactions, it was a year later that both Buchwald and Hartwig published work detailing 
the development of tin-free coupling of primary and secondary amines with aryl bromides, 
through the use of an additional bulky base.246,247  
Buchwald et al. detailed the use of a slight stoichiometric excess of sodium tert-butoxide 
(NaOtBu) in conjunction with [PdCl2(P(o-tolyl)3)2] or [Pd(dba)2]/2 P(o-tolyl)3 to couple primary 
and secondary amines with aryl bromides. They found that when K2CO3 or NaOMe were used 
there was no conversion to the product. Hartwig et al. detailed the use of lithium silylamide 
LiN(SiMe3) (LHMDS) as base to successfully conduct N-arylation reactions, and noted much 
slower conversions were obtained using LiOtBu or NaOtBu as the base.247 
 
Scheme 74: Buchwald-Hartwig catalytic cycle for palladium- and base-mediated N-arylation.248 
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Hartwig et al. proposed that the dimeric Pd(II) complex would break-down into the 
monophosphine complex to facilitate addition of the amine, and once conjugated the acidity of 
the amine proton would be enhanced.247 Deprotonation using the bulky silyl amide base would 
result in formation of an amido complex, which would rapidly undergo reductive elimination to 
afford the arylamine product. This proposed catalytic cycle, as shown in Scheme 74, has since 
been largely maintained as the accepted mechanism for the Buchwald-Hartwig coupling 
reaction.248 
 
1.6.3.2.3.2. Catalyst and ligand systems. 
Through the use of bidentate and bulky phosphine ligands, the scope of the Buchwald-Hartwig 
N-arylation reaction has advanced significantly. The use of P(o-tolyl)3 ligands had been strongly 
emphasized by Buchwald, Hartwig and Migita, with the general consensus that the enhanced 
steric constraints of the o-tolyl group helped to reduce formation of bisphosphine-palladium 
complexes.249 This was desirable as it had been proven by Hartwig that the monophosphine 
palladium complex was the active species in the catalytic cycle.243 However, significant β-hydride 
elimination was noted when this ligand system was used for the coupling of primary amines and 
aryl bromides.   
Buchwald et al. found that, through the use of the chelating bisphosphine ligand BINAP and the 
bispalladium catalyst Pd2(dba)3 in the presence of NaOtBu, yields of N-arylation using primary 
amines were drastically improved.249 Reduction in the extent of β-hydride elimination was 
speculated to be due to inaccessibility of the unsaturated three-coordinate monophosphine 
from the BINAP ligated complex. 
 
There have been a number of generations of catalyst-ligand systems developed for Buchwald-
Hartwig coupling, including integration of more complex aromatic bisphosphine ligands such as 
Figure 33: Examples of bisphosphine ligands: racemic BINAP, dppf, XantPhos and hindered ferrocenyl alkyl 
bisphopshine 115.252 
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dppf and XantPhos used similarly to BINAP (see Figure 33). More sterically-hindered alkyl 
monophosphines and NHCs have been used for the activation of less-reactive aryl 
halides,248,250,251 and the use of hindered ferrocenyl alkyl bisphosphines (for example, 115) have 
been documented to extend catalyst lifetimes to improve catalyst efficiency.252  
 
1.6.3.2.3.3. Applications in medicinal chemistry. 
The impressive advances that have been made in the coupling of aryl halides and amines using 
Buchwald-Hartwig chemistry has opened up a whole field of efficient and tolerant methods for 
the synthesis of pharmaceutically and industrially-relevant compounds.253  
For example, Kamikawa et al. in their preparation of polysubstituted phenazines, which have 
been noted for their interesting biological activities, adopted two sequential Buchwald-Hartwig 
N-arylation reactions to construct a fused heterocylic ring system (see Scheme 75).254  
 
The base and catalyst system used in this total synthesis was a slight variation on those discussed 
previously, with the use of the milder base Cs2CO3 endowing wider functional group tolerance.255 
For instance, Luker et al. developed a milder N-arylation route to couple methyl 3-
bromothiophene-2-carboxylates and primary amines, using Cs2CO3 with Pd2(dba)3 or Pd(OAc)2 
and BINAP in toluene (see Scheme 76).256 They found that use of other metal carbonates or 
tertiary amines as the base gave inferior results, and that use of NaOtBu resulted in formation 
of the amide side product. 
Scheme 75: Kamikawa et al.'s Buchwald-Hartwig mediated synthesis of phenazines. Reaction conditions: i) 
Pd(OAc)2, BINAP, Cs2CO3, toluene, 100 °C, 99%; ii) H2, Pd(C), EtOAc, 100%; iii) Br2, NaHCO3, CHCl3, 91%; iv) Pd(OAc)2, 
BINAP, Cs2CO3, toluene, 100 °C, 50%.254 
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The analgesic and selective α4β2 neuronal nicotinic receptor (NNR) antagonist A-366833 has 
also been constructed using Buchwald-Hartwig coupling in the final step of the total synthesis.257 
The group developed a convergent synthetic route, separately building an enantiomerically pure 
fused diazabicyclo[3.2.0]heptane unit, before coupling with an aryl bromide using the 
Pd2(dba)3/BINAP catalytic system.  
 
The group found that when they used tBuONa as base for the coupling, only a 47% yield was 
achieved after 10 h, with significant production of the tert-butoxide exchange partner. However, 
through the use of Cs2CO3 this was circumvented, and the CBz (benzyl carbamate) protecting 
group could be safely removed to give the final product in high yield (see Scheme 77). 
Buchwald-Hartwig N-arylation is a mild and efficient method for the synthesis of aryl amines, 
and was adopted as the method of choice for a key N-arylation step during the construction of 
the fused heterocyclic scaffold for PF-3644022 (25) in this project (see Chapter 3). 
     
  
Scheme 76: Luker et al.'s Buchwald-Hartwig coupling of methyl bromobenzothiophene-2-carboxylates. Reaction 
conditions: i) Pd2(dba)3, BINAP, Cs2CO3, toluene, 94%.256 
Scheme 77: Ji et al.'s Buchwald-Hartwig coupling step for the synthesis of NNR antagonist A-366833. Reaction 
conditions: i) Pd2(dba)3, BINAP, Cs2CO3, toluene, 100 °C, 40 h, 73%; ii) TFA, 65 °C, 1 h, 93%.257 
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1.7. Overall project objectives. 
The goals of this project were to deconvolute the stress-signalling pathways which contribute to 
accelerated ageing in the progeroid syndrome WS. The project aims were to corroborate 
previous biological studies completed on WS cells using p38 MAPK inhibitors, to establish the 
major p38-mediated pathways contributing to premature cellular senescence and to explore the 
potential of p38 MAPK inhibitors to be re-purposed as chemical probes. 
Therefore the aims of this project were to synthesize the p38 MAPK inhibitor RO3201195 (10) 
and the MK2 inhibitor PF-3644022 (25) in sufficient yields and purity for biological studies, to 
verify the ability of the inhibitor to modulate their target in WS cells, and ascertain the role of 
the targets in accelerated ageing in WS (see Scheme 78). 
 
Additionally, studies were to be completed to explore the potential of the p38 MAPK inhibitor 
BIRB 796 (14) towards drug-repurposing. By altering the steric and electronic features of the 
N,N’-diaryl urea pharmacophore an analogue library would be synthesized. This library would 
then be tested against a panel of kinases of interest for their role in the MAPK stress-signalling 
cascade, in cell-proliferation and in age-related diseases such as cancer and Alzheimer’s disease.   
  
Scheme 78: Investigating the stress-signalling pathways which contribute to accelerated ageing in Werner 
syndrome. 
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Chapter 2. RO3201195. Corroborating the role 
of p38α MAPK on accelerated ageing in WS 
cells. 
2.1. Background and aims. 
One of the biggest limitations in the development of small molecule p38α inhibitors for 
therapeutic use has been their lack of selectivity.28 Bain et al. identified this lack of selectivity to 
be true for a number of ‘specific’ inhibitors and urged caution in their application, instead 
suggesting parallel testing of inhibitors targeting the same protein to assess and confirm 
physiological effects.32  
One of the most promising p38α inhibitor pharmacophores identified over the past decade is 
that of the 5-aminopyrazole ketone RO3201195 (10). This chemotype demonstrated a unique 
binding mode, exploiting an amino acid residue in the p38 ATP-binding pocket that is rare to the 
human kinome, endowing an additional degree of selectivity not present in other type 1 p38α 
MAPK inhibitors (see Section 1.3.2.). 
The aim of the first part of this project was to synthesize RO3201195 (10) to explore its biological 
properties in WS cells, to investigate new routes towards key intermediates and utilize 
microwave-assisted dielectric heating to improve efficiency and yields. The efficacy of 
RO3201195 (10) as a p38α inhibitor in WStert fibroblasts has been verified by Bagley et al.,258 and 
this project aimed to advance this research by investigating the effect of RO3201195 (10) on the 
rate of proliferation of WS primary cells. By drawing a direct comparison against the prototypical 
p38α inhibitor SB203580 (1) it was hoped that a better understanding of the function of p38α 
and the MAPK stress-signalling pathway and their roles in the premature aging of WS cells could 
be gained.14,19   
 
 
 
 
84 
 
2.1.1. RO3201195: Hit-to-lead optimization of a highly selective 
p38 MAPK inhibitor. 
RO3201195 (10) was developed as one candidate in an extensive drug discovery programme led 
by Goldstein et al. at Roche towards the development of novel and selective small molecule 
inhibitors of p38α, for the modulation of TNF-α and IL-β cytokine production.45  
 
HTS at Roche identified the 4-benzoyl-5-aminopyrazole 116 as a new lead in the development 
of potent and selective p38α inhibitors.45 Co-crystallization of 116 with unphosphorylated p38α 
identified a novel hydrogen bonding interaction between the exo-cyclic amine and the side chain 
hydroxyl group of threonine 106, as discussed in Section 1.3.2. It was postulated that this exo-
cyclic amine could bestow significant kinase selectivity to the inhibitor. 
 
Preliminary studies by Goldstein et al. confirmed the importance of the 5-amino group, with 
complete loss of binding affinity for p38α observed for 5-hydroxyl or 5-cyanopyrazole analogues 
(such as 117). Additionally, it was found that only small hydrophobic substituents were tolerated 
on the 1N-pyrazole aryl substituent, with the most favourable group found to be a 4-
Figure 35: Hit-to-lead optimization of 5-aminopyrazole p38 inhibitors.45 
Figure 34: Selective p38α MAPK inhibitor RO3201195 (10). 
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fluorophenyl. Subsequent X-ray co-crystallization studies rationalized this as, when bound to the 
kinase, the phenyl ring slotted into a hydrophobic region at the back of the ATP-binding pocket, 
and so any large or hydrophilic substituents would not be well tolerated.  
Initial stages of lead optimization concentrated on improving the pharmacokinetics (PK) of the 
pyrazole group, as the compounds had been found to be extremely insoluble. Installation of 
ionizable and polar groups connected via linkers at the meta-position of the benzoyl ring were 
found to dramatically improved solubility, but also resulted in severe off-target effects. 
Therefore, the group focused on non-ionizable solubilizing groups, and incorporated amides, 
ethers and alcohols into their scaffold. 
The glycerol based diols 118 and 10 were both found to be extremely potent inhibitors, though 
the (S)-enantiomer (10) demonstrated enhanced PK properties, with higher relative 
bioavailability, a lower rate of clearance, and favourable pharmacodynamics (PD) with a high 
selectivity for p38α against a panel of 105 kinases.  
In pharmacological studies, Goldstein et al. found that RO3201195 (10) decreased production of 
pro-inflammatory cytokines, including TNF-α and IL-β, in a concentration dependent manner in 
vitro and in vivo.  
 
2.1.2. Application in WS cells. 
Continuing their work into the effect of p38α inhibitors on the growth rate of WS fibroblasts (see 
Chapter 1), Bagley et al. sought to verify the activity of RO3201195 (10) and related 5-
aminopyrazol-4-yl ketones as p38α inhibitors in WS cells.258  
An aspect of great interest for the group was to ascertain whether 10 exhibited any off-target 
activity, especially with respect to Jun N-terminal kinases (JNKs). JNKs are another MAPK 
subfamily and a well-known subject of off-target activity for many p38α inhibitors, including 
SB203580 (1) and BIRB 796 (14).10,259 Hence, when using RO3201195 (10) as a probe for p38α 
activity in WS fibroblasts, ascertaining its propensity for off-target activity with other stress-
signalling kinases was an issue of high priority. 
The inhibitors were tested through the use of ELISA and immunoblot assays,ii using telomerase 
immortalized human cells and WStert cells. ELISA assays rely on antibodies which detect the 
                                                          
ii ELISA: Enzyme-linked immunosorbent assay. All biological testing for Bagley et al. BMCL 2008 conducted 
at the Department of Pathology, Cardiff University.258 
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activity of specific kinases and calculate the ratio of phosphorylated kinase to total protein. The 
cells were treated with relevant concentrations of respective inhibitors and activated with 
anisomycin, an antibiotic which up-regulates stress-signalling kinases. Blank and activated 
controls of the cells were grown to provide baseline and maximal activity of the kinases under 
investigation. 
Through the use of ELISA assays on telomerase immortalized human cells, the activity of 
RO3201195 (10) as asserted by Goldstein et al. was verified, with inhibition of anisomycin-
induced activity of p38α observed upon treatment with 10 in a concentration-dependent 
manner.258 Anisomycin-induced JNK activation did not appear to be inhibited. However, no 
definitive target-specific conclusions could be drawn as the ELISA assay could not differentiate 
between JNK1 and JNK2 activation. Hence it was unclear whether 10 exhibited its inhibitory 
effects specific to one of the isoforms of JNK.  
Treatment of WStert cells with RO3201195 (10) was analyzed using Western blot, 
phosphorylation state of anisomycin-activated p38α, MK2 and HSP27 proteins (see Figure 36). 
 
In the immunoblot analysis, the control WS cells (Lane 1) showed low levels of activated p38α 
as assessed by the presence of activated MK2, as indicated by the upper band in the MK2 row. 
This is indicative of the upregulation of this stress-signalling pathway in WStert cells.10  
WStert cells were pre-treated with three different concentrations of 10 before activation with 
anisomycin, and it was found that activity of the p38 stress-signalling cascade was inhibited in a 
Figure 36: Bagley et al.'s Western blot analysis of WStert cells treated with RO3201195 (10). Lane 1: Control cells; Lane 
2: Activated cels; Lane 3-5: Activated WStert cells, pre-treated with 10 at 2.5, 10.0 and 25.0 μM concentration, 
respectively; Lane 6: Activated  WStert cells, pre-treated with SB230580 (1) at 2.5 μM concentration.258  
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concentration-dependent manner, with progressively lower levels of p-HSP27 (phosphorylated 
HSP27) observed across lanes 3 to 5 as the concentration of 10 increased from 2.5 to 25 μM.  
Lane 6 was a comparative immunoblot using the prototypical p38 inhibitor SB203580 (1), to 
observe whether the two different p38α inhibitors affected WS cells in distinct ways. It was 
found that pre-treatment with 10 at 10 and 25 μM concentration exhibited very similar profiles 
to pre-treatment with SB203580 (1) at 2.5 μM (Figure 36, lanes 4, 5 and 6). Very low levels of p-
HSP27 similar to that of control lane 1 were observed, and no activation of MK2, as indicated by 
the lack of the upper band in the MK2 row.258 
From this data, it was inferred that both SB203580 (1) and RO3201195 (10) inhibited the stress-
signalling pathway mediated by p-p38α and MK2 activation in WStert cells; the stress-signalling 
pathway believed to transduce genomic stress in WS cells.10,14  
It was determined that further tests needed to be conducted in order to ascertain whether the 
p38α-selective inhibitor 10 would exhibit the same effect on the rate of WS fibroblast cell 
proliferation observed following treatment with SB203580 (1) (Chapter 1.2), and to determine 
unequivocally whether 10 inhibited either of the JNK isoforms to any significant extent. 
 
2.2. Synthetic routes towards RO3201195. 
Goldstein et al.’s original publication on the discovery, synthesis and biology of RO3201195 (10) 
was not accommodating for replication of the synthesis, with no yields or experimental methods 
given that directly related to the total synthesis of 10.45 Bagley et al. developed their own 
synthetic route towards 10 in order to verify its activity as a p38α inhibitor in WS cells, and 
adopted microwave-assisted techniques to facilitate higher yields and shorter reaction times.258 
For synthesis of their benzoylpyrazole library, Goldstein et al. chose a combinatorial approach, 
with pre-functionalized or functionalizable groups installed on the phenyl ring prior to 
cyclocondensation of the pyrazole. For instance, towards 122 (see Scheme 79), Claisen ester 
condensation of methyl 4-iodobenzoate (119) with acetonitrile (MeCN) gave benzoylacetonitrile 
120, and homologation with N,N-diphenylformamidine afforded enamine 121. 
Cyclocondensation of 121 with a functionalized hydrazine afforded the 1,4-disubstituted-5-
aminopyrazole 122 in high yield.45 
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When a halogen was installed on the aromatic ring, such as in iodinated intermediate 122, 
Goldstein et al. were able to readily functionalize the aryl ring through metal-mediated coupling 
techniques to assess the viability of different substituents and substitution patterns on the 
benzoyl ring for their binding affinity with p38α.  
 
Bagley et al. adopted a similar constructive strategy, forming intermediate 107 through Claisen 
condensation of methyl ester 123 with MeCN and NaOMe (no yields provided). Formylation with 
N,N’-diphenylformamidine provided enamine 124 in 85% yield, after heating to reflux for 2 h in 
dry xylenes. The group adopted microwave-assisted techniques to shorten reaction times and 
improve yields, with irradiation at 180 °C for 20 minutes giving 124 in 90% yield (see Scheme 
80).258 5-Aminopyrazole 125 was synthesized in 86% yield when 124 was irradiated with 4-
fluorophenylhydrazine hydrochloride and NEt3 in ethanol for 1 h at 140 °C. This method was also 
Scheme 79: Goldstein et al.’s synthesis of intermediate 5-aminopyrazoles. Reaction conditions: i) MeCN, n-BuLi, 
DIPA, THF −50 °C, 3 h, 84%; ii) N,N’-diphenylformamidine, toluene, Δ, 8 h, 62%; iii) 4-fluorophenylhydrazine, EtOH, 
Δ, 30 min, 87%.45 
 
Scheme 80: Bagley et al.'s microwave-mediated synthesis of 1,4-disubsituted-5-aminopyrazole 125. Reaction 
conditions: i) MeCN, NaOEt, 80 °C; ii) N,N’-diphenylformamidine, xylenes, MW 180 °C, 20 min, 90%; iii) 4-fluorophenyl 
hydrazine hydrochloride, NEt3, EtOH, MW 140 °C, 1 h, 86%.258 
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used by Bagley et al. in their synthesis of a small pyrazoyl library based upon the RO3201195 
(10) pharmacophore for use as probes in WS cells.1,260  
Functionalization of 125 to RO3201195 (10) was conducted similarly by both Goldstein et al. and 
Bagley et al., though Goldstein did not publish yields or experimental procedures for some steps. 
Protodemethylation of 125 using boron tribromide conducted by Bagley et al. proceeded to give 
a reasonable yield, though subsequent O-alkylation of 126 using an acetal-protected chiral 
glycerol tosylate and acidic deprotection towards 10 suffered from low yields (see Scheme 81). 
Nevertheless, for their purposes, enough material was synthesized to conduct the biological 
tests described in Chapter 2.1.2. 
 
  
Scheme 81: Bagley et al.'s synthesis of RO3201195 (10).258 Reaction conditions: i) BBr3, CH2Cl2, 0 °C to RT, 2.5 h, 59%; 
ii) (S)-L-α,β-isopropylideneglycerol-γ-tosylate, K2CO3, DMF, 80 °C, 24 h, 9%; iii) p-TsOH, MeOH, H2O, 50 °C, 18 h, 
48%.258 
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2.2. Deconstructing RO3201195. 
Over the course of this project several alternative synthetic methods were explored for the 
construction of RO3201195 (10), in addition to adapting the routes tried and tested by Goldstein 
et al. and Bagley et al. Endeavours were made to explore new synthetic methods towards 
intermediates and, when adapting routes used previously in the literature, every effort was 
made to improve yields, and to construct an overall more efficient, streamlined total synthesis 
of 10. 
 
One of the major adaptations explored in an effort to facilitate a more efficient and streamlined 
synthesis was an alternative carbon-carbon bond forming reaction using the metal-mediated 
Mizoroki-Heck coupling (see Figure 37 and Chapter 1.6.3.2.1). 
The spatial arrangement of substituents on the pyrazole pharmacophore is extremely important 
for optimal ligand-kinase interactions with p38α. There are many methods to synthesize 
pyrazoles; however for this specific substitution pattern there are a limited number of routes 
available (see Chapter 1.6.2.1). 
 
  
Figure 37: Retrosynthetic strategy for the synthesis of RO3201195 (10). Proposed Mizoroki-Heck aryl cross-
coupling and pyrazole constructive strategy. 
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2.3. Synthesis of RO2301195. 
2.3.2. Benzoylacetonitrile synthesis. 
As mentioned in Chapter 1.6.3.2, it was hypothesized that rather than adopting traditional 
Claisen condensation chemistry towards benzoylacetonitrile 107, an alternative route was 
proposed through the use of palladium-mediated Heck coupling of iodoanisole 127 and 
acrylonitrile 128 (see Scheme 82).   
 
It was predicted that coupling would occur at the α-position of the alkene to generate an 
intermediate enol ether, with subsequent acidic hydrolysis of the coupled product affording the 
desired benzoylacetonitrile 107.196 
 
2.3.2.1. Application of Heck coupling towards the synthesis of 
benzoylacetonitriles. 
For the desired coupling of 3-iodoanisole 127 and 3-methoxyacrylonitrile 128, it was found that 
Jeffery’s conditions had been used to great effect for related acrylonitriles197 and α-
methoxyacrylates261 using TBAB, Pd(OAc)2 and an inorganic base in an aqueous-solvent 
mixture.211 Coupling trials using this system were conducted to test the feasibility of the 
reaction.  
Scheme 83: Heck coupling of 3-iodoanisole 127 and 3-methoxyacrylonitrile 128. Reaction conditions: i) Pd(OAc)2 
(10 mol%), TBAB (10 mol%), K2CO3 (2 equiv.), MeCN-H2O (3:1), MW 130 °C, 1.5 h; ii) conc. HCl-MeOH (1:4), MW 110 
°C, 30 min, 20%. 
Scheme 82: Proposed Heck coupling towards intermediate benzoylacetonitrile 107. Reaction conditions: i) Heck 
coupling conditions; ii) acidic hydrolysis. 
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3-Iodoanisole was reacted with an excess of 3-methoxyacrylonitrile in an MeCN-H2O mixture 
using Pd(OAc)2 (10 mol%) catalyst, TBAB (10 mol%) additive, and two equivalents of K2CO3 base. 
The reaction mixture was irradiated using microwave-assisted dielectric heating to 130 °C in a 
sealed vessel for 1.5 h (see Scheme 83). Formation of the desired α-aryl enol ether 129 was 
confirmed by 1H NMR spectroscopic analysis, after aqueous work up, as a mixture of (E)- and (Z)-
diastereoisomers in an approximate 2:1 ratio (see Figure 38).  
 
The diastereoisomers could be separated by flash column chromatography, though they were 
isolated in variable and poor yield. The two diastereoisomers were differentiated by two-
dimensional 1H NMR spectroscopic NOSEY analysis (see Figure 39) and by reference to similar 3-
aryl-3-ethoxyacrylonitriles in the literature.201  
The mixture of diastereoisomers and poor isolated yield were not anticipated to be an issue for 
the total synthesis of RO3201195 (10) as it was intended that the crude material would be 
hydrolyzed directly to form benzoylacetonitrile 107.  
Figure 38: Crude 1H NMR spectrum (500 MHz, CDCl3, δH 5.5 - 4.0 ppm) illustrating the two alkenyl protons of 
the (E)- and (Z)-isomers of 129. Integration of peaks gives the diastereomeric ratio as approximately 2:1. 
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Unexpectedly, it was found that the enol ether intermediate 129 was quite stable under typical 
acidic hydrolysis conditions. Doucet and Santelli worked with α- and β-disubstituted enol ethers 
when exploring the utility of a new tetraphosphane/palladium complex for Heck arylations, 
including β-methoxystyrene (130), methyl 3-methoxyacrylate (131) and 3-ethoxyacrylonitrile 
(132) (see Scheme 84).196 They successfully synthesized the α-enol ether intermediates of all 
derivatives and hydrolyzed them to the 1-arylpropanones under relatively mild conditions, using 
a THF/H2O/HCl mixture.201 However, it was notable that they did not hydrolyze the 3-aryl-3-
alkoxyacrylonitriles. 
 
 
 
Figure 39: 1H NMR 2D NOSEY experiment (X-axis δH 8 - 6.5 ppm, Y-axis δH 5.5 - 3 ppm). (Z)-isomer of 129 identified 
from through-space interaction of alkenyl proton at δH 4.93 ppm and the ortho-benzoyl protons at δH 7.11 and 7.06 
ppm. 
Scheme 84: Doucet and Santelli's Heck reaction to form benzoylacrylates. Reaction conditions: i) [Pd(C3H5)Cl]2/0.5 
Tedicyp, DMF, NaHCO3, 150 °C; ii) HCl or H2SO4, THF, H2O, 25 °C.196 
94 
 
Towards benzoylacetonitrile 107, the diastereomeric mixture of 129 was eventually hydrolyzed 
successfully using microwave-assisted dielectric heating of the crude mixture, after aqueous 
work up, at 110 °C for 30 minutes in a solution of concentrated HCl and MeOH. Application of 
this method to the aforementioned crude material, gave modest yields of 107 after purification 
by flash column chromatography over the two steps (Table 1, entry 4, 20%).  
 
Under conductive heating conditions the viability of the popular inorganic bases K2CO3 and 
NaHCO3 were assessed.197,201,211,261 After 24 h at 90 °C using the above mentioned conditions 
there was some improvement in the yield over the microwave-assisted conditions, with K2CO3 
giving a modest yield (Table 1, entry 1, 36%) and a slight improvement over NaHCO3 (entry 2, 
34%). 
Microwave-assisted heating in a sealed tube at elevated temperatures was further probed. With 
K2CO3 as the base, irradiation at 130 °C for 1 h (entry 3, 26%) and 1.5 h (entry 4, 20%) gave lower 
yields compared to the conductive heating route. The use of NaHCO3 improved the yield 
modestly under microwave-assisted heating (entry 5, 37%), comparable to those yields achieved 
under conductive heating. Raising the reaction temperature to 140 °C was found to be 
detrimental to yields (entry 6).  
A ligated system using the bidentate ligand 1,3-bis(diphenylphosphine)propane (DPPP) was also 
investigated. After irradiation at 150 °C for 1.5 h and the established acidic work-up, a lower 
Table 1: Heck reaction conditions for the synthesis of benzoylacetonitrile 107 (Scheme 83).a 
Entry Time (h) Base Additive Temp (°C) % Yieldb 
1 24 K2CO3 TBAB 90c 36 
2 24 NaHCO3 TBAB 90c 34 
3 1 K2CO3 TBAB 130d 26 
4 1.5 K2CO3 TBAB 130d 20 
5 1.5 NaHCO3 TBAB 130d 37 
6 1 K2CO3 TBAB 140d 19 
7 1.5 K2CO3 DPPP 150d 31 
a Reaction conditions: 3-Iodoanisole (127) (1 equiv.), 3-methoxyacrylonitrile (128) (4 equiv.), base (2 equiv.), 
additive (10 mol%) and Pd(OAc)2 (10 mol%) in MeCN:H2O (3:1) under given conditions. 
b Isolated yield after aqueous work-up, microwave irradiation at 110 °C for 30 min in conc. HCl- MeOH (4:1) and 
purification by flash column chromatography. 
c Conductive heating.  
d Microwave dielectric heating. Held at temperature for indicated length of time through modulation of the initial 
power (150 W). 
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yield was achieved than the ligand-less systems (entry 7, 31%), corroborating that Jeffery’s 
conditions were better suited for this coupling reaction.  
These studies illustrated that, though a Heck-mediated synthetic route towards 107 was viable, 
the additional step required for hydrolysis, and the modest yields achieved (Table 1, entry 5, 
37%), did not support this method as the most efficient route for the synthesis of RO3201195 
(10). Therefore, alternative methods were explored for their utility and compared with the Heck-
mediated route. 
 
2.3.1.4. Claisen condensation routes for the synthesis of 
benzoylacetonitrile. 
A more traditional Claisen condensation approach, akin to those adopted by Goldstein et al. and 
Bagley et al. in their total syntheses, was acknowledged as potentially a more efficient route 
towards the benzoylacetonitrile 107. 
Following the route illustrated in Scheme 85, Fischer esterification of 3-methoxybenozic acid 
(134) gave methyl 3-methoxybenzoate (123) in excellent yields (90%) after heating to reflux with 
MeOH and catalytic sulfuric acid (H2SO4) for 3 h. Yields were improved upon subjecting the same 
reaction mixture to microwave-assisted heating in a sealed vessel at 110 °C for 10 minutes (94%).  
 
Traditional Claisen condensation of methyl ester 123 had been explored by previous members 
of our research group using NaOMe or NaOEt as base to generate the acetonitrile anion. 
However, the immediate formation of intractable mixtures upon addition of the base frustrated 
these attempts and gave poor yields of the product (9%).1 
In order to improve this method two alternative, stronger bases were explored for the formation 
of the acetonitrile anion. Use of sodium hydride (NaH) in dry toluene and heating to 90 °C for 16 
Scheme 85: Fischer esterification and Claisen condensation for the synthesis of benzoylacetonitrile 107. Reaction 
conditions: i) Catalytic conc. H2SO4, MeOH, MW 110 °C, 10 min, 94%; ii) n-BuLi, DIPA, MeCN, THF −50 °C, 3 h, 70%. 
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h gave 107 in 34% yield after aqueous work-up and purification by flash column 
chromatography. Further improvements were achieved with in situ formation of the bulky base 
lithium diisopropylamine (LDA), from the reaction of n-butyl lithium (n-BuLi) and 
diisopropylamine (DIPA) at −50 °C. Slow addition of dry MeCN, followed by methyl 3-
methoxybenzoate (123), and stirring at −50 °C for 3 h gave the desired benzoyl acetonitrile 107 
in 70% yield after purification.  
Given the improved yield and efficiency of this two-step approach, compared to the Heck 
coupling route, it was decided that the esterification-condensation method would be adopted 
to access the key benzoylacetonitrile intermediate. 
 
2.3.2. Pyrazole formation. 
The central 1,4-disubsituted-5-aminopyrazole scaffold of 10 was synthesized via a homologation 
and cyclocondenation strategy (see Scheme 86). A slight excess of N,N’-diphenylformamidine 
was used to conduct a Knoevenagel-type condensation with 107. Microwave-assisted heating in 
a sealed vessel at 180 °C for 20 minutes in dry xylenes gave enamine 124 in 74% yield after 
trituration with hexanes. Identification of the product was confirmed by 1H NMR spectroscopic 
analysis, with a distinct loss of the methylene CH2 protons of 107, seen previously at δH 4.07 
ppm, and addition of the enamine NH proton broad resonance downfield at δH 12.76 ppm (in 
CDCl3). 
 
Enamine 124 was reacted with 4-fluorophenylhydrazine hydrochloride with catalytic amounts 
of NEt3, mediated by microwave-assisted heating in a sealed vessel at 140 °C for 1 h, to afford 
pyrazole 125 in high yield (86%) after purification by flash column chromatography. The yield 
achieved was an improvement on that quoted by Bagley et al. for the same reaction conducted 
on a similar scale (124 mg; 68%).258 
Scheme 86: Synthesis of pyrazole scaffold 125. Reaction conditions: i) N,N’-Diphenylformamidine, dry xylenes, MW 
180 °C, 20 min, 74%; ii) 4-fluorophenylhydrazine hydrochloride, NEt3, EtOH, MW 140 °C, 1 h, 86%. 
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2.3.3. O-Alkylation and diol installation. 
In order to functionalize the benzoyl ring, the methoxy protecting group was cleaved to expose 
the phenol group of 126. Traditional ether deprotection methods can be very harsh, including 
conditions such as refluxing in HBr.262 In order to improve functional group tolerance, milder 
deprotective strategies have been developed, employing nucleophilic displacement routes such 
as base-mediated reactions with thiols and mildly Brønsted acidic and Lewis acidic techniques.262 
Boron tribromide (BBr3) is a popular Lewis acidic reagent for protodemethylation of aryl methyl 
ethers that can operate at or below room temperature, and has a high tolerance for other 
functional groups. Thus it was decided that BBr3 would be used for the penultimate step of the 
synthesis. 
The mechanism for protodemethylation using BBr3 is generally thought to occur via 
complexation of the strongly Lewis acidic boron with the methoxy lone pair, which on formation 
of an alkyl bromide gives the ether-BBr2 adduct. Hydrolysis of this adduct then affords the 
desired phenol. However, new evidence has suggested a bimolecular reaction pathway, wherein 
two ether-BBr2 adducts interact to effect the same outcome.263 This suggests that more sterically 
hindered methyl ethers may not be amenable to BBr3-mediated protodemethylation. 
Aryl methyl ether 125 was subjected to an excess of BBr3 in dry CH2Cl2 and stirred at room 
temperature under argon for 20 h to afford phenol 126 in quantitative yields after aqueous work 
up (Scheme 87). 
 
Scheme 87: Protodemethylation of 125 with BBr3. Reaction conditions: i) BBr3 (1 M in CH2Cl2), 0 °C - RT, 20 h; ii) 
aqueous work up, quant. 
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O-Alkylation was conducted through an SN2 displacement reaction with (S)-2,2-dimethyl-1,3-
dioxolan-4-ylmethyl p-toluenesulfonate (135) under basic conditions (see Scheme 88). This 
reaction had been reported to occur in very low yield by Bagley et al. in their 2008 publication 
(9%).258 However, by changing the solvent from DMF to DMSO and heating the reaction mixture 
to 100 °C for 25 h, it was possible to isolate 136 in a much increased 42% yield. However, there 
were still issues which complicated the reaction. 
 
The tosylate 135 was a viscous liquid and was used in excess to promote the reaction, hence it 
was found that the crude product was quite gelatinous. After flash column purification on silica 
gel and confirmation of purity by 1H NMR spectroscopic analysis, the product still tended to be 
quite gelatinous in nature. Recrystallization from hot EtOAc returned 136 as a colourless 
powder, though this led to a significant loss of material and no improvement in purity by 1H NMR 
spectroscopic analysis. Therefore, it was decided that for the final step of the synthesis, 136 
would be carried forward once determined pure by 1H NMR spectroscopic analysis. 
Deprotection of the diol was completed using para-toluenesulfonic acid monohydrate in a 
MeOH-water solution. Heating at 50 °C for 18 h, purification by flash column chromatography 
and recrystallization gave final product RO3201195 (10) in 37% yield over two steps. Comparison 
of spectroscopic data with the literature confirmed product formation. 
 
2.3.4. Conclusion. 
RO3201195 (10) was successfully synthesized over seven steps in an overall yield of 15%. A new 
palladium-mediated route towards β-ketonitriles was developed using microwave-assisted 
heating, albeit in low yield. Alternative classical condensation methods were found to be more 
suitable for the total synthesis of RO3201195 (10) and were achieved in high yield. The scale of 
Scheme 88: O-Alkylation and deprotection to RO3201195 (10). Reaction conditions: i) 135, K2CO3, DMSO, 100 °C, 40 
h ii) p-TSA.H2O, MeOH-H2O, 50 °C, 18 h, 37%. 
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reactions carried out and the overall yield of the synthetic process were improved compared to 
previously published data, and the target compound was synthesized in sufficient purity for 
biological studies, as ascertained by comparison with previous data.1 
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2.4. Biological studies of RO3201195 in WS cells. 
Bagley et al. verified RO3201195 (10) to be a potent p38α inhibitor in WS cells, albeit with a 
lower potency than SB230580 (1).258 In collaboration with Dr Terence Davis at Cardiff University, 
the aim of these new biological studies was to investigate what effect, if any, 10 had on the rate 
of proliferation of WS cells. It was hoped that direct comparison of results with prototypical p38 
MAPK inhibitor SB203580 (1) would help advance understanding of the role of the p38α-
mediated stress-signalling pathway in the premature ageing phenotype of WS cells.iii 
Due to limited supplies of primary WS cells, initial biological tests were conducted on WStert cells, 
which should demonstrate similar rates of proliferation as primary WS cells, and hence 
demonstrate similar responses when treated with p38α inhibitors.  
Firstly, the optimal concentration of each inhibitor to effect total inhibition of p38α was 
determined for WStert cells. This was done by growing WStert cells in a medium of each inhibitor 
and monitoring the extent of protein activation by ELISA. For SB203580 (1) the optimal 
concentration was found to be 1 μM and above, and 10 μM for RO3201195 (10).1 The higher 
optimal concentration of 10 was due to a lower intrinsic potency for p38α in WStert cells than 
SB203580 (1). However, this lower potency was not of concern for these studies as 10 was only 
being used as a probe in vitro.  
Observing the rate of proliferation for WStert cells grown in the presence of SB203580 (1) at 2.5 
μM concentration, the rate of growth increased by approximately 22% compared to DMSO 
control cells. For RO3201195 (10) at 10 μM concentration, the rate of proliferation also 
increased, with a 19% increase compared to DMSO controls.1 
Figure 40 illustrates the rate of cell proliferation as % p38 activity against % population growth 
of WStert cells. The sigmoidal curves recorded for SB203580 (1) and RO3201195 (10), at 2.5 and 
10 μM respectively, were almost identical. This indicated that as the p38 activity in the cells 
decreased the rate of population growth increased. This data confirmed the contributory role of 
p38α MAPK in reducing the rate of cell proliferation in WS cells. 
                                                          
iii Biological testing as conducted by Dr Terence Davis, Institute of Cancer and Genetics, Cardiff University. 
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SB203580 (1) has been noted to have off-target activity with JNKs, another stress-signalling 
kinase family which could potentially play a role in the premature ageing seen in WS fibroblasts. 
Western blots were completed in order to ascertain whether inhibition of JNKs occurred at the 
maximal concentrations established in these studies. Figure 41 illustrates the blots, in which the 
extent of activation of phosphorylated-HSP27 (p-HSP27), HSP27, phosphorylated JNK (p-JNK) 
and JNK were monitored upon treatment with the optimal concentrations of SB203580 (1) and 
RO3201195 (10), with blank control cells and activated cells grown in DMSO for comparison. 
 
Figure 40: Plot of % p38 activity against % population growth for WStert cells growth in 2.5 μM SB203580 (1) 
and 10 μM RO3201195 (10) concentration.1 
 
Figure 41: Western blot of RO3201195 (10) and SB203580 (1) against WStert cells. Blot key; C: Control, run in DMSO; 
A: run in DMSO and activated with anisomycin. RO 2.5 and RO 10; cells run at 2.5 μM and 10 μM RO2301195 (10); 
SB 2.5: cells run at 2.5 μM SB203580 (1).1 
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From the blot it could be seen that p-HSP27 was greatly reduced when the WStert cells were pre-
treated with RO3201195 (10) at 10 μM and with SB230580 (1) at 2.5 μM, matching the profile 
of the lane 1 control. This confirmed that the p38α-mediated stress-signalling pathway was 
being inhibited at these concentrations. It can also be seen that there was no inhibition of JNK 
signalling at any inhibitor concentration, with lanes 3-5 all showing the same extent of p-c-JNK 
and c-JNK activation as the anisomycin-activated control in lane 2. 
From this evidence it can be concluded that inhibition of JNK was not responsible for the 
increased rates of proliferation observed in these studies.1  
Investigation into the the effect of treatment with RO3201195 (10) and SB203580 (1) on the 
aged morphology of WS cells at the established optimal concentrations was then conducted. A 
primary strain of WS fibroblasts that was determined close to replicative senescence was treated 
with SB203580 (1) and RO3201195 (10), at 2.5 and 10 μM concentrations, respectively. The cells 
were fed the optimal concentrations of the inhibitors and left for 88 days (Figure 42). 
 
A control sample of DMSO-fed primary WS fibroblasts was observed to only undergo one 
population doubling in this time. On the other hand, the inhibitor-treated cells had a much 
increased rate of proliferation, reaching 7.5 population doublings before growth arrest, with 
essentially no difference in the rate of growth between the two inhibitors.1 
Figure 42: Proliferation of primary WS fibroblasts in the presence of SB203580 (1)  at 2.5 μM and RO3201195 (10)  at 
10 μM, measured as population doublings against days.1  
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The two p38α inhibitors SB230580 (1) and RO3201195 (10) demonstrate very different kinase 
selectivity profiles, with p38α being the only common target. Hence, it can be inferred that the 
remarkably comparable effect of these two inhibitors upon the rate of proliferation of primary 
WS cells must result from inhibition of the p38α MAP kinase.  
 
2.5. Overall conclusions and future perspectives. 
A new synthetic route towards p38 inhibitor RO3201195 (10) and its intermediates has been 
developed, with an improved overall yield over preceding published routes and an increased 
efficiency established through the use of microwave-assisted heating in a number of the steps. 
Biological testing of RO3201195 (10) established an astounding correlation in activity with the 
prototypical p38 inhibitor SB203580 (1) in WS cells. Comparative studies conducted at the 
lowest optimal concentrations of the two inhibitors found that the two inhibitors demonstrated 
almost identical profiles to increase the rate of cell proliferation of WStert cells and extended the 
replicative lifespan of primary WS cells. Off-target JNK inhibition by SB203580 (1) has been 
disproven as a contributing factor in effecting the increased replicative life span of WS cells at 
the concentrations used in these studies; confirming that the results observed were due to 
inhibition of the p38 stress-signalling pathway. 
These studies demonstrated that RO3201195 (10) can be adopted as a very useful chemical tool 
to investigate the stress-signalling pathways of human cells, to corroborate results of alternative 
p38α inhibitors and to help further our understanding of the effects of p38α inhibitors on cell 
proliferation in WS and progeroid fibroblasts. 
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Chapter 3. Synthesis of PF-3644022. Probing 
an MK2 inhibitor for the modulation of 
cellular ageing in WS cells. 
 
3.1. Introduction. 
Having found that inhibition of p38α positively affects the proliferation rate of WS cells, it was 
desirable to gain a better understanding of the mechanism by which this occurs. One method 
proposed was to target kinases downstream of p38. However, as mentioned in Chapter 1.3, p38 
mediates a number of important stress-signalling pathways.  
MK2 mediates activation of the small heat shock protein HSP27 (see Chapter 1.4),19 which 
regulates and stabilizes the actin-cytoskeleton and production of F-actin stress fibres.57 These 
fibres have been found to be up-regulated in senescent WS cells and greatly reduced in WS cells 
grown in the presence of the p38α inhibitor SB203580 (1).14,264 These findings support MK2 as a 
key kinase in the p38α-mediated pathway inhibited by SB203580 (1).  
MK2 presents itself as a therapeutically viable target as MK2 knockout mice exhibit normal 
healthy phenotypes, while p38 knockout mice are lethal.59 A variety of MK2 inhibitors have been 
developed spanning a range of chemotypes,22 though most tend to exhibit poor activity in 
cellular models and in vivo (see Chapter 1.4).69 The benzothiophene based MK2 inhibitor PF-
3644022 (25) however possesses nanomolar potency, good projected ADME characteristics and 
selectivity against a panel of 200 kinases.68,69 It was therefore proposed that the MK2 inhibitor 
Figure 43: MK2 inhibitor PF-3644022 (25).68 
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PF-3644022 (25) should be synthesized and used to investigate the role of MK2 in the premature 
senescence of WS cells.  
Efforts were made to design a novel, rapid and efficient route towards the inhibitor, ready for 
testing in normal human cells and WS cells to assess its viability as a selective MK2 inhibitor, and 
its effect, if any, upon the rate of proliferation of primary WS cells.  
 
3.1.1. Hit-to-lead identification of PF-3644022 (25). 
Anderson et al. at Pfizer completed a number of projects towards the development of MK2 
inhibitors as therapeutics for inflammatory conditions, such as rheumatoid arthritis (RA) and 
Crohn’s disease. Their specific target of interest was to inhibit production of TNF-α, a cell-
signalling cytokine modulated by MK2.59  
PF-3644022 (25) arose from an SAR-led investigation of a new benzo[b]thiophene-based 
chemotype 24 that had not been previously explored towards inhibition of MK2, though it 
shared a number of pharmacophoric similarities to previous MK2 inhibitors (see Chapter 1.4, 
Figure 16).59,62,66,265–267  
 
Anderson et al. synthesized 24 through cyclization of 3-methoxycinnamic acid with thionyl 
chloride (SOCl2) to afford the 3-chlorobenzo[b]thiophene intermediate 72 (see Chapter 
1.6.2.4.1, Scheme 33).67 Buchwald-Hartwig N-arylation of the chloride with a chiral mono-Boc-
protected diamine (137) and subsequent deprotection and lactamization gave the cyclized 
benzothiophene lactam 24. Carbon and sulfur analogues of the lactam ring and alternative 
Scheme 89: Synthesis of benzothiophene-based scaffold 24. Reaction conditions: i) SOCl2, chlorobenzene, 120 °C 
then MeOH; b) Pd2(dba)3, (±)-BINAP, Cs2CO3 toluene, 110 °C, 24 h, then TFA/CH2Cl2 and NaOMe/MeOH.67 
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functionalities at the 3-position were used to explore the inhibitor SAR with MK2 (see Figure 
44). 
 
Nitrogen-containing rings demonstrated enhanced binding to MK2, though by X-ray co-
crystallization studies there were no direct amino acid interactions that could be observed. It 
was postulated that the nitrogen was modulating electron density through the thiophene π-
system to enhance HBA properties of the carbonyl group.67  
Substitution at the 3-position of the diazepinone was explored, with the (R)-enantiomers found 
to be about 10-fold more potent inhibitors for MK2. Introduction of a heteroatom onto the 
substituted chain (138 and 139) was found to improve potency of binding with MK2, though cell 
permeability and cell potency were found to be dramatically reduced.67  
Hydrogen bonding of the methoxy group of 24 was determined to be an essential interaction 
for binding with the hinge region of MK2. Based upon previous work,59 Anderson et al. 
speculated that interaction with the hinge region of the kinase may be enhanced through a more 
rigid structure, hence the group proceeded to synthesize a small collection of furan and pyridine 
analogues of 24 (see Figure 45). 
Figure 44: Fused benzothiophene-lactam compounds explored for MK2 inhibitor viability by Anderson et al.67 
Figure 45: Anderson et al.'s heteroaromatic fused ring systems, exploring inhibitor binding to the hinge region of 
MK2.68 
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The group found that when a fused furan system was incorporated (140) there was a significant 
increase in potency of binding with MK2 compared to 24. In an effort to improve inhibitor 
selectivity, a 2-phenyl ring was introduced onto the furan (141). However, it was found that 141 
exhibited reduced cell and inhibitor potency. 
For the pyridine analogues 142 and 143 there was a similar reduction in cell and inhibitor 
potency upon addition of a phenyl ring, though the reduction was much less severe and an 
increased specificity for MK2 over other structurally similar kinases was observed.68  
To synthesize pyridine analogues 142 and 143, the group started from a 6-nitroquinoline, 
converting it to 6-amino-5-cyanoquinoline (144) using ethyl cyanoacetate and potassium 
hydroxide (KOH) (see Scheme 90). Deaminative bromination via diazotization of the amine 
enabled benzo[b]thiophene (145) formation through cyclocondensation with methyl 
thioglycolate under basic conditions. A second deaminative bromination step was carried out to 
give the Buchwald-Hartwig precursor 146, which was then coupled with the desired Boc-
protected amine (137). Acidic Boc-deprotection, and lactamization under basic conditions 
afforded the final cyclised product 142. 
 
In order to synthesize the biaryl pyridine analogue 143, Anderson et al. settled upon a Suzuki-
Miyaura cross-coupling approach. N-Protecting groups were installed on the diazepinone ring, 
and the pyridine ring was oxidized to the pyridine N-oxide 146 using mCPBA, and functionalized 
to 2-chloropyridine 147 using oxalyl chloride ((COCl)2) followed by Boc-deprotection. Suzuki 
coupling was carried out using phenylboronic acid under basic conditions to give 142 (see 
Scheme 91). 
Scheme 90: Synthesis of fused pyridine-benzothiophene analogue 142. Reaction conditions: i) Ethyl cyanoacetate, 
KOH, DMF, then HCl; ii) NaNO2, then HBr; iii) Methyl thioglycolate, NaOMe MeOH; iv) tBuONO, CuBr2; v) Buchwald 
Hartwig conditions, 137, acidic deprotection and basic cyclization.68 
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Analogues of 143 were explored by coupling the advanced 2-chloropyridine intermediate 148 
with a variety of aromatic rings, through which PF-3644022 (25) was identified as the most 
promising drug candidate, with nanomolar potency for MK2.68 
Since initial publication of its biological activity, 25 has been of major interest as a probe to 
delineate the mechanisms of stress-signalling in the body and as a potential therapeutic for 
inflammatory conditions.  
 
3.1.2. Deconstructing PF-3644022 (25). 
The synthetic route published by Anderson et al. for PF-3644022 (25) was driven from lead 
optimization, with functionalization of a late-stage intermediate affording their candidate 
compound. It was proposed that a more streamlined total synthesis of 25 could be designed. 
 
Scheme 91: Synthesis of biaryl phenyl-pyridine fused analogue 143. Reaction conditions: i) Boc2O, DMAP, NEt3 then 
mCPBA; ii) (COCl)2, DMF, then HCl; iii) PhB(OH)2, Pd(PPh3)4, Na2CO3, 80 °C.68 
Figure 46: Key heterocycles of PF-3644022 (25). 
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Over the course of this project a number of retrosynthetic approaches were investigated. Each 
one utilized a different heterocyclic component of the core scaffold and explored how it could 
be functionalized and built-up to the target compound.  
There are three main heterocycles which are fused or linked together to form PF-3644022 (25): 
a pyridine, quinoline and benzothiophene (see Figure 46). Each of these has been discussed in 
Chapter 1.6.2. To diversify the main heterocyclic scaffold, a number of essential carbon-carbon 
and carbon-heteroatom bond-forming reactions were used over the course of this project, 
including Suzuki-Miyaura cross-coupling, Buchwald-Hartwig N-arylation and amide bond 
formation (see Figure 47). These reactions have been discussed in detail in Chapter 1.6.3. 
 
A number of different disconnective strategies presented themselves as viable options for the 
synthesis of PF-3644022 (25). Though not all were successful in affording the final product due 
to issues of reactivity, reproducibility and tractability of intermediates, through each iteration 
of the synthesis a cumulative knowledge was accrued which led to an overall diverse and 
innovative route towards PF-3644022 (25). Each of these routes will be discussed in turn. 
 
  
Figure 47: Key bond-forming reactions in approaches towards PF-3644022 (25). 
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3.2. Retrosynthesis 1. Quinoline based scaffold. 
The initial route explored was closely related to Anderson et al.’s synthetic route towards 
pyridine-fused benzothiophene 142. It was proposed that the total synthesis could be 
streamlined through installation of the biaryl unit using Suzuki coupling at the beginning of the 
reaction (see retrosynthetic Scheme 92).  
 
It was anticipated that the thieno ring could be installed on the quinoline in a manner similar to 
Anderson et al., with aspirations to incorporate microwave-assisted techniques to reduce 
reaction times and improve yields. Final stage N-arylation and lactamization of the chiral amine 
would then negate the need for additional protective steps, to deliver the final enantiopure 
product. 
 
3.2.1. Chloroquinoline synthesis and Suzuki coupling. 
Suzuki precursor 151 was synthesised through nitration of 3,4-dihydroquinol-2(1H)-one (149), 
using a concentrated HNO3/H2SO4 mixture to give 150 in high yield,iv and subsequent tandem 
chlorination and oxidation with POCl3 in the presence of 2,3-dichloro-5,6-dicyano-p-
benzoquinone (DDQ) (see Scheme 93). 
                                                          
iv Step completed and yields given for result obtained by Dr Irina Chuckowree.3 
Scheme 92: Retrosynthesis 1. Quinoline based scaffold with early stage Suzuki coupling. 
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Microwave-assisted Suzuki-Miyaura cross-coupling was completed using 3-pyridineboronic acid 
to test viable conditions. Using PdCl2(PPh3)2 catalyst and Na2CO3 base in MeCN-H2O, microwave-
assisted heating at 140 °C in a sealed vessel for 15 minutes gave the biaryl cross-coupled product 
152 in reasonable yield. Thus the reaction was completed using 6-methylpyridin-3-boronic acid 
under the same conditions to give 153 in very agreeable yield (69%). Given the satisfying results 
of this catalytic system, no others were probed.  
 
3.2.2. Synthesis of 6-amino-5-cyanoquinoline intermediates.   
In order to facilitate formation of the fused thieno ring, the nitroquinoline needed to be 
functionalized. Anderson et al. adopted Yamazaki et al.’s vicarious nucleophilic substitution 
method of nitration and reduction using ethyl cyanoacetate under basic conditions.68,268,269  
However, it was found after reacting 153 with ethyl cyanoacetate, KOH  and DMF for 72 h at 
room temperature, with subsequent hydrolysis in 5% NaOH aqueous solution, only trace 
amounts of the desired product 154 were collected after purification by flash column 
chromatography (see Scheme 94).  
  
Scheme 93: 2-Chloroquinoline synthesis and Suzuki coupling. Reaction conditions: i) HNO3, H2SO4, 0 °C, 15 min, 93%; 
ii) POCl3, DDQ, DMF, RT, 1 h, 97%; iii) Pyridinyl-boronic acid, Na2CO3, PdCl2(PPh3)2, MeCN-H2O, MW 140 °C, 15 min. 
Scheme 94: Cyanation of nitroquinolines. Reaction conditions: i) Ethyl cyanoacetate, KOH, DMF, RT, then 5% NaOH, 
H2O, Δ, 3h.268,269 
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This meagre yield was unexpected given the apparent ease of use in Anderson et al.’s 
synthesis.67 It was speculated that under basic conditions, the acidity of the 2-methylpyridine 
group of 153 may have impacted the reaction unfavourably. Hence, related substrates were 
investigated for their viability under the same reaction conditions (see Scheme 94).  
Unsubstituted biaryl 152 was reacted under the same conditions and only a trace of product 155 
was observed by 1H NMR spectroscopic analysis. The 6-nitroquinolone intermediate 150 was 
found to be inert under the reaction conditions, and the chlorinated intermediate 151 afforded 
a complex mixture of products after 64 h and subsequent hydrolysis, with none of the desired 
product 156 observed to be present.  
As a control, the reaction was conducted on 6-nitroquinoline 157 using the same conditions and 
reagents. After purification, a 72% yield of 6-amino-5-cyanoquinoline 144 was achieved 
confirming the reaction was a viable method of cyanation, though it appeared to be 
incompatible with the 6-nitro-2-pyridinylquinolines 152 and 153 and their earlier intermediates.  
Potential reasons why this method was not viable for the biaryl-pyridine-quinoline compounds 
could include deprotonation of 153, resulting in a mixture of side products under the reaction 
conditions, competing reaction of the pyridine ring or deactivation of the nitro group as an 
ortho-director (see vicarious nucleophilic addition, Chapter 1.6.2.3.2), perhaps through 
complexation. Nevertheless, this method was deemed inappropriate for the total synthesis of 
PF-3644022 (25), and thus alternative disconnective strategies were investigated. 
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3.3. Retrosynthesis 2. Thieno[3,2-f]quinolone scaffold. 
Reviewing the heterocyclic analysis of PF-3644022 (25), it was postulated that the next viable 
strategy would be to start from the benzo[b]thiophene ring 158 (see retrosynthetic Scheme 95). 
As has been discussed, it is possible to synthesize quinolones and quinolines from anilines 
through intramolecular EAS (see Chapter 1.6.2.3.). It was proposed that an intermediate fused 
thienoquinolone system 160A could be built via intramolecular EAS from 159. Chlorination 
would then give chlorothienoquinoline 161 ready for Suzuki coupling. Installation of the 
diazepinone ring was proposed for the closing steps of the synthesis through halogenation of 
the benzothiophene, to enable Buchwald-Hartwig N-arylation and lactamization as the final step 
to give 25. 
 
Mid-stage Suzuki-coupling by this route would still avoid any additional protective steps for the 
diazepinone ring, though it was recognized at the outset that there was the potential for 
regioselectivity issues during the cyclization step from 159 to 160A, with potential formation of 
the alternative thienoquinolone 160B. 
Scheme 95: Retrosynthesis 2, via thienoquinolone based scaffold.  
114 
 
3.3.1. Thienoquinolone synthetic route. 
The first approach to the thienoquinoline scaffold was completed in the group by Dr Irina 
Chuckowree, as illustrated in Schemes 96 and 97, but has a bearing on our approach.v 
Benzo[b]thiophene 162 was synthesized by cyclocondensation of methyl thioglycolate and 2-
chloro-5-nitrobenzaldehyde under basic conditions in high yield (93%). Reduction of the nitro 
group using palladium on charcoal (Pd/C) under an atmosphere of hydrogen gave 158 in 
quantitative yields, and subsequent amide bond formation with 3-ethoxyacrylic acid was 
completed using peptide coupling reagents EDCI.HCl and HOBt at room temperature to give 159 
in reasonable yields (63%).  
 
Subsequent thienoquinoline formation was conducted under Knorr-carbostyril cyclization 
conditions, stirring in conc. H2SO4 at 0 °C and warming to room temperature over 3 h (see 
Scheme 97).109 Quantitative conversion to the quinoline was obtained, with a mixture of the two 
regioisomers in an 88:12 ratio in favour of the desired thieno[3,2-f]quinoline 160A, as 
ascertained by 1H NMR spectroscopic analysis (see Scheme 97).  
The crude mixture was subjected to chlorination by heating to reflux in POCl3 for 3 h, and the 
desired chloroquinoline 161 was isolated from its regioisomer in reasonable yields after 
purification by flash column chromatography on SiO2 (65%). Microwave-assisted Suzuki coupling 
of 161 was conducted using a non-aqueous system to avoid hydrolysis of the ester functionality, 
but gave reduced yields of biaryl 163 compared to the Suzuki coupling of nitroquinoline 150 (see 
                                                          
v Dr Irina Chuckowree, Prof. M. C. Bagley, unpublished results, 2013. 
Scheme 96: Synthesis of thienoquinoline precursor 159 completed by Dr Irina Chuckowree. Reaction conditions: i) 
Methyl thioglycolate, K2CO3, DMF, RT, overnight, 96%; ii) H2 (1 atm), Pd/C, MeOH, RT, 3 h, quant.; iii) 3-ethoxyacrylic 
acid, EDCI.HCl, HOBt.H2O, DIEA, DMF, RT, overnight, 63%. 
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previous section, Chapter 3.2.1). This lower yield was most likely due to poor solubility, as the 
compounds became a lot less tractable once the thienoquinoline scaffold had been constructed.  
 
Further problems were encountered upon attempting halogenation of the thieno ring. Use of N-
iodo, bromo or chlorosuccinimide (NIS, NBS, NCS) were all investigated with no success. A variety 
of different solvent systems were investigated, with additional Lewis acids and mineral acids 
used in an attempt to promote the reaction, however only the starting material 163 or a complex 
mixture of multi-halogenated products was returned. 
Halogenation of the thienoquinoline scaffold at an earlier stage was also investigated. 
Treatment of 161 with NBS, NIS, NCS or bromine with zinc chloride also either resulted in 
multiply halogenated products, or returned unreacted starting material. It was concluded that 
in order to proceed with a synthetic strategy via a thieno[3,2-f]quinolone scaffold, a much 
earlier-stage halogenation would be required.  
 
 
Scheme 97: Cyclization to form thienoquinolones 160A and 160B, and functionalization to biaryl quinoline 163. 
Reaction conditions: i) Conc. H2SO4, RT, 3 h, quant.; ii) POCl3 Δ, 2 h, 65%; iii) 6-Methylpyridinyl-3-boronic acid, 
Cs2CO3, PdCl2(PPh3)2, 1,4-dioxane, MW 140 °C, 1 h, 47%; iv) NBS, no reaction. 
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3.4. Retrosynthesis 3. Halothieno[3,2-f]quinolone 
scaffold. 
Having established synthetic routes towards a number of key intermediate frameworks, 
including the Knorr-carbostyril quinolone formation and Suzuki coupling procedures to 2-
(pyridin-3-yl)quinolines, it was desirable to maintain these key steps in the total synthesis. It was 
decided that an alternative strategic route towards PF-3644022 (25) would require only slight 
alteration. Synthesis of halobenzo[b]thiophene 164 was proposed as the first step, followed by 
reduction to aminobenzothiophene 165 which should facilitate functionalization to 
dihalogenated intermediate 166 (see Scheme 98). 
 
The proposed sequence of cross-coupling steps was to conduct the Suzuki coupling at this 
intermediate stage, followed by final Buchwald-Hartwig N-arylation and lactam ring formation. 
It was noted that the presence of two halogens during the Suzuki coupling of 166 could cause 
issues of chemoselectivity.  
It had been decided that the halogen to be installed in 164 would be a bromine, as this is most 
commonly used in Buchwald-Hartwig N-arylation reactions. C-Br bonds are typically more 
activated towards oxidative addition at a metal centre than C-Cl bonds. However, at this stage 
Scheme 98: Retrosynthesis 3, via halothieno[3,2-f]quinoline and dihalogenated intermediate. 
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it could not be anticipated whether the high reactivity endowed to the C-Cl bond at the 2-
chloroquinoline centre would challenge this order of reactivity. In order to probe the 
amenability of this route, it was proposed that the dihalogenated intermediate 166 be 
synthesized and tested for its reactivity towards Suzuki conditions. With most steps of the 
synthesis already validated in related systems, it was anticipated that repurposing the reaction 
conditions for the synthesis of 166 would not be too problematic. 
 
3.4.1. Synthesis of 3-bromobenzo[b]thiophene. 
Initial routes explored direct bromination of benzo[b]thiophene 162. As discussed in Chapter 
1.6.2.4, the heteroaromatic ring of benzo[b]thiophenes tends to be more reactive, however, 
due to the electron-withdrawing 5-nitro group of 162, it was expected that the benzothiophene 
would be somewhat deactivated towards EAS.  
As discussed in Section 1.6.2.4,152,160 bromination can be directed to the 3-position of a 
benzothiophene-2-carboxylic acid when converted to the carboxylate salt. Hence Mbere’s route 
was explored for its applicability to methyl 5-nitrobenzo[b]thiophene-2-carboxylate (162) (see 
Scheme 99). 
 
Methyl 5-nitrobenzothiophene-2-carboxylate (162) was synthesized from condensation of 2-
chloro-5-nitrobenzaldehyde under basic conditions with methyl thioglycolate in 95% yield after 
17 h at room temperature. To facilitate a potentially more rapid synthetic route, the application 
of microwave-assisted dielectric heating was explored. Irradiation at 90 °C in a sealed vessel 
reduced the reaction time to 15 minutes and maintained high yields. Saponification to carboxylic 
Scheme 99: Bromination of methyl 5-nitrobenzothiophene-2-carboxylate (162). Reaction conditions: i) Methyl 
thioglycolate, K2CO3, DMF, RT, 17 h, 95% ii) methyl thioglycolate, K2CO3, DMF, MW 90 °C, 15 min, 88%; iii) NaOH aq. 
(1 M  sol.), MeOH, Δ, 3 h (or MW 100 °C, 3 min), then 1 M HCl, 95% (94%); iv) Br2, NaOAc, AcOH, 55°C, 17 h, 75%; v) 
MeI, K2CO2, DMF, RT, 3 h, 93%. 
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acid 167 was also amenable to microwave-assisted techniques, with the reaction time shortened 
from 3 h with conventional reflux to a 3 minute irradiation in a sealed vessel at 100 °C, with no 
detrimental effect on the yield (see Scheme 99).vi    
5-Nitrobenzo[b]thiophene-2-carboxylic acid (167) was then subjected to Mbere et al.’s 
bromination conditions, using excess bromine and anhydrous sodium acetate (NaOAc) in glacial 
AcOH, and heated to 55 °C for 17 h. The brominated carboxylic acid 168 was isolated successfully 
and esterified to methyl ester 164 in high yield using methyl iodide under basic conditions. 
Unfortunately, the bromination step was found to be quite variable in its efficiency, often 
returning mixtures of 162 and 164. Therefore an alternative route for bromination using 
diazotization chemistry was explored via methyl 3-amino-benzothiophene-2-carboxylate 170. 
Beck established the cyclocondensation of 2-nitrobenzonitrile with methyl thioglycolate to form 
benzo[b]thiophenes in 1971, and this method has been adapted by a number of groups to set 
up substrates for ortho-halogen displacement.147,270–272 To this end, a microwave-assisted 
method towards 170 was designed (see Scheme 100). Methyl thioglycolate and 2-fluoro-5-
nitrobenzonitrile (169) were condensed under basic conditions using triethylamine in DMSO to 
give aminobenzothiophene 170 in very high yield, either via conductive heating  at 100 °C for 2 
h (95%) or microwave-assisted heating at 130 °C for 11 minutes (94%). Subsequent deaminative 
bromination using copper(II) bromide and tert-butyl nitrite (t-BuNO2) in MeCN afforded the 
brominated benzo[b]thiophene 164 in excellent yield (99%).2 
 
3.4.2. N-Functionalization of methyl 3-bromo-5-nitrobenzo[b] 
thiophene-2-carboxylate. 
Now that a viable route for the synthesis of 3-bromo-5-nitrobenzothiophene 164 had been 
established, it was necessary to append a group onto the carbocyclic ring ready for cyclization 
                                                          
vi Microwave-mediated saponification optimised by Alexander Rand, University of Sussex, 2013 
Scheme 100: Synthesis of 3-bromobenzothiophene 170. Reaction conditions: i) Methyl thioglycolate, NEt3, DMSO, 
100 °C, 2 h, 95% or MW 130 °C, 11 min, 94%; ii) CuBr2, tBuNO2, MeCN, 0 °C to RT, 2 h, 99%.2 
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to thienoquinoline 166 by EAS. It was intended that this would be conducted through N-
functionalization with a suitable electrophilie bearing carboxylic acid.  
In order to transform nitrobenzothiophene 164 to the corresponding amine 165, it was found 
that the traditional hydrogenation procedure conducted under an atmosphere of hydrogen gas 
and promoted by catalytic Pd/C, used previously in Scheme 96 (Chapter 3.3), was not a viable 
route to 165, affording the hydrodehalogenated product. Thus, an electron transfer and 
protonation method was investigated with the reaction of 164 with tin(II) dichloride (SnCl2) in a 
conc. HCl-EtOH solvent system affording the desired methyl 5-amino-3-
bromobenzo[b]thiophene-2-carboxylate 165 in excellent yield (97%) after heating to reflux for 
3 h  (see Scheme 101). 
 
The amide bond forming conditions used previously by Dr Chuckowree returned quite 
disappointing yields. After stirring amine 165 with 3-ethoxyacrylic acid for 24 h, in the presence 
of peptide-coupling reagents EDCI.HCl, HOBt.H2O and DIEA as base in DMF at RT, the coupled 
product 171 was isolated in 40% yield after purification by flash column chromatography (see 
Scheme 102).  
 
In order to try and improve yields alternative conditions were explored, as illustrated in Table 2. 
These included the use of DMAP as an alternative acyl-transfer agent instead of HOBt (entries 
2-4).273 Similarly the use of pyridine was explored as an additive, aprotic solvent and proton 
scavenger. However, lower yields than the original peptide-coupling system were obtained (10-
15%). The use of Schotten-Baumann type conditions with an acid chloride, 3-ethoxyacryloyl 
Scheme 101: Electron transfer and protonation to afford 5-amino-3-bromobenzo[b]thiophene 165. Reaction 
conditions: i) SnCl2.2H2O, conc. HCl, EtOH, Δ, 3 h, 97%. 
Scheme 102: Amide bond formation to quinolone precursor 171. Reaction conditions: i) 3-Ethoxyacrylic acid, 
EDCI.HCl, HOBt.H2O, DIEA, DMF, N2, RT, 24 h, 40%. 
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chloride, and catalytic amounts of DMAP in pyridine-CH2Cl2 were unsuccessful with no isolable 
products (entry 5).162  
Table 2: Amide bond formation trials for synthesis of 171 (see Scheme 102).a 
Entry No. Coupling reagents Additive Solvent Yield (%)b 
1 EDCI.HCl, HOBt.H2O DIEA DMF 40 
2c EDCI.HCl, DMAPd Pyridine DMF 10 
3 EDCI.HCl, DMAP Pyridine DMF 10 
4 EDCI.HCl, DMAPd n/a Pyridine 15 
5e Pyridine DMAPd CH2Cl2 n/a 
a Reaction conditions: 165, 3-ethoxyacrylic acid (1.1 equivalents), coupling reagents and additives were stirred at 
RT for 24 h, unless otherwise indicated. 
b Isolated yield after purification by flash column chromatography. 
c Reaction stirred for 17 h. 
d Used catalytically. 
e Reaction conducted using the acid chloride, 65 h reaction time. 
 
From these trials it was determined that the original peptide-coupling strategy was the best 
route. However, upon repetition it was apparent that the yields were quite inconsistent and 
often fell below 40%, with a lot of degradation observed during purification. It was postulated 
that the carboxylic acid may be acting as a Michael acceptor in solution, to undergo a number 
of side reactions. Due to these issues alternative coupling partners were investigated, with 
consideration of the desired subsequent acidic activation step required for the Knorr-carbostyril 
quinolone reaction. Considering an acid-mediated cyclization, the required cyclization partner 
would need to be able to form an oxonium ion under acidic conditions for intramolecular EAS. 
Thus it was proposed that 3,3-dimethoxypropanoic acid (172) could be an appropriate 
alternative acyl partner for coupling (see Scheme 103) and so was investigated. 
 
 
Scheme 103: Proposed acid-mediated Knorr-carbostyril mechanism using 3,3-dimethoxypropanoic acid (172), via 
formation of an oxonium ion. 
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Saponification of methyl ester 173 gave 3,3-dimethoxypropanoic acid (172) in high yields as a 
clear, colourless oil after careful acidification (see Scheme 104).  
 
Using the EDCI.HCl, HOBt.H2O coupling system, 172 was coupled with non-brominated 158 to 
ascertain the reaction viability. After stirring at RT for 24 h, a reasonable yield of coupled product 
174 (59%) was obtained after purification by flash column chromatography (see Scheme 105). 
Use of a higher reaction temperature and submission of the reaction mixture to microwave-
assisted dielectric heating in a sealed vessel at 78 °C for 1 h, gave amide 174 in an improved yield 
(72%). Thus, the same set of conditions were applied to methyl 5-amino-3-
bromobenzo[b]thiophene-2-carboxylate (165), with similar yields obtained after stirring at RT 
for 24 h (59%), though slightly lower yields were observed after microwave-assisted heating at 
80 °C for 1h (56%). 
 
Yields of the coupling reaction of 165 was further improved through use of the new coupling 
reagent COMU as a substitute for both HOBt and EDCI. With an excess of carboxylic acid 172, 
DIEA and 1.5 equivalents of COMU, microwave-assisted heating under a nitrogen atmosphere 
at 120 °C for 30 minutes gave 175 in excellent yield (89%). 
 
  
Scheme 104: Synthesis of 3,3-dimethoxypropanoic acid 172. Reaction conditions: i) Aq. NaOH (4 M in H2O), 110 °C, 
30 min; ii) 6 M HCl, 79%. 
Scheme 105: Amide bond formation using carboxylic acid 172. Reaction conditions for the synthesis of 174: i) 158, 
172, EDCI.HCl, HOBt.H2O, DIEA, N2, RT, 24 h or ii) MW 78-80 °C, 1 h. Reaction conditions for synthesis of 175: i) 165, 
172, EDCI.HCl, HOBt.H2O, DIEA, N2, RT, 24 h or iii) 172, COMU, DIEA, DMF, N2, MW 120 °C, 30 min.  
Microwave-mediated yields given in parentheses. 
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3.4.3. Acidic cyclization to thienoquinolone. 
With the advent of a new cyclization precursor, it was uncertain how successful the quinolone 
formation would be and if the ratio of regioisomers would be affected. Hence the non-
brominated dimethoxy cyclization precursor 174 was stirred with conc. H2SO4 at 0 °C and 
allowed to warm to room temperature over 3 h. Isolation by pouring into iced water and 
collection of the solid by vacuum filtration gave 160 in quantitative yields, with a ratio of 88:12 
of 160A:160B (see Scheme 106), ascertained by 1H NMR spectroscopic analysis (see Figure 48). 
Scheme 106: Acidic cyclization of non-brominated precursor 174. Reaction conditions: i) Conc. H2SO4, RT, 3 h, quant., 
88:12 160A:160B. 
Figure 48: 1H NMR spectrum (DMSO-d6, 500 MHz, δH 9.0 - 6.0 ppm) of crude quinolone mixture 160A and 160B from 
acidic cyclization of 174. Quinolones with chemical structures annotated with chemical shift assignments. Ratio of 
products calculated by averaging the integration of peaks for each chemical structure: 88:12 ratio A:B. 
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The two regioisomers were easily differentiated by 1H NMR spectroscopic analysis due to their 
very different coupling patterns. As illustrated in Figure 48, for thieno[3,2-f]quinolone 160A, 
each of the two quinolone fused rings had two vicinal protons which coupled strongly but had 
very different chemical shifts. The 9-CH proton in 160A was much more deshielded by the 
electron-withdrawing carbonyl, which resulted in a more downfield resonance (δH 8.64 ppm) 
than the 8-CH proton (δH 6.63 ppm). The shielding of the 9-CH resonance in 160B was much less 
pronounced. 
The two protons of the carbocyclic ring were more similar in their chemical environments, 
constituting an AB system with ‘roofing’ of the doublets apparent in the 1H NMR spectrum (as 
illustrated on Figure 48). This AB relationship confirmed that the fused benzo ring was para-
disubstituted.101 As the difference in the chemical shifts of the two protons was still quite large, 
the ‘roofing’ effect was only slight.  
These coupling relationships were confirmed through 2D COSY 1H NMR spectroscopic 
experiments (see Figure 49). For 160B, due to the manner of cyclization, the protons of the 
carbocyclic ring were para to one another and hence would only give rise to a very small coupling 
and appeared as singlets in the 1H NMR spectrum at δH 8.26 and 7.87 ppm. 
 
 
Figure 49: 2D COSY 1H NMR experiment for crude quinolone mixture 160A and 160B (DMSO-d6, 500 MHz). The 
higher concentration of 160A resulted in only the proton-proton coupling relationships of this compound being 
visible in the spectrum. 
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The ratio of quinolone products echoed those reported by Dr Chuckowree from the alternative 
cyclization precursor 159 (see Chapter 3.3.1). Hence it was ascertained that the regioselectivity 
of reaction had not changed significantly from a change in the cyclization precursor and so the 
brominated cyclization precursors 171 and 175 were subjected to the acidic cyclization 
conditions (see Scheme 107). 
  
By 1H NMR spectroscopic analysis, it was found that there was a change in the ratio of 
regioisomers. The major product was still the desired thieno[3,2-f]quinolone 176A, but it was 
Figure 50: 1H NMR spectrum (DMSO-d6, 500 MHz, δH 9.8 - 6.4 ppm) for crude mixture of quinolones 176A and 176B. 
Signals associated with 176A illustrated with integrations circled. Averaged integration gave the ratio of products as 
approximately 3:1. 
Scheme 107: Acidic cyclization of ethoxyprop-2-ene amide 171. Reaction conditions: i) Conc. H2SO4, RT, 3 h, 70%. 
70:30 ratio of 176A: 176B 
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found that the overall yield had reduced to 70% and there was an approximate 3:1 ratio of 176A 
to 176B (see Scheme 107 and Figure 50). The two regioisomers were assigned as previously, 
with inference from the coupling patterns, relative integrations of the peaks and the 2D COSY 
1H NMR data. 
The change in quinolone regioisomer ratio with the addition of the bromine group may be due 
to a reduction in electron density at the 4-position of the benzothiophene, reducing the 
difference in activation energy for EAS at the 4- and 6-positions, or it could be due to steric 
effects. Nevertheless, the reaction proceeded in favour of the desired regioisomer, and so the 
alternative cyclization precursor 175 was subjected to the same reaction conditions. 
From the dimethoxy precursor 175, the reaction yields and ratios were found to be more 
variable than those from 171. The proportion of 176A to 176B was found to be more comparable 
than in any previous cyclization, with a 65:35 ratio of products, though the best yields obtained 
were slightly higher than the previous iteration (87%, see Scheme 108).  
 
Though this change in the ratio and yield of cyclized products was inconvenient, it was reasoned 
most likely to be due to small changes in reaction profile. It was proposed that the crude 
cyclization product should be carried forward to determine the viability of the Suzuki coupling 
step before undertaking optimization of the cyclization step. 
 
Scheme 108: Reaction scheme for acidic cyclization of (3,3-dimethoxypropanamido)benzothiophene 175. Reaction 
conditions: i) conc. H2SO4, RT, 3 h, 87%. 65:35 ratio 176A to 176B. 
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3.4.4. Chlorination to dihalogenated thienoquinoline and Suzuki 
coupling. 
Chlorination using POCl3 was completed using the previously described method (see Chapter 
3.3.1). The crude quinolone mixture 176 (Scheme 108) was heated to reflux in neat POCl3 for 
2.5 h, and purified by flash column chromatography to give chloroquinoline 166 in 42% yield 
(see Scheme 109). 
 
Upon purification, the presence of protodemethylated side products was noted. Additionally, 
the purification was somewhat complicated by the poor solubility of the crude material. 
Nevertheless, given the ratio of quinolone regioisomers in the crude starting material, the yield 
of the chlorothieno[3,2-f]quinoline regioisomer 166 that was collected was extremely 
reasonable and could be improved further in parallel with any improvements in the quinolone 
regioisomeric ratio. 
Given successful isolation, the Suzuki coupling of 166 with 6-methylpyridine-3-boronic acid was 
investigated. The aqueous reaction system used in Chapter 3.1 for the Suzuki coupling of 2-
chloro-6-nitroquinoline was found to protodemethylate the reactants, and so an alternative 
non-aqueous system was adopted using caesium fluoride (CsF) as base and PdCl2(PPh3)2 as 
catalyst in anhydrous 1,4-dioxane. 
Unfortunately, after microwave-assisted heating at 140 °C for 30 minutes and purification by 
flash column chromatography, exclusively the unwanted bromine-substituted coupling product 
Scheme 109: Chlorination of crude mixture of thienoquinolone 176. Reaction conditions: i) POCl3, Δ, 2.5 h, 42%. 
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177 was collected in 18% yield (see Scheme 110). This was confirmed through 1H NMR 
spectroscopic analysis and high-resolution mass spectrometry (HRMS), in which the two chlorine 
isotopes of the parent ion could be clearly differentiated in a characteristic 3:1 ratio.  
 
By 1H NMR spectroscopic analysis, the AB system of the benzo ring protons was significantly 
more pronounced, with the extent of ‘roofing’ illustrative of how the chemical environments of 
the 4-CH and 5-CH protons were much more similar than in the quinolone system (illustrated in 
Figure 51). The additional proton peaks of the 6-methylpyridine were differentiated through 
their coupling patterns and a 2D COSY 1H NMR spectroscopic experiment.  
Figure 52 illustrates the proton-proton interactions of the 4’-CH proton with 2’-CH and 5’-CH. 
The 2’-CH proton (δH 8.54 ppm) was strongly deshielded by proximity to the pyridine nitrogen 
Scheme 110: Suzuki coupling of dihalogenated intermediate 166. Reaction conditions: i) 6-Methylpyridinyl-3-
boronic acid, CsF, PdCl2(PPh3), 1,4-dioxane, N2, MW 140 °C, 30 min, 18%. 
Figure 51: 1H NMR spectrum (DMSO-d6, 500 MHz, δH 10.5 - 7 ppm) of 177, illustrating the 7 aromatic proton peaks. 
Chemical structure labelled with those peaks visible in the spectroscopic window. 
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and appeared as a broad singlet due to residual coupling with the meta-proton 4’-CH (δH 7.63 
ppm), whereas 4’-CH appeared as a doublet of doublets due to vicinal and meta-coupling with 
the pyridine 5’-CH and 2’-CH protons, respectively. 
  
 
3.4.5. Conclusion.  
It was concluded that Suzuki coupling of the dihalogenated intermediate was not a suitable 
route for the total synthesis of PF-3644022 (25). Despite this set-back in completing the 
synthesis, very important synthetic methods towards key intermediates had been designed and 
carried out in high yield. These included a new microwave-assisted synthetic route towards 
methyl 3-bromo-5-nitrobenzothiophene-2-carboxylates2 and a new approach for regioselective 
thienoquinoline synthesis using amide bond formation with COMU as the coupling reagent, 
which gave excellent yields of cyclization precursors via microwave-assisted synthesis. 
 
Figure 52: 2D COSY 1H NMR spectroscopic experiment for 177, used to differentiate between the two aromatic ring 
systems. Gridlines indicate the proton-proton interactions of the 4’-CH proton at δH 7.63 ppm.  
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3.5. Retrosynthesis 4. Benzo[4,5]thieno[3,2-
e][1,4]diazepin-5-one scaffold. 
Early stage installation of the diazepinone ring of PF-3644022 (25) had been avoided up until 
this point as the ring contained a number of potentially reactive functional groups. However, at 
this stage of the project, the synthetic options available towards alternative intermediates were 
becoming more limited, and so it was decided this approach would now be adopted, and that 
protecting group strategies could be used if found to be necessary. 
 
As illustrated in Scheme 111, a new retrosynthetic strategy was proposed with final stage Suzuki 
coupling, from a 2-chloroquinoline derived from a thieno[3,2-f]quinoline-diazepinone (180). It 
was proposed that the lactam ring would be built up via Buchwald-Hartwig N-arylation using 
methyl 3-bromo-4-nitrobenzo[b]thiophene-2-carboxylate (164), and cyclized thereon to form 
the diazepinone ring in 178. Reduction of the nitro group thereafter to 179 would ensure no 
homocoupling of the aminobenzothiophene under the Buchwald-Hartwig coupling conditions. 
Subsequent amide bond formation with carboxylic acid 172 was proposed, to be carried forward 
as established in Chapter 3.4, via the Knorr-carbostyril quinolone reaction and subsequent 
chlorination ready for final-stage Suzuki coupling to afford PF-3644022 (25). 
 
Scheme 111: Retrosynthesis 4, via benzo-thieno-diazepin-one intermediates 178 and 179. 
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3.5.1. Buchwald-Hartwig N-arylation and lactam ring formation. 
Buchwald-Hartwig N-arylation was chosen to construct the scaffold for diazepinone ring 
formation as it is a mild, functional group tolerant and generally high-yielding method (see 
Chapter 1.6.2.3). Additionally, through this method it should be possible to install the 
asymmetric centre without significant racemization. For the chiral centre of PF-3644022 (25), 
enantiopure Boc-D-alanine (181) was used to derive the mono-Boc-protected diamine 137 ready 
for N-arylation. 
Initially, carboxylic acid 181 was converted to the amide using a mixed anhydride method, 
through reaction with ethyl chloroformate under basic conditions and substitution with 
ammonia to give amide 182 in up to 41% yield.274 However, it was found that a peptide coupling 
strategy using EDCI.HCl and HOBt.H2O with DIEA and ammonia boosted yields to 75% (see 
Scheme 112). 
 
Reduction of the amide group was completed using a Lewis acidic borane complex. 182 was 
stirred with borane dimethylsulfide (BH3●SMe2) at 0 °C under an inert atmosphere and allowed 
to warm to room temperature overnight. Heating the reaction was found to decompose the Boc 
group. Once reaction completion had been confirmed by thin layer chromatography (TLC) 
analysis, the excess BH3●SMe2 was removed under reduced pressure and the residues washed 
with MeOH to decomplex the borane.275 Purification by SCX-2 chromatography gave the chiral 
mono-Boc-protected diamine 137 in high yield (84%). Characterization of the amine by 1H NMR 
spectroscopic analysis confirmed the presence of two diastereotopic protons. Each of these 
protons coupled with the 2-CHMe centre and with each other, resulting in a doublet of doublets 
for each proton (see Figure 53, δH 2.75-2.5 ppm).  
Scheme 112: Amide bond formation and reduction of Boc-D-Alanine to chiral Boc-protected diamine 137. Reaction 
conditions: i) NEt3, ethyl chloroformate, THF, N2, 0 °C, 45 min, then NH3 (aq. 35%), THF, 0 °C, 45 min 41%; ii) EDCI.HCl, 
HOBt.H2O, DIEA, CH2Cl2, 0 °C to RT, 30 min, then NH3 (aq. 35%), 0 °C to RT, 30 min, 75%; iii) BH3●SMe2, THF, N2, 0 °C 
to RT, 18 h, then MeOH, 84%. 
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For the Buchwald-Hartwig N-arylation of 164, reaction conditions were adapted from studies 
completed by Queiroz et al. for the coupling of aryl amines and electron-rich and electron-poor 
3-halogenatedbenzo[b]thiophenes.276  
 
Initial trials were conducted using methyl 3-bromobenzo[b]thiophene-2-carboxylate (183) (see 
Scheme 113, and Table 3 entries 1-3). Conductive heating routes were investigated first, using 
equimolar benzothiophene and amine with Cs2CO3 (2 equiv.), (±)-BINAP (10 mol%) and Pd(OAc)2 
catalyst (5 mol%) in dry toluene and heating to reflux for 24 h. After purification quite a low yield 
of the coupled product 184 was isolated (entry 1, 27%), and some formation of the 
transesterification side product was noted.  
Scheme 113: Buchwald-Hartwig N-arylation of bromobenzo[b]thiophenes 183 and 164. Reaction conditions: i) 137, 
Cs2CO3, (±)-BINAP, Pd(OAc)2, toluene, MW 150 °C, 1.25 h. 
Figure 53: 1H NMR spectrum (CDCl3, 500 MHz, δH 5.0 – 1.0 ppm) of 137, illustrating the doublet of doublet peaks for 
the diastereotopic protons. 
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Through the use of microwave-assisted dielectric heating in a sealed vessel, the reaction time 
was dramatically reduced from 24 h to 1-1.25 h, with achieve similar yields of 184 achieved 
(entry 2, 25%). Additionally, the amount of base was reduced, which helped reduce the extent 
of transesterification.  
Table 3: Buchwald-Hartwig N-arylation trial reactions, see Scheme 113.a 
Entry No. Precursor Time (h) Temperature (°C) Yield (%)b 
1 183 24 110 27c 
2 183 1 150 25 
3 183 1.25 150 60 
4 164 1.25 150 76 
5 164 2 150 69 
a Reaction conditions: Equimolar methyl 3-bromobenzo[b]thiophene-2-carboxylate and 137, Cs2CO3 (1.5 equiv.), 
(±)-BINAP (15 mol%) and Pd(OAc)2 (5 mol%) in dry toluene, under N2, were irradiated at 150 °C for the stated 
time using microwave dielectric heating. 
b Isolated yield after purification by flash column chromatography on SiO2 
c Conductive heating, and 2 equiv. Cs2CO3. 
 
By extending the reaction time to 75 minutes, the yield of 184 was increased significantly (entry 
3, 60%). Coupling of 3-bromo-5-nitrobenzothiophene 164 to amine 137 under these conditions 
was found to produce the coupled product 185 in excellent yield (entry 4, 76%). However, 
attempts to improve the yield through prolonged heating gave a slightly diminished yield (entry 
5, 69%). 
Given the success of the conditions explored and the improved efficiency achieved through 
application of microwave-assisted heating, no other methods were investigated and the 
synthesis was carried forward. 
Using a general procedure, Boc-deprotection was carried out using a 10% solution of 
trifluoroacetic acid (TFA) in CH2Cl2, stirring the mixture at room temperature overnight (see 
Scheme 114). Attempts to reduce the reaction time through heating resulted in decomposition 
of materials. Upon confirmation the reaction was complete by TLC analysis, volatile components 
were carefully removed and subsequent basic cyclization was conducted using a procedure 
reported by Khatana et al. and applied to similar benzothieno-1,4-diazepin-5-one 
frameworks.277 The TFA salt was stirred with NaOMe in MeOH and heated to 50 °C for 2 h before 
heating at reflux for an additional 2 h. The crude mixture was then poured into iced water and 
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neutralized using 1 M HCl aqueous solution. Isolation by vacuum filtration gave 178 as a red 
powder in quantitative yields. 
 
Upon attempted reduction of 178 to 179, it was again found that some conventional methods 
were not applicable. This was attributed to be due to poor or limited solubility of 178 in most 
solvents, as many hydrogenation methods rely upon heterogeneous catalysis with adsorption 
of a soluble reactant onto the solid catalyst surface.  
Hydrogenation using H2 gas with Pd/C in MeOH, EtOAc and AcOH all resulted in either 
decomposition or return of starting materials. Electron transfer and protonation using SnCl2.H2O 
in acidic ethanol returned a mixture of products, with similar results when ammonium formate 
and zinc were used. The use of acidic solvents was explored thoroughly as a method to reduce 
in situ catalyst poisoning through complexation of the basic nitrogen formed. However, even 
despite this precaution, no reduction product was observed. 
The best route found was developed by Spencer et al. as a microwave-mediated route for the 
reduction of poly-functionalized nitroaromatics using molybdenum hexacarbonyl (Mo(CO)6) and 
1,8-diazabicycloundec-7-ene (DBU) in ethanol.278,279 A highly functional group tolerant method, 
the reaction is believed to occur through formation of a metal nitrene complex, with 
deoxygenation of the nitrogen and loss of carbon dioxide (CO2) via metal carbonyl mediated 
carbonylation.280 The non-nucleophilic base DBU was used as an additive as it is known to aid 
CO liberation from Mo(CO)6,281 and so facilitate generation of open coordination sites for nitro 
complexation. Once deoxygenated, protonolysis of the nitrogen affords the primary amine.280  
Scheme 114: TFA deprotection and base-mediated lactam ring formation: Reaction conditions: i) TFA (10% in 
CH2Cl2), RT, overnight: ii) NaOMe (25 w% in MeOH), MeOH, 50 °C, 2 h, then Δ, 2 h. iii) 1 M HCl, >99% 
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Microwave-assisted heating of 178 with one equivalent of Mo(CO)6 and three equivalents of 
DBU in EtOH in a sealed vessel at 150 °C for 30 minutesvii and purification by flash column 
chromatography gave 179 in excellent yield (96%, see Scheme 115).  
Characterization by 1H NMR spectroscopic analysis confirmed nitro reduction, with significant 
upfield shift of the carbocyclic ring proton resonances. Additionally, when the 1H NMR spectrum 
was conducted in DMSO-d6 as the solvent medium, the NH2 proton resonances were visible as a 
broad singlet at δH 5.04 ppm.  
 
3.5.2. N-Functionalization and acidic cyclization to quinolones. 
To form the acidic cyclization precursor 186, the amide bond formation methods screened 
towards in Chapter 3.4.2 were again trialled.  
 
After irradiation at 120 °C for 15 minutes using traditional peptide coupling reagents, 186 was 
collected in low yield after a problematic purification by flash column chromatography (Table 4, 
                                                          
vii Caution was taken when preparing the reaction vessel for microwave irradiation, as liberation of CO2 
gas over the course of the reaction could lead to a significant build-up of pressure. It was important to 
ensure enough headspace was left in the reaction vessel to allow for this. 
Scheme 115: Mo(CO)6-mediated reduction of aminobenzothiophene 178. Reaction conditions: i) Mo(CO)6, DBU, 
EtOH, MW 150 °C, 30 min, 96%.279 
Scheme 116: Amide bond formation to give acidic cyclization precursor 186. Reaction conditions: i) 172, COMU, 
EDCI.HCl, DIEA, DMF, MW 120 °C, 1 h, 83%. 
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entry 1, 36%). The yield using these reagents was improved through extending the reaction time 
to 1 h and 40 minutes and use of SCX-2 chromatographic purification (entry 2). 
 
Application of COMU as the coupling-reagent dramatically improved the isolated yield (entry 3, 
70%). However the isolated product was deemed only approximately 50% pure after SCX-2 
chromatography, as determined by reverse-phase liquid chromatography mass spectrometry 
(RP-LCMS).viii The purity of the sample and the isolated yield were greatly improved through the 
combined use of COMU and EDCI.HCl under the same reaction conditions (entry 4, 83%, Scheme 
116), with a >80% purity determined by RP-LCMS.  
Acidic cyclization of 186 was then conducted as previously described in Chapter 3.4.3, before 
isolation by vacuum filtration. Isolation of the crude solid was very problematic, and the yield 
obtained was greatly reduced compared to previous studies (20%, see Scheme 117). 
                                                          
viii LCMS data was recorded on a Waters 2695 HPLC using a Waters 2487 UV detector and a Thermo LCQ 
ESI-MS. Samples were eluted through a Phenomenex Lunar 3µ C18 50 mm × 4.6 mm column, using 
acetonitrile and water acidified by 0.01% formic acid. Samples were eluted using acetonitrile and water 
(1:9 to 9:1) acidified by 0.01% formic acid, at a flow rate of 3 µl/min. 
Table 4: Amide bond formation to give acidic cyclization precursor 186 (see Scheme 116).a 
Entry No. Coupling reagents Temperature (°C) Hold time (h) Yield (%)b 
1 EDCI.HCl, HOBt.H2O 120 0.25 36d 
2 EDCI.HCl, HOBt.H2O 120 1.7 43 
3 COMU 120 1 70d 
4 COMU, EDCI.HCl 120 1 83e 
a Reaction conditions: Benzothiophene 179 and carboxylic acid 172, the coupling reagents stated and two 
equivalents of DIEA in DMF were irradiated under argon at 120 °C for the indicated hold time. 
b Isolated yield after SCX-2 purification. 
c Isolated yield after purification by flash column chromatography on SiO2. 
d 50% purity, by LCMS trace. 
e >85% purity, by LCMS trace. 
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Surprisingly, the only regioisomer that could be clearly observed in the crude 1H NMR spectrum 
was the thieno[3,2-f]quinolone regioisomer 187A (see Figure 54). It was identified with 
inference from previous acidic cyclization products. The diazepinone NH protons were visible in 
the ‘aromatic’ region of the spectrum using DMSO-d6 as solvent medium, and have been labelled 
as such in Figure 54.  
Scheme 117: Acidic cyclization of advanced intermediate 186. Reaction conditions: i) Conc. H2SO4, 0 °C to RT, 3 h. 
Figure 54: 1H NMR spectrum (DMSO-d6, 500 MHz, δH 9.0 - 6.0 ppm) of crude acidic cyclization product. Only 
regioisomer 187A was clearly observed. Illustrative chemical structure labelled with proton chemical shifts (only 
those visible in this spectral window). 
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Due to solubility issues the signals of the 1H NMR spectrum were very weak. Upon repeating the 
1H NMR experiment with a more concentrated sample it was found that the crude material 
rapidly decomposed. Additionally, mass spectrometry showed significant fragmentation. 
In case decomposition was occurring in the reaction vessel, the reaction was repeated using a 
more dilute acidic system and longer reaction time; however this resulted in a mixture of 
unidentifiable products by 1H NMR spectroscopic analysis.  
Unfortunately, it appeared that the harshly acidic conditions were decomposing the 
diazepinone-based intermediates, a possible outcome that had been speculated on at the 
beginning of this chapter. It was concluded that alternative cyclization procedures should be 
investigated. 
 
3.5.3. Alternative cyclization methods. 
As was described in Chapter 1.6.2.3, there are a number of different routes towards multi-
functionalized quinolines. Towards 2-substituted quinolines a number of routes were discussed 
based upon the Skraup and Doebner-von Miller quinoline cyclizations. Most reactions tend to 
proceed through intramolecular EAS of an aniline derivative, similar to those routes adopted in 
Chapters 3.2 and 3.3.  
 
3.5.3.1. Doebner-von Miller quinoline formation. 
The Doebner-von Miller reaction proceeds from a starting aniline, with N-functionalization via 
Michael addition of an α,β-unsaturated aldehyde to give an intermediate imine. It was proposed 
that a Doebner-von Miller cyclization may be a viable method to synthesize a thienoquinoline 
from the advanced aniline intermediate 179 and a pyridine-derived cinnamaldehyde (see 
Scheme 118). 
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Trial reactions were completed to assess the viability of the reaction using a simplified model 
with methyl 4-aminobenzo[b]thiophene-2-carboxylate (158) and cinnamaldehyde (see Scheme 
119). As described by Matsugi et al. in their synthesis of 2-methylated quinolines,282 a two-phase 
system of aqueous acid and organic solvent was adopted in order to reduce unwanted aldehyde 
polymerization, by keeping the aldehyde in the organic phase whilst the protonated aniline 
occupies the aqueous phase. However, after heating to reflux for 2 h in a 6 M HCl-toluene (4:1) 
solution, only the starting materials were collected. 
The use of phase-transfer catalysts TBAB or TBAC was explored to aid the interfacial movement 
of reagents, but only the Schiff base condensation product 189 was collected.283,284 Use of more 
forcing conditions, including heating to reflux overnight and stirring the isolated Schiff base in 
neat concentrated HCl overnight, resulted in decomposition of materials.  
 
There are various mechanisms postulated for the Doebner-von Miller quinoline reaction, with 
debate over whether the reaction proceeds through initial Schiff base formation114 or a Michael 
addition of the aniline, with subsequent EAS at the carbonyl centre (see Chapter 1.6.2.3).81 For 
this reaction, it may be that the cinnamaldehyde was too bulky to allow Michael addition to 
Scheme 119: Doebner-von Miller reaction of model aminobenzothiophene 158. Reaction conditions: i) 
Cinnamaldehyde, TBAB/TBAC, 6 M HCl-toluene (4:1), Δ, 2 h, no reaction. 
Scheme 118: Retrosynthesis 4.1. Proposed Doebner-von Miller quinoline formation from advanced intermediate 179 
and pyridine-derived cinnamaldehyde 188. 
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occur or that the benzothiophene ring was not electron dense enough to promote 
intramolecular EAS. Therefore alternative methods of cyclization were investigated. 
 
3.5.3.2. Multi-component Lewis acid-mediated quinoline formation. 
The multi-component Doebner quinoline synthesis was traditionally conducted between an 
aniline, functionalized aldehyde and pyruvic acid to give the 2-subsituted-4-carboxyl quinoline, 
which could then be decarboxylated to give the 2-subsituted quinoline.115,116  
As has been discussed in Chapter 1.6.2.3, the Doebner multi-component quinoline synthesis has 
been explored extensively by Wang et al. to develop a one-pot multi-component reaction (MCR) 
for the synthesis of fused quinoline ring systems.119–123 Specifically, they developed a route 
towards 2-subsituted quinolines using n-butyl vinyl ether (n-BVE) as the reactive ethene unit, 
with proposed loss of butanol upon aromatization.123 
This method offered an alternative path for synthesis of the quinoline unit in PF-3644022 (25) 
under mild conditions. It was proposed that a Doebner-type multi-component convergent 
cyclization reaction could be conducted between advanced intermediate 179, 6-methylpyridine-
3-carboxaldehyde (190) and n-BVE under Lewis acidic conditions to give direct access to 25 in a 
one-pot procedure (see Scheme 120) 
 
3.5.3.2.1. Lewis acid-mediated quinoline formation. 
A trial system had been briefly investigated by Lorna Brigham, a summer student in the research 
group,ix to ascertain the viability of reacting together pyridine-3-carboxaldehyde (191) and 
                                                          
ix Experiments and analysis of results completed by Lorna Brigham, M.C. Bagley, University of Sussex, 
2015, unpublished. 
Scheme 120: Proposed Doebner-type multi-component quinoline synthesis to PF-3644022 (25). 
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aniline (192) to promote this type of cyclization and to investigate the applicability of Wang et 
al.’s published methods. 
It was found that using Wang et al.’s procedure with a higher quantity of molecular iodine (50 
mol%), equimolar quantities of aldehyde 191 and aniline (192), and 1.5 equivalents of n-BVE, 
heating to reflux for 20 h in tetrahydrofuran (THF) resulted in quinoline 194 formation (see 
Scheme 121), as ascertained by 1H NMR spectroscopic analysis of the crude material after 
aqueous work-up. A number of side products were also observed, but efforts to isolate the pure 
quinoline by flash column chromatography on SiO2 were complicated by significant co-elution 
of components. 
 
Bagley and Brigham found that pre-stirring the aniline and aldehyde in the minimum amount of 
solvent at room temperature for 1 h to form the Schiff base (193) before addition of the Lewis 
acid and n-BVE, helped reduce the amount of side products formed. Also, microwave-assisted 
dielectric heating in a sealed vessel at 120 °C for 1 h was found to improve the ratio of quinoline 
to side products in the crude reaction mixture. Alternative Lewis acids were also briefly 
examined before the project was handed over, with similar product conversions observed by 1H 
NMR spectroscopic analysis when the reaction was mediated by SnCl2.2H2O as for iodine.  
Upon taking over these studies, it was decided that a few additional conditions would be 
examined before swiftly moving onto closer analogues of PF-3644022 (25).  
Alternative solvents were screened for their viability, including toluene, MeCN and THF. The use 
of less iodine was also investigated for its impact on the reaction conversion. Furthermore, 
analysis of the crude material was conducted using RP-LCMS in addition to 1H NMR 
spectroscopic analysis. The microwave-assisted method developed by Bagley and Brigham was 
utilized, as it reduced reaction times and increased efficiency. 
Use of toluene as solvent resulted in a number of unknown side products being generated, as 
ascertained by RP-LCMS and 1H NMR spectroscopic analysis, and so was ruled out as a potential 
solvent. The crude reaction mixtures of the THF- and MeCN-mediated reactions, after aqueous 
Scheme 121: Trial multi-component quinoline synthesis. Reaction conditions: i) Pyridine-3-carboxaldehyde (191), 
solvent; ii) n-BVE, Lewis acid, Δ, 20 h, or MW 100 °C, 1 h. 
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work-up, appeared to contain far fewer side-products, though there was still a significant side 
reaction occurring. The RP-LCMS chromatographic trace of the crude reaction mixtures tended 
to indicate at least two major UV-active species were present (see Figure 55 and 56).x  
 
                                                          
x LCMS data was recorded on a Waters 2695 HPLC using a Waters 2487 UV detector and a Thermo LCQ 
ESI-MS. Samples were eluted through a Phenomenex Lunar 3µ C18 50 mm × 4.6 mm column, using 
acetonitrile and water acidified by 0.01% formic acid. Samples were eluted using acetonitrile and water 
(1:9 to 9:1) acidified by 0.01% formic acid, at a flow rate of 3 µl/min. 
Figure 55: RP-LCMS chromatogram of the crude reaction mixture from Scheme 121, using I2 (10 mol%) as Lewis acid 
via microwave-assisted heating, illustrating the UV traces corresponding to compound of interest 194: m/z = 207 
(MH+).  
Figure 56: RP-LCMS chromatogram of the crude reaction mixture from Scheme 121, using SnCl2 (10 mol%) as Lewis 
acid, via microwave-assisted heating, illustrating the UV traces corresponding to compound of interest 194: m/z = 
207 (MH+). 
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Product conversion, as ascertained by integration of the UV active peaks of the chromatogram, 
appeared to be fairly similar when the reaction was mediated by the two different Lewis acids 
in MeCN (Figure 55 and 56, top row). The mass ion of the second UV active peak at retention 
time 2.05-2.25 minutes correlated to the protonated quinoline 194 (m/z = 207 [MH●+]), 
confirming product formation.  
However, for the THF-mediated reactions, there were inconsistencies between the two different 
Lewis acid-mediated reactions. The mass ion was still present on analysis of the crude reaction 
mixtures, confirming reaction conversion (Figure 55 and 56, bottom row), however, it was 
apparent that molecular iodine was only poorly soluble in THF, and hence MeCN became the 
solvent of choice for further reactions.   
In these reactions, the equivalents of Lewis acid had been reduced compared to the previous 
trials conducted by Bagley and Brigham, from 50 mol% to 10 mol%. It was speculated that this 
may have been detrimental to the reaction conversion and so for further reactions the 
equivalence was increased back to 50 mol%.   
 
3.5.3.2.2. Extending the model: thienoquinoline formation. 
Having established the viability of a simple model, the compatibility of this method for 
thienoquinoline formation was probed, using methyl 5-aminobenzo[b]thiophene-2-carboxylate 
(158) and reacting with pyridine-3-carboxaldehyde (191) (see Scheme 122). 
 
Scheme 122: Proposed thienoquinoline formation reaction microwave-assisted heating. Reaction conditions: i) 
Pyridine-3-carboxaldehyde (191) (1 equiv.), RT, 1 h; ii) n-BVE (2 equiv.), Lewis acid (50 mol%), MW heating. 
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Wang et al. had reported high regioselectivity for the cyclization of naphthalene-2-amines to 
occur at C-1 (see Chapter 1.6.2.3.1, Scheme 24),123 though it was uncertain whether this trend 
in reactivity would favour formation of thieno[3,2-f]quinoline 195A.  
However, across previous work there had been a positive distribution in favour of the 
thieno[3,2-f]quinoline in the ratio of acidic cyclization products. Additionally, as discussed in 
Chapter 1.6.2.3, 5-aminobenzothiophenes can favour EAS at the 4-position over the 6-position 
(see Scheme 41), most likely due to a combination of kinetic and electronic effects. 
Consequently, the regioselectivity of this MCR method towards our model was approached with 
an optimistic outlook. 
A simple model reaction of 158 with pyridine-3-carboxaldehyde (191) was completed as 
illustrated in Scheme 123, using iodine as the Lewis acid (50 mol%) in THF with two equivalents 
of n-BVE under microwave-assisted dielectric heating in a sealed vessel at 120 °C for 1 h (Table 
5, entry 1). Fortunately, purification by flash column chromatography after an aqueous work-up 
gave a single thienoquinoline product, identified as the desired thieno[3,2-f]quinoline 195A by 
1H NMR spectroscopic analysis and HRMS.  
 
Characterization and differentiation between the pyridine and quinoline ring systems was 
inferred by reference to previous spectra and using 2D COSY 1H NMR spectroscopy experiments. 
The pyridine ring had characteristically high chemical shifts for the 2′-CH and 6′-CH protons due 
to deshielding by the adjacent nitrogen (see Figure 57). The multiplet at δH 8.74 ppm which 
integrated to two protons was identified as overlapping resonances from the 9-CH and 6′-CH 
protons. This was confirmed through the 2D COSY 1H NMR experiment, with proton-proton 
interactions between the δH 8.74 ppm multiplet and 8-CH of the quinoline and 5′-CH of the 
pyridine (at δH 8.06 and 7.5 ppm respectively), as illustrated in Figure 58. The 5′-CH exhibited a 
much more upfield resonance due to the comparatively shielded environment. 
Scheme 123: Reaction scheme for trial theino[3,2-f]quinoline formation from 158. Reaction conditions; i) Pyridine-
3-carboxyaldehyde (191) (1 equiv.), THF, RT, 1 h; ii) Iodine (50 mol%), n-BVE (2 equiv.), MW 120 °C, 1 h, 7%. 
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Figure 57: 1H NMR spectrum (CDCl3, 500 MHz, δH 9.7 - 7.0 ppm) of thieno[3,2-f]quinoline 195A with chemical 
structure annotated with chemical shifts of protons within the spectral window. 
Figure 58: 2D COSY 1H NMR experiment for 195A, with gridlines illustrating the proton-proton relationships 
associated with the two 9-CH and 6′-CH protons of the δH 8.74 ppm multiplet. 
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The quinoline ring was characterized in the 1H NMR spectroscopic analysis with inference from 
previous spectra, with large chemical shift differences noted between the 9-CH and 8-CH 
protons, and characteristic roofing of the 4-CH and 5-CH AB system (see Figure 57). Hence it was 
confirmed that only the thieno[3,2-f]quinoline (195A) had been isolated.101  
The 13C NMR spectrum of 195A was interpreted through the use of a heteronuclear single bond 
correlation (HSQC) and heteronuclear multiple bond correlation (HMBC) experiments.  
 
From the 13C spectrum, the sp2 hybridized carbons could generally be differentiated from the 
quaternary carbons due to their characteristically stronger signals. This phenomenon is due to 
the proximity of the proton nucleus speeding up the rate of relaxation of the excited carbon 
nuclei between scans, resulting in stronger signals for sp2 and sp3 hybridized carbons (see Figure 
59).101 The more downfield 13C peaks correlated with the extremely deshielded carbonyl and α-
pyridine quaternary carbons, with 2′-CH and 6′-CH centres at δC 148.7 and 150.3 ppm 
respectively. The other pyridine carbon centres 5′-CH and 4′-CH were identified using the HSQC 
experiment, at δC 134.8 and 123.7 ppm, respectively (see Figure 59 and 60a). 
 
 
Figure 59: 13C NMR spectrum (CDCl3, 100 MHz, δC 165-115 ppm) for 195A, with chemical stucture annotated. 
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The sp2 hybridized carbons of the quinoline were identified similarly, with the 9-CH carbon 
centre significantly deshielded compared to 8-CH (δC 132.5 and 119.1 ppm, respectively). One 
quaternary carbon was not observed in the spectrum, but it was believed to have coalesced with 
the resonance of an sp2 hybridized carbon at δC 134.8 ppm. This was ascertained using an HMBC 
experiment, which detects through bond interactions over longer ranges than the HSQC. 
a) HSQC 
b) HMBC 
Figure 60: 1H and 13C correlation experiments for 195A. a) HSQC experiment plot, illustrating single-bond 
interactions between protons and carbons of the molecule; b) HMBC, illustrating more distant proton-carbon 
relationships, specifically highlighting the interactions of the 13C shift at δC 137.8 ppm. 
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Through the two-dimensional HMBC experiment notable interactions were observed between 
the 13C resonance at δC 137.8 ppm and two proton peaks at δH 9.41 and 8.11 ppm, correlating 
to protons of the pyridine and quinoline ring respectively (see Figure 60b). From this cumulative 
data, it was concluded that quinoline product 195A had been successfully isolated. 
Unfortunately, the yield of 195A from this initial reaction was very low (Table 5, entry 1, 7%). A 
variety of conditions were screened in an attempt to improve the reaction outcome, as shown 
in Table 5. Adjustments were made to the equivalents of n-BVE, the temperature, hold time of 
the reaction and the solvent used. 
 
 
Broadly speaking, it was found that the isolated yield improved upon changing the solvent from 
THF to MeCN (Table 5, entry 1, 7%; and entry 4, 9.5%) and upon lowering the equivalents of n-
BVE (entry 2, 11%). Additionally, lowering the temperature was found not to affect the yield 
detrimentally (entries 2 and 3). 
Once these small changes had been confirmed as beneficial to the isolated yield, the hold time 
for the reaction was evaluated. Reducing the reaction time to 30 minutes reduced the yield 
Table 5: Thienoquinoline formation, using model aminobenzothiophene 158 and pyridine-3-
carboxaldehyde (191) (see Scheme 123).a 
Entry No. n-BVE (equiv.) Time (h) Temp. (°C) Solvent Yield (%)b 
1 2 1 120 THF 7 
2 1.5 1 120 THF 11 
3 1.5 1 100 THF 11.5 
4 2 1 120 MeCN 9.5 
5 1.5 0.5 100 MeCN 5 
6 1.5 1.5 100 MeCN 14 
7 1.5 3 100 MeCN 27 
8c 1.5 3 100 MeCN 10 
9 1.1 3 100 MeCN 10.5 
10d 1.5 3 100 MeCN 13 
11e 1.5 24 Reflux MeCN 5.5 
a Reaction conditions: An equimolar amount of benzothiophene 158 and pyridine-3-carboxaldehyde (191) were 
stirred for 1 h at RT in solvent, then I2 (50 mol%) and n-BVE were added and solution irradiated in a sealed vessel.  
b Isolated yield of 195A after purification by flash column chromatography; quoted to the nearest 0.5%. 
c 1.25 equiv. of aldehyde were used. 
d Trimethyl(vinyloxy)silane was used instead of n-BVE. 
e Conductive heating at reflux. 
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(entry 5, 5%), while incrementally increasing the hold time resulted in significant improvements. 
After 90 minutes (entry 6, 14%) and 3 h (entry 7, 27%) at 100 °C in MeCN with 1.5 equivalents 
of n-BVE the yields improved incrementally, though the isolated yields were still quite low. 
Analysis of the side products of the reaction indicated formation of an alternative 
thienoquinoline framework. HRMS and 1H NMR spectroscopic analysis was used to deduce that 
the side product was methyl 6-methylthieno[2,3-g]quinoline-2-carboxaldehyde (196).  
Figure 61: a) 1H NMR (CDCl3, 500 MHz, δH 9.0 - 2.5 ppm) of side product 196 and b) 2D HSQC exepriment used 
to confirm two protons from different environments had coelesed into one peak at δH 8.03 ppm in the 1H NMR 
spectrum. 
a) 1H NMR spectrum 
b) HSQC 
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Characterization by 1H NMR spectroscopic analysis was completed, with two very prominent 
singlets which both integrated to three protons; one at δH 4.00 ppm, typical of the CO2Me group, 
and one at δH 2.79 ppm. The integration and chemical shift of this new peak inferred it to be a 
new methyl group.  
In the aromatic region, there were two doublets and two singlets, though one of those singlets 
integrated to 2 protons (at δH 8.03 ppm, see Figure 61a). Using a 2D HSQC experiment, it was 
ascertained that the two protons resonating at δH 8.03 ppm could be attributed to two protons 
on different carbon centres. Considering the frameworks being constructed, it was proposed 
that the overlapping resonances at δH 8.03 ppm were the 1- and 4-CH peaks of a thieno[2,3-
g]quinoline, with the other singlet assigned as the 9-CH proton and the two doublets inferring 
that the 7-C centre was occupied by the methyl group. HRMS was used to verify the identity of 
the side product, with a parent ion found with m/z 258.0578, corresponding to [MH]⁺, 
C14H12NO2S. 
It was proposed that this side product could form through a reversible Schiff base intermediate, 
with 158 reacting with two equivalents of n-BVE via an alternative Schiff base pathway (see 
Scheme 124). Additionally, it was interesting to observe that the cyclization of this alternative 
Schiff base favoured the alternative thieno[2,3-g]quinoline, with EAS at the 6-position of the 
benzothiophene ring. 
 
 
Scheme 124: Postulated mechanism for formation of methyl thienoquinoline side product 196.  
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Attempts to reduce the extent of this side reaction included trial reactions with an excess of 
pyridine-3-carboxaldehyde (191) (Table 5, entry 8, 10%) and reducing the equivalents of n-BVE 
to just over one equivalent (entry 9, 10.5%). Unfortunately, the yields were considerably lower 
than for previous reactions and side product 195 was still formed.  
The alternative vinyl ether trimethyl(vinyloxy)silane was probed in this process, as it was 
hypothesized that a different profile of reactivity could modulate the reaction outcome. Alas, 
the isolated yield of the reaction was found to suffer (entry 10, 13%). 
A conductive heating trial confirmed microwave-assisted heating in a sealed vessel was the 
superior method of heating for this reaction, with low yields obtained after heating the reaction 
mixture to reflux for 24 h (entry 11, 5.5%).  
Having determined the best conditions using iodine as the Lewis acid, a number of other acids 
and Lewis acids were investigated (see Table 6). Additionally, the equivalents of n-BVE were 
lowered to try and reduce the extent of side reactions that were occurring. 
 
No reaction occurred when there was no Lewis acid present or when the Brønsted acid AcOH 
was used (Table 6, entries 1 and 2). This result confirmed the necessity of a Lewis acid rather 
than a protic acid to facilitate Schiff base activation in this quinoline formation (see Chapter 
1.6.2.3.1 for discussion of the mechanism). 
Other Lewis acids were probed including SnCl2.2H2O, zinc(II) bromide (ZnBr2) (used in reduced 
quantity as it has been documented that 30-35 mol% resulted in better Lewis acidic 
properties285), iron(III) chloride (FeCl3) and titanium tetrachloride (TiCl4).  
Table 6: Exploring different acids and equivalents of n-BVE, in the synthesis of 195A.a 
Entry No. Acid (mol%) n-BVE (equiv.) Time (h) Yield (%)b 
1  -  1.1 1.5  -  
2 AcOH (50) 1 3 - 
3 ZnBr2 (38) 1.1 3 14.5 
4 SnCl2 (36) 1.1 3 9.5 
5 TiCl4 (50) 1.1 3 4c 
6 FeCl3 (50) 1.1 3 -d 
a Reaction conditions: Equimolar amounts of benzothiophene 158 and pyridine-3-carboxaldehyde (191) were 
stirred for 1 h at RT in MeCN, then the Lewis acid and n-BVE were added and the solution irradiated at 100 °C for 
the stated time. 
b Isolated yield after purification by flash column chromatography; quoted to the nearest 0.5%. 
c ≤50% pure by 1H NMR spectrum analysis. 
d Only Schiff base 193 was isolated. 
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Using the reactions mediated by 50 mol% iodine under similar conditions as the benchmark 
reaction (Table 5, entry 9, 10.5%), the yields obtained using ZnBr2 showed a slight improvement 
in the isolated yield (Table 6, entry 3, 14.5%), though the results were not consistent between 
experimental runs, with notable co-elution of products and decomposition occurring in one 
experiment.  
SnCl2 gave a very similar isolated yield to the use of iodine (Table 6, entry 4, 9.5%), though both 
Lewis acids also resulted in significant side product formation. Use of TiCl4 gave a much lower 
yield of the quinoline, with significant impurities detected by 1H NMR spectroscopic analysis 
(entry 5, 4%), and it was found that use of FeCl3 did not mediate the cyclization, with only the 
Schiff base intermediate formed.  
The best yield obtained in these trials was mediated by ZnBr2. However, the co-elution and 
decomposition noted during the reaction was troubling. Hence, it was decided that iodine would 
be progressed into trials with advanced intermediates, and that use of ZnBr2 should be further 
investigated in future studies. 
 
3.5.3.2.3. Application of convergent quinoline route to complex intermediates. 
In order to conduct the final synthetic step towards PF-3644022 (25), 6-methylpyridin-3-
carboxaldehyde (190) was synthesized by oxidation of alcohol 197. Initially oxidation using Dess-
Martin periodinane (DMP) was investigated, as a mild and functional group tolerant reagent.286 
Typically oxidations mediated by DMP occur quickly at room temperature. However, after 
stirring 197 in dry CH2Cl2 under argon with 2.5 equivalents of DMP for 3 h, the isolated yield of 
190 was still very low (11%).  
 
Adopting Swern oxidation conditions greatly improved the reaction yield (see Scheme 125). 
Reacting oxalyl chloride and DMSO in dry CH2Cl2 at −78 °C, before slow addition of 197, with 
subsequent deprotonation of the sulfur ylide by addition of NEt3 base, afforded aldehyde 190 in 
high yield (75%) after purification by flash column chromatography. 
Scheme 125: Oxidation of (6-methylpyridine)alcohol (197) to 6-methylpyridine-3-carboxaldehyde (190). Reaction 
conditions: i) (COCl)2, DMSO, NEt3, CH2Cl2, −78 °C, 75%. 
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Reaction of 179 and aldehyde 190 was carried out using the best conditions from the model 
system, with 1 h pre-stir of the aniline and aldehyde at room temperature in MeCN, and then 
addition of iodine (50 mol%) and n-BVE (1.5 equiv.) and heating the reaction mixture using 
microwave-assisted dielectric heating in a sealed vessel at 100 °C for 3 h (see Scheme 126). 
The reaction was carried out a number of times on a small scale and the yields were found to be 
very low. Isolation of the product and purification by flash column chromatography were both 
problematic, with poor purity ascertained by 1H NMR spectroscopic analysis. Trituration of the 
contaminated product with diethyl ether did help remove impurities, but this method was not 
consistent. Recrystallization was found to be an impractical method of purification on the small 
scale used. Only when an excess of aldehyde 190 was used did purification by flash column 
chromatography return a clean product, ascertained by 1H NMR spectroscopic analysis, giving a 
final yield of 6%. 
 
Identity of the product was confirmed through 1H NMR spectroscopic analysis and HRMS. The 
alkyl protons of the diazepinone ring were assigned using 2D COSY 1H NMR correlation 
experiments. The diazepinone NH protons were notable between δH 6.40 and 5.40 ppm (in 
CDCl3), and the aromatic quinoline and pyridine protons were assigned by reference to previous 
spectra, recognizable coupling patterns and use of 2D COSY and HSQC NMR correlation 
experiments (see Figure 62). 
The 13C NMR spectrum was assigned with inference from previous spectra and through use of 
HSQC and HMBC NMR correlation experiments. There was one quaternary carbon not observed, 
but this had been noted for the similar pyridinyl-thieno[3,2-f]quinoline 195A, and so it was 
inferred that a similar coalescence of a quaternary carbon signal had occurred. 
Scheme 126: Multi-component reaction towards PF-3644022 (25). Reaction conditions: i) 190 (1.4 equiv.), MeCN, 
RT, 1 h; ii) I2 (50 mol%), n-BVE (1.6 equiv.), MW 100 °C, 3 h, 6%. 
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From the cumulative spectroscopic data, it was concluded that final compound PF-3644022 (25) 
had been synthesized successfully. 
 
Upon purification of the crude reaction mixture from the reaction of diazepinone 179 and 
pyridine-3-carboxaldehyde 190 (see Scheme 126), unreacted pyridinyl-carboxaldehyde and the 
α-methylthienoquinoline side product 198 were often also isolated.  
Figure 63: 1H NMR spectrum (DMSO-d6, 500 MHz, δH 9.5 - 6.5 ppm) of α-methylthienoquinoline side product 
198, with annotated chemical structure, illustrating the proton resonances visible in the spectral window. 
Figure 62: 1H NMR spectrum (CDCl3, 500 MHz, δH 9.8 - 5.3 ppm) of PF-3644022 (25), with annotated chemical structure, 
illustrating the shifts visible in the spectral window. 
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Characterization of 198 was conducted through 1H NMR spectroscopic analysis, with 
characteristic roofing of the two carbocylic protons indicating that the thieno[3,2-f]quinoline 
product from the alternative reaction pathway had been formed (see Figure 63). 
It was postulated that the alternative reaction product had been formed due to subtle changes 
in the electronic and steric demands of the system, favouring the alternative condensation 
rather than Schiff base formation. Nevertheless, it was clear that the reaction was not 
proceeding as favourably as anticipated, and so some further investigations were conducted 
using the benzothiophene based system. 
 
3.5.3.2.4. Assessing the viability of aromatic aldehydes. 
The yields achieved in this convergent MCR for quinoline synthesis were significantly lower than 
those documented by Wang et al., who reported yields of 82-93% for reactions mediated by n-
BVE.123 Furthermore, the substantial difference in yields between the model system (see 
Scheme 123, 27%) and those achieved for PF-3644022 (25) (see Scheme 126, 6%) implied there 
may be some additional, fundamental reduction in reactivity of the substrates. 
 
A limited set of trial reactions were run using the aromatic aldehydes benzaldehyde, pyridine-3-
carboxaldehyde (191) and its methyl analogue 190 (see Table 7). It was hoped that these trials 
would help ascertain whether the lower reactivity and reaction yields were due to the 
electronics of the pyridine-3-carboxaldehyde, some interaction of the Lewis acid with the 
pyridine heteroatom or due to changing steric demands. 
Scheme 127: Convergent quinoline synthesis, exploring the viability of aromatic aldehydes. Reaction conditions: i) 
aromatic aldehyde, MeCN, RT, 1 h; ii) I2, n-BVE, MeCN, MW 100 °C, 3 h. 
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Table 7: Convergent quinoline synthesis with alternative aromatic aldehydes (Scheme 127).a 
Entry No. Y R Yield (%)b 
1 CH H 30 
2 NH H 27 
3 NH Me 4 
a Reaction conditions: An equimolar amount of benzothiophene 158 and aldehyde was stirred in MeCN for 1 h 
at RT in MeCN, then I2 (50 mol%) and n-BVE (1.5 equiv.) were added and solution irradiated at 100 °C for 3 h. 
b Isolated yield after purification by flash column chromatography. 
 
There was a slight improvement in the isolated yield of the cyclized quinoline product when 159 
was reacted with benzaldehyde under the standard conditions (Table 7, entry 1, 30%) compared 
to reaction with unsubstituted pyridine analogue 191 (entry 2, 27%). Interestingly, it was found 
that the yield for reaction of 159 with 6-methylpyridine-3-carboxaldehyde (190) was very low 
(entry 3, 4%). 
Wang et al. reported consistent yields upon altering the electronic properties of the aromatic 
aldehyde in their synthesis of fused quinoline systems,123 though these results indicated there 
was a clear reduction in efficiency when the aromatic aldehyde was altered. 
At this stage it could not be determined whether the unfavourable change in the yield of the 
quinoline product was due to the change in electron density of the aromatic group, some 
association between the heteroatom and the Lewis acid in solution, or because of subsequent 
degradation due to the pyridine α-methyl group of 25 that could readily tautomerize under the 
Lewis acidic reaction conditions. 
 
3.5.4. Future perspectives. 
The low efficiency of the cyclization method designed by Wang et al.123 was noted for the 
convergent synthesis of advanced intermediates diazepinone 179 and 6-methylpyridine-3-
carboxaldehyde (190). Low yields were achieved of the final compound PF-3644022 (25, 6%) and 
also in the reaction of a simple 5-aminobenzothiophene with different aromatic aldehydes giving 
fused quinolines 195A, 199 and 200. In order to optimize this route towards the desired 
substrates, there are a number of options available.  
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Further investigation of alternative Lewis acids would be beneficial, as the screening conducted 
herein was by no means exhaustive and would benefit from further experimentation with 
models and with 190 as the carboxaldehyde coupling partner.  
Exploration as to the cause of the reactivity issues would also be beneficial, although it would 
seem that this reaction is just not ideal for this highly complex target. Therefore, it has been 
proposed that an alternative method to synthesize our final target, could be conducted via a 
Skraup cyclization from advanced intermediate 179 to give unsubstituted quinoline 201.287 Using 
the chemistry established by Anderson et al. (see Chapter 3.1.1, Scheme 91), the pyridine ring 
could then be functionalized to the N-oxide (202) and chlorinated to give 180, ready for 
subsequent Suzuki coupling to afford PF-3644022 (25) (see Scheme 128). Work on this chemistry 
is currently ongoing in our research group. 
 
3.6. Conclusion.  
The MK2 inhibitor PF-3644022 (25) was synthesized in 6 steps and 4% overall yield (see Scheme 
129). New methods and syntheses have been developed and optimized towards a number of 
advanced intermediate scaffolds through a variety of different disconnective strategies. These 
included a new and efficient microwave-assisted route towards 3-amino and 3-
halobenzo[b]thiophenes, improved microwave-assisted amide bond forming reactions using 5-
aminobenzo[b]thiophenes for synthesis of acidic cyclization precursors, and the development of 
new microwave-assisted routes towards thieno[3,2-f]quinolines.  
Scheme 128: Proposed alternative route for the synthesis of PF-3644022 (25). Reaction conditions: i) Glycerol, 
H2SO4, B(OH)3, Ac2O, Fe2(SO4)3;287 ii) Boc2O, DMAP, NEt3 then mCPBA; iii) (COCl)2, DMF, then HCl; iv) 2-
methylpyridinyl-5-boronic acid, Pd(PPh3)4, Na2CO3, 80 °C.68 
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The development of PF-3644022 (25) towards a viable therapeutic candidate has been 
progressed by Pfizer, with pre-clinical studies conducted on 25 and a number of more 
pharmacokinetically-viable candidates. The application of a variety of MK2 inhibitor 
chemotypes, including 25, have been explored by Davis et al. in WS cells with some intriguing 
results obtained when compared to treatment with the prototypical p38 inhibitor SB203580 (1). 
 
 
  
Scheme 129: Total synthesis of PF-3644022 (25). Reaction conditions: i) Methyl thioglycolate, NEt3, DMSO, MW 130 
°C, 11 min, 94%; ii) CuBr2, tBuONO, MeCN, 0 °C to RT, 2 h, 99%; iii) 137, Cs2CO3, (±)-BINAP, Pd(OAc)2, toluene, MW 
150 °C, 75 min, 76%; iv) a) TFA (10 % in CH2Cl2), RT, 16 h; b) NaOMe (25 w% in MeOH), MeOH, 50 °C, 2 h, then Δ, 2 
h; c) 1 M HCl, >99%; v) Mo(CO)6, DBU, EtOH, MW 150 °C, 30 min, 96%; vi) 190, I2, nBVE, MeCN, MW 100 °C, 3 h, 6%. 
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3.7. Biological studies.  
Initial screenings of MK2 inhibitor PF-3644022 (25) by Pfizer found it to possess good kinase 
selectivity across a panel of two hundred protein kinases, with potency on the nanomolar scale 
and projected ADME (adsorption, distribution, metabolism and excretion) characteristics 
suitable for oral human dosing.68,69,288 Hence, it was considered an ideal candidate to take 
forward into pre-clinical trials. 
 
3.7.1. Progress in the clinic. 
Despite good projected ADME characteristics, pre-clinical investigations of the in vivo activity of 
PF-3644022 (25) at Pfizer by Daniels et al., in 2013, found that it caused acute liver damage and 
hepatotoxicity in dogs.288 The group completed an in vitro ADME analysis on transfected human 
cells and found that 25 underwent hepatic bioactivation and inhibited a number of important 
transporter proteins which regulate the movement of toxic substances around the hepatobiliary 
system.  
In previous work, the group had found that fused thiophene-diazepinone scaffolds were liable 
to undergo bioactivation in the liver into glutathione conjugates, and that installation of a 
metabolic shunt could temper this unwanted reaction. It was important that the diazepinone 
section of the molecule be maintained, as it had been found through X-ray co-crystallization 
studies to be involved in critical binding interactions with MK2 and that the biaryl linkage was 
important for kinase selectivity.67,68 Therefore efforts to improve the pharmacokinetics (PK) of 
the PF-3644022 (25) chemotype were completed while bearing these important 
pharmacophoric properties in mind. 
 
Figure 64: First alternative candidate (203) to improve the pharmacokinetic properties of PF-3644022 (25).288 
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PF-318 (203) was synthesized, with a new polyether chain installed as a metabolic shunt on the 
distal aryl group. 203 maintained inhibitory potency akin to 25 and was confirmed to 
preferentially undergo O-dealkylation upon metabolism. However, severe liver injuries were still 
noted in dogs when given a single oral dose of 203.  
Further in vitro studies identified 203 to be an even more potent inhibitor towards hepatobiliary 
efflux transporter proteins than 25, with enhanced distribution and exposure characteristics. To 
reduce this unwanted transporter protein inhibition, the group used studies completed by 
Pedersen et al. which identified a number of prevalent characteristics to distinguish between 
inhibitors and non-inhibitors of transporter proteins.289 For instance, inhibitors generally tended 
to have a higher average molecular weight, with higher degrees of aromaticity and to be either 
anionic or neutral at physiological pH. 
 
MK2 inhibitors 25 and 203 both possessed pKaH values of around 4, and so were more likely to 
be neutral at physiological pH. To increase basicity, a piperazine group was installed via a 
methylene linkage to give PF-029 (204). This new candidate possessed a pKaH of approximately 
8, and so the majority of molecules would be present as the cationic conjugate acid at 
physiological pH. Tests completed by Daniels et al. validated their approach and found that 204 
did not inhibit transporter proteins or result in liver toxicity in vivo.288 
These pharmacokinetic improvements at the pre-clinical stage of development for PF-3644022 
(25) were very fortuitous for Pfizer, as toxicity is one of the major factors which leads to attrition 
in late stage drug design.290 
Originally designed towards the development of therapeutics for inflammatory disorders, PF-
3644022 (25) was designed to target MK2 as an alternative to the typical p38 targeting 
inhibitors.67,69 Since its design and publication, 25 has been used as a chemical tool to probe 
Figure 65: Daniels et al.'s second candidate (204) to improve the pharmacokinetics of PF-3644022 (25). 
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MAPK stress-signalling pathways in a variety of cell types. For example, Cao et al. used 25 to 
probe links between p38 and MK2 in Sonic Hedgehog (Shh) pathways in breast cancer cells.291 
Shh is a member of the Hedgehog (Hh) family of proteins, and is overexpressed in breast cancer 
cells.291 The exact role of Shh in breast cancer signalling is unclear, though it is known to be 
involved in developmental processes, including cancer pathology and tissue regeneration. It was 
postulated that there was some cross-talk between the Shh and MAPK signalling pathways, and 
so MK2 inhibitor PF-3644022 (25) and p38 inhibitor SB203580 (1) were used as tools to 
investigate the mechanism of action of Shh. It was found that upon treatment with these 
inhibitors there was a reduction in phosphorylation of one of the key members of the Shh 
signalling pathway, demonstrating direct involvement of the p38-MK2 pathway in the cell 
proliferation of breast cancer cells.55,291 
 
3.7.3. Application in WS cells. 
As has been discussed in Chapter 1.2, the p38α/MK2-mediated stress-signalling pathway has 
been postulated to play a key role in the stressed and aged morphology of prematurely aged WS 
cells. This is due in part to prominent F-actin stress fibres observed in senescent WS cells, 
production of which is mediated by MK2 phosphorylation of HSP27.  
P38α MAPK has been confirmed to play a crucial role in the stress-signalling events of WS cells, 
leading to the stressed and aged morphology of WS cells and premature cellular senescence.1,14 
In order to gain a better understanding of the mechanisms of the prematurely aged phenotype, 
and for the development of more therapeutically-viable drug candidates, the role of the kinases 
downstream of p38α have become of more prominent interest. 
Unfortunately, investigations into the MAPK stress-signalling pathway in WS cells using MK2 
inhibitors have been largely inconclusive due to a pervasive cessation of cell growth.60 Cessation 
in these tests did not appear to be a direct effect of MK2 inhibition, but predominantly due to 
the small therapeutic window of the compounds.63  
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For instance, Davis et al. found that although the aminocyanopyridine ATP-competitive MK2 
inhibitor 18 inhibited the MK2/HSP27 stress-signalling cascade in normal cells,62,63 growth 
studies completed on WStert cells were inconclusive.60  
 
After treatment with 18, WStert cells exhibited a reduction in cell growth and no effect on the 
extent of F-actin stress fibre production. Davis et al. determined from these results that either 
MK2 inhibition was limiting cell growth, which was inconsistent with the role of MK2 established 
from cell cycle arrest pathways,55,60 or that the inhibitor had some off-target or toxic effects. 
Hence it was determined that more selective and potent MK2 inhibitors would be required for 
conclusive results.  
 
In 2013 Davis et al. published a selection of studies on the use of MK2 inhibitors in WS cells, 
including the tetrahydropyrrolo[3,2-c]pyridine-4-one 21,60 an MK2 inhibitor designed by Pfizer 
with high potency and target specificity (see Chapter 1.4.1.).59 Tests on primary WS cells showed 
a notable increase in their replicative capacity and little comparative effect on normal human 
cells.60 Additionally, it was found that continuous treatment with 21 resulted in a dramatic 
reduction in F-actin stress fibres.60 
Treatment of the same primary WS cells with the p38 inhibitor SB203580 (1) still resulted in a 
more enhanced increase in the replicative capacity. Though it was found that 21 exhibited a 
higher efficacy at reverting the production of stress fibres in WS primary cells to resemble those 
of normal cells.  
Figure 67: Tetrahydropyrrolo[3,2-c]pyridine-4-one MK2 inhibitor 21.59 
Figure 66: Diaminocyanopyridine MK2 inhibitor 18.62 
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From this evidence Davis et al. inferred that, although the accelerated senescence of WS cells 
was at least partially due to activation of MK2, the results were not conclusive. Additionally, the 
studies confirmed that MK2 inhibitor 21 was not as effective at extending the replicative 
capacity as the p38α inhibitor SB203580 (1).  
It was speculated that there could be several reasons why MK2 inhibitor 21 did not elicit the 
same response as SB203550 (1), including the possibility that the therapeutic window of 21 may 
have been too small, causing off-target effects and inhibition of cell growth at higher 
concentrations.60 Also, it was proposed that the superior effect of SB203580 (1) could have been 
due to off-target effects, or that there may be multiple kinases downstream of p38α which have 
a role in mediating the cellular response to treatment.  
Biological tests of MK2 inhibitor PF-3644022 (25) have been run by Davis et al. on primary WS 
cells, although the extent of tests has been restricted due to limited supplies of primary WS 
cells.3 The results collected complement those collected previously using the MK2 inhibitor 21.60 
 
Primary WS cells grown in the presence of PF-3644022 (25), at a concentration where MK2 was 
fully inhibited (1.0 μM and 2.0 μM), were found to show a replicative lifespan extended by 
approximately 50% compared to controls (see Figure 68). Comparative studies using SB203580 
(1) on the same cell line demonstrated a higher cellular lifespan extension.  
More informatively, the stressed morphology of the WS cells was corrected upon treatment 
with 25. As shown in Figure 69, the comparison of treated cells with control WS cells clearly 
illustrated the extent to which stress fibre production had been reduced after treatment with 
25 (comparative data for SB203580 (1) not available).3  
 
 
Figure 68: Graph representing % increased lifespan of primary WS cells. Cont = control. SB = SB203580 (1) at 2.5 
μM. PF1.0 and PF2.0 = PF-3644022 (25) 1.0 μM and 2.0 μM, respectively.3 
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Unfortunately, similar to 21, it was ascertained that the therapeutic window of PF-3644022 (25) 
was too small to gain an accurate representation of the effect of MK2 inhibition on reversing the 
aged phenotype of primary WS cells.292 
These results support further investigation of MK2 and its role in the accelerated senescence of 
WS cells. In order to conduct these tests more therapeutically viable candidates with higher 
selectivity and cell potency would be required to give firmer conclusions as to the role of MK2 
in the premature senescence of WS cells.  
 
3.7.3. Development of more efficacious MK2 inhibitors. 
Significant developments have been made over the past few years towards more potent and 
selective MK2 inhibitors (see Chapter 1.4), though one of the major limitations in the 
development of ATP-competitive MK2 inhibitors has been low biochemical efficiency (BE).55  
Manetii et al. published a perspective recognizing a trend in ATP-competitive MK2 inhibitors and 
a large disparity between the cell based potency (EC50) and the enzymatic assay potency (IC50). 
The group speculated this to be due to ATP’s very high affinity for MK2 and a trend in low 
solubility and cell permeability of the MK2 inhibitors that have been developed and widely 
studied.55 Hence, even if an inhibitor exhibited a high binding affinity (Ki), its cellular response 
would be limited due to an inability to enter the cell and access the active site, as well as intense 
competition for binding with the high concentrations of ATP in the cell. To counteract low BE 
and achieve reasonable potency, higher drug concentrations tend to be required,293 though with 
Figure 69: F-actin stress fibres in primary WS cells. Cont = control grown in DMSO. PF2.0 = Grown in 2.0 μM PF-
3644022 (25).3 
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increasing concentrations there is a higher probability of cytotoxicity, off-target effects and drug 
attrition.55  
Therefore, Manetii et al. postulated that non-ATP-competitive inhibitors would offer much 
higher selectivity profiles.55 A limited number of non-ATP-competitive MK2 inhibitors have been 
designed, with some examples discussed in Chapter 1.4.2. Given that theoretically lower 
concentrations of these inhibitors should be necessary to effect a desirable inhibitory response 
in cells, problems of cytotoxicity and off-target effects should be reduced. Consequently, it may 
be beneficial to shift the scope of MK2 inhibitors being probed in WS cells to non-ATP-
competitive or allosterically binding candidates.  
 
3.7.4. Conclusion and future perspectives. 
Inconclusive results have been obtained so far when MK2 inhibitors have been used to 
investigate the premature ageing phenotype of WS cells. This has been postulated to be due to 
low cell potency and a typically small therapeutic window, often resulting in cessation of cell 
growth. Therefore there is still a need for the development of more selective and therapeutically 
viable MK2 inhibitors.  
One repository that has a wealth of potential is the use of non-ATP-competitive MK2 inhibitors. 
These compounds should offer an enhanced cell potency and kinase selectivity profile, lowering 
the concentration of the inhibitor required and so reducing the probability of cytotoxicity from 
off-target effects.  
Additionally, it may be beneficial for future studies to be completed using an alternative 
standard p38 inhibitor for comparison. The prototypical p38 inhibitor SB203580 (1) has been 
used extensively as a standard against which MK2 inhibitors have been measured, despite its 
known off-target effects.28 As a result, further questions tend to be raised, specifically as to 
whether specific inhibition of p38α is indeed eliciting the cellular responses being recorded.18 
Therefore, in future studies it may be beneficial to conduct comparative assays additionally 
against the p38α inhibitors RO3201195 (10) or BIRB 796 (14), both of which demonstrate much 
more selective profiles towards p38α, and have a similar effect upon the proliferation rate of 
WS cells.1,18 
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Chapter 4. Looking back ‘upstream’. The 
potential of p38 MAPK inhibitors. 
 
4.1. Introduction. 
Despite the precedent for MK2 inhibitors to act as an effective method for inhibition of the 
p38α/MK2-mediated stress-signalling pathway, thus reversing the aged phenotype of WS 
cells,19,58 it was found that the cellular response was much reduced when compared to the 
prototypical p38 inhibitor SB203580 (1).60  
It has been postulated that when the signalling cascade is interrupted downstream, other 
kinases can compensate for the disruption and use alternative pathways to regulate and elicit 
the desired immunological response.36 Therefore, continuing to probe the ‘upstream’ kinases 
remains a viable avenue of investigation.  
 
4.1.2. BIRB 796, a novel p38α MAPK inhibitor. 
Though a wide variety of structural chemotypes have been investigated as potential p38 
inhibitors (see Chapter 1.3),37 the prevalence of ATP-competitive inhibitors is quite apparent. 
Boehringer Ingelheim’s p38α MAPK inhibitor BIRB 796 (Dormapimod) (14) binds allosterically to 
the kinase outside the ATP-binding pocket,50,51 to exhibit a unique binding mode that induces a 
conformational change to catalytically inactivate the enzyme.294  
The key binding interactions were identified by Regan et al. through co-crystallization of BIRB 
796 (14) with p38α (see Figure 70).51 In addition to binding allosterically outside the ATP-pocket, 
BIRB 796 (14) interacts through an ether-linked methionine residue in the ATP-hinge region. This 
additional hydrogen-bonding interaction was found to improve the binding efficiency of the 
molecule,50 and classified 14 as a type 2 inhibitor.294 
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The molecular mechanism for inhibition of p38α by BIRB 796 (14) is through a major 
conformational change of the activation loop, or DFG motif (Asp-Phe-Gly). When the kinase is in 
its active form, the activation loop adopts the DFG-in conformation, wherein the phenylalanine 
(Phe) residue occupies a hydrophobic pocket between the two lobes of the kinase.49 When 
bound to BIRB 796 (14) this loop is flipped ‘out’ relative to the active state, into a DFG-out 
conformation.  
From X-ray co-crystallization studies of p38α with BIRB 796 (14), it has been identified that the 
Phe residue has moved out of this hydrophobic pocket, to be replaced by the tert-butyl group 
of the pyrazole.51 It has been speculated that the pyrazole moiety is crucial as a scaffold for 
positioning the tert-butyl group into this pocket,49 and helps slow dissociation rates of the ligand 
from the kinase.51  
Schneider et al. endeavoured to emulate the DFG-out conformation and slow dissociation rates 
of BIRB 796 (14) by adopting the same scaffold in their design of CDK8/CycC inhibitors (see 
Figure 71).295 They synthesized 205, with a residence time calculated to be up 1600 minutes. 
However they determined this extended residence time to be due to the number of productive 
ligand interactions rather than restriction of the kinase into the DFG-out conformation.295,296 
Figure 70: BIRB 796 (14), illustrating the key interactions when bound to p38α, as identified by Regan et al.51 
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Moffett et al. also investigated the allosteric binding potential of BIRB 796 (14), adopting the 
pyrazole-urea pharmacophore as a model with the aim to improve drug-likeness and reduce off-
target activity through removal of the ATP hinge binding element.53 Using computationally 
assisted hypotheses, the group synthesized potential candidates, some of which are detailed in 
Figure 71. The tert-butyl group and urea backbone were conserved, with the use of thiophenes 
in addition to pyrazoles explored as the 5-membered heterocyclic scaffold. It was found that 
through replacement of the toluene group with a dioxothiomorpholine (206) or diazepanone 
group (207), and the use of extended linkers, new binding interactions could be achieved. Upon 
exploring the kinase selectivity pocket, occupied by the naphthalene group in BIRB 796 (14), it 
was found that 207 exhibited a similar binding efficiency with p38α as BIRB 796 (14) with 
improved oral bioavailability in animal efficacy models. 
Interestingly, Moffett et al. found that, in a broad kinase selectivity screening against 150 
kinases, the only other kinase that was inhibited by 207 within a 150-fold range of the p38α 
MAPK IC50 value was the p38β isoform; a great improvement in selectivity over BIRB 796 (14). In 
the same panel BIRB 796 (14) was found to exhibit cross-kinase activity with 29 out of the 150 
screened kinases.53 
Figure 71: Drug candidates based upon the BIRB 796 (14) chemotype: Schneider et al.’s CDK8/CycC inhibitor 205295 
and Moffett et al.‘s azole-based p38α inhibitors 206 and 207.53 
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Indeed, despite being a very potent inhibitor for p38α, BIRB 796 (14) has been reported to 
exhibit significant binding affinity for a number of kinases,297 including the other isoforms of p38 
(p38α, p38β, p38γ and p38δ) and the Jun N-terminal kinases (JNK);259 an alternative MAPK-
signalling subfamily and a subject of great interest in the development of therapeutics for 
inflammatory diseases.24  
The significant promiscuity of BIRB 796 (14), despite the selectivity elements designed by Regan 
et al. and its novel binding mode, inspired a project to explore the potential of the BIRB 796 
pharmacophore, upon repurposing, as a chemical tool. 
 
4.1.2. Exploring the potential of the BIRB 796 pharmacophore. 
The identification of new and more pharmacologically-viable drug candidates through the 
modification of other drugs is known as the repurposing or reengineering of drugs, and is 
becoming a more prevalent trend in drug discovery.298–300 The studies conducted by Schneider 
et al.295 and Moffett et al.53 are prime examples of how medicinal chemists can adapt lead 
candidates or unsuccessful drugs, abandoned or rejected from previous development 
programmes, and repurpose them towards new targets with hindsight from former failure. 
Another emerging method is the selective optimization of side activities (SOSA). Unlike 
traditional high-throughput screening (HTS) methods employed by industry, and becoming 
acknowledged as a large investment with potentially little gain,301 SOSA methods tend to adopt 
a small screening library consisting of drug-like, bioavailable molecules. This method reduces 
the likelihood of failure at late-stage development, and tends to enable the screening of a wide 
variety of pharmacophores to ensure diversity in potential candidates.301 For instance, the 
triarylimidazole core of SB203580 (1) was originally designed as a dual inhibitor for 
cyclooxygenase (COX) and 5-lipoxygenase, and was found to inhibit the biosynthesis of 
interleukin-1 (IL-1).29,30 With further studies, the pyridinylimidazole chemotype was found to be 
a selective inhibitor for p38α MAPKs, leading to the widespread use of SB203580 (1) as a model 
p38α inhibitor and chemical tool (for more information, see Chapter 1.3.2).31,32 
These new advents in drug discovery and the potential of utilizing the novel binding mode of 
BIRB 796 (14) promoted a SOSA-inspired project with the aim of investigating the potential of 
the BIRB 796 (14) scaffold for the design of new chemical probes. Chemical probes are very 
important tools for target validation in drug discovery. They can help evaluate the roles and 
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mechanisms of kinases in vivo and in vitro and give some return on investments by companies 
in the drug discovery program.302,303 
For this project, focus was placed on adapting the selectivity elements of BIRB 796 (14), in 
particular its side activities, to find what other potential targets could be explored and if it was 
possible to increase selectivity for those kinases, whilst reducing ligand binding affinity with 
p38α. 
 
4.1.3. Identifying structural features of initial interest. 
 
In order to reduce affinity for p38α, a step-wise approach was adopted in which incremental 
changes were made to the structural features of BIRB 796 (14) identified by Regan et al. as 
important for p38α selectivity (Figure 70). One section of the molecule was focused on at a time, 
as illustrated in Figure 72, and a small library of compounds was synthesized varying the 
electronic and steric effects of R1, R2 or R3 of 208. This library was then screened for binding 
potential against a small profile of kinases and the biological results were used to determine the 
direction of further enquiries.  
In this project initial studies concentrated on modification of the aromatic ring attached to the 
urea: altering R3 of 208. The presence of an aromatic ring at this position had been a consistent 
feature, even in the early stages of Boehringer Ingelheim’s project, and so exploring its 
importance to p38α recognition was of great interest.304,305 Computational modelling by Regan 
et al. to compare the binding of SB203580 (1) and BIRB 796 (14) when bound to p38α MAPK 
found that both inhibitors had aromatic rings occupying the same kinase selectivity pocket (see 
Figure 73).50 From SAR studies of these azole-based inhibitors Regan et al. determined the 
Figure 72: Scaffold 208. R1, R2 and R3 illustrate the points of interest of the BIRB 796 (14) chemotype that will be 
altered and explored over the course of this project. 
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presence of the phenyl group at this position to be paramount for p38α inhibitor potency and 
kinase specificity.50,306  
 
Therefore, it was hypothesized that by modifying the electronic and steric factors of this ring it 
could be possible to quickly determine other kinases which would bind to this structural 
chemotype, while reducing binding affinity for p38α. Thus the synthesis of a small library of 
compounds based upon scaffold 208 was proposed. This library would be generated by 
synthesizing an initial aminopyrazole building block and reacting it with a selection of 
isocyanates to produce a range of ureas with three potential points of diversity. 
 
4.1.3. Synthetic approaches to 3,5-disubstituted pyrazoles. 
For a general introduction to pyrazoles, and synthetic approaches towards pyrazoles, see 
Chapter 1.6.2.1. For the synthesis of 3,5-disubsituted pyrazoles, like BIRB 796 (14), issues of 
regioselectivity must be considered. For instance, in the cyclocondensation of ethynyl ketones 
and hydrazines, though a well-established route to both 3- and 5-substituted pyrazoles, the 
regioselectivity of these processes can be quite low.307,308 Bagley et al. conducted a study to 
explore the regioselectivity of reactions between mono-substituted hydrazines and ethynyl 
ketones (Scheme 130) and developed a metal-free route using microwave-assisted techniques 
to facilitate rapid conversion to 3- and 5-substituted pyrazoles.308  
Figure 73: BIRB 796 (14) and SB203580 (1) highlighting the aromatic ring regions that occupy the same space when 
bound to p38α. 
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It was found that a two-step process, with initial condensation of the ethynyl ketone and 
hydrazine, followed by addition of acid and conductive heating or microwave-assisted heating, 
generally improved regioselectivity to favour formation of the 1,3-pyrazole. Additionally, it was 
found that microwave-assisted heating reduced reaction times significantly, from refluxing for 
4 to 15 h in acidified methanolic solution, to just 2 minutes heating in a sealed vessel at 120 °C.  
 
The ratio of regioisomers still varied, depending upon the substrate, but some trends in 
reactivity were observed. The mechanism for the reaction was proposed to occur either through 
a 1,4-Michael addition of the hydrazine and the ethynyl ketone, or by 1,2-addition (see Scheme 
131). Under acidic conditions, the latter process was generally observed, forming an 
intermediate ethynyl hydrazone, which on cyclization gave the 1,3-pyrazole. In the absence of 
acid, or when certain very electron-rich ethynyl ketones were used, 1,4-Michael addition was 
favoured, which on cyclocondensation, gave the 1,5-pyrazole. 
 
 
Scheme 131: Mechanistic reasoning for regioselectivity of pyrazole formation. 
Scheme 130: Synthetic route towards 1,3- or 1,5-pyrazoles investigated by Bagley et al.308 
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Togo et al. developed a regioselective, one-pot route for the synthesis of 1,3,5-trisubstituted 
pyrazoles in 2014 from mono-substituted alkynes, aldehydes and hydrazines (see Scheme 
132).309 Deprotonation of the alkyne using n-butyl lithium (n-BuLi), followed by reaction with a 
functionalized aldehyde, was proposed to form a propargylic alkoxide intermediate (209). 
Treatment with iodine and base gave a functionalized ethynyl ketone in situ, which reacted 
smoothly with hydrazine when heated to reflux to give the desired pyrazole with high 
regioselectivity in yields of 75-99%, with no need for purification of intermediates. 
 
Propargyl alcohols have also been used to direct the 1,2-addition of hydrazines to form 
intermediate propargyl hydrazines suitable for cyclization to the pyrazole. Yoshimatsu et al.310 
and Zhan et al.311 developed routes employing a tosylhydrazine and catalytic Lewis acids, 
including AuCl, Sc(OTf)3, and AgOTf to promote nucleophilic attack at the alcohol α-carbon. 
Independently, Reddy et al. developed a metal-free route, reacting N-acetyl-N-tosylhydrazine 
210 with propargyl alcohols in the presence of 10 mol% BF3●Et2O to form an intermediate 
propargyl hydrazine (211). The N,N-disubstituted hydrazine could then be reacted under basic 
conditions to give the 3,5-disubstituted pyrazole via a proposed 5-endo-dig cyclization (see 
Scheme 133).312 
Scheme 132: Togo et al.'s proposed route for synthesis of 3,5-disubstituted pyrazoles via mono-substituted 
alkynes, aldehydes and hydrazines. Reaction conditions: i) n-BuLi; ii) R2CHO; iii) I2; iv) K2CO3; v) H2NNHR3.309 
Scheme 133: Reddy et al.'s proposed mechanism for the synthesis of 3,5-disubstituted pyrazoles from propargyl 
alcohols and N,N-disubstituted hydrazines.312 Reaction conditions: i) BF3●Et2O; ii) KOtBu, iii) Base. 
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The key scaffold in BIRB 796 (14) is a 5-aminopyrazole. One popular route towards 5-
aminopyrazoles is by condensation of a β-ketonitrile and hydrazine to form an intermediate 
hydrazone (212), which undergoes 5-exo-dig cyclization and tautomerization in air to give the 
pyrazole (see Scheme 134, and Chapter 1.6.2.).76  
 
Regan et al. adopted this route to build the scaffold of BIRB 796 (14), by derivatization of the 5-
aminopyrazole as a urea through reaction with an isocyanate at room temperature.50 The utility 
of this method towards 1,3-disubstituted-5-aminopyrazoles was verified by Bagley et al. and, 
through the use of microwave-assisted techniques, they were able to improve yields and 
shorten reactions times from hours to minutes.52  
On this basis, it was proposed that the most efficient route towards the new analogue library 
would be to proceed via the microwave-mediated synthesis of 1,3-disubstituted 5-
aminopyrazoles. Using β-ketonitriles and functionalized hydrazines as starting materials, this 
route had the potential to be rapid and high yielding, as well as readily-amenable to further 
functionalization of scaffold 208 at R2 and R3 at later stages in the project (see Figure 72).  
 
4.1.4. An introduction to ureas. 
In medicinal chemistry, ureas have been found to be very useful as scaffolds due to their 
structural rigidity. For example, cyclic ureas have been used in the design of seven-membered 
scaffolds as HIV protease (HIV PR) inhibitors (Figure 74).313  
Scheme 134: Synthesis of 5-aminopyrazoles from a functionalized hydrazine and β-ketonitrile via a 5-exo-dig 
cyclization. Reaction conditions i) H2NNHR2. 
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The carbonyl groups of ureas 213 and 214 mimic the interactions of a key water molecule 
normally ligated to the protease which is unique to the retroviral proteases. The carbonyl oxygen 
forms two hydrogen bonds with isoleucine residues on either side of the symmetrical HIV PR 
dimer backbone. Lam et al. hypothesized that displacement of the water molecule should be 
energetically favourable and the rigid structure of the cyclic urea would provide a positive 
entropic effect.314 Initial lead DMP 323 (213) was found to have good oral bioavailability in dogs 
and mice, and a relatively high potency.314 However, it had reduced bioavailability in humans 
due to poor water solubility. Hence DMP 450 (214) was designed to have an enhanced 
bioavailability, through installation of weakly basic residues with a pKaH of 4.6, so that the 
molecule would be protonated in the stomach and neutral in the cell.315  
The urea group in BIRB 796 (14) is very important for binding to p38α, as ascertained by Regan 
et al. in their initial investigations.50 X-ray co-crystallization studies identified a complex 
hydrogen bonding network between the urea and glutamic acid and aspartic acid residues (see 
Figure 70). The importance of these interactions was confirmed through exchange of the 
secondary amide NH groups for tertiary NMe and methylene bridge units, which resulted in huge 
reductions in binding affinity. Also, when a thiourea was used as the central scaffold there was 
a 60-fold decrease in potency, confirming the importance of the urea moiety for binding, in 
addition to maintaining the geometry of the scaffold.   
 
 
 
 
Figure 74: HIV Protease (HIV PR) inhibitors, employing a cyclic urea to form a rigid scaffold, and hydrogen bonding 
across the dimer of the enzyme. 
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4.1.4.1. Synthetic approaches to ureas. 
 
Regan et al. synthesized their original HTS ‘hit’ urea compound 216 by reacting together 5-
aminopyrazole 215 and 4-chlorophenyl isocyanate, with stirring at room temperature in THF or 
CH2Cl2, affording 216 in high yield (85%) (see Scheme 135).50 However, as their molecular target 
became more complex, alternative methods of synthesis were necessitated. 
   
Their chosen method was via in situ formation of an isocyanate through reaction of 5-
aminopyrazole with phosgene (COCl2). In this reaction, COCl2 reacts with the amine to form a 
carbamoyl chloride with elimination of HCl. This intermediate can then collapse or undergo a 
second nucleophilic attack to eliminate another equivalent of HCl and give the isocyanate (see 
Scheme 136).316 Typically, this reaction is conducted through slow addition of the amine to cold 
phosgene to prevent build-up of the amine and carbamoyl chloride together in solution. An 
excess of phosgene is typically used to promote initial nucleophilic attack and 
dehydrohalogenation to the isocyanate.  
Regan et al. conducted their phosgene-mediated reactions in the presence of saturated aqueous 
sodium hydrogen carbonate solution (NaHCO3) to neutralize the HCl produced in solution. In 
order to synthesize BIRB 796 (14), 5-aminopyrazole 217 was reacted with phosgene. Once the 
isocyanate was formed, addition of the aminonaphthalene 219 afforded a 22% yield of 14 (see 
Scheme 135: Regan et al.'s synthesis of the initial lead compound 216 in the development of BIRB 796 (14). Reaction 
conditions: i) 4-chlorophenyl isocyanate, THF or CH2Cl2, 25 °C, overnight, 85%.50 
Scheme 136: Isocyanate formation from 5-aminopyrazoles and phosgene. Reaction conditions: i) phosgene, aq. 
NaHCO3, CH2Cl2.50 
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Scheme 137). However, phosgene is highly toxic, and will react with amines and amino acids in 
the body, and so alternative methods of urea formation are highly desirable. 
 
Bagley et al. developed a microwave-assisted synthetic route towards BIRB 796 (14) in order to 
test the p38 inhibitor in WS cells.52 They developed a route that negated the addition of 
phosgene and afforded the final urea in much improved yields (see Scheme 138). 
 
Rather than forming an isocyanate in situ, the group synthesized intermediate carbamate 218 
in moderate yield from the pyrazole-5-amine hydrochloride salt 217.HCl by reacting under basic 
Scheme 138: Bagley et al.'s microwave-assisted synthesis of BIRB 796 (14). Reaction conditions: i) p-tolylhydrazine 
hydrochloride, MeOH, MW 120 °C, 40 min, 98%; ii) 2,2,2-trichloroethyl chloroformate, NaOH, EtOAc-H2O, 0 °C to 
RT, 3 h, 49%; iii) 4-(2-chloroethyl)morpholine hydrochloride, NaOH, K2CO3, NMP, 100 °C, 2 h, 86%; iv) Pd/C, 
NH4CO2H, EtOH, MW 100 °C, 15 min, 96%; v) DMSO, MW 100 °C, 30 min, 62%52  
Scheme 137: Regan et al's synthesis of BIRB 796, using intermediate isocyanate formation. Reaction conditions: i) 
phosgene, NaHCO3, toluene, 0 °C; ii) aminonaphthalene 219, DIEA, THF, RT, overnight, 22% 
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conditions with 2,2,2-trichloroethyl chloroformate.52 Concurrently, morpholine-linked naphthyl 
amine 219 was synthesized by a base catalyzed alkylation of 4-nitronaphth-1-ol, and reduced via 
microwave-assisted palladium-catalysed transfer hydrogenation. The two fragments were then 
combined, and microwave-assisted heating at 100 °C in DMSO afforded 14 in higher overall yield 
than Regan et al.’s published route. 
For the synthesis of the first analogue library, it was determined that the reaction of 1,3-
disubstituted-5-aminopyrazoles and a diverse range of isocyanates would likely be the most 
rapid and efficient method to generate a broad spectrum of ureas. The biological results of the 
first library would determine the direction of further study. It was noted that the synthesis of 
intermediate carbamates or isocyanates may be necessitated at this later stage in order to 
investigate any areas highlighted to be of specific interest through biological studies. 
 
4.2. Synthesis of analogue library 1. 
4.2.1. Synthesis of the core pyrazole. 
For initial investigations the potential of the aromatic ring directly attached to the urea scaffold 
208, was investigated to identify alternative targets which would bind in a distinct fashion to the 
BIRB 796 (14) chemotype. It was resolved that the pyrazole section of the molecule would be 
kept consistent through the first iteration of screening, with an unsubstituted phenyl group at 
the 1N-pyrazole position and a tert-butyl group at the 3-C centre (215). 
 
Following the literature approach towards 215,52 a solution of 4,4-dimethyl-3-oxopentanitrile 
(220) and phenyl hydrazine (221) (1:1 ratio) in methanol was heated to 120 °C for 40 minutes in 
a sealed vessel using a microwave synthesizer. However, purification of 215 by trituration in light 
petroleum was problematic due to low conversion to product. Efforts to improve the reaction 
Scheme 139: Retrosynthesis for urea formation from isocyanates and 5-amino pyrazoles. 
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included conducting the reaction under an inert atmosphere, increasing the reaction 
temperature to 140 °C, extending the reaction time and using alternative methods of 
purification, including flash column chromatography on silica and by SCX-2 chromatography. 
Yields were inconsistent across all methods when methanol was used as the reaction solvent, 
ranging from zero to 76% isolated yield. The best yield was achieved by microwave-assisted 
heating in a sealed vessel at 140 °C for 60 minutes hold time and purification by SCX-2 
chromatography. By 1H NMR spectroscopic analysis, conversion to the product could be easily 
confirmed through loss of the 2-CH2 proton resonance of 220 at δH 4.23 ppm, and a new 
resonance at δH 5.40 ppm for the 4-CH pyrazole proton of 215. 
Yield and reproducibility of the reaction were improved through the use of a toluene and glacial 
AcOH mixture (5:1), and microwave-assisted heating at 120 °C for 40 minutes in a sealed vessel, 
with yields of up to 91% achieved after purification by flash column chromatography (see 
Scheme 140).317 After initial investigations, it was found a slight excess of the hydrazine favoured 
complete reaction and more efficient purification procedures, preventing any unreacted nitrile 
from co-eluting with the product. 
 
 
 
  
Scheme 140: Synthesis of 1-phenyl-3-tert-butylpyrazol-5-amine 215. Reaction conditions: i) Toluene-AcOH (5:1), 
MW 120 °C, 40 min, 91%. 
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4.2.2. Synthesis of urea analogue library 1. 
 
Once a reliable route towards 215 was established, synthesis of the first urea library was 
completed as illustrated in Table 8. A selection of isocyanates was chosen to be investigated, 
each selected to explore how changes in the steric, electronic and lipophilic properties of the 
aromatic ring might affect the selectivity of binding to p38. 
Following this synthetic route, 215 was stirred with the relevant isocyanate for 20 minutes at 
room temperature (unless otherwise stated in Table 8). The reaction mixture was then 
evaporated and the residues triturated with light petroleum to afford the urea product, with 
additional recrystallization from hot methanol if required (see Scheme 142).  
 
Overall, the results obtained were extremely satisfactory, with all isolated yields of the urea 
product  being in excess of 60% and half of them being formed in >80% yield. However, in some 
cases additional purification by recrystallization was required.  
 
Scheme 141: Retrosynthesis of urea scaffold, with reference to R3 of scaffold 208. 
Scheme 142: Reaction scheme for the synthesis of analogue library 1. Reaction conditions i) CH2Cl2, 20 min, RT.  
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Table 8: Analogue library 1 (see Scheme 142).a 
Entry No. Compound No. R1 Yield (%)b 
1 215A 1-Naphthalene 65d 
2 215B 2-Napathalene 81e 
3 215C o-Toluene 53 
4 215D 4-Ethoxyphenyl 86f 
5 215E 4-Fluorophenyl 87 
6 215F 3,5-Bis(trifluoromethyl)phenyl 88 
7 215G 4-(Benzyloxy)phenyl 82 
8 215H 3,5-Dimethylphenyl 89 
9 215I 5-Fluoro-2-methylphenyl 67 
10 215J 3,4-Difluorophenyl 67 
11 215K Phenyl 85c 
12 215L p-Toluenesulfonyl 75 
13 215M 3-Methoxyphenyl 65 
14 215N p-Toluene 62c 
a General reaction conditions: an equimolar mixture of aminopyrazole 215 and isocyanate was stirred at RT for 
20 min in CH2Cl2, unless otherwise stated. 
b Yield after evaporation in vacuo and trituration with light petroleum. 
c Yield after recrystallization from hot methanol. 
Extended reaction time: d 90 min, e 30 min, f 25 min. 
 
There were specific difficulties in the purification of products synthesized from 4-fluorophenyl 
isocyanate and 3,5-bis(trifluoromethyl)phenyl isocyanate (Table 8, entries 5 and 6). The starting 
isocyanates in these cases were viscous oils and consequently handling them was quite 
problematic, especially upon purification. If any starting isocyanate remained, trituration 
became very challenging with the product often trapped within an intractable, viscous mixture. 
Perseverance with trituration and accurate attention to stoichiometry was essential to facilitate 
the purification of these analogues, with very agreeable results.  
All products were obtained as off-white or colourless powders and structural identification was 
conducted through 1H NMR spectroscopic analysis in DMSO-d6. The final product could clearly 
be identified from a shift of the 4-CH pyrazole singlet resonance downfield and two broad singlet 
resonances for the urea protons between δH 9.5-8.5 ppm, depending upon the electron density 
of the attached aromatic group. In the 13C NMR spectroscopic analysis, the appearance of a new 
carboxyl signal was observed at approximately δC 155-150 ppm and 2D NMR 1H-13C correlation 
experiments were essential to assign the different aromatic peaks of the carbon spectrum. For 
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instance, the carboxyl and the pyrazole 3-C centre had very similar carbon shifts in all spectra. 
Differentiation could only be achieved with analysis of through-bond interactions using HMBC 
experiments, with the pyrazole 3-C centre assigned by a distinctive interaction with the nearby 
4-CH pyrazole proton. Additionally, correlations between the NH proton of the urea and ortho-
protons on the aromatic ring were required for complete assignment of resonances. 
 
4.2.3. Improving the synthesis. 
Though mostly satisfactory yields were obtained for the urea products, efforts were made to 
further optimize reaction efficiency. The reaction time was considered first, with some results 
in Table 8 taken from reactions run over slightly longer periods (entries 1, 2 and 4); overall it was 
found that the yields were extremely acceptable after just 20 minutes reaction time. The effect 
of temperature was also briefly examined; heating reactions to 25-30 °C, again, gave only 
negligible improvements to the yield compared to reactions run at 20-22 °C (room temperature). 
 
Table 9: Exploring the effect of changing solvent on urea formation (Scheme 143).a 
Entry R1 Solvent Yield (%)b 
1 o-Toluene DMF - 
2 o-Toluene THF 36c 
3 4-Ethoxyphenyl DMF - 
4 4-Ethoxyphenyl MeOH 23 
5 4-Ethoxyphenyl THF 65c 
6 3,5-Dimethylphenyl Toluene:AcOH (5:1) 65 
a General reaction conditions: An equimolar mixture of aminopyrazole 215 and isocyanate was stirred at 
RT for 20 min. 
b Yield after evaporation in vacuo and trituration with light petroleum. 
c 25 °C, overnight. 
Scheme 143: Reaction scheme for exploring the effect of changing solvents on urea formation. Reaction 
conditions: i) DMF, THF, MeOH or toluene-AcOH (5:1) 
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There were a number of problems with the solubility of both starting materials and products, 
with precipitation tending to be observed quite early in the reaction. In order to try and maintain 
homogeneity and boost yields, alternative solvents were investigated, as illustrated in Table 9.  
Solvents chosen as potential reaction media included CH2Cl2 (solvent used in library synthesis), 
DMF and THF; the solvent of choice in Regan et al.’s original route to BIRB 796 (14).50 However, 
when comparing the reaction of 215 with 4-ethoxyphenyl isocyanate in CH2Cl2 (Table 8, entry 4) 
and in THF (Table 9, entry 5), the yield was significantly reduced, from 86% to 65%, even after 
stirring overnight at 25 °C. When reactions were conducted in DMF, despite all reactants 
dissolving, the reaction failed to result in product formation after the 20 minute reaction time 
(Table 9, entries 1 and 3). 
Methanol was proposed as a desirable solvent to design a one-pot urea formation reaction, as 
acidified methanol or ethanol was the desired reaction medium for the synthesis of pyrazoles 
from hydrazine hydrochloride salts (see Chapter 4.5.3 for alternative pyrazole synthetic route). 
Thus a one-pot synthesis of ureas from the starting β-ketonitrile and hydrazine was 
hypothesized, in which simultaneous addition of all reactants could be conducted, negating 
additional time-consuming purification, to improve the efficacy of the total urea synthesis. 
However, yields were very low when reacting with 4-ethoxyisocyanate in methanol (23%) (entry 
4). Similarly, when using toluene-AcOH (5:1) solvent mixture (entry 6), investigated for the same 
aforementioned reasons, yields were greatly diminished when compared to the use of CH2Cl2 as 
solvent; from 89% (Table 8, entry 8) to 65%. Hence, plans to develop a one-pot synthetic method 
were abandoned in favour of the higher yielding step-wise route. 
After these studies, it was decided that the original synthetic method was the most reliable to 
provide a broad range of acceptable yields. Once the first library was complete, all compounds 
were purified by recrystallization from hot methanol before biological evaluation by the 
Structural Genomics Consortium (SGC) against a panel of kinases to assess their binding affinity 
compared to BIRB 796 (14). 
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4.3. Biological evaluation of analogue library 1. 
4.3.1. Introduction to drug/fragment screening. 
To assess the potential affinity and selectivity of the urea analogues in library 1, and their 
prospects as chemical probes, the thermal shifts for the ligands when bound to a range of 
protein kinases were completed using differential scanning fluorimetry (DSF) in collaboration 
with the SGC at Oxford.xi DSF is a measure of the thermal stabilization endowed by a ligand when 
bound to a protein.318 The procedure is carried out by melting the ligand-bound protein and 
comparing its melting temperature with that of the unbound protein. If the ligand binds strongly, 
more energy will be required to unfold the protein and break the new bonds, raising the melting 
temperature. The range over which the protein melts is measured using a fluorescence probe, 
and the change in melting temperature gives the thermal shift (Tm).  
The fluorescent probe used in these tests was designed to fluoresce in non-polar environments 
and quench in aqueous environments. Hence, as the protein unfolded and the hydrophobic 
areas were exposed to solvent, the probe in solution bound to those regions, protecting them 
from the solvent, would fluoresce. The fluorescence intensity was plotted as a function of 
increasing temperature and the melting temperature (Tm) was recorded at the mid-point of 
increasing fluorescence. 
This technique tends to be used as a rapid screening method, with any positive results carried 
forward into further biological assays for verification and to estimate the extent to which the 
compound could inhibit, activate or modulate the target process. 
 
4.3.2. Kinase screening panel. 
Analogue library 1 was screened in triplicate when bound to p38α, SRPK1, SRPK2, PIM1, CLK1 
and DYRK1A, kinases which are currently of interest to the SGC for the development of new 
chemical probes.  
                                                          
xi Completed by Dr Ana Clara Redondo, Professor Stefan Knapp, Structural Genomic Consortium at the 
University of Oxford. 
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Provirus integration site for Moloney murine leukemia virus (PIM-1) is a protein kinase encoded 
by the Pim1 gene and classified as a proto-oncogene.319,320 It plays an important role in the 
regulation of cell cycle progression and apoptosis, and has been found to be overexpressed in 
haematological malignancies and solid tumours, implicating an important role for it in tumour 
growth. Hence PIM kinases have been widely explored as drug targets for anticancer 
therapeutics. 
Cdc2-like kinase (CLK1) protein kinases are dual specificity kinases that can phosphorylate 
serine-threonine and tyrosine sites.321 CLK1 is the primary member of the CLK family that has 
been shown to be involved in the activation of members of the MAP kinase cascade and plays a 
role in regulating pre-mRNA splicing.322,323 Serine-arginine protein kinases (SRPK) are also heavily 
involved in pre-mRNA splicing, and both SRPK and CLK1 have been shown to phosphorylate the 
serine-arginine (SR)-rich splicing protein ASF/SF2, though they exhibit distinct specificities.324 
SRPK1 and SRPK2 are very similar in structure and function, both phosphorylating the serine-
arginine rich domains of SR proteins; a family of nuclear RNA binding proteins (RBPs) essential 
for recruiting maturing pre-mRNA for splicing.325 Pre-mRNA splicing is essential to allow 
alternative splicing, which is a key step in controlling gene expression and increasing organismal 
complexity. SR proteins demonstrate key roles in regulating splice site selection,326 and their 
activity is modulated by reversible phosphorylation. SRPK1 and SRPK2 are the main mediators 
of this phosphorylation and help to maintain levels of phosphorylated SR proteins even under 
conditions of stress and shock.325 
Dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) is also an important 
protein in the alternative splicing of genes, and has become a protein kinase of specific interest 
in the development of treatments for Downs syndrome (DS) and Alzheimer’s disease (AD).32,327 
It has been reported that individuals with neurodegenerative diseases, including DS and AD, 
exhibit increased activity of DYRK1A in the brain, with the percentage of DYRK1A positive nuclei 
in AD brains at about 10% compared to 0.5% in normal brains.327 
These protein kinases are a just a small set of the over 500 protein kinases in the human 
kinome,32  and though they have been studied widely, the development of new chemical probes 
with a high degree of selectivity are desirable for target validation and to gain a better 
understanding of the roles of these proteins in vivo and in vitro.302,303 
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4.3.3. DSF results for analogue library 1. 
 
 
 
Table 10: DSF results for BIRB 796 (14) against the panel of kinases selected.a 
Compound 
Thermal shift (Tm) (°C) 
P38α SRPK1 SRPK2 CLK1 DYRK1A PIM1 
BIRB 796 (14) 20.56 12.53 1.16 1.69 0.40 0.48 
a Thermal melting experiments were carried out using a Stratagene Mx3005p Real Time PCR machine (Agilent 
Technologies). SYPRO Orange (Molecular Probes) was added as a fluorescence probe, excitation and emission 
filters for the SYPRO-Orange dye were set to 465 nm and 590 nm, respectively. The temperature was raised 
with a step of 3 °C per minute from 25 °C to 96 °C, and fluorescence readings were taken at each interval. The 
observed temperature shifts, 'Tmobs, were recorded as the difference between the transition midpoints of 
sample and reference wells containing protein without ligand in the same plate and determined by non-linear 
least squares fit. Experiments were performed in triplicate and data were analyzed as previously described.318 
Table 11: Analogue library 1 (215A-215N) Tm shifts as measured by DSF when bound to p38α 
and SRPK1.a 
Entry No. Compound No. R1 
Tm Shift (°C) 
P38α MAPK SRPK1 
1 215A 1-Naphthalene 15.80 2.92 
2 215B 2-Naphthalene 10.64 8.55 
3 215C o-Toluene 13.08 1.34 
4 215D 4-Ethoxyphenyl 7.59 8.02 
5 215E 4-Fluorophenyl 12.25 7.13 
6 215F 3,5-Bis(trifluoromethyl)phenyl 2.03 9.19 
7 215G 4-(Benzyloxy)phenyl 4.56 5.75 
8 215H 3,5-Dimethylphenyl 7.88 4.39 
9 215I 5-Fluoro-2-methylphenyl 12.09 2.82 
10 215J 3,4-Difluorophenyl 12.43 11.69 
11 215K Phenyl 12.30 3.91 
12 215L p-Toluenesulfonyl 0 0 
13 215M 3-Methoxyphenyl 9.60 4.38 
14 215N p-Tolyl 11.40 4.71 
15 BIRB 796 (14) 20.56 12.53 
a Thermal melting experiments carried out as detailed in Table 10. 
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As a comparison, BIRB 796 (14) was also screened against the panel of kinases for its activity 
(see Table 10). A thermal shift (Tm shift) above 7 was indicative of good stabilization of binding 
with the protein. BIRB 796 (14) strongly stabilized p38α and SRPK1, with Tm shifts of 20.6 and 
12.5 °C respectively, however against the other kinases in the panel there was a very low binding 
affinity. 
For analogue library 1 similar results were observed, with most compounds exhibiting some 
stabilizing effect when bound to p38α and SRPK1, and very low affinities for SRPK2, PIM1, CLK1 
and DYRK1A (for full data see supplementary information). Table 11 illustrates the results of the 
DSF screening for analogue library 1 against p38α and SRPK1. Heat mapping has been used to 
help illustrate the results obtained, with red for the high, white for the average, and green for 
the low Tm shift values. 
From these results, a number of trends were observed. With regards to p38α activity, the 
addition of polar groups seemed to reduce affinity of the ligand for p38α. For instance, 
compounds 215D and 215M, with thermal shifts of 7.59 and 9.60 °C, respectively, had a much 
reduced affinity compared to the non-functionalized phenyl derivative 215K, with a thermal shift 
of 12.30 °C (see Figure 75). Conversely, the polar 4-(benzyloxy)phenyl derivative 215G had a 
lower thermal shift value of 4.56 °C, but this may have been due to unfavourable steric clashes 
or entropic changes due to movement of the benzyloxy-chain when bound to the kinase, 
reducing its binding affinity. 
 
Despite increasing lipophilicity in 3,5-disubstituted compounds 215F and 215H, a characteristic 
that Regan et al. claimed to contribute to p38α binding affinity,50 when bound to p38α there 
was a decrease in the thermal shift when compared to the fairly lipophilic 215K and 215N (see 
Figure 75: Analogue library 1. Thermal shift data (°C) when R1 = tert-butyl, R2 = phenyl, observing the effect of addition 
of polar groups on the degree of stabilization when bound to p38α and SRPK1. 
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Figure 76). However, it was found that when a large, lipophilic aromatic group was substituted 
onto the compound, such as with naphthalene based molecule 215B, the stabilizing effect when 
bound to p38α was significantly higher. This suggested that the positioning of the lipophilic 
groups at the meta positions of the phenyl ring could be important to destabilizing binding with 
p38α. 
 
Looking at binding affinity with SRPK1, two interesting trends were observed. The first was the 
propensity of fluorine-containing substituents on the ring to enhance the binding affinity. For 
instance, the 3,4-difluorophenyl based urea 215J had the strongest binding affinity for SRPK1 of 
all the tested molecules, with a thermal shift of 11.69 °C (see Figure 76). Despite offering no 
selectivity for SRPK1, exhibiting a high thermal shift when bound to p38α as well, the stabilizing 
effect endowed by this compound when bound to SRPK1 presented itself as a good prospective 
lead for the design of the next library.  
Figure 76: Analogue library 1. Thermal shift data (°C) when R1 = tert-butyl, R2 = phenyl, observing the effect of 
lipophilicity and steric factors on Tm shift when bound to p38α and SRPK1. 
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The 3,5-bis(trifluoromethyl) analogue 215F also exhibited a high degree of stabilization for 
SRPK1, and a lower affinity for p38α when compared to its protonated equivalent 215H (see 
Figure 76). Thus it was decided that the potential of fluorinated analogues would be further 
explored in analogue library 2, with special attention to meta-substituted derivatives, to further 
assess the potential destabilization of binding with p38α. 
The second trend observed was that when an electron-donating substituent was in the para 
position of the ring, affinity of binding with p38α was reduced (see Figure 75, 215D and 215G), 
while binding with SRPK1 appeared to exhibit a higher stabilizing effect. For instance, the 4-
ethoxyphenyl compound 215D had a higher stabilizing effect on SRPK1 than the unsubstituted 
phenyl 215K, with thermal shifts of 8.02 and 3.91 °C, respectively. Though it should be noted 
that 4-(benzyloxy)phenyl (215G) had a lower thermal shift with SRPK1 of 5.75 °C; though, again, 
this may have been due to additional steric factors or ligand flexibility. Nevertheless, an increase 
in the electron density of the aromatic ring bound to the urea through the addition of small 
electron-donating substituents at the para position could be another avenue of investigation.  
 
4.3.4. Conclusion. 
 
Using the data collected from the biological studies of analogue library 1, it was decided that 
another library would be synthesized to focus on the ‘hit’ compound 3,5-
bis(trifluoromethyl)phenyl urea 215F. This compound exhibited an increase in stabilization when 
bound to SRPK1 whilst also dramatically reducing affinity for p38α.  
Figure 77: Inferred SAR from analysis of DSF data generated by analogue library 1. 
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From the biological assay, an inferred structure-activity relationship (SAR) was assembled 
(Figure 77) exploring how substitution on the aromatic ring might have affected binding to p38α 
and SRPK1. It was decided that development of analogue library 2 would continue to probe the 
characteristics found to be conducive to reducing p38α affinity, with additional exploration of 
the potential to increase SRPK1 stabilization through the use of meta-substituted fluorinated 
aromatics. Hence, in addition to the 3,5-bis(trifluoromethyl)phenyl, it was decided that 3,5-
difluorophenyl ureas would be an interesting pharmacophore to explore. 
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4.4. Analogue library 2. Taking the ‘hit’ forward. 
A second library of compounds was designed to probe the role of the pyrazole substituent in 
selectivity and binding, whilst retaining those characteristics found to be most promising for 
SRPK1 activity, most notably, the incorporation of fluorinated aromatics. 
 
4.4.1. An introduction to fluorine. The C-F bond as a tool in 
medicinal chemistry. 
The carbon-fluorine single bond is one of the strongest known, with a bond strength only 
surpassed by the silicon-fluorine bond (485 and 582 kJ mol-1, respectively101). This is due to 
silicon being slightly more electropositive and polarizable than carbon. The dipole of the carbon-
fluorine bond is so extreme that the bond can be considered to have more electrostatic than 
covalent character. Hence this functionality tends to interact intermolecularly through 
electrostatic interactions, specifically dipole-dipole or point charge-dipole interactions. Time-
dependent interactions, including ion-induced dipole, dipole-induced dipole and dispersion 
interactions however are not as common due to the low polarizability of the bond.328 The 
fluorine in the carbon-fluorine bond also has suppressed nucleophilicity compared to other 
halogens, and so will tend not to act as a HBA in solution, though such interactions have been 
observed in the gas phase and are possible when there is an excess of proton donors 
present.328,329  
Fluorine is widely used in medicinal chemistry as a method to improve the pharmacokinetics 
(PK) of molecules, to reduce molecular susceptibility to metabolism and as probes to investigate 
the metabolic stability of certain functional groups in lead development.  
The size of fluorine makes it a good candidate to exchange with protons and oxygens when 
investigating their potential roles in ligand-kinase binding. For instance, exchange of a fluorine 
for a proton can help elucidate its significance while conserving the steric environment. This 
exchange can result in significant changes to the electronic properties of the molecule, for 
example, lowering the pKa of neighbouring functional groups, which in some instances can 
increase solubility and improve PK.330  
Exchange of fluorine for oxygen does not significantly affect the electronic properties of a 
structure, as both are very electronegative atoms, but can be used to probe the significance of 
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π-bonding and proton acidity. For example, exchange of a carbon-oxygen double bond in favour 
of a carbon-fluorine single bond, or a CF2 group, necessitates a change in the hybridization state 
of carbon. Exchange of a carbon-oxygen single bond, like in C-OH, for a C-F group, removes the 
acidic proton and can help probe potential significance as a HBD. This method can also be used 
to investigate the relative importance of hydrogen bonding versus polarisation for a C-OH unit, 
exploiting the ‘polar hydrophobic’328 nature of C-F relative to C-OH; as fluorine reduces 
polarizability and increases hydrophobicity.329 
As a tool to improve the PK of a drug candidate, not only does fluorine improve solubility and 
hence absorption and distribution, but it can also affect drug metabolism and excretion. The 
excretion of drug molecules from the body is very important to prevent the build-up of foreign 
toxins in cells and fatty-tissues. Foreign compounds that cannot be assimilated into normal 
pathways of excretion are metabolized to make them more soluble, often through addition of 
polar groups, or conjugation with more hydrophilic groups to enable excretion through urine or 
bile.331–333  
The extent of metabolism can be predicted from the physicochemical characteristics of the 
molecule, including lipophilicity, pKa, molecular weight and the sites open to potential metabolic 
modification. Since the carbon-fluorine bond is so strong, exchange of a hydrogen for a fluorine 
can block metabolism as well as increase polarity. Additionally, fluorine can inductively reduce 
electron density of groups to diminish the extent of oxidation. Hence, para-fluoro substitution 
of electron rich aromatic compounds is a common method to protect the ring from oxidative 
enzymes, whilst retaining the steric environment.  
Figure 78: Fluorine containing drugs; Trametinib (222), Olaparib (223) and Prevacid (224).334,335 
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Examples of fluorine-containing drugs are detailed in Figure 78, including Trametinib (222), a 
MEK (MAPK/ERK kinase) inhibitor used in the treatment of melanomas with BRAFV600E/K 
mutations. Installation of the 2-fluoroaniline substitutent increased hydrophobicity and 
antitumor potency 4-fold.334 Olaparib (223), a poly(ADP-ribose) polymerase (PARP) inhibitor, 
developed for treatment of numerous cancers when combined with DNA-damaging agents. 
Introduction of fluorine on the central benzene ring enhanced cellular activity whilst maintaining 
potency. Additionally it was speculated that repulsive electrostatic interactions between the 
fluorine and the C-3 carboxyl group restricted rotation, lowering the molecular entropy to 
enhance cell permeability of the compound.335 And the trifluoromethyl-containing Prevacid 
(224) is a ‘proton-pump inhibitor’ which reacts with acid in the stomach to undergo 
rearrangement to a sulfenamide, which then binds irreversibly to the K⁺/H⁺ ATPase via a cysteine 
residue.334 
With the number of new and approved drugs containing fluorine increasing from an estimated 
20% in 2010336 to approximately 30% in 2016, the impact of fluorine upon medicinal chemistry 
has been dramatic, especially as a tool in lead optimization.334 
 
4.4.2. Pyrazole modification. 
Regan et al. found early on in their hit-to-lead development towards BIRB 796 (14) that 
substitution of a phenyl group at the 1N-pyrazole position could improve ligand binding affinity 
40-fold, when compared to a methyl group in the same position.50 X-ray co-crystallization 
studies identified that the phenyl ring conducted important lipophilic ligand-kinase interactions 
and acted as a ‘water shield’ for the urea moiety, protecting it from solvation and enabling the 
urea oxygen and NH to act as HBA and HBD with aspartic acid and glutamic acid residues in the 
allosteric binding pocket. Regan et al. deemed these interactions essential for the strong binding 
of the inhibitor, and to stabilize the DFG-out conformation.50  
These studies implied that altering the phenyl ring may result in dramatic changes to p38α 
binding affinity. Hence, for analogue library 2, the potential of 3,5-bis(trifluoromethyl)phenyl (F) 
and 3,5-difluorophenyl (O) derived ureas were explored with a range of 1N-pyrazole 
substituents, as illustrated in new scaffold 225. Changes to R2 concentrated on the importance 
of steric bulk and changes to the lipophilicity of the phenyl ring, in addition to the importance 
of the aromatic group for SRPK1 activity, with analogues exchanging the phenyl ring in favour of 
an aliphatic group. 
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Another moiety of interest was the tert-butyl group of the pyrazole (225, R1), another consistent 
feature in Regan et al.’s development of a suitable clinical candidate.50 The group found even 
small alterations resulted in dramatic changes to activity, with reduction in size to a methyl 
group causing complete loss of activity and addition of polar groups reducing binding affinity. 
They inferred the importance of a lipophilic unit at 3-C to enable p38α binding, with X-ray co-
crystallization studies used to confirm that the tert-butyl group occupied a Phe pocket vacated 
upon binding with BIRB 796 (14), helping to maintain the DFG-out conformation (see Chapter 
4.1).51 It was decided that only slight changes should be made for analogue library 2, with further 
investigation to be considered in light of any interesting results from this screening iteration.  
In order to generate a new analogue library incorporating all these features, a new pyrazole 
precursor subset library was synthesized. 
 
4.4.3. Synthesis of pyrazole subset library. 
Using the same retrosynthetic approach as described previously, 3-oxopentanitrile derivatives 
were reacted with substituted hydrazines or hydrazine hydrochloride salts to prepare the 
desired precursor subset.   
 
For the hydrazine free-base derived reactions, conditions were employed as previously stated, 
with microwave-assisted heating at 120 °C for 40 minutes in toluene-glacial AcOH (5:1), and 
purification by flash column chromatography. For reactions adopting the hydrazine 
Figure 80: Pyrazole model for the design of a new subset library. 
Figure 79: Analogue library 2 scaffold, with a fluorine-containing 3,5-disubstituted phenyl ring, varying R1 and R2 
substituents on the pyrazole. 
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hydrochloride salt precursor, the nitrile and hydrazine salt were reacted at 130 °C for 20 minutes 
using microwave-assisted heating in a sealed vessel, in the presence of a catalytic amount of 
conc. HCl in ethanol. The hydrazine salt tended to be used in slight excess to promote complete 
reaction and the excess was easily removed through a basic work-up to give the pure product, 
usually without the need for further purification.  
All members of the pyrazole subset library were isolated and carried forward as the free base, 
and the synthetic results are shown in Table 12. For compound 229 (entry 6), 1,3-di-tert-butyl-
1H-pyrazol-5-amine, the mixture was heated overnight at reflux. This was because it had 
previously been reported that conducting the reaction in a closed vessel could result in an 
explosive rupture of the tube52 due to a build-up of pressure, possibly as a result of the 
production of isobutene gas.317 
Table 12: Synthetic results of pyrazole subset library. 
Entry No. Compound No. R1 R2 Yield (%) 
1 215 tert-Butyl Phenyl 91a 
2 217 tert-Butyl 4-Methylphenyl 83b 
3 226 tert-Butyl Methyl 95a 
4 227 tert-Butyl 4-Fluorophenyl 88b 
5 228 tert-Butyl 4-Nitrophenyl 48a 
6 229 tert-Butyl tert-Butyl 61b,c 
7 230 tert-Butyl 4-Bromophenyl 58b 
8 231 Phenyl Methyl 50a,d 
9 232 Phenyl Phenyl 91a,d 
Microwave-assisted reaction conditions: A mixture of 4,4-dimethyl-3-oxopentanitrile (220) (1 equiv.) and 
ahydrazine (1.01 equiv.) in  toluene-AcOH (5:1) were irradiated at 120 °C (initial power 100 W) for 40 minutes; or 
bhydrazine.HCl (1.01 equiv) in EtOH with catalytic conc. HCl was irradiated at 130 °C (initial power 200 W) for 20-
30 min. Reaction times refer to hold times at the given temperature through modulation of the initial power. 
c Reflux conditions, 18 h reaction time. 
d Using benzoylacetonitrile. 
 
Scheme 144: Synthesis of pyrazole subset library. Reaction conditions: i) toluene-AcOH (5:1); ii) MeOH, cat. conc. HCl. 
(Table 12). 
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From the results in Table 12, it was clear that the use of the hydrazine free-base or the 
hydrochloride salt did not adversely impact the isolated yields, which overall were very high. 
However there were some compounds which were problematic in their synthesis and isolation.  
 
The synthesis of 228 and 230 (entries 5 and 7), under the chosen reaction conditions, did not go 
to completion, resulting in residual nitrile in the crude reaction mixture which caused 
complications during flash column chromatography purification. Extending the reaction time 
(overnight reflux towards 229) and using a large excess of the hydrazine did not improve the 
conversion. The reason for this poor reactivity was most likely due to the electron-withdrawing 
group on the phenyl hydrazine, as both the 4-nitro and 4-bromophenyl substituents would 
reduce the nucleophilicity of the hydrazine.  
Figure 81: Pyrazole subset library. Yields given as shown in Table 12. 
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For 231, the yield was also quite low, but this was due to an accidental excess of the hydrazine 
being used, resulting in co-elution during purification by flash column chromatography. 
Recrystallization of the crude material afforded the final product in 50% yield. 
 
4.4.4. Synthesis of analogue library 2. 
 
Table 13: Synthesis of analogue library 2.a 
Entry No. Compound No. R1 R2 Yield (%)b 
1 217F CMe3 p-Tolyl 40c 
2 226F CMe3 Methyl 30c 
3 227F CMe3 4-Fluorophenyl 75 
4 228F CMe3 4-Nitrophenyl 35c 
5 229F CMe3 tert-Butyl 72 
6 230F CMe3 4-Bromophenyl 59 
7 231F Phenyl Methyl 73 
8 232F Phenyl Phenyl 65c 
9 215O CMe3 Phenyl 49c 
10 217O CMe3 p-Tolyl 64 
11 226O CMe3 Methyl 78c 
12 227O CMe3 4-Fluorophenyl 40c 
13 228O CMe3 4-Nitrophenyl 25d 
14 229O CMe3 tert-Butyl 69c 
15 230O CMe3 4-Bromophenyl 54c 
16 231O Phenyl Methyl 85c 
17 232O Phenyl Phenyl 70c 
a Reaction conditions: 1.1 equivalents of 5-aminopyrazole and the corresponding isocyanate was stirred at RT for 
20 min in CH2Cl2.  
b Isolated yield after evaporation in vacuo and trituration with light petroleum . 
c Yield after recrystallization from hot methanol. 
d Reaction was stirred at RT for 18 h 
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Using 3,5-bis(trifluoromethyl)phenyl (F) isocyanate and 3,5-difluorophenyl (O) isocyanate, 
synthesis of analogue library 2 was carried out as described previously, by stirring a solution of 
the respective 5-aminopyrazole and isocyanate in CH2Cl2 for 20 minutes at room temperature, 
followed by product isolation by trituration and recrystallization where necessary. The results of 
the synthesis of analogue library 2 are detailed in Table 13. 
Overall the reactions yields were far lower than those of analogue library 1, though this was 
mostly due to problems with product purification. As previously mentioned (Chapter 4.2.2) the 
fluorinated isocyanates were viscous oils and this complicated trituration if any unreacted 
isocyanate remained. It was also necessary for most of the ureas to be recrystallized as, unlike 
for library 1, trituration was seldom sufficient to remove all impurities.  
In particular, isolation and purification of the 4-nitrophenyl and 4-bromophenyl derivatives, 
228F, 228O, 230F and 230O, were problematic. Poor reproducibility of reactions, low reactivity 
and poor stability of products became prevalent issues, especially when reacting the respective 
5-aminopyrazoles with 3,5-difluorophenyl isocyanate. For instance, when reacting 228 with 3,5-
difluorophenyl (O) isocyanate only starting material was isolated upon trituration after stirring 
at room temperature for 20 minutes. An overnight reaction was necessary for product formation 
in these cases, with a 25% yield of 228O achieved after recrystallization (Table 13, entry 13).  
Isolation of 3,5-difluorophenyl derived urea 230O was also extremely problematic. When first 
attempted the reaction gave a reasonable yield with no substantial issues, however 
reproduction of results was inconsistent, with reaction mixtures necessitating isolation by flash 
column chromatography and additional trituration to provide enough compound for biological 
evaluation. Efforts to further purify 230O by recrystallization only returned an oily residue, and 
so a sample was submitted for biological testing following 1H NMR spectroscopic analysis 
without prior recrystallization.  
Structural characterization of these products was carried out by 1H and 13C NMR spectroscopic 
analysis. In the 1H NMR spectrum, a downfield shift of the pyrazole 4-CH proton resonance was 
characteristic of urea formation, and differentiation of resonances in the two aromatic rings was 
facilitated by analysis of fluorine-proton and fluorine-carbon splitting patterns. Identification of 
resonances in the 13C spectrum for the 3,5-bis(trifluoromethyl)phenyl (F) and the 3,5-
difluorophenyl (O) rings were unambiguously clarified by carbon-fluorine splitting.  
For the 3,5-difluorophenyl rings, interesting splitting patterns were noted, especially  for the 2,6-
CH carbons, which exhibited second order coupling with the fluorine. For example, N-(3,5-
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difluorophenyl)-N’-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)urea (217O) featured an AA’XX’ 
spin system, and was observed upon 13C NMR spectroscopic analysis (see Figure 82). This 
splitting pattern arose as a result of the two fluorines of the ring being chemically equivalent but 
magnetically inequivalent,337 resulting in the unusual resonance at δC 100.9 ppm correlating to 
the 2,6-CH aromatic carbons. This splitting pattern was consistently observed in all 13C NMR 
spectra generated from the O-derived urea compounds. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 82: 13C NMR spectrum (δC 103 - 95 ppm) of N-(3,5-difluorophenyl)-N’-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-
yl)urea (217O), illustrating the second order C-F coupling. 
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4.5. Biological evaluation of analogue library 2. 
4.5.1. DSF results from analogue library 2. 
Analogue library 2 was screened against the same panel of kinases as investigated previously, 
with calculation of the thermal shifts conducted using identical DSF methods. Similar to library 
1, there was minimal ligand binding with SRPK2, CLK1, DYRK1A and PIM1A (see supplementary 
information for full data), however, there were some interesting changes in the thermal shifts 
observed upon ligand binding to p38α and SRPK1. Table 14 contains the thermal shift data for 
all 3,5-bis(trifluoromethyl)phenyl (F) derived ureas and Table 15 contains the data for all 3,5-
difluorophenyl (O) derived ureas when bound to p38α and SRPK1. 
 
Table 14: DSF results for analogue library 2, compounds 217F, 226F-232F.a 
Entry No. Compound No. R1 R2 
Tm  Shift (°C) 
P38α MAPK SRPK1 
1 217F CMe3 p-Toluene 1.17 9.95 
2 226F CMe3 Methyl 1.24 11.80 
3 227F CMe3 4-Fluorophenyl 0.82 11.81 
4 228F CMe3 4-Nitrophenyl 1.54 -0.61 
5 229F CMe3 tert-Butyl 0.49 1.15 
6 230F CMe3 4-Bromophenyl 0.70 12.25 
7 231F Phenyl Methyl 1.86 2.57 
8 232F Phenyl Phenyl 0.81 1.72 
a Thermal melting experiments carried out as detailed in Table 10. 
 
The first very noticeable aspect of these findings compared to the thermal shift data collected 
for analogue library 1 (Table 11) was that, in general, the affinity of the compounds for p38α 
appeared to be greatly reduced, whilst the stabilizing effect upon binding to SRPK1 appeared to 
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be significantly higher; as can be seen through comparison of the heat maps between Tables 11, 
14 and 15.  
 
Table 15: DSF results for analogue library 2, compounds 215O, 217O, 226O - 232O.a 
Entry No. Compound no. R1 R2 
Tm Shift (°C) 
P38α MAPK SRPK1 
1 215O CMe3 Phenyl 5.18 13.72 
2 217O CMe3 p-Toluene 6.48 14.82 
3 226O CMe3 Methyl 2.84 6.37 
4 227O CMe3 4-Fluorophenyl 5.33 12.62 
5 228O CMe3 4-Nitrophenyl 7.51 14.15 
6 229O CMe3 tert-Butyl 0.10 0.14 
7 230O CMe3 4-Bromophenyl 5.10 12.72 
8 231O Phenyl Methyl 0.22 1.34 
9 232O Phenyl Phenyl 2.59 2.27 
a Thermal melting experiments carried out as detailed in Table 10. 
 
Regarding comparison of the two branches of analogue library 2, and the contrasting heat maps 
produced from the thermal shift data of the compounds, there were some notable differences 
upon altering the phenyl urea substituents. 
The 3,5-difluorophenyl (O) ureas in Table 15 exhibited, overall, a much higher degree of 
stabilization for binding with SRPK1, but appeared to result in some low to moderate 
stabilization when bound to p38α. When compared with the thermal shift data for all the 3,5-
bis(trifluoromethyl)phenyl (F) ureas (Table 11, entry 6 and Table 14), the larger fluorinated 
substituents appeared to have a markedly more significant destabilizing effect when bound to 
p38α, whilst seeming to promote stabilization of binding with the SRPK1 kinase to a similar 
degree as the O-urea series. 
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Reviewing the pyrazole modifications, there were some changes which appeared to 
considerably affect binding to both kinases, though with varying degrees of severity. Foremost, 
the most significant loss of binding stabilization was when the 3C-pyrazole tert-butyl group (R1) 
had been exchanged for a phenyl group; 231F, 232F, 231O and 232O all demonstrated thermal 
shifts below 3 °C for SRPK1 and p38α (see Figure 83).  
 
In Regan et al.’s original findings they stated that the tert-butyl group at the pyrazole 3-position 
was essential to maintain the DFG-out conformation of p38α, as it occupied a hydrophobic 
pocket vacated by a phenylalanine residue upon rearrangement (discussed in Chapter 4.1).51 
Therefore, it could be concluded that a phenyl group cannot successfully sustain the same 
lipophilic interactions as the bulky tert-butyl group in the binding pocket. This would infer a 
conserved binding pocket in this region for p38α and SRPK1, and suggested that retaining the 
tert-butyl group could also be important for SRPK1 activity. Further investigation of this binding 
pocket in SRPK1 could be conducted once more is understood about the ligand-binding of these 
models, for instance, through exploring the use of isopropyl or ethyl groups, or fluorinated 
variants. 
The thermal shift data generated from the compounds in which the 1N-pyrazole phenyl ring (R2) 
was exchanged for an alkyl group, with retention of the 3C-tert-butyl group, proved to be quite 
interesting. From the hypotheses of Regan et al. on the significance of the phenyl ‘water 
shield’,50 it was expected that there would be a significant loss of binding affinity upon 
substitution of a methyl group, however this was not found to be the case (see Figure 84).  
 
 
Figure 83: Analogue library 2. Thermal shift data (°C) for compounds with reduced binding affinity when R1 = phenyl. 
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Though compounds 226F and 226O both exhibited very low thermal shifts when bound to p38α, 
these were not dissimilar to the other compounds of analogue library 2. Interestingly, for the 
3,5-bis(trifluoromethyl)phenyl urea 226F, the exchange actually increased the stabilization of 
binding to SPRK1 with a thermal shift of 11.80 °C, compared to when R2 = p-toluene (Tm = 9.9 °C) 
(Table 14, entry 1).  
This trend was not emulated by 3,5-difluorophenyl urea 226O, which had only a moderate 
stabilization effect when bound to SRPK1 (see Figure 84). X-ray co-crystallographic studies of 
these compounds when bound to SRPK1 would help to elucidate this curious result, and 
potentially enable comparisons to be drawn between the hydrogen bonding networks present 
when SRPK1 and p38α were bound to this molecular pharmacophore.  
Conversely, when the 1N-pyrazole position (R2) was substituted with a tert-butyl group, a 
dramatic reduction in binding affinity was observed for both incarnations of the urea in analogue 
library 2 (see Figure 84, 231F and 231O). This implied that steric bulk at the 1N-pyrazole position 
was not conducive to support stabilization of the complex when bound to p38α or SRPK1.   
Looking at the effect of substituents on the phenyl ring at the pyrazole 1N-position in analogue 
library 2, when R2 was 4-fluorophenyl (see Figure 85, 227F and 227O), the compounds appeared 
to exhibit a much higher degree of stabilization when bound to SRPK1. It was noted that 3,5-
difluorophenyl urea 227O still appeared to demonstrate moderate affinity for p38α; this was, as 
mentioned, a consistent trend for the 3,5-difluorophenyl series. 
 
 
 
Figure 84: Analogue library 2. Thermal shift data (°C) when R2 = alkyl group when bound to p38α and SRPK1. 
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The para-toluene 3,5-difluorophenyl urea derivative 217O also resulted in a higher thermal shift 
when bound to SRPK1 than its trifluoromethyl counterpart 217F, with thermal shift values of 
14.82 and 9.95 °C respectively (Figure 86. Table 14, entry 1 and Table 15, entry 2). Therefore it 
may be worth investigating this aryl para-substituent further, either by substituting with larger 
alkyl groups or some fluorinated groups.  
 
An interesting change in activity between the different urea derivatives was seen with the 4-
nitrophenyl pyrazole series (228). The 3,5-difluorophenyl urea analogue 228O had a very high 
degree of stabilization for SRPK1, with a thermal shift of 14.15 °C and a marginal affinity for p38α 
(see Figure 86. Table 15, entry 5), whilst the 3,5-bis(trifluoromethyl)phenyl analogue 228F 
exhibited a low affinity for p38α (Tm shift = 1.54 °C), and a negative thermal shift with SRPK1 
(Table 14, entry 4). A negative value could be due to the compound binding preferentially to the 
Figure 85: Analogue library 2. Thermal shift data (°C) when R2 = 4-fluorophenyl when bound to p38α and SRPK1. 
 
Figure 86: Analogue library 2. Thermal shift data (°C) when altering the para-phenyl substituent from slightly 
electron donating (Me) to electron withdrawing (NO2).  
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unfolded state of the protein or may indicate that the fluorescence of the compound had 
interfered with the fluorescence of the dye. Nevertheless, this change in activity was very 
interesting as these were the only compounds of the series which exhibited such dissimilar 
behaviour upon switching the urea phenyl ring. 
One compound of particular interest was the 3,5-bis(trifluoromethyl)phenyl 4-bromophenyl 
pyrazoyl urea 230F. This compound not only demonstrated a high affinity for SRPK1 and low 
affinity for p38α (Figure 86), but also showed some binding affinity for the other kinases tested 
in the DSF assay: CLK1A and PIM1A, with thermal shifts of 19.53 and 11.48 °C respectively (see 
supplementary information). This was of particular interest as none of the other compounds 
exhibited this stabilizing effect. In order to confirm the apparent activity of 230F, further 
biological tests could be carried out to ascertain why this activity was exhibited.  
 
4.5.2. Conclusion. 
Overall, from the thermal shift data heat map generated from analogue library 2, it could be 
observed that there was a much higher degree of stabilization for these compounds when bound 
to SRPK1 than observed for analogue library 1. Additionally, the affinity of binding for p38α had 
been dramatically decreased, with most compounds in analogue library 2 exhibiting moderate 
to low thermal shifts when bound to p38α. Therefore, from this data, it can be inferred that the 
BIRB 796 (14) chemotype has indeed been reengineered to favour a new target, with selective 
improvement in binding with SRPK1 and a dramatic reduction in binding affinity for the p38α 
kinase. 
Through fluorination of the urea aromatic ring, significant stabilization was observed when the 
molecules were bound to SRPK1. With further investigation, it was found that the size or nature 
of the fluorine substituents seemed to be an important factor in determining the extent of 
stabilization when bound to p38α, with the larger 3,5-bis(trifluoromethyl)phenyl ureas 
exhibiting reduced affinity for p38α compared to the 3,5-difluorophenyl ureas. 
The potential of the bulky trifluoromethyl substituent, sometimes referred to as being “slightly 
larger” than an isopropyl group,330 may be worth further investigation. For instance, exploring 
the potential of isopropyl or CHF2 substitution, or some larger substituents at the 3,5-postions, 
symmetrical and unsymmetrical, to further probe this region of chemical space. 
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Compound 227F was determined to be the compound with the most promise for further 
development in the design of an SRPK1 probe. With a very low binding affinity for p38α, and a 
high degree of stabilization when bound to SRPK1, the poly-fluorinated 227F also presented 
itself as the most pharmacokinetically viable candidate (see Figure 85). 
Bearing this ‘lead compound’ in mind, other potential aspects which could warrant further 
investigation include the importance of the ‘water shield’ 1N-pyrazoyl phenyl group (R2), and 
whether there is a similar hydrogen bonding network present when the urea scaffold is bound 
into SRPK1 as with p38α. Also, exploring the potential of the para-substitution on the 1N-
pyrazolyl phenyl group, including extending the group further into chemical space, with more 
varied substituents and the potential of heteroatoms and heteroaromatic rings. 
 
4.6. Future perspectives. 
In order to progress this work, the results of the thermal shift data needs to be verified through 
additional biological tests to validate the conclusions that have been drawn. From these 
additional tests, a better understanding of the compound pharmacodynamics (PD) with SRPK1 
would be established, including the mode of binding, amino acids involved and the kinetics of 
binding; all insights which would help in the design of a third library.  
Pharmacokinetics (PK) are extremely important to consider when designing any biological 
probe. For the probe to be useful in vivo it must be stable to metabolism in order to reach the 
target of interest. Hence the design of a new library should also concentrate on developing 
compounds with more drug-like properties, with an emphasis on improving the potential ADME 
characteristics of the compounds.  
 
4.6.1. Pharmacodynamics and verifying biological interactions. 
In order to verify the DSF results, there are a number of additional biological screens that would 
be beneficial before progressing in the design of a new library. For instance, isothermal titration 
calorimetry (ITC) is a method that can be used to determine the enthalpy of binding. This is done 
by measuring the heat released on binding a ligand to a protein against a blank sample.338 This 
method is widely used to validate initial hits, and the comparison of ITC values with the library 
DSF results could help direct efforts to further optimize binding.  
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NMR spectroscopic studies could also be used to observe the strength of ligand binding. Periodic 
spectra would be run of the target protein and ligand mixed in solution, with slow addition of a 
competitive ligand of known binding affinity. This method could also be used to help confirm 
whether the compounds of libraries 1 and 2 bind allosterically to SRPK1 and p38α, through use 
of ATP as the competitive ligand.338  
X-ray co-crystallization studies of a ligand-bound protein can be extremely beneficial in 
determining the SAR of a binding ligand. This technique can be used to determine where the 
ligand binds, what residues are important for that binding, whether it binds allosterically and if 
it is ATP- or non-ATP-competitive. It can also be used to determine if there are any amino acid 
residues in the binding pocket which could be used to improve binding, or any additional space 
which could be employed to improve kinase selectivity and binding affinity.  
This method of investigation would be ideal to identify the best potential course of investigation 
for this compound series, as it would help to qualify the hypotheses already formulated. For 
instance, if increasing bulk at the 3- and 5-positions of the urea aromatic ring would be beneficial 
when binding with SRPK1, if extension of the pyrazole 1N-aromatic substitution might utilize 
additional interactions inside or outside of the pocket, and if the urea moiety plays a similar, 
important role when binding to SRPK1 as with p38α in the BIRB 796 scaffold (see Figure 87).  
 
Still, more importantly, co-crystallization would help to confirm if the compounds of analogue 
libraries 1 and 2 are binding allosterically, in a similar mode to BIRB 796 (14), or if they are ATP-
competitive compounds. 
Figure 87: Areas of potential PD for the new N,N'-diaryl urea pharmacophore with SRPK1. 
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Recent work by Morooka et al. on the dual SRPK1 and CK2 inhibitor SRPIN340 (233) has included 
the solved X-ray co-crystal structure of this small molecule inhibitor bound to SRPK1 in the ATP-
binding pocket.339 Extensive hydrophobic interactions between the inhibitor and the ATP-
binding cleft of SRPK1 were identified and essential hydrogen bonding interactions were noted 
between the carbonyl oxygen and the kinase. Additionally, they identified that the 
trifluoromethyl group of 233 had induced a ‘flip’ of the main peptide chain from its position in 
the un-ligated kinase, and the CF3 group occupied the region that had been vacated. It was 
identified that as a consequence of the ‘flip’, an additional hydrogen bonding interaction was 
facilitated between two peptide chains of the kinase, potentially stabilizing the binding of 
SRPIN340 (233) in the ATP-pocket. 
 
Figure 88 illustrates the important trifluoromethyl and carbonyl groups of SRPIN340 (233). Upon 
visual comparison with lead compound 227F a high degree of similarity could be recognized in 
the spatial arrangement of substituents in these two compounds. Therefore it may be possible 
that the compounds of analogue library 2 interact with SRPK1 in a type 1, ATP-competitive 
fashion. However, only through additional biological testing could this be evaluated.  
Until these studies are carried out, there are other aspects of the lead compound which could 
still be evaluated to improve PK, drug-likeness and viability as a chemical probe in biological 
systems. 
 
4.6.2. Pharmacokinetics. 
Lipinski’s rule of 5 has been sacrosanct as a tool for the design of drugs since publication of the 
first seminal paper in 1997.340 In an effort to reduce rates of pipeline attrition in drug design, a 
Figure 88: SRPK1 inhibitor SRPIN340 (233) and lead compound 227F. 
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change in perspective to take these ‘rules’ as guidelines is helping hit-to-lead discovery expand 
its perspective and design candidates of a quality that are more ‘fit for purpose’.290  
One of the key features of drug-likeness is relative lipophilicity.341 In order to be orally-
bioavailable a drug must be able to solubilize in the blood and saliva, but also be lipophilic 
enough to permeate the cell membrane and pass through the stomach or gut cell-lining. Hence 
some believe “lipophilicity remains the single most important physical property to optimize”.341  
Other important factors to consider include total polar surface area (TPSA),342 defined as the 
sum of polar atom surfaces in a molecule. A good predictor of permeability, it can be used to 
help calculate whether a molecule is likely to permeate the gut and even the blood-brain barrier. 
Therefore it is a very important measure of bioavailability and potential toxicity.  
The number of HBDs and HBAs is expected to affect permeability into cells, as they will tend to 
interact unfavourably with lipophilic cell membranes. A high proportion of tetrahedral carbon 
atoms are predicted to have a favourable effect on solubility and bioavailability, whilst reducing 
promiscuity and potential toxicity.290,343,344  
There is a vast array of factors that need to be considered over the course of a drug design 
project, and it is a balancing act to achieve a favourable ratio of each aspect whilst also retaining 
a high binding affinity for the target molecule.  
 
Upon examination of BIRB 796 (14) as a drug candidate, the ligand does not appear to be very 
drug-like, demonstrating a high-proportion of lipophilic areas at risk of phase 1 metabolism and 
oxidation (see Figure 89). The ether chain of BIRB 796 (14) is very important to the PD of the 
compound with respect to p38α MAPK, and increases the favourable PK of the molecule by 
contributing a number of rotatable bonds and heteroatoms. However, this would most likely be 
a high risk area for metabolism, acting much like the metabolic shunt of Pfizer’s alternative MK2 
Figure 89: Areas of BIRB 796 (14) contributing to high lipophilicity, and at risk of oxidation and metabolism.  
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inhibitors PF-318 (203) and PF-029 (204). Additionally, as a very planar molecule, BIRB 796 (14) 
would be expected to have a low solubility, and has the potential to get trapped in lipophilic cell 
lining and DNA.276 There is a drive in the pharmaceutical industry to move away from highly 
unsaturated molecules, which have thrived through HTS and fragment-based lead identification, 
to develop more architecturally diverse, complex molecules and drugs which are more natural 
product-like.343  
Indeed, despite advancing to phase 3 human clinical trials, BIRB 796 (14) did not demonstrate 
any sustained improvement in treating the disease345 and was reported to induce 
gastrointestinal distress, with other potentially drug-related side-effects including infections in 
the upper-respiratory tract, dizziness, rashes and abnormal liver function test.37 
In this project, the extensive π-system of BIRB 796 (14) was retained in the new analogue 
libraries. However, depending upon the substituents of the pyrazole and aromatic rings, the 
planarity of the molecule could be altered. For instance, X-ray crystallographic data collected for 
231O, a less active compound by DSF analysis, demonstrated the molecule to crystallize into a 
triclinic unit cell and adopt a flat, planar geometry. Three molecules crystallized to arrange 
themselves around three water molecules, interacting through the urea NHs and the pyrazole 
2-N lone pair (Figure 90).xii 
 
                                                          
xii Single crystal X-ray diffraction experiments were performed using an Agilent Excalibur with CCD plate detector using 
Cu-Kα (λ = 1.514184 Å), and solved using SHELX.373 See supplementary information for complete CIF report. 
Figure 90: X-ray crystal structure of 231O. Triclinic crystal, bound via three water molecules. 
210 
 
Comparison with the hit compound from library 1, 215F, the X-ray crystal structure illustrated 
the molecule to be much more twisted about the urea group (Figure 91). Crystallized into a 
monoclinic cell, the positioning of the phenyl and tert-butyl substituents on the pyrazole 
appeared to prevent the same water hydrogen bonding network from occurring as with 231O 
in Figure 90.  
 
Despite the observation that this slight twist removed some planarity in the molecule, there was 
still a high degree of sp2 character to this molecule. In order to improve drug-likeness, a 
favourable change could be to increase the sp3 character; for instance, through the 
incorporation of saturated rings. These changes could help increase solubility and evaluate the 
importance of π-π stacking within the protein binding pocket. Also the incorporation of 
saturated rings could potentially open up new areas of diversification to harness additional 
amino acid interactions.   
When considering the potential ADME characteristics of lead compound 227F compared to BIRB 
796 (14), it could be observed that not all of the modifications made may be conducive towards 
improving compound PK. Figure 92 highlights the areas of 227F which have been altered from 
the BIRB 796 (14) pharmacophore. In blue are shown the areas which appear to have had a 
positive effect on the PD; to reduce affinity for p38α and increase stabilization when bound to 
SRPK1. In red are highlighted the sites potentially still at risk of phase 1 metabolism. Though the 
number of sites at risk are reduced compared to BIRB 796 (14), and the addition of fluorinated 
groups should temper metabolism of the aromatic rings, there are still high risk areas on the 
molecule.  
Figure 91: X-ray crystal structure of 215F, demonstrating the twist in the molecule due to steric interactions of the 
pyrazole substituents. 
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Additionally, it should be noted that, with the loss of the ether-linked morpholine group of BIRB 
796 (14), the number of rotatable bonds and heteroatoms in the molecule has been reduced, 
which may adversely affect the solubility and bioavailability of the molecule. Hence, the 
balancing act of developing an efficacious biological probe should continue with further 
investigation and the design of new compound libraries. 
 
4.6.3. Conclusion. 
There is a lot of potential work on this project that could be carried forward. Many avenues of 
investigation are available and this was only the first step in this, a promising project, the results 
of which were already astounding.  
Further investigation of the potential of this library could conceivably lead to some very 
interesting and important discoveries on the role of SRPK1 in the human kinome, and towards 
the development of new, selective chemical probes to help in the validation of targets of interest 
for drug discovery programmes. 
 
  
Figure 92: Highlighting the areas of significance for the PK and PD of lead compound 227F. 
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Chapter 5. Conclusions. 
The major objectives of this research project have been to develop new, rapid routes towards 
p38α and MK2 inhibitors, and to evaluate their use as chemical probes for investigating the 
mechanisms of ageing using WS as our model. 
The p38α inhibitor SB203580 (1) has been proven to reverse the aged morphology of WS 
fibroblasts; however, due to the cross-kinase activity of this inhibitor it could not be explicitly 
asserted that this was the key kinase being inhibited to elicit this effect. Hence, the alternative 
p38α inhibitor RO3201195 (10), which is much more selective to p38α, was synthesized through 
a rapid microwave-assisted route, and investigated in a comparative study of the two inhibitors. 
The 4,5-disubstituted pyrazole inhibitor RO3201195 (10) was synthesized in 15% overall yield 
over seven steps, with three steps employing microwave-assisted heating, including the rapid 
formation of the key pyrazole ring scaffold of the drug.1 Upon testing in WS fibroblasts it was 
found that RO3201195 (10) had an almost identical effect on the rate of cell proliferation as 
SB203580 (1). This evidence strongly supported previous assertions that the rate of proliferation 
of WS cells is subject to the activity of the p38α stress-signalling pathway.2 Additionally, the 
biological studies completed established RO3201195 (10) as a reliable tool for investigating 
stress-signalling pathways, as it is highly kinase specific and relatively potent compared to 
SB203580 (1). 
In order to further probe the role of the p38α MAPK stress-signalling pathway, synthesis of the 
MK2 inhibitor PF-3604422 (25) was investigated. MK2 is downstream of p38α in the stress-
signalling cascade and it was hypothesized that, by obstructing the cascade further downstream, 
the likelihood of off-target effects would be reduced. Testing an MK2 inhibitor in WS cells would 
give greater insight into the mechanism of premature ageing in WS fibroblasts, and potentially 
help in the development of efficacious therapeutics. 
Initial synthetic routes to PF-3644022 (25) concentrated on building up a core quinoline unit and 
using Suzuki-coupling chemistry to establish the biaryl linkage,3 onto which the fused ring 
system would be installed, with final installation of the chiral centre. However, the yields and 
reproducibility of these reactions was not viable for a total synthesis. 
An alternative route was investigated concentrating on the initial synthesis of a poly-substituted 
benzo[b]thiophene heterocyclic core, ready for further functionalization thereon to form the 
fused quinoline ring and chiral centre.2 Through trial and error, the best sequential route was 
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determined to proceed via synthesis of the bromobenzo[b]thiophene,2 with subsequent 
diazepinone formation and a final Doebner multi-component quinoline reaction to install the 
fused heterocyclic ring and the linked pyridine in one step. The total synthesis was completed in 
six steps and 4% overall yield. Future work on this project should focus on optimizing this yield. 
Biological tests have been completed on WS fibroblasts using PF-3644022 (25) and found that 
treatment of cells with this MK2 inhibitor did indeed improve the growth rate, though 
comparative studies with the p38 inhibitor SB203580 (1) demonstrated a significantly higher 
growth rate.3 Additionally, due to the small therapeutic window of PF-3644022 (25) an accurate 
representation of the effect of MK2 inhibition could not be gleaned from the studies. Work is 
still ongoing into the potential of MK2 inhibitors as therapeutic agents and chemical probes. 
Alongside these main projects, work has also been carried out to investigate the potential re-
purposing of the potent non-ATP-competitive p38α inhibitor BIRB 796 (14). The novel 
chemotype and binding mode of the inhibitor presented itself as a candidate for the design of 
new and selective chemical probes to be used to delineate mechanisms of kinase signalling 
pathways in cells. 
Primary investigations focussed on the selectivity elements of BIRB 796 (14) to explore how 
changes to electronic and steric factors of the molecule might influence activity with a small 
selection of kinases. The first library of molecules was very fruitful, with an unexpected re-
optimization of the kinase selectivity towards SRPK1 with congruent reduction in potency for 
p38α. From these initial results, a second library of compounds was synthesized, to investigate 
how changing the substituents on the pyrazole ring might increase or decrease the newly 
established activity. Further biological studies are on-going with this project in association with 
the SGC, but initial DSF results have been very positive, continuing to maintain the affinity 
established for SRPK1 over p38α. From the results of these biological studies, the potential of 
this project to be carried on will be assessed and taken forward in the research group. 
The key objectives of the project have been met, with advances in our understanding of the WS 
premature-ageing stress-signalling pathway. Through the rapid and efficient synthesis of 
RO3201195 (10), a greater understanding of the role of p388α in the premature aged phenotype 
of WS fibroblasts has been achieved. Synthesis of the MK2 inhibitor PF-3644022 (25) has been 
completed, exploring new synthetic routes towards advanced intermediates and the final 
compound. Though fairly low yields were achieved in the final steps of the synthesis, work is on-
going in the group to optimize the reaction. Unfortunately due to the small therapeutic window 
of PF-3644022 (25), the information gathered from tests in WS fibroblasts was limited, though 
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there was a positive correlation between the growth rate and treatment with the MK2 inhibitor. 
Additionally, new unexpected results have been obtained into how the p38α inhibitor BIRB 796 
(14) can be repurposed to target alternative kinases. This research has a great deal of potential 
for the development of chemical probes and tools to advance understanding of stress-signalling 
events in cells, and their influence on the ageing process in vivo. 
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Chapter 6. Experimental. 
All procedures were completed in air unless otherwise stated. Commercially available reagents 
were used throughout without purification, with solvents dried by standard procedures. Light 
petroleum refers to the fractions with bp 40-60 °C. Analytical thin layer chromatography was 
carried out using aluminium-backed plates coated with Merck TLC Silicagel 60 F254. Plates were 
visualized under UV light (at 254 and/or 360 nm), and/or with ninhydrin and potassium 
permanganate solutions. Microwave-assisted reactions were carried out using a CEM DiscoverTM 
with a CEM Explorer at the given temperature using the instrument’s in-built IR temperature 
measuring device, by varying the irradiation power (initial power given in parentheses). Column 
chromatography was carried out on a Biotage Isolera Prime flash purification system. SCX-2 ion 
exchange chromatography was carried out using Biotage Isolute SPE SCX-2 flash columns. 
Fully characterized compounds were chromatographically homogeneous. Melting points were 
determined using a Stanford Research Systems Optimelt and are uncorrected. IR spectra were 
recorded in the range 4000-600 cm-1 using a Perkin Trans FT-IR Spectrum. NMR spectra were 
recorded using a Varian VNMRS instrument operating at 600, 500 or 400 MHz for 1 H NMR and 
126 or 100 MHz for 13C NMR. J values were recorded in Hz and multiplicities were expressed in 
the usual conventions. ESI mass spectra were obtained using a Bruker Daltonics Apex III, with 
ESI source Apollo ESI, using methanol as the spray solvent. For EI mass spectra a Fissons VG 
Autospec instrument was used at 70 eV and were captured by Dr. Alla K. Abdul-Sada of the 
University of Sussex Mass Spectrometry Centre. A number of high resolution mass spectra were 
obtained courtesy of the EPSRC Mass Spectrometry Service at Swansea University, UK using the 
ionization methods specified. 
LCMS data was recorded on a Waters 2695 HPLC using a Waters 2487 UV detector and a Thermo 
LCQ ESI-MS. Samples were eluted through a Phenomenex Lunar 3µ C18 50 mm × 4.6 mm 
column, using acetonitrile and water acidified by 0.01% formic acid. Samples were eluted using 
acetonitrile and water (1:9 to 9:1) acidified by 0.01% formic acid, at a flow rate of 3 µl/min. 
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6.1. Chapter 2. 
6.1.1. Methyl 3-methoxybenzoate (123) 
Chemical Formula: C9H10O3 
Mr: 166.18 
3-Methoxybenzoic acid (1.48 g, 9.71 mmol) in MeOH (10 mL) and a catalytic amount of conc. 
H2SO4 (0.01 mL, 0.20 mmol) was irradiated at 110 °C for 10 min in a pressure-rated glass vial (35 
mL) using a CEM Discover microwave synthesizer by moderating the initial power (200 W). After 
cooling in a flow of compressed air, the volatiles were removed and the residue partitioned 
between water and Et2O. The organic fraction was washed with saturated aqueous NaHCO3 
solution, dried (Na2SO4), filtered and evaporated in vacuo to give the title compound (1.52 g, 
94%) as a clear colourless oil, (Found [ESI+]: 189.0520. C9H10O3Na [MNa] requires 189.0522); IR 
(neat) νmax/cm-1: 2953 (C-H str), 1718 (C=O str), 1601 (C-C str), 1276 (C-O str), 1221 (C-O str); 1H 
NMR (500 MHz, CDCl3) δH/ppm: 7.64 (1H, d, J = 8 Hz, 6-CH), 7.57 (1H, br. s, 2-CH), 7.35 (1H, t, J = 
8 Hz, 5-CH), 7.11 (1H, dd, J = 8, 2 Hz, 4-CH), 3.92 (3H, s, CO2Me), 3.86 (3H, s, OMe); 13C NMR (126 
MHz, CDCl3) δC/ppm: 166.9 (C), 159.6 (3-C), 131.5 (1-C), 129.3 (5-CH), 122.0 (6-CH), 199.5 (4-CH), 
144.0 (2-CH), 55.4 (OMe), 52.1 (CO2Me); m/z (EI+): 166 (M●⁺, 14), 135 (M-OMe⁺, 39), 93 (100). 
 
6.1.2. 3-Methoxybenzoylacetonitrile (107) 
 
Chemical Formula: C10H9NO2 
Mr: 175.19 
6.1.2.1. Claisen ester condensation. 
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According to a modified procedure,45 under argon, n-BuLi (2.5 M in hexanes; 5.3 mL, 13.2 mmol) 
was added dropwise to a solution of DIPA (1.9 mL, 13.6 mmol) in dry THF (2 mL) cooled to 0 °C, 
and allowed to stir at 0 °C for 10 min. In a separate flask, methyl 3-methoxybenzoate (123) (1.1 
g, 6.6 mmol) and dry MeCN (0.5 mL, 9.5 mmol) in dry THF (5 mL) was cooled to −50 °C. The cold 
LDA solution was added dropwise and the reaction mixture was stirred at −50 °C for 3 h. 
Saturated aqueous NH4Cl solution (10 mL) was then added. The solution was allowed to warm 
to RT, extracted with EtOAc (3 x 20 mL), washed with aqueous HCl solution (1 M; 20 mL) and 
brine (20 mL), dried (MgSO4), filtered and evaporated in vacuo. Purification by flash column 
chromatography on SiO2 (dry-load), gradient eluting with hexanes to EtOAc-hexanes (40:60), 
gave the title compound (0.82 g, 70%) as a yellow solid, mp 86.3-87.4 °C (MeOH) mp 87.3-88.2 
°C (EtOAc) (lit346 87-88), (Found [ESI+]: 198.0523. C10H9NO2Na [MNa] requires 198.0525); IR 
(neat) νmax/cm-1: 2948 (C-H str), 2252 (C≡N str), 1694 (C=O str), 1580 (C-C str), 1451 (C-H bend), 
1258 (C-O str), 1012 (C-O str); 1H NMR (500 MHz, CDCl3) δH/ppm: 7.49-7.41 (3H, m, 2, 5, 6-CH), 
7.21 (1H, d, J = 8 Hz, 4-CH), 4.07 (2H, s, CH2), 3.88 (3H, s, Me); 13C NMR (126 MHz, CDCl3) δC/ppm: 
186.9 (C), 160.2 (3-C), 135.7 (1-C), 130.1 (5-CH), 121.2 (4-CH), 120.9 (6-CH), 113.6 (CN), 112.8 (2-
CH), 55.6 (Me), 29.4 (CH2); m/z (EI+): 175 (M●⁺, 36), 135 (M⁺-CH2CN, 100). 
6.1.2.2. Heck reaction. Conductive heating. 
Under argon, 3-methoxyacrylonitrile (0.24 g, 2.92 mmol) was added to a solution of 3-
iodoanisole (0.14 g, 0.61 mmol), K2CO3 (0.24 g, 1.71 mmol), tetrabutylammonium bromide (39 
mg, 0.12 mmol) and Pd(OAc)2 (21 mg, 93 µmol) in a solution of H2O-MeCN ([3:1]; 3 mL) and 
heated at 90 °C for 20 h. Once cooled, the solution was partitioned between water and EtOAc, 
and the aqueous layer extracted with EtOAc (2 x 10 mL). The organic extracts were combined, 
washed with brine (1 x 20 mL), dried (Na2SO4), filtered and evaporated in vacuo. In air, the 
residue was taken up in MeOH (2 mL) and conc. HCl (10.2 M; 0.5 mL) and irradiated at 110 °C 
for 1 h in a pressure-rated glass vial (10 mL) using a CEM Discover microwave synthesizer by 
moderating the initial power (150 W). After cooling in a flow of compressed air, the solution was 
partitioned between water and EtOAc, and extracted into EtOAc (2 x 10 mL). The organic extracts 
were combined and washed with brine (1 x 20 mL), dried (Na2SO4), filtered and evaporated. 
Purification by flash column chromatography on SiO2, (dry-load) eluting with hexanes to EtOAc-
hexanes (4:6), gave the title compound as a yellow solid (39 mg, 36%) mp 87.0-87.6 °C (MeOH), 
with identical spectroscopic data. 
6.1.2.3. Heck reaction. Microwave-assisted method. 
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Under argon, 3-methoxyacrylonitrile (0.26 g, 3.43 mmol) was added to a solution of 3-
iodoanisole (0.17 g, 0.72 mmol), NaHCO3 (0.15 g, 1.78 mmol), TBAB (30 mg, 93 µmol) and 
Pd(OAc)2 (22 mg, 98 µmol) in a solution of H2O:MeCN ([3:1]; 3 mL) was irradiated at 130 °C for 
1.5 h in a pressure-rated glass vial (10 mL) using a CEM Discover microwave synthesizer by 
moderating the initial power (150 W). After cooling in a flow of compressed air the solution was 
partitioned between water and EtOAc, and the aqueous layer extracted with EtOAc (2 x 10 mL). 
The organic extracts were combined, washed with brine (1 x 20 mL), dried (Na2SO4), filtered and 
evaporated in vacuo. The residues were treated as above, irradiating in MeOH and with conc. 
HCl. Purification by flash column chromatography on SiO2 (dry-load), gradient eluting with 
hexanes to EtOAc-hexanes (40:60) gave the title compound (47 mg, 37%) as a yellow solid, with 
identical spectroscopic data. 
 
6.1.3. 2-(3-Methoxybenzoyl)-3-(phenylamino)prop-2-enenitrile 
(124) 
  
Chemical Formula: C17H14N2O2 
Mr: 278.30  
A solution of N,N’-diphenylformamidine (0.24 g, 1.20 mmol) and 3-methoxybenzoylacetonitrile 
(107) (0.20 g, 1.13 mmol) in dry xylenes (7.5 mL) was irradiated at 180 °C for 20 min under argon 
in a pressure-rated glass vial (35 mL) using a CEM Discover microwave synthesizer by moderating 
the initial power (200 W). After cooling in a stream of compressed air, the solution was diluted 
with hexanes and the precipitate isolated by gravity filtration to afford the title compound (0.23 
g, 74%) as a colourless solid, mp 107.4-108.8 °C (lit347 105 °C) (Found [ESI+]: 279.1126. C17H15N2O2 
[MH] requires 279.1128); IR (neat) νmax/cm-1: 3062 (=C-H str), 2921 (C-H str), 2204 (C≡N str), 
1634 (C=O str), 1596 (N-H bend), 1571 (C-C str), 1392 (C-C str), 1313 (C-N str), 1225 (C-O str), 
1044 (C-O str), 990 (=C-H bend), 867 (N-H wag); 1H NMR (500 MHz, CDCl3) δH/ppm: 12.76 (1H, d, 
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J = 13 Hz, NH), 8.06 (1H, d, J = 13 Hz, 3-CH), 7.57 (1H, d, J = 8 Hz, 6’-CH), 7.46 (3H, m, 2’-CH, 3’’, 
5’’-CH), 7.40 (1H, t, J = 8 Hz, 5’-CH), 7.30 (1H, m, 4’’-CH), 7.23 (2H, d, J = 8 Hz, 2’’, 6’’-CH), 7.11 
(1H, d, J = 8 Hz, 6’-CH), 3.89 (3H, s, CH3); 13C NMR (126 MHz, CDCl3) δC/ppm: 192.1 (C), 159.6 (3’-
PhC), 154.1 (3-CH), 139.2 (1’-PhC), 138.1 (1’’-PhC), 130.2 (3’’, 5’’-PhCH), 129.4 (5’-CH), 126.6 (4’’-
PhCH), 120.5 (6’-CH), 120.3 (1-CN), 118.9 (4’-CH), 117.9 (2’’, 6’’-PhCH), 112.7 (2’-CH), 83.5 (2-C), 
55.5 (Me); m/z (EI+): 278 (M●⁺, 49), 277 (M-H, 100), 135 (52). 
 
6.1.4. [5-Amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-3-
methoxyphenyl ketone (125) 
  
Chemical Formula: C17H14N3O2F 
Mr: 311.32 
A solution of 2-(3-methoxybenzoyl)-3-(phenylamino)prop-2-enenitrile (X3) (0.13 g, 0.46 mmol), 
4-fluorophenylhydrazine hydrochloride (0.073 g, 0.47 mmol) and NEt3 (0.02 mL, 0.14 mmol) in 
EtOH (3 mL) was irradiated at 140 °C for 1 h in a pressure-rated glass vial (10 mL) using a CEM 
Discover microwave synthesizer by moderating the initial power (100 W). After cooling in a 
stream of compressed air, the volatiles were removed in vacuo. Purification by flash column 
chromatography on SiO2 (dry-load), gradient eluting with hexanes to EtOAc-hexanes (30:70), to 
give the title compound as a pink solid (0.11 g, 86%), mp 130.1-132.0 °C (Found [ESI+]: 312.1138. 
C17H15N3O2F [MH] requires 312.1143); IR (neat) νmax/cm-1: 3318 (N-H str), 2925 (C-H str), 1610 
(C=O str), 1595 (N-H bend), 1539 (C-C str), 1286 (C-N str), 1223 (C-O str), 1051 (C-O str), 838 (N-
H wag); 1H NMR (500 MHz, CDCl3) δH/ppm: 7.81 (1H, s, 3-CH), 7.56 (2H, pdd, 3JHH = 8 Hz, 4JHF = 5 
Hz, 2’, 6’-CH), 7.42 (2H, m, 5’’, 6’’-CH), 7.35 (1H, s, 2’’-CH), 7.25 (2H, pt, 3JHH, 3JHF = 8 Hz, 3’, 5’-
CH), 7.11 (1H, m, 4’’-CH), 6.04 (2H, br. s, NH2), 3.89 (3H, s, Me); 13C NMR (126 MHz, CDCl3) 
δC/ppm: 189.4 (C), 162.2 (d, 1JCF = 250 Hz, 4’-CF), 159.8 (3’’-C), 150.6 (5-C), 142.0 (3-CH), 141.1 
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(1’’-C), 133.3 (d, 4JCF = 4 Hz, 1’-C), 129.5 (5’’-CH), 126.1 (d, 3JCF = 9 Hz, 2’, 6’-CH), 120.7 (6’’-CH), 
117.8 (4’’-CH), 116.9 (d, 2JCF = 23 Hz, 3’, 5’-CH), 113.0 (2’’-CH), 104.8 (4-C), 55.4 (OMe). 
 
6.1.5. [5-Amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-3-
hydroxyphenyl ketone (126) 
 
Chemical Formula: C16H12N3O2F 
Mr: 297.29  
Boron tribromide solution (1M in CH2Cl2; 1.7 mL, 1.70 mmol) was added dropwise to [5-amino-
1-(4-fluorophenyl)-1H-pyrazol-4-yl]-3-methoxyphenyl ketone (125) (0.10 g, 0.34 mmol) in dry 
CH2Cl2 (1 mL) at 0 °C under argon and the mixture allowed to warm to RT and stirred for 20 h. 
Water (15 mL) was then cautiously added and the mixture extracted with EtOAc (3 x 15 mL). The 
organic extracts were combined, washed with brine (1 x 20 mL), dried (MgSO4), filtered and 
evaporated in vacuo to give the title compound (0.10 g, quant.) as a brown solid, mp 192.2-194.9 
°C (Found [ESI+]: 298.0984. C16H13N3O2F [MH] 298.0986); IR (neat) νmax/cm-1: 3320 (N-H str), 3204 
(br. O-H), 3072 (C-H str), 1610 (C=O str), 1592 (N-H bend), 1538 (C-C str), 1310 (C-N str), 1126 
(C-O str), 841 (N-H wag); 1H NMR (500 MHz, MeOH-d4) δH/ppm: 7.78 (1H, s, 3-CH), 7.59 (2H, pdd, 
3JHH = 9 Hz, 4JHF = 5 Hz, 2’, 5’-CH), 7.37-7.29 (3H, m, 3’, 5’, 5’’-CH), 7.23 (1H, d, J = 7 Hz, 6’’-CH), 
7.18 (1H, s, 2’’-CH), 7.00 (1H, dd, J = 7, 1 Hz, 4’’-CH); 13C NMR (100 MHz, MeOH-d4) δC/ppm: 191.6 
(C), 164.1 (d, 1JCF = 247 Hz, 4’-CF), 159.2 (3’’-C), 153.4 (5-C), 143.6 (3-CH), 142.7 (1’’-C), 135.0 (d, 
4JCF = 3 Hz, 1’-C), 131.1 (5’’-CH), 128.5 (d, 3JCF = 9 Hz, 2’, 6’-CH), 120.6 (6’’-CH), 120.1 (4’’-CH), 
118.0 (d, 3JCF = 24 Hz, 3’, 5’-CH), 116.0 (2’’-CH), 105.7 (4-C); m/z (EI+): 297 (M●⁺,  91), 296 (M-H⁺, 
100), 204 (31). 
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6.1.6. 5-Amino-1-(4-fluorophenyl)-4-{3-[2(S)-3-
dihydroxypropoxy]benzoyl} pyrazole (RO3201195) (10) 
 
Chemical Formula: C19H18N3O4F 
Mr: 371.37  
(S)-2,2-Dimethyl-1,3-dioxolan-4-ylmethyl p-toluenesulfonate (0.60 mL, 2.52 mmol) and 
anhydrous K2CO3 (0.59 g, 4.25 mmol) were added to a solution of [5-amino-1-(4-fluorophenyl)-
1H-pyrazol-4-yl]-3-hydroxyphenyl ketone (126) (0.48 g, 1.61 mmol) in dry DMSO (15 mL) under 
argon and heated at 100 °C  for 40 h. Once cooled, the solution was diluted with water (25 mL) 
and extracted into EtOAc (3 x 20 mL). The organic extracts were combined, washed with brine 
(1 x 20 mL), dried (MgSO4), filtered and evaporated in vauo. Purification by flash column 
chromatography on SiO2 (dry-load), eluting with light petroleum to EtOAc-light petroleum 
(40:60), gave the crude intermediate [5-amino-1-(4-fluorophenyl)-1H-pyrazo-4-yl]{3-[(R)-2,2-
dimethyl-1,3-dioxolan-4-yl)methoxy]phenyl} ketone (x6), which was taken up in a MeOH-H2O 
solution ([4:1]; 4 mL), p-toluene sulfonic acid monohydrate (0.04 g, 0.21 mmol) was added and 
the solution heated at 50 °C for 18 h. Once cooled, volatiles were removed in vacuo and the 
residue taken up in EtOAC (25 mL), washed with saturated aqueous NaHCO3 solution (20 mL), 
dried (MgSO4), filtered and evaporated in vacuo. Purification by flash column chromatography 
on SiO2 (dry-load), gradient eluting with light petroleum to EtOAc, and recrystallization from hot 
EtOAc and hexanes gave the title compound (0.22 g, 37%) as a colourless solid, mp 154.1-154.6 
°C (EtOAc) (Found [ESI+]: 372.1353. C19H19N3O4F [MH] requires 372.1354); [α]D22 −28 (𝑐 0.2, 
EtOAc), [α]D22 +6.5 (𝑐 0.6, MeOH); IR (neat) νmax/cm-1: 3440 (N-H str), 3330 (O-H str), 3229 (O-H 
str), 2896 (C-H str), 1633 (C=O str), 1597 (NH2 str), 1540 (C=N str), 1498 (C-C str), 1292 (C-O str), 
1222 (C-F str), 1053 (C-O str), 839 (NH2 wag.); 1H NMR (500 MHz, DMSO-d6) δH/ppm: 7.80 (1H, s, 
3H), 7.61 (2H, pdd, 3JHH = 8 Hz, 4JHF = 5 Hz, 2’, 6’-CH), 7.47-7.37 (3H, m, 3’, 4’, 5’’-CH), 7.33 (1H, d, 
J = 7 Hz, 6’’-CH), 7.25 (1H, m, 2’’-CH), 7.14 (3H, m, 4’’-CH, NH2), 4.95 (1H, br. s, CHOH), 4.65 (1H, 
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br. s, CH2OH), 4.09 (1H, m, OCHH), 3.95 (1H, m, OCHH), 3.82 (1H, m, CHOH), 3.47 (2H, d, J = 5 Hz, 
CH2OH); 13C NMR (126 MHz, DMSO-d6) δC/ppm: 187.5 (C), 161.1 (d, 1JCF = 244 Hz, 4’-C), 158.7 
(3’’-C), 151.2 (5-C), 141.4 (3-CH), 140.9 (1’’-C), 133.7 (d, 4JCF = 3 Hz, 1’-C), 129.6 (5’’-CH), 126.4 
(d, 3JCF = 9 Hz, 2’, 6’-CH), 120.1 (6’’-CH), 117.8 (4’’-CH), 116.3 (d, 2JCF = 23 Hz, 3’, 5’-CH), 113.3 (2’’-
CH), 103.5 (4-C), 69.9 (CHOH), 69.8 (CH2O), 62.6 (CH2OH); m/z (EI+): 371 (M●⁺, 10), 325 (33), 160 
(100). 
6.1.6.1. Procedure for isolation of [5-Amino-1-(4-fluorophenyl)-1H-
pyrazo-4-yl]{3-[(R)-2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]phenyl} 
ketone (136). 
(S)-2,2-Dimethyl-1,3-dioxolan-4-ylmethyl p-toluenesulfonate (0.15 mL, 0.64 mmol) and 
anhydrous K2CO3 (0.11 g, 0.80 mmol) were added to a solution of [5-amino-1-(4-fluorophenyl)-
1H-pyrazol-4-yl]-3-hydroxyphenyl ketone (126) (0.095 g, 0.32 mmol) in dry DMSO (5 mL) under 
argon and heated at 100 °C  for 25 h. Once cooled the solution was diluted with water (15 mL) 
and extracted with EtOAc (3 x 20 mL), washed with brine, dried (MgSO4), filtered and evaporated 
in vacuo. Purification by flash column chromatography on SiO2 (dry-load), gradient eluting with 
EtOAc-hexanes (25:75) to (50:50), followed by crystallisation from hot EtOAc and hexane gave 
the title compound (0.056 g, 42%) as a colourless powder, mp 53.7-58.3 °C (EtOAc) (lit347 58-61) 
(Found [ESI+]: 412.1657. C22H23N3O4F [MH] requires 412.1667); [α]D21 −20 (𝑐 0.6, EtOAc); IR 
(neat) νmax/cm-1: 3457 (N-H str), 3319 (N-H str), 2987 (C-H str), 1613 (C=O str), 1593 (NH2), 1535 
(C=N str), 1217 (C-O-C str), 1155 (C-F str), 1055 (C-O-C str), 829 (NH2 wag); 1H NMR (500 MHz, 
CDCl3) δH/ppm: 7.80 (1H, s, 3-CH), 7.56 (2H, pdd, 3JHH = 9, 4JHF = 5 Hz, 2’, 6’-CH), 7.45-7.39 (2H, m, 
5’’, 6’’-CH), 7.36 (1H, m, 2’’-CH), 7.25 (2H, pt, 3JHH, 3JHF = 9 Hz, 3’, 5’-CH), 7.13 (1H, m, J = 7 Hz, 4’’-
CH), 6.03 (2H, br. s, NH2), 4.52 (1H, q, J = 6 Hz, CH), 4.19 (1H, m, CHH), 4.14 (1H, dd, J = 9, 6 Hz, 
CHH), 4.03 (1H, dd, J = 9, 6 Hz, CHH), 3.93 (1H, dd, J = 8, 6 Hz, CHH), 1.48 (3H, s, Me), 1.42 (3H, 
s, Me); 13C NMR (126 MHz, CDCl3) δC/ppm: 189.2 (C), 162.2 (d, 1JCF = 250 Hz, 4’-CF), 158.8 (3’’-C), 
150.6 (5-C), 142.0 (3-CH), 141.1 (1’’-C), 133.2 (1’-C), 129.6 (5’’-CH), 126.2 (d, 3JCF = 9 Hz, 2’, 6’-
CH), 121.1 (6’’-CH), 118.4 (4’’-CH), 116.9 (d, 2JCF = 24 Hz, 3’, 5’-CH), 113.6 (2’’-CH), 109.9 (CMe2), 
104.8 (4-C), 74.0 (CH), 69.1 (CH2), 66.8 (CH2), 26.8 (Me), 25.4 (Me); m/z (EI+): 411 (M●⁺, 68), 310 
(42), 204 (58). 
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6.2. Chapter 3. 
6.2.1. 2-Chloro-6-nitroquinoline (151) 
Chemical Formula: C9H5N2O2Cl 
Mr: 208.60  
POCl3 (1.2 mL, 13.0 mmol) was added drop-wise to a stirred solution of 3,4-dihydro-6-
nitroquinolin-2(1H)-one (1.00 g, 5.2 mmol) and DDQ (1.30 g, 5.7 mmol) in DMF (20 mL) and 
stirred at RT for 1 h. The reaction mixture was then poured into iced water and the precipitate 
formed collected by vacuum filtration, washed with water and dried in air to give the title 
compound (1.05 g, 97%) as an orange solid, mp 226.8-227.9 °C (lit.348 230-230.5 °C) (Found [ESI+]: 
209.0112. C9H635ClN2O2 [MH⁺] requires 209.0112); IR (neat) νmax/cm-1: 3068 (C-H str), 1619 (C=C 
str), 1523 (N-O str), 1485 (C=C str), 1337 (N-O str), 1105 (C-N str); 1H NMR (500 MHz, DMSO-d6) 
δH/ppm: 9.13 (1H, d, J = 2 Hz, 5-CH), 8.78 (1H, d, J = 9 Hz, 4-CH), 8.52 (1H, dd, J = 9, 3 Hz, 7-CH), 
8.18 (1H, J = 9 Hz, 8-CH), 7.84 (1H, d, J = 9 Hz, 3-CH); 13C NMR (126 MHz, DMSO-d6) δC/ppm: 
153.6 (C), 149.2 (C), 145.3 (C), 141.9 (4-CH), 129.7 (8-CH), 125.9 (C), 125.0 (5-CH), 124.4 (3-CH), 
124.1 (7-CH); m/z (EI+): 208 (M•+35Cl, 100), 162 (48), 150 (49), 127 (81). 
 
6.2.2. General procedure for Suzuki coupling 
According to a modified procedure,349 a solution of 2-chloro-6-nitroquinoline (151), boronic acid 
(1.5-1.6 equiv.), aqueous Na2CO3 (2 equiv.) and PdCl2(PPh3)2 (10 mol%) in MeCN (0.2 M) was 
irradiated at 140 °C for 15 min in a pressure-rated glass vial (35 mL) using a CEM Discover 
microwave synthesizer by moderating the initial power (200 W). After cooling in a flow of 
compressed air, volatiles were removed in vacuo and the residues triturated with water. 
Purification by flash column chromatography on SiO2 gave the desired 2-pyridinyl-6-
nitroquinoline. 
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6.2.2.1. 2-(6-Methylpyridin-3-yl)-6-nitroquinoline (153) 
 
Chemical Formula: C15H11N3O2 
Mr: 265.27  
Biaryl 153 was prepared according to the general synthetic procedure using 2-chloro-6-
nitroquinoline (151) (0.45 g, 2.20 mmol), 6-methyl-3-pyridinylboronic acid (0.44 g, 3.20 mmol), 
aqueous Na2CO3 (1.5 M; 3 mL) and PdCl2(PPh3)2 (0.15 g, 0.21 mmol) in MeCN (12 mL). Purification 
by flash column chromatography on SiO2 (dry-load), gradient eluting with CH2Cl2 to CH2Cl2-
MeOH (90:10), gave the title compound as an orange solid (0.39 g, 69%), mp 237.5-239.1 °C 
(Found [ESI+]: 266.0923. C15H12N3O2 [MH] requires 266.0924); IR (neat) νmax/cm-1: 3070 (C-H str), 
2921 (C-H str), 1596 (C-C str), 1534 (N-O str), 1327 (N-O str); 1H NMR (500 MHz, CDCl3) δH/ppm: 
9.30 (1H, d, J =1 Hz, 2'-CH), 8.82 (1H, d, J = 2 Hz, 5-CH), 8.50 (2H, 4'-CH and 7-CH), 8.43 (1H, d, J 
= 9 Hz, 4-CH), 8.28 (1H, d, J = 9 Hz, 8-CH), 8.05 (1H, d, J = 9 Hz, 3-CH), 7.36 (1H, d, J = 8 Hz, 5’-CH), 
2.68 (3H, s, Me); 13C NMR (126 MHz, CDCl3) δC/ppm: 160.6 (C), 158.2 (C), 150.4 (C), 148.4 (2’-
CH), 145.5 (C), 138.7 (4-CH), 135.4 (4’-CH), 131.4 (8-CH), 131.3 (C), 126.0 (C), 124.3 (5-CH), 123.4 
(7-CH), 123.4 (5’-CH), 120.0 (3-CH), 24.5 (Me). 
 
6.2.2.2. 6-Nitro-2-(pyridin-3-yl)quinoline (152) 
Chemical Formula: C14H13N3O2 
Mr: 251.24 
Biaryl 152 was prepared according to the general procedure using 2-chloro-6-nitroquinoline 
(151) (0.15 g, 0.71 mmol), 3-pyridinylboronic acid (0.10 g, 1.14 mmol), aqueous Na2CO3 (1.4 M, 
1 mL) and PdCl2(PPh3)2 (0.05 g, 0.07 mmol) in MeCN (3.6 mL). Purification by flash column 
chromatography on SiO2 (dry-load), gradient eluting with EtOAc: CH2Cl2 (30:70), gave the title 
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compound (0.11 g, 62%) as a yellow solid, (Found [ESI+]: 252.0776. C14H10N3O2 [MH] requires 
252.0768); IR (neat) νmax/cm-1: 3081 (C-H str), 1607 (C=C str), 1528 (N-O str), 1337 (N-O str); 1H 
NMR (500 MHz, CDCl3) δH/ppm: 9.43 (1H, br. s, 2’-CH), 8.84 (1H, d, J = 2 Hz, 5-CH), 8.78 (1H, d, J 
= 3 Hz, 6’-CH), 8.58 (1H, d, J = 8 Hz, 4’-CH), 8.53 (1H, dd, J = 9, 2 Hz, 7-CH), 8.48 (1H, d, J = 8 Hz, 
4-CH), 8.31 (1H, d, J = 9 Hz, 8-CH), 8.08 (1H, d, J = 9 Hz, 3-CH), 7.52 (1H, m, 5’-CH); 13C NMR (126 
MHz, CDCl3) δC/ppm: 158.0 (C), 151.2 (6’-CH), 150.4 (C), 149.0 (2’-CH), 138.9 (4-CH), 135.2 (4’-
CH), 131.6 (8-CH), 128.5 (C), 128.4 (C), 126.1 (C), 124.3 (5-CH), 123.8 (C), 123.5 (7-CH), 120.2 (3-
CH); m/z (EI+): 251 (M•+, 100), 205 (35). 
 
6.2.3. 6-Amino-5-cyanoquinoline (144) 
 
Chemical Formula: C10H7N3 
Mr: 169.06  
According to a modified procedure,268,269 6-nitroquinoline (0.50 g, 2.85 mmol) was added to a 
solution of ethyl cyanoacetate (0.91 mL, 8.61 mmol) and KOH (0.97 g, 17.0 mmol) in DMF (8.7 
mL) and stirred for 64 h. The volatiles were then removed in vacuo and the residues taken up in 
aqueous NaOH solution (5%; 12 mL) and heated to reflux for 3 h. Once cooled, the reaction 
mixture was extracted into CHCl3 (3 x 15 mL), the organic extracts combined, dried (MgSO4), 
filtered and evaporated. Purification by flash column chromatography on SiO2, eluting with 
CH2Cl2 to CH2Cl2-MeOH (9:1), gave the title compound (0.35 g, 72%) as an orange solid, mp 181.2-
182.8 °C (lit.268 181 °C) (Found [ESI+]: 170.0711. C10H8N3 [MH] requires 170.0713); IR (neat) 
νmax/cm-1: 3391 (N-H str), 3337 (N-H str), 3159 (C-H str), 2199 (C≡N str), 1635 (N-H bend), 1615 
(C=C str), 1337 (C-N str); 1H NMR (500 MHz, CDCl3) δH/ppm: 8.74 (1H, d, J = 3 Hz, 2-CH), 8.24 (1H, 
d, J = 8 Hz, 4-CH), 8.06 (1H, d, J = 9 Hz, 8-CH), 7.47 (1H, m, 3-CH), 7.15 (1H, d, J = 9 Hz, 7-CH), 4.88 
(2H, br. s, NH2); 13C NMR (126 MHz, CDCl3) δC/ppm: 150.3 (C), 147.7 (2-CH), 142.4 (C), 136.0 (8-
CH), 131.2 (4-CH), 128.9 (C), 123.4 (3-CH), 120.3 (7-CH), 116.1 (CN), 86.9 (5-C); m/z (EI+): 169 
(M•+, 100). 
226 
 
 
6.2.4. Methyl 5-nitrobenzo[b]thiophene-2-carboxylate (162)  
 
Chemical Formula: C10H7NO4S 
Mr: 237.23  
6.2.4.1. Conductive synthesis. 
Based upon the procedure by Deng et al.,350 methyl thioglycolate (0.48 mL, 5.4 mmol) and K2CO3 
(0.89 g, 6.5 mmol) were added sequentially to a solution of 2-chloro-5-nitrobenzaldehyde (1.01 
g, 5.4 mmol) in DMF (6.5 mL), and stirred at RT for 17 h. The reaction was then quenched with 
iced water and the precipitate was isolated by vacuum filtration and dried in air to give the title 
compound (1.22 g, 95%) as an off-white solid, mp 213.3-217.6 °C (lit.351 mp 213-215) (Found 
[FTMS+]: 255.0435. C10H11O4N2S [MNH4⁺] requires 255.0434); IR (neat) νmax/cm-1: 3093 (C-H str), 
1701 (C=O str), 1528 (N-O str), 1439 (C-C str), 1342 (N-O str), 1302 (C-O str); 1H NMR (500 MHz, 
CDCl3) δH/ppm: 8.79 (1H, d, J = 2 Hz, 4-CH), 8.32 (1H, dd, J = 9, 2 Hz, 6-CH), 8.20 (1H, s, 3-CH), 
8.01 (1H, d, J = 9 Hz, 7-CH), 4.00 (3H, s, Me); 13C NMR (125 MHz, CDCl3) δC/ppm: 162.2 (C), 147.4 
(C), 145.9 (C), 138.3 (C), 137.2 (C), 130.7 (3-CH), 123.6 (7-CH), 121.2 (9-CH), 120.9 (7-CH), 52.9 
(Me); m/z (EI+): 237 (M•+, 100), 206 (64), 160 (27).  
6.2.4.2. Microwave-assisted synthesis. 
A mixture of 2-chloro-5-nitrobenzaldehyde (0.75 g, 4.0 mmol), methyl thioglycolate (0.45 mL, 5 
mmol) and K2CO3 (0.67 g, 4.8 mmol) in DMF (4.5 mL) was irradiated at 90 °C for 15 min in a 
pressure-rated glass vial (35 mL) using a CEM Discover microwave synthesizer by moderating 
the initial power (100 W). After cooling in a flow of compressed air, the crystallised solid was 
poured into water and the solid filtered off under reduced pressure, washed with water and 
dried in air to give the title compound (0.84 g, 88%) as an off-white solid, mp 216.8-218.5 °C 
(lit351 211-212), with identical spectroscopic data. 
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6.2.5. 5-Nitrobenzo[b]thiophene-2-carboxylic acid (167)  
 
Chemical Formula: C9H5NO4S 
Mr: 223.21  
6.2.5.1. Conductive synthesis. 
According to a modified procedure,352 a solution of aqueous NaOH (1 M; 5 mL, 5 mmol) was 
added to a solution of methyl 5-nitrobenzo[b]thiophene-2-carboxylate (162) (0.40 g, 1.7 mmol) 
in MeOH (5.5 mL) and heated to reflux for 3 h. After cooling to RT the solution was acidified with 
1 M HCl, the solid isolated by vacuum filtration and dried in air to give the title compound (0.36 
g, 95%) as an off-white powder, mp 241.4-242.7 °C (lit.353 239-241), (Found [TOF MS ASAP+]: 
224.0020. C9H6NO4S [MH] requires 224.0018); IR (neat) νmax/cm-1: 2844 (br. O-H str), 1670 (C=O 
str), 1600 (C-C str), 1511 (N-O str), 1344 (N-O str), 1313 (C-O str); 1H NMR (500 MHz, MeOH-d4) 
δH/ppm: 8.87 (1H, d, J = 2 Hz, 4-CH), 8.30 (1H, dd, J = 9, 2 Hz, 6-CH), 8.24 (1H, s, 3-CH), 8.15 (1H, 
d, J = 9 Hz, 7-CH); 13C NMR (125 MHz, MeOH-d4) δC/ppm: 164.8 (C), 148.9 (5-C), 147.7 (C), 140.3 
(C), 140.0 (C), 132.0 (3-CH), 125.1 (7-CH), 122.3 (4-CH), 121.9 (6-CH); m/z (EI+):  223 (M•+, 100), 
195 (38), 149 (37).  
6.2.5.2. Microwave-assisted synthesis. 
A mixture of methyl 5-nitrobenzo[b]thiophene-2-carboxylate (162) (0.20 g, 0.84 mmol), aqueous 
NaOH solution (1M; 2.5 mL) and MeOH (3.5 mL) was irradiated at 100 °C for 3 min in a pressure-
rated glass vial (10 mL) using a CEM Discover microwave synthesizer by moderating the initial 
power (100 W). After cooling in a flow of compressed air, the crystallised reaction mixture was 
diluted with water, acidified with 1 M HCl and the solid filtered under reduced pressure, washed 
with water  and dried in air to give the title compound (0.16 g, 94 %) as an off-white powder, mp 
241.3-242.1 °C, with identical spectroscopic data. 
 
6.2.6. 3-Bromo-5-nitrobenzo[b]thiophene-2-carboxylic acid (168) 
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Chemical Formula: C9H4BrNO4S 
Mr: 302.10  
According to a modified procedure,160 bromine (1.4 mL, 27 mmol) was added portion-wise to a 
solution of 5-nitrobenzo[b]thiophene-2-carboxylic acid (167) (1.0 g, 4.5 mmol) and anhydrous 
NaOAc (1.13 g, 13 mmol) in glacial AcOH (28 mL) under N2. A reflux condenser was fitted and 
the solution heated at 55 °C for 27 h. Once cooled to RT the solution was poured into iced water, 
the solid isolated by vacuum filtration and dried in air to give the title compound (1.02 g, 75%) 
as a yellow powder, mp 309.5-316.8 (lit.152 307-309) (Found [TOF MS ASAP+]: 303.9126. 
C9H5NO4S79Br [MH] requires 301.9123); IR (neat) νmax/cm-1: 2961 (br, O-H str), 1701 (C=O str), 
1600 (C-C str), 1511 (N=O str), 1347 (N=O str), 1270 (C-O str), 620 (C-Br str); 1H NMR (500 MHz, 
MeOH-d4) δH/ppm: 8.83 (1H, d, J = 2 Hz, 4-CH), 8.39 (1H, dd, J = 9, 2 Hz, 6-CH), 8.21 (1H, d, J = 9 
Hz, 7-CH); m/z (EI+): 303 (M81Br •⁺, 98), 301 (M79Br •+, 96), 293 (17), 291 (13). 
 
6.2.7. Methyl 3-bromo-5-nitrobenzo[b]thiophene-2-carboxylate 
(164)  
 
Chemical Formula: C10H6BrNO4S 
Mr: 316.13  
6.2.7.1. From 3-bromo-5-nitrobenzo[b]thiophene-2-carboxylic acid (168)  
According to a modified method, 160,354 iodomethane (0.46 mL, 7.4 mmol) was added to a 
solution of 3-bromo-5-nitrobenzo[b]thiophene-2-carboxylic acid (168) (1.12 g, 3.7 mmol) and 
K2CO3 (1.28 g, 9.2 mmol) in DMF (15 mL) and stirred at RT for 3 h. The reaction mixture was then 
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quenched with saturated aqueous NH4Cl solution, poured into water and filtered under reduced 
pressure. The solid collected was washed with water and dried in air to give the title compound 
(1.09 g, 93%) as an off-white powder, mp 211.5-212.5 °C (lit.152 211-212) (Found [TOF MS 
ASAP+]: 315.9279. C10H7NO4S79Br [MH] requires 315.9279); IR (neat) νmax/cm-1: 3101 (C-H str), 
1691 (C=O str), 1600 (C-C str), 1514 (N-O str), 1347 (N-O str), 1089 (C-O str), 1052 (C-O str), 617 
(C-Br str); 1H NMR (500 MHz, CDCl3) δH/ppm: 8.89 (1H, d, J = 2 Hz, 4-CH), 8.37 (1H, dd, J = 9, 2 
Hz, 6-CH), 7.99 (1H, d, J = 9 Hz, 7-CH), 4.02 (3H, s, Me); 13C NMR (500 MHz, CDCl3) δc/ppm: 161.0 
(C), 146.5 (5-C), 144.6 (C), 138.9 (C), 131.0 (C), 123.8 (7-CH), 122.2 (6-CH), 121.3 (4-CH), 115.6 
(3-CH), 53.0 (Me); m/z (EI+): 317 (M81Br •⁺, 100), 315 (M79Br •⁺, 94), 286 (58), 284 (55). 
6.2.7.2. From methyl 3-amino-5-nitrobenzothiophene-2-carboxylate 
(170). 
Following the procedure of Iaroshenko et al.,270 CuBr2 (0.94 g, 4.2 mmol) was added to a solution 
of tert-butyl nitrite (0.45 mL, 3.8 mmol) in dry MeCN (11 mL) cooled to 0 °C under argon. Methyl 
3-amino-5-nitrobenzo[b]thiophene-2-carboxylate (170) (0.69 g, 2.7 mmol) was then added 
portion-wise and the solution kept at 0 °C until N2 evolution stopped, at this point the reaction 
mixture was allowed to warm to RT and stirred for 2h. The reaction mixture was then poured 
into dilute HCl (10%, 25 mL). The aqueous mixture was then extracted with EtOAc (3 x 30 mL), 
dried (Na2SO4), filtered and evaporated in vacuo to give the title compound (0.86 g, 99%) as an 
orange solid, mp 212.3-213.0 °C (acetone) (lit.152 mp 211-212 °C), with identical spectroscopic 
data. 
 
6.2.8. Methyl 3-amino-5-nitrobenzothiophene-2-carboxylate 
(170) 
 
Chemical Formula: C10H8N2O4S 
Mr: 252.25  
6.2.8.1. Conductive method. 
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Based upon the procedure of Bridges et al.,355 NEt3 (3.8 mL, 26 mmol) was added to a solution 
of 2-fluoro-5-nitro-benzonitrile (1.5 g, 9.0 mmol) and methyl thioglycolate (0.85 mL, 9.5 mmol) 
in DMSO (4.5 mL) under N2 and heated to 100 °C for 2 h. With reaction completion confirmed 
by TLC analysis (hexanes:CH2Cl2 [50:50]), the reaction mixture was allowed to cool to RT, poured 
into iced water and the solid filtered off under reduced pressure and dried in air to give the title 
compound (2.16g, 95%) as an orange solid, mp 241.7-242.2 °C (lit.356 244-246 °C), (Found [FTMS 
+ p NSI full ms [120.00 – 2000.00]]): 253.0280. C10H9N2O4S [MH] requires 253.0278); IR (neat) 
νmax/cm⁻1: 3445 (N-H str), 3342 (N-H str), 3052 (C-H str aryl), 1681 (C=O str), 1572 (N-O str), 1432 
(C-C str) 1328 (N-O str), 1276 (C-O str), 1093 (C-O str); 1H NMR (DMSO-d6, 500 MHz) δH/ppm: 
9.24 (1H, d, J = 2 Hz, 4-CH), 8.29 (1H, dd, J = 9, 2 Hz, 6-CH), 8.12 (1H, d, J = 9 Hz, 7-CH), 7.47 (2H, 
br. s., NH2), 3.82 (3H, s, Me); 13C NMR (DMSO-d6, 100 MHz) δC/ppm: 164.3 (C), 149.6 (C), 144.9 
(C), 144.5 (C), 131.4 (C), 124.3 (7-CH), 122.0 (6-CH), 119.4 (4-CH), 96.8 (3-C),  51.5 (Me); m/z 
(EI+): 252 (M•+, 100), 219 (72). 
 
6.2.8.2. Microwave-assisted synthesis.A mixture of 2-fluoro-5-nitro-benzonitrile 
(0.50g, 3.0 mmol), methyl thioglycolate (0.3 mL, 3.3 mmol) and NEt3 (1.3 mL, 9.3 mmol) in DMSO 
(1.5 mL) under N2 was irradiated at 130 °C for 11 min in a pressure-rated glass vial (10 mL) using 
a CEM Discover microwave synthesizer by moderating the initial power (200 W). After cooling 
in a flow of compressed air, the crystallised reaction mixture was poured into water and the 
solid filtered off under reduced pressure, washed with water and dried in air to give the title 
compound (0.71 g, 94%) as an orange solid, mp 243.4-244.1 °C (acetone), with identical 
spectroscopic data. 
 
6.2.9. Methyl 5-aminobenzo[b]thiophene-2-carboxylate (158)  
 
Chemical Formula: C10H9NO2S 
Mr: 207.25 According to a modified procedure,357 SnCl2.2H2O (7.18 g, 32 mmol) in EtOH (31 mL) 
and conc. HCl (10 M; 31 mL) was added to a solution of methyl 5-nitrobenzo[b]thiophene-2-
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carboxylate (162) (1.50 g, 6.3 mmol) in EtOH (47 mL) and heated to reflux for 3 h. Once cooled 
to RT, the reaction mixture was diluted with water, slowly basified with saturated aqueous 
NaHCO3 solution, extracted with Et2O (3 x 40 mL). The organic extracts were combined, dried 
(Na2SO4), filtered and evaporated in vacuo to give the title compound (1.22g, 93%) as a yellow 
solid, mp 172.8-174.4 °C (Found [ESI+]: 208.0428. C10H10NO2S [MH] requires 208.0427); IR (neat) 
νmax/cm⁻1: 1658 (C=O str), 1589 (N-H bend), 1449 (C-C str), 1252 (C-N str), 1018 (C-O str), 919 (N-
H wag); 1H NMR (500 MHz, DMSO-d6) δH/ppm: 7.92 (1H, s, 3-CH), 7.65 (1H, d, J = 9 Hz, 7-CH), 
7.06 (1H, d, J = 1 Hz 4-CH), 6.90 (1H, dd, J = 9, 1 Hz, 6-CH), 5.25 (2H, s, NH2), 3.85 (3H, s, Me); 13C 
NMR (126 MHz, DMSO-d6) δC/ppm: 162.6 (C), 146.7 (C), 139.8 (C), 132.1 (2-C), 130.0 (3-CH), 
129.5 (5-C), 122.9 (7-CH), 117.9 (6-CH), 107.3 (4-CH), 52.3 (Me); m/z (EI+): 207 (M•+, 100), 176 
(45), 148 (30). 
 
 
6.2.10. Methyl 5-amino-3-bromobenzo[b]thiophene-2-
carboxylate (165)  
 
Chemical Formula: C10H8BrNO2S 
Mr: 286.15  
According to a modified method,357 SnCl2.2H2O (3.36 g, 14.9 mmol) was taken up in EtOH (14 
mL) and conc. HCl (10 M; 13 mL) and added to a solution of methyl 3-bromo-5-
nitrobenzo[b]thiophene-2-carboxylate (164) (0.94 g, 3.0 mmol) in EtOH (15 mL), and heated to 
reflux for 3.5 h. Once cooled the solution was diluted with water, slowly basified with saturated 
aqueous Na2CO3 solution and extracted with Et2O (3 x 40 mL). The organic extracts were 
combined, dried (Na2SO4), filtered and evaporated in vacuo to give the title compound (0.83 g, 
97%) as a yellow solid, mp 147.8-150.7 °C (lit.152 211-212) (Found [ESI+]: 285.9529. 
C10H1079BrNO2S [MH] requires 285.9532); IR (neat) νmax/cm-1: 3419 (N-H str), 3328 (N-H str), 1693 
(C=O str), 1604 (N-H bend), 1506 (C-C str), 1286 (C-N str), 1087 (C-O str), 804 (N-H bend), 623 
(C-Br str); 1H NMR (500 MHz, DMSO-d6): 7.70 (1H, d, J = 9 Hz, 7-CH), 7.04 (1H, d, J = 1 Hz, 4-CH), 
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6.97 (1H, dd, J = 9, 1 Hz, 6-CH), 5.33 (2H, br. s, NH2), 3.87 (3H, s, Me); 13C NMR (126 MHz, DMSO-
d6): 161.2 (C), 147.8 (C), 139.3 (C), 126.3 (5-C), 123.4 (7-CH), 119.1 (6-CH), 112.9 (3-C), 105.7 (4-
CH), 52.5 (Me) one signal not observed; m/z (EI+): 287 (M81Br •+, 100), 285 (M79Br •+, 99), 256 
(34), 254 (35). 
 
6.2.11. (2E)-3-Ethoxyprop-2-enoyl chloride 
Chemical Formula: C5H7ClO2 
Mr: 134.01  
Oxalyl chloride (0.25 mL, 2.9 mmol) was added dropwise to a solution of (2E)-3-ethoxyprop-2-
enoic acid (0.15 g, 1.3 mmol) and catalytic DMF in dry CH2Cl2 (3.3 mL) at 0 °C, and the solution 
allowed to warm to RT over 2.5 h. Volatiles were removed in vacuo to give the title compound 
(0.17 g, 98%) and used crude in the next step. 1H NMR (500 MHz, CDCl3) δH/ppm: 7.79 (1H, d, J 
= 12 Hz, 2-CH), 5.52 (1H, d, J = 12 Hz, 3-CH), 4.06 (2H, q, J = 7 Hz, 5-CH2), 1.41 (3H, t, J = 7 Hz, 6-
CH3) matches literature spectral data.358 
 
6.2.12. Methyl 3-bromo-5-{[(2E)-3-ethoxyprop-2-enoyl]amino} 
benzo[b]thiophene-2-carboxylate (171) 
 
Molecular Formula: C15H14BrNO4S 
Mr: 384.24  
6.2.12.1. Table 2, entry 1. 
(2E)-3-Ethoxyprop-2-enoic acid (30 mg, 0.26 mmol) was added to a solution of methyl 5-amino-
3-bromobenzo[b]thiophene-2-carboxylate (165) (70 mg, 0.24 mmol), HOBt.H2O (40 mg, 0.29 
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mmol), EDCI.HCl (56 mg, 0.29 mmol) and DIEA (0.1 mL, 0.61 mmol) in DMF (2.2 mL) under N2, 
and the solution was stirred at RT for 24 h. Volatiles were then removed in vacuo and residues 
taken up the CH2Cl2 and washed with brine (3 x 15 mL), dried (Na2SO4), filtered and evaporated. 
Purification by flash column chromatography on SiO2 (dry-load), gradient eluting with CH2Cl2 to 
EtOAc-CH2Cl2 (10:90), gave the title compound (38 mg, 40%) as a brown solid, mp 205.7-206.8 
°C (Found [ESI+]: 383.9885. C15H15 81BrNO4S [MH] requires 385.9885); IR (neat) νmax/cm-1: 3263 
(N-H str), 2956 (C-H str), 1719 (C=O str), 1672 (C=C str), 1598 (C-C str), 1202 (C-O str), 1138 (C-O 
str); 1H NMR (500 MHz, DMSO-d6) δH/ppm: 10.07 (1H, s, NH), 8.48 (1H, s, 4-CH), 8.02 (1H, d, J = 
9 Hz, 7-CH), 7.73 (1H, d, J = 8 Hz, 6-CH), 7.54 (1H, d, J = 12 Hz, 2’-CH), 5.56 (1H, d, J = 12 Hz, 3’-
CH), 3.98 (2H, q, J = 7 Hz, 5’-CH2), 3.90 (3H, s, Me), 1.29 (3H, t, J = 7 Hz, 6’-CH3); m/z (EI+): 385 
(M81Br •+, 35), 383 (M79Br •+, 34), 287 (96), 285 (95), 99 (100), 71 (90).  
6.2.12.2. Table 2, Entry 2. 
According to a modified procedure,273 catalytic DMAP was added to a solution of methyl 5-
amino-3-bromobenzo[b]thiophene-2-carboxylate (165) (69 mg, 0.24 mmol), (2E)-3-ethoxyprop-
2-enoic acid (31 mg, 0.26 mmol) and EDCI.HCl (95 mg, 0.5 mmol) in pyridine (0.05 mL) and DMF 
(0.1 mL) and stirred at RT for 17 h. Solution was then diluted with EtOAc (50 mL), washed with 
aqueous HCl solution (10%; 3 x 40 mL), saturated aqueous NaHCO3 solution (3 x 40 mL) and brine 
(2 x 40 mL), dried (Na2SO4), filtered and evaporated in vacuo. Purification by flash column 
chromatography on SiO2 (dry-load), gradient eluting with Et2O-light petroleum (50:50) to (20:80) 
to give the title compound (9.4 mg, 10%) as a brown solid, with identical spectroscopic data.  
6.2.12.3. Table 2, Entry 3.Following the procedure of Boger et al.,273 (2E)-3-ethoxyprop-
2-enoic acid (41 mg, 0.35 mmol) was added to a solution of methyl 5-amino-3-
bromobenzo[b]thiophene-2-carboxylate (165) (71 mg, 0.24 mmol), EDCI.HCl (94 mg, 0.49 
mmol), pyridine (50 μL, 0.62 mmol), DMAP (60 mg, 0.40 mmol) in DMF (1.25 mL) and stirred at 
room temperature for 22 h. Purification by the above procedure gave the title compound (1.0 
mg, 10%) with identical spectroscopic data. 
6.2.12.4. Table 2, Entry 4.  
(2E)-3-ethoxyprop-2-enoic acid (35 mg, 0.29 mmol) was added to a solution of methyl 5-amino-
3-bromobenzo[b]thiophene-2-carboxylate (165) (70 mg, 0.24 mmol), EDCI.HCl (92 mg, 0.48 
mmol) and DMAP (33 mg, 0.27 mmol) in pyridine (1.25 mL, 16 mmol), and stirred at RT for 22 h. 
Purification by the above methods gave the title compound (14 mg, 15%) with identical 
spectroscopic data. 
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6.2.12.5. Table 2, entry 5.  
Catalytic DMAP was added to a solution of methyl 5-amino-3-bromobenzo[b]thiophene-2-
carboxylate (165) (50 mg, 0.17 mmol) in pyridine (0.25 mL) cooled to 0 °C, to this (2E)-3-
ethoxyprop-2-enoyl chloride (34 mg, 0.25 mmol) in dry CH2Cl2 was added. The solution was 
allowed to warm to RT and stirred for 65 h. Volatiles were removed in vacuo and the residues 
taken up in CH2Cl2, washed with aqueous HCl solution (1 M, 10 mL), saturated aqueous NaHCO3 
solution (1 x 10 mL) and brine (1 x 10 mL), dried (MgSO4), filtered and evaporated in vacuo. 
Purification by flash column chromatography on SiO2 (dry-load), gradient eluting with CH2Cl2 to 
EtOAc-CH2Cl2 (20:80). No discernible product formation. 
 
6.2.13. 3,3-Dimethoxypropanoic acid (172) 
 
Chemical Formula: C5H10O4 
Mr: 134.13 
Following the procedure of Edwankar et al.,359 methyl 3,3-dimethoxypropnaoate (173) (0.53 g, 
3.6 mmol) in a solution of NaOH (3.9 M; 0.18 g in 1.14 mL H2O) was stirred at 110 °C for 30 min, 
with reaction completion confirmed by TLC analysis (EtOAc-hexanes [50:50]). The solution was 
allowed to come to RT, cooled to 0 °C and carefully neutralized with cold 6 M HCl, then acidified 
to pH 3-4 at RT. The solution was then extracted with EtOAc (2 x 10 mL) and CH2Cl2 (1 x 10 mL), 
acidifying the aqueous phase after each extraction. The organic extracts were combined, dried 
(MgSO4), filtered and evaporated in vacuo to give the title compound (0.36 g, 79%) as a clear, 
colourless oil, IR (neat) νmax/cm-1: 2940 (O-H str) 1714 (C=O str), 1118 (C-O str acid), 1046 (C-O 
str, ether); 1H NMR (500 MHz, CDCl3) δH/ppm: 4.84 (1H, t, J = 6 Hz, 3-CH), 3.40 (6H, s, OMe), 2.72 
(2H, d, J = 6 Hz, 2-CH2); 13C NMR (126 MHz, CDCl3) δC/ppm: 175.0 (1-C), 101.0 (3-CH), 53.6 (OMe), 
38.7 (2-CH2); m/z (EI+): 133 ([M⁺−H], 25) 103 ([M⁺−OMe], 65), 75 (100), 61 (97). Data matches 
literature.360  
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6.2.14. Methyl 5-(3,3-
dimethoxypropanamido)benzo[b]thiophene-2-carboxylate 
(174)  
 
Chemical Formula: C15H17NO5S 
Mr: 323.36  
6.2.14.1. Conductive synthesis 
EDCI.HCl (0.12 g, 0.64 mmol), HOBt.H2O (0.09 g, 0.64 mmol) and DIEA (0.22 mL, 1.3 mmol) were 
added to a solution of methyl 5-aminobenzo[b]thiophene-2-carboxylate (158) (0.11 g, 0.53 
mmol) and 3,3-dimethoxypropanoic acid (172) (0.08 g, 0.41 mmol) in DMF (4.6 mL) under N2, 
and stirred at RT for 24 h. Volatiles were removed under reduced pressure and the residues 
dissolved in CH2Cl2 (15 mL) and washed with brine (3 x 15 mL), dried (MgSO4), filtered and 
evaporated in vacuo. Purification by flash column chromatography on SiO2 (dry-load), gradient 
eluting with CH2Cl2 to EtOAc-CH2Cl2 (50:50), gave the title compound (0.10 g, 59%) as a pale 
brown solid, (Found [ESI+]: 346.0686. C15H17NNaO5S [MNa] requires 346.0720); IR (neat) 
νmax/cm-1: 3262 (N-H str), 2948 (C-H str) 1723 (C=O str), 1651 (C=O str), 1252 (C-N str), 1053 (C-
O str); 1H NMR (500 MHz, CDCl3) δH/ppm: 8.25 (1H, d, J = 1 Hz, 4-CH), 8.22 (1H, br. s, NH), 8.01 
(1H, s, 3-CH), 7.78 (1H, d, J = 8 Hz, 7-CH), 7.44 (1H, dd, J = 8, 1 Hz, 6-CH), 4.78 (1H, t, J = 5 Hz, 3’-
CH), 3.95 (3H, s, OMe), 3.48 (6H, s, 3’-OMe), 2.77 (2H, d, J = 5 Hz, 2’-CH2); 13C NMR (126 MHz, 
CDCl3) δC/ppm: 167.3 (1’-C), 163.1 (C), 139.3 (C), 137.9 (C), 135.3 (C), 134.5 (C), 130.5 (3-CH), 
123.0 (4-CH), 120.4 (6-CH), 115.9 (7-CH), 102.1 (3’-CH), 54.4 (C(OMe)2), 52.5 (OMe), 42.0 (2’-
CH2). 
6.2.14.2. Microwave-assisted synthesis. 
EDCI.HCl (73 mg, 0.38 mmol), HOBt.H2O (53 mg, 0.39 mmol) and DIEA (0.1 mL, 0.61 mmol) were 
added to a solution of 3,3-dimethoxypropnaoic acid (172) (41 mg, 0.30 mmol) and methyl 5-
aminobenzo[b]thiophene-2-carboxylate (158) (50 mg, 0.24 mmol) in DMF (2.5 mL) under N2 and 
irradiated at 78 °C for 1 h in a pressure-rated glass vial (10 mL) at using a CEM Discover 
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microwave synthesizer by moderating the initial power (200 W). After cooling in a flow of 
compressed air, the volatiles were removed and the residues dissolved in EtOAc and CH2Cl2 (20 
mL) and washed with water (3 x 15 mL), brine (2 x 15 mL), dried (MgSO4), filtered and evaporated 
in vacuo. Purification by flash column chromatography on SiO2 (dry-load), gradient eluting with 
EtOAc-CH2Cl2 (5:95) to (50:50), gave the title compound (56 mg, 72%) as a pale brown solid, with 
identical spectroscopic data. 
 
6.2.15. Methyl 3-bromo-5-(3,3-
dimethoxypropanamido)benzo[b]thiophene-2-carboxylate 
(175) 
 
Chemical Formula: C15H16BrNO5S 
Mr: 402.26  
6.2.15.1. Conductive synthesis. 
EDCI.HCl (1.58 g, 8.2 mmol), HOBt.H2O (1.06 g, 7.8 mmol) and DIEA (2.2 mL, 13.4 mmol) were 
added to a solution of 3,3-dimethoxypropanoic acid (172) (0.74 g, 5.5 mmol) and methyl 5-
amino-3-bromobenzo[b]thiophene-2-carboxylate (165) (1.49 g, 5.21 mmol) in DMF (50 mL) 
under N2 and the solution was stirred at 25 °C for 26 h. Volatiles were removed and the residues 
taken up in EtOAc, washed with brine (5 x 15 mL), dried (Na2SO4), filtered and evaporated in 
vacuo. Purification by flash column chromatography on SiO2 (dry-load), gradient eluting with 
EtOAc-CH2Cl2 (5:95) to (15:75), gave the title compound (1.24 g, 59%) as a pale brown solid, mp 
161.9-162.9 °C (Found [ESI+]: 425.9808. C15H16 81BrNNaO5S [MNa] requires 425.9810); IR (neat) 
νmax/cm-1: 3369 (N-H str), 2950 (C-H str), 1705 (C=O str), 1572 (N-H str), 1508 (C-C str), 1233 (C-
O str), 1066 (C-O str), 981 (C-H bend); 1H NMR (500 MHz, DMSO-d6) δH/ppm: 10.31 (1H, s, NH), 
8.47 (1H, s, 4-CH), 8.04 (1H, d, J = 8 Hz, 7-CH), 7.71 (1H, d, J = 8 Hz, 6-CH), 4.83 (1H, t, J = 6 Hz, 
3’-CH), 3.90 (3H, s, OMe), 3.30 (6H, s, OMe), 2.69 (2H, d, J = 6 Hz, 2’-CH2); 13C NMR (125 MHz, 
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DMSO-d6) δC/ppm: 167.7 (1’-C), 160.9 (C), 138.4 (C), 137.7 (C), 133.1 (C), 127.7 (C), 123.7 (7-CH), 
121.2 (6-CH), 114.0 (5-C), 113.4 (4-CH), 101.8 (3’-CH), 53.2 (C(OMe)2), 52.7 (OMe), 41.4 (2’-CH2). 
6.2.15.2. Microwave-assisted synthesis. 
EDCI.HCl (107 mg, 0.56 mmol), HOBt.H2O (70 mg, 0.52 mmol) and DIEA (0.15 mL, 0.92 mmol) 
were added to a solution of 3,3-dimethoxypropanoic acid (172) (57 mg, 0.42 mmol) and methyl 
5-amino-3-bromobenzo[b]thiophene-2-carboxylate (165) (105 mg, 0.37 mmol) in DMF (3.5 mL) 
under N2, and irradiated at 80 °C for 1 h in a pressure-rated glass vial (10 mL) using a CEM 
Discover microwave synthesizer by moderating the initial power (100 W). After cooling in a flow 
of compressed air, the volatiles were removed in vacuo and the residue was taken up in EtOAc 
and CH2Cl2 (20 mL) and washed with water (3 x 15 mL) and brine (2 x 15 mL), dried (Na2SO4), 
filtered and evaporated in vacuo. Purification by flash column chromatography on SiO2 (dry-
load), gradient eluting with EtOAc-CH2Cl2 (10:90) to (50:50), gave the title compound (79 mg, 
56%) as an off-white solid, with identical spectroscopic data. 
6.2.15.3. Microwave synthesis, using COMU reagent 
DIEA (0.20 mL, 1.22 mmol) was added to a solution of methyl 5-amino-3-bromobenzothiophene-
2-carboxylate (165) (0.15 g, 0.60 mmol), COMU (0.39 g, 0.92 mmol) and 3,3-dimethoxypropanoic 
acid (172) (0.11 g, 0.80 mmol) in DMF (4 mL) under N2, and irradiated at 120 °C for 30 min in a 
pressure-rated glass vial (10 mL) using a CEM Discover microwave synthesizer through 
modulation of the initial power (120 W). After cooling in a flow of compressed air, the volatiles 
were removed in vacuo and the residue was taken up in EtOAc (20 mL) and washed with water 
(1 x 20 mL) and brine (3 x 30 mL), dried (Na2SO4), filtered and evaporated in vacuo. Purification 
by flash column chromatography on SiO2 (dry-load), gradient eluting with CH2Cl2 to EtOAc-CH2Cl2 
(50:50), to give the title compound (0.22 g, 89%) as a brown solid, with identical spectroscopic 
data. 
 
6.2.16. Methyl 7-oxo-6,7-dihydrothieno[3,2-f]quinoline-2-
carboxylate (160A and 160B)  
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Chemical Formula: C13H9NO3S 
Mr: 259.28  
Conc. H2SO4 (1.4 mL) was cooled to 0 °C and added to methyl 5-(3,3-dimethoxy-
propanamido)benzo[b]thiophene-2-carboxylate (174) (90 mg, 0.28 mmol) and stirred at RT for 
3 h. The solution was then poured into iced water and the precipitate isolated by vacuum 
filtration, washed with water and dried in air to give a white solid (105 mg, >100%, wet). The 1H 
NMR spectrum confirmed a mixture of two regioisomers; the title compound (88%) and a side 
product (12%). This product was used crude in the next step. (Found [ESI+]: 260.0373. 
C13H10NO3S [MH] requires 260.0376); IR (neat) νmax/cm-1: 2842 (OH str), 1723 (C=O str), 1651 
(C=O str), 1514 (C-C str), 1221 (C-O str), 1071 (N-H str); 1H NMR (500 MHz, DMSO-d6) δH/ppm: 
(160A) 8.75 (1H, s, 1-CH), 8.64 (1H, d, J = 9 Hz, 9-CH), 8.16 (1H, d, J = 9, 4-CH), 7.51 (1H, d, J = 9 
Hz, 5-CH), 6.63 (1H, d, J = 9 Hz, 8-CH), 3.91 (3H, br. s, Me); (160B): 8.38 (1H, s, 3-CH), 8.26 (1H, s, 
4-CH), 7.99 (1H, d, J = 10 Hz, 8-CH), 7.87 (1H, s, 9-CH), 6.58 (1H, d, J = 9, 7-CH), 3.91 (3H, br. s, 
Me). 
 
6.2.17. Methyl 1-bromo-7-oxo-6,7-dihydrothieno[3,2-
f]quinoline-2-carboxylate (176A and 176B)  
 
Chemical Formula: C13H8BrNO3S 
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Mr: 336.94  
6.2.17.1. Using Methyl 3-bromo-5-{[(2E)-3-ethoxyprop-2-enoyl]amino} 
benzo[b]thiophene-2-carboxylate (171). 
Conc. H2SO4 (2 mL) cooled to 0 °C was added to methyl 3-bromo-5-{[(2E)-3-ethoxyprop-2-
enoyl]amino}benzo[b]thiophene-2-carboxylate (171) (72 mg, 0.19 mmol) and the solution 
allowed to warm to RT and stirred for 3 h. The solution was poured into iced water and the 
precipitate isolated by vacuum filtration, washed with water and dried in air to give a white solid 
(44 mg, 70%). The proton NMR indicated the presence of two regioisomers; the title compound 
(75%) and a side product (25%). Carried forward into next step with no purification. IR (neat) 
νmax/cm-1: 1727 (C=O str), 1652 (C=O str), 1549 (C-C str), 1207 (C-O str), 1069 (C-) str); 1H NMR 
(500 MHz, DMSO-d6) δH/ppm: (176A) 12.21 (1H, s, NH), 9.67 (1H, d, J = 10 Hz, 9-CH), 8.25 (1H, d, 
J = 9 Hz, 5-CH), 7.62 (1H, d, J = 9 Hz, 4-CH), 6.72 (1H, d, J = 10 Hz, 8-CH), 3.92 (3H, s, Me); (176B): 
11.90 (1H, s, 5-NH), 8.45 (1H, s, 4-CH), 8.03 (1H, d, J = 10 Hz, 8-CH), 7.88 (1H, s, 9-CH), 6.63 (1H, 
d, J = 10 Hz, 7-CH), 3.92 (3H, s, Me); m/z (EI+): 339 (M81Br •+, 97), 337 (M79Br •+, 93), 308 (46), 306 
(43).   
6.2.17.2. Using Methyl 3-bromo-5-(3,3-
dimethoxypropanamido)benzo[b]thiophene-2-carboxylate (174).Following 
the above method, 174 (75 mg, 0.19 mmol) was stirred with cooled conc. H2SO4 (2 mL), to give 
an off-white solid (55 mg, 87%). A mixture of products by 1H NMR, title compound 176A (65%), 
minor regioisomer 176B (35%), 1H NMR data matches above. Crude carried forward. 
 
6.2.18. Methyl 1-bromo-7-chlorothieno[3,2-f]quinoline-2-
carboxylate (166)  
 
Chemical Formula: C13H7BrClNO2S 
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Mr: 356.62 The crude mixture of methyl 1-bromo-7-oxo-6,7-dihydrothieno[3,2-f]quinoline-2-
carboxylate (176A) and its regioisomer (176B) (40 mg, 0.12 mmol) was heated to reflux in POCl3 
(0.6 mL) for 2.5 h and then poured carefully into iced water, filtered, washed with water and 
dried in air. Purification by flash column chromatography on SiO2 (dry-load), gradient eluting 
with light petroleum to Et2O-light petroleum (10:90), gave the title compound (18 mg, 42%) as 
an off white solid, mp 211.8-223.6 °C (dec.) (Found [ESI+]: 357.9126. C13H881Br35ClNO2S [MH] 
requires 357.9127); IR (neat) νmax/cm-1: 2922 (C-H str), 2853 (C-H str), 1731 (C=O str), 1490 (C-C 
str), 1212 (C-O str), 813 (C-Cl str); 1H NMR (500 MHz, CDCl3) δH/ppm: 10.18 (1H, d, J = 9 Hz, 9-
CH), 8.09 (2H, m, 5-CH and 4-CH), 7.60 (1H, d, J = 9 Hz, 8-CH), 4.02 (3H, s, Me); 13C NMR (125 
MHz, CDCl3) δC/ppm: 161.4 (C), 150.2 (C), 147.9 (C), 139.8 (C), 133.5 (9-CH), 130.9 (C), 129.6 (CH), 
128.6 (C), 124.9 (CH), 124.4 (C), 122.2 (8-CH), 113.5 (C), 52.8 (CH3). 
 
6.2.19. Methyl 7-chloro-1-(6-methylpyridin-3-yl)thieno[3,2-
f]quinoline-2-carboxylate (177) 
 
Chemical Formula: C19H13ClN2O2S 
Mr: 368.84  
According to a modified procedure,361 a mixture of 166 (70 mg, 0.20 mmol), 6-methylpyridine-
3-boronic acid (31 mg, 0.23 mmol), CsF (96 mg, 0.63 mmol) and PdCl2(PPh3)2 (15 mg, 0.021 
mmol)  in anhydrous 1,4-dioxane (1.4 mL) under N2 was irradiated at 140 °C for 30 min in a 
pressure-rated glass vial (10 mL) using a CEM Discover microwave synthesizer by moderating 
the initial power (200 W). After cooling in a flow of compressed air, the reaction mixture was 
poured into water, the solid filtered off under reduced pressure, washed with water and dried 
in air. Purification by flash column chromatography on SiO2 (dry-load), gradient eluting with 
CH2Cl2 to EtOAc-CH2Cl2 (10:90), gave the title compound (13 mg, 18%) as an off white solid, mp 
119.7-125.5 °C (Found [ESI+]: 369.0448. C19H1435ClN2O2S [MH] requires 369.0465); IR (neat) 
241 
 
νmax/cm-1: 3295 (C-H str), 2925 (C-H str), 1720 (C=O str), 1554 (C-C str), 1050 (C-O str), 815 (C-Cl 
str); 1H NMR (500 MHz, CDCl3) δH/ppm: 8.54 (1H, s, 2’-CH), 8.14 (1H, d, J = 9 Hz, 4-CH), 8.07 (1H, 
d, J = 9 Hz, 5-CH), 7.68 (1H, d, J = 9 Hz, 9-CH), 7.63 (1H, dd, J = 8, 2 Hz, 4’-CH), 7.40 (1H, d, J = 8 
Hz, 5’-CH), 7.18 (1H, d, J = 9 Hz, 8-CH), 3.80 (3H, s, OMe), 2.75 (3H, s, Me); 13C NMR (126 MHz, 
CDCl3) δc/ppm: 162.1 (C), 158.8 (6’-C), 149.8 (7-C), 148.7 (2’-CH), 147.9 (C), 141.3 (C), 140.2 (C), 
136.9 (4’-CH), 133.6 (9-CH), 133.4 (C), 131.2 (C), 129.8 (C), 129.0 (5-CH), 125.1 (4-CH), 124.4 (C), 
123.4 (5’-CH), 122.2 (8-CH), 52.5 (OMe), 24.5 (Me). 
 
6.2.20. (R)-tert-Butyl-(1-amino-1-oxopropan-2-yl)carbamate (182)   
 
Chemical Formula: C8H16N2O2 
Mr: 188.22 
Method 1:362  
Under N2, ethyl chloroformate (0.55 mL, 5.8 mmol) was added drop-wise to a stirred solution of 
Boc-D-alanine (1.0 g, 5.3 mmol) and NEt3 (0.80 mL, 5.8 mmol) in dry THF (8.8 mL) at 0 °C. The 
reaction mixture was stirred at 0 °C for 45 min before addition of a solution of aqueous NH3 
(35%; 4 mL) in THF (1 mL). The resultant solution was stirred at 0 °C for 45 min, and then 
partitioned between water (20 mL) and EtOAc (30 mL) and the aqueous layer was further 
extracted with EtOAc (2 x 30 mL). The organic extracts were combined, washed with saturated 
aqueous NaHCO3 solution (1 x 30 mL), brine (1 x 30 mL), aqueous HCl solution (1 M; 1 x 30 mL) 
and brine (2 x 30 mL), dried (Na2SO4), filtered and evaporated in vacuo. Purification by 
recrystallization from EtOAc and light petroleum gave the title compound (0.41 g, 41%) as 
colourless crystals, mp 125.8-126.9 °C (EtOAc) (lit.363 mp 120-121) (Found [ESI+]: 211.1060. 
C8H16N2NaO3 [MNa] requires 211.1053); IR (neat) νmax/cm-1: 3387 (N-H str), 3351 (N-H str), 3190 
(N-H str), 2980 (C-H str), 1678 (C=O str), 1643 (C=O str), 1517 (N-H bend), 1320 (C-N str), 1244 
(C-O str), 1164 (C-N str), 864 (N-H wag); 1H NMR (500 MHz, CDCl3) δH/ppm: 6.25 (1H, br s, exch. 
D2O, 1-NHH), 5.66 (1H, br. s., exch. D2O, 1-NHH), 5.09 (1H, br s, exch. D2O, NH), 4.21 (1H, m, 2-
CH), 1.45 (9H, s, CMe3), 1.38 (3H, d, J = 6 Hz, 3-Me); 13C NMR (126 MHz, CDCl3) δC/ppm: 175.5 
(CONH2), 155.5 (C), 80.1 (CMe3), 49.7 (2-CH), 28.3 (CMe3), 18.4 (3-Me).  
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6.2.21. tert-Butyl ([2R]-1-aminopropan-2-yl)carbamate (137)  
 
Chemical Formula: C8H18N2O2 
Mr: 174.24 
According to a modified method,364 a solution of Boc-D-Ala-OH (0.50 g, 2.64 mmol) and 
HOBt.H2O (0.41 g, 3.0 mmol) in CH2Cl2 (20 mL) was cooled to 0 °C and EDCI.HCl (0.58 g, 3.0 mmol) 
added, the solution was allowed to warm to RT and stirred for 30 min. The solution was then 
cooled to 0 °C, aqueous NH3 solution (18.1 M; 0.6 mL) was added drop-wise, stirred for 30 min 
at RT and the solids removed by filtration under reduced pressure. The filtrate was washed with 
water (1 x 20 mL) and brine (2 x 20 mL), dried (MgSO4), filtered and evaporated in vacuo. 
Purification by flash column chromatography on SiO2, gradient eluting with MeOH (3-7%) in 
CH2Cl2, gave the intermediate (R)-tert-butyl-(1-amino-1-oxopropan-2-yl)carbamate (182) (0.37g, 
75%) as a white crystalline solid, mp 127.5-128.2 °C (lit.363 120-121); with identical spectroscopic 
data. 
According to a modified method,365 a solution of BH3•SMe2 in THF (2 M; 13.5 mL, 27 mmol) was 
added portion-wise to a solution of (R)-tert-butyl-(1-amino-1-oxopropan-2-yl)carbamate (182) 
(0.5 g, 2.7 mmol) in dry THF (9 mL) under N2 at 0 °C. The reaction mixture was then allowed to 
warm to RT and stirred for 18 h, with reaction completion determined by TLC. The reaction 
mixture was concentrated in vacuo and the residue treated with MeOH (3 x 15 mL), stirring and 
concentrating to dryness in vacuo. Purification by SCX-2 ion exchange chromatography, gradient 
eluting with MeOH to 2 M NH3 in MeOH, gave the title compound (0.39 g, 84%) as a colourless 
oil, (Rf 0.3; MeOH-CH2Cl2 [10:90]) (Found [ESI+]: 175.1443. C8H19N2O2 [MH] requires 175.1441); 
[α]D24 −5.7 (c 1.1, MeOH); IR (neat) νmax/cm-1: 2973 (C-H str), 1685 (C=O str), 1521 (N-H bend), 
1247 (C-O str), 1165 (C-N str), 1045 (C-O str), 872 (N-H wag); 1H NMR (500 MHz, CDCl3) δH/ppm: 
4.78 (1H, d, J = 7 Hz, NHBoc), 3.60 (1H, m, 2-CH), 2.70 (1H, m, 1-CHH), 2.59 (1H, m, 1-CHH), 1.40 
(9H, s, CMe3), 1.08 (3H, d, J = 7 Hz, 3-Me); 13C NMR (126 MHz, CDCl3) δC/ppm: 155.7 (C), 79.1 
(CMe3), 48.6 (2-CH), 47.4 (1-CH2), 28.4 (CMe3), 18.5 (Me).  
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6.2.22. (R)-Methyl 3-((2-((tert-
butoxycarbonyl)amino)propyl)amino)-benzo[b]thiophene-2-
carboxylate (184) 
 
Chemical Formula: C18H24N2O4S  
Mr: 364.46  
6.2.22.1. Conductive synthesis. 
Under N2, tert-butyl ([2R]-1-aminopropan-2-yl)carbamate (137) (70 mg, 0.37 mmol) was added 
to a stirred solution of methyl 3-bromobenzo[b]thiophene-2-carboxylate (100 mg, 0.37 mmol), 
Cs2CO3 (240 mg, 0.74 mmol), (±)-BINAP (23 mg, 0.037 mmol) and Pd(OAc)2 (5 mg, 0.02 mmol) in 
dry toluene (1.2 mL) and heated to reflux for 22 h. Once cooled to RT, the reaction mixture was 
partitioned between water (15 mL) and Et2O (15 mL) and the aqueous layer extracted with Et2O 
(2 x 15 mL). The organic extracts were combined, dried (MgSO4), filtered and evaporated in 
vacuo. Purification by flash column chromatography on SiO2 (dry-load), gradient eluting with 
light petroleum to Et2O-petroleum (75:25) gave the title compound (37 mg, 27%) as a gummy 
solid, IR (neat) νmax/cm−1: 3368 (N-H str), 2957 (C-H str), 1704 (C=O str), 1652 (C=O str), 1516 (C-
C str), 1286 (C-N str), 1235 (C-N str), 1165 (C-O str), 756 (N-H wag); 1H NMR (500 MHz, CDCl3,) 
δH/ppm: 8.09 (1H, d, J = 8 Hz, 4-CH), 7.71 (1H, d, J = 8 Hz, 7-CH), 7.42 (1H, t, J = 8 Hz, 6-CH), 7.31 
(1H, t, J = 8 Hz, 5-CH), 4.66 (1H, br. s, NH), 3.99 (1H, m, 2’-CH), 3.88 (3H, s, OMe), 3.80 (1H, m, 
1’-CHH), 3.72 (1H, m, 1’-CHH), 1.42 (9H, s, CMe3), 1.28 (3H, d, J = 6 Hz, 3’-Me); 13C NMR (CDCl3, 
126 MHz) δC/ppm: 166.2 (C), 155.3 (C), 152.0 (C), 140.6 (C), 136.9 (C), 131.9 (C), 127.7 (6-CH), 
124.9 (4-CH), 123.7 (5-CH), 123.5 (7-CH), 121.2 (CMe3), 51.5 (OMe), 47.0 (2’-CH), 29.7 (1’-CH2), 
28.3 (CMe3), 18.5 (3’-Me); m/z (EI+): 364 (M•+, 62), 220 (85), 188 (100). 
6.2.22.2. Microwave-assisted synthesis. 
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Under N2, tert-butyl ([2R]-1-aminopropan-2-yl)carbamate (137) in dry toluene (55 mg, 0.6 mL, 
0.32 mmol) was added to a stirred solution of methyl 3-bromobenzo[b]thiophene-2-carboxylate 
(86 mg, 0.32 mmol), Cs2CO3 (145 mg, 0.44 mmol), (±)-BINAP (20 mg, 0.032 mmol) and Pd(OAc)2 
(3.5 mg, 0.02 mmol) in dry toluene (1.1 mL) was irradiated at 150 °C for 75 min in a pressure-
rated glass vial (10 mL) using a CEM Discover microwave synthesizer by moderating the initial 
power (200 W). After cooling in a flow of compressed air, the reaction mixture was partitioned 
between water (10 mL) and Et2O (10 mL) and the aqueous layer extracted with Et2O (3 x 15 mL). 
The organic extracts were combined, dried (MgSO4), filtered and evaporated in vacuo. 
Purification by flash column chromatography on SiO2 (dry-load), gradient eluting with light 
petroleum to Et2O, gave the title compound (45 mg, 60%) as a gummy colourless solid, with 
identical spectroscopic data. 
 
6.2.23. (R)-Methyl 3-((2-((tert-
butoxycarbonyl)amino)propyl)amino)-5-
nitrobenzo[b]thiophene-2-carboxylate (185)  
 
Chemical Formula: C18H23N3O6S 
Mr: 409.46 
According to a modified procedure,276 tert-butyl ([2R]-1-aminopropan-2-yl)carbamate (137) (35 
mg, 0.20 mmol) was added to a mixture of methyl 3-bromo-5-nitrobenzo[b]thiophene-2-
carboxyaldehyde (164) (50 mg, 0.16 mmol), Cs2CO3 (73 mg, 0.22 mmol), (±)-BINAP (13 mg, 0.02 
mmol) and Pd(OAc)2 (2.0 mg, 2.0 μmol) in dry toluene (1.0 mL) under N2 and irradiated at 150 
°C for 75 min in a pressure-rated glass vial (10 mL) using a CEM Discover microwave synthesizer 
by moderating the initial power (200 W). After cooling in a flow of compressed air, the reaction 
mixture was taken up in water (20 mL) and extracted with EtOAc (3 x 30 mL). The organic extracts 
were combined, washed with brine (1 x 30 mL), dried (Na2SO4), filtered and evaporated in vacuo. 
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Purification by flash column chromatography on SiO2 (dry-load), gradient eluting with light 
petroleum to Et2O-light petroleum (50:50), gave the title compound (50 mg, 76%) as a red solid, 
mp 182.9-184.0 °C, (Found [ESI+]: 410.1378. C18H24N3O6S [MH] requires 410.1380); [α]D24 +55.3 
(c 0.11, MeOH); IR (neat) νmax/cm-1: 3355 (N-H str), 2954 (C-H str), 1672 (C=O str), 1588 (N-O str) 
1508 (C-C str), 1325 (N-O str), 1230 (C-O str), 1060 (C-N str); 1H NMR (500 MHz, DMSO-d6) 
δH/ppm: 8.94 (1H, m, 4-CH), 8.27 (1H, d, J = 9 Hz, 6-CH), 8.15 (1H, d, J = 9 Hz, 7-CH), 7.54 (1H, m, 
3-NH), 6.87 (1H, d, J = 6 Hz, 2’-NH), 3.81 (4H, 1’-CHH and OMe), 3.76 (1H, m, 2’-CH), 3.57 (1H, m, 
1’-CHH), 1.32 (9H, s, CMe3), 1.12 (1H, d, J = 6 Hz, 3’-Me); 13C NMR (126 MHz, DMSO-d6) δC/ppm: 
164.0 (C), 155.1 (C), 150.3 (3-C), 145.2 (C), 144.3 (C), 131.1 (C), 124.7 (7-CH), 121.6 (6-CH), 120.5 
(4-CH), 99.5 (2-C), 77.6 (CMe3), 51.7 (OMe), 50.5 (1’-CH2), 46.2 (2’-CH), 28.1 (CMe3), 18.3 (3’-
Me); m/z (EI+): 410 (MH⁺, 100), 409 (M●⁺, 70).  
 
 6.2.24. (3R)-3-Methyl-9-nitro-1,2,3,4-tetrahydro-5H-[1]benzothieno[3,2-
e][1,4]diazepin-5-one (178)  
 
Chemical Formula: C12H11N3O3S 
Mr: 277.30  
According to a modified procedure,277,366 a solution of (R)-methyl 3-((2-((tert-
butoxycaronyl)amino)propyl)amino)-5-nitrobenzo[b]thiophene-2-carboxylate (185) (0.30 g, 
0.73 mmol) in TFA (10% v/v in CH2Cl2) (5.7 mL, 7.3 mmol) was stirred at RT until salt formation 
was confirmed by TLC analysis (Rf 0.3; MeOH-CH2Cl2 [10:90]) and the volatiles removed in vacuo. 
The residue was dissolved in a solution of NaOMe (25 wt. % in MeOH; 1 mL, 4.4 mmol) in MeOH 
(5 mL) and warmed to 50 °C for 2 h before heating to reflux for 2 h. The reaction mixture was 
then allowed to cool to RT, cooled in an ice bath and neutralized by the addition of aqueous HCl 
solution (1 M) and stirred at 0 °C for 30 min. The solid was then isolated by vacuum filtration, 
washed with water and dried in air to give the title compound (0.18 g, 100%) as a red powder, 
mp 337.4-342.4 (dec.) (Found [ESI+]: 278.0590. C12H1sN3O3S [MH] requires 278.0594); [α]D24 + 
110.6 (c 0.04, MeOH); IR (neat) νmax/cm-1: 3307 (N-H str), 1598 (C=O str), 1501 (N-O str), 1438 
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(C-C str), 1318 (N-O str), 1102 (C-N str), 736 (N-H wag); 1H NMR (500 MHz, DMSO-d6) δH/ppm: 
9.03 (1H, d, J = 2 Hz, 10-CH), 8.22 (1H, dd, J = 9, 2 Hz, 8-CH), 8.05 (1H, d, J = 9 Hz, 7-CH), 8.02 (1H, 
m, 1-NH), 7.95 (1H, d, J = 3 Hz, 4-NH), 3.60 (1H, m, 3-CH), 3.39 (2H, m, 2-CH2), 1.16 (3H, d, J = 7 
Hz, Me); 13C NMR (126 MHz, DMSO-d6) δC/ppm: 164.2 (C), 145.3 (C), 144.2 (C), 141.8 (C), 132.9 
(C), 123.8 (7-CH), 120.8 (8-CH), 118.6 (10-CH), 108.6 (C), 50.6 (2-CH2), 47.6 (3-CH), 18.6 (Me); 
m/z (EI+): 277 (M●⁺, 87), 262 (M-CH3, 24), 234 (29), 206 (30). 
 
6.2.25. (3R)-9-Amino-3-methyl-1,2,3,4-tetrahydro-5H-
[1]benzothieno[3,2-e][1,4]diaepin-5-one (179) 
 
Chemical Formula: C12H13N3OS 
Mr: 247.32 
Following the procedure of Spencer et al.,279 DBU (0.3 mL, 2.1 mmol) was added to a solution of 
178 (0.19 g, 0.69 mmol) and Mo(CO)6 (0.18 g, 0.69 mmol) in EtOH (7 mL) in a pressure-rated 
glass vial (35 mL) and irradiated at 150 °C for 30 min using a CEM Discover microwave synthesizer 
by moderating the initial power (300 W). After cooling in a flow of compressed air the volatiles 
were removed in vacuo. Purification by flash column chromatography on SiO2 (dry-load), 
gradient eluting with CH2Cl2 to MeOH-CH2Cl2 (10:90), gave the title compound (0.16 g, 96%) as a 
brown solid, mp 154.1-160.4 °C (dec.) (Found [ESI+]: 248.0851. C12H14N3OS [MH] requires 
248.0852); [α]D24 + 48.7 (c 0.11 MeOH); IR (neat) νmax/cm-1: 3238 (NH str), 1596 (N-H str), 1419 
(C-C str), 1324 (C-N str), 1244 (C-N str); 1H NMR (500 MHz, DMSO-d6) δH/ppm: 7.60 (1H, d, J = 2 
Hz, 4-NH), 7.37 (1H, d, J = 8 Hz, 7-CH), 7.14 (1H, m, 1-NH), 6.98 (1H, m, 10-CH), 6.79 (1H, d, J = 8 
Hz, 8-CH), 5.04 (2H, br. s, 9-NH2), 3.54 (1H, m, 3-CH), 3.30 (2H, m, 2-CH2), 1.13 (3H, d, J = 7 Hz, 
Me); 13C NMR (126 MHz, DMSO-d6) δC/ppm: 164.8 (C), 145.4 (C), 141.2 (C), 134.1 (C), 126.7 (9-
C), 122.7 (7-CH), 117.1 (8-CH), 106.6 (C), 104.9 (10-CH), 51.0 (2-CH2), 47.7 (3-CH), 18.6 (Me). 
 
247 
 
6.2.26. 3,3-Dimethoxy-N-((3R)-3-methyl-5-oxo-2,3,4,5-
tetrahydro-1H-[1]benzo[4,5]thieno[3,2-e][1,4]diazepin-9-
yl)propanamide (186) 
 
Chemical Formula: C17H21N3O4S 
Mr: 363.43 
6.2.26.1. EDCI-HOBt mediated microwave-assisted synthesis 
DIEA (0.2 mL, 1.2 mmol) was added to a solution of (R)-9-amino-3-methyl-1,2,3,4-tetrahydro-
5H-[1]benzothieno[3,2-e][1,4]diaepin-5-one (179) (96 mg, 0.39 mmol), 3,3-dimethoxypropanoic 
acid (172) (65 mg, 0.48 mmol), HOBt.H2O (87 mg, 0.64 mmol), and EDCI.HCl (120 mg, 0.60 mmol) 
in DMF (6 mL) under N2, and irradiated at 120 °C for 15 min in a pressure-rated glass vial (10 mL) 
using a CEM Discover microwave synthesizer by modulating the initial power (200 W). After 
cooling in a flow of compressed air, the volatiles were removed in vacuo and the residue was 
taken up in CH2Cl2 and washed with water (3 x 30 mL) and brine (2 x 30 mL), dried (Na2SO4), 
filtered and evaporated in vacuo. Purification by flash column chromatography on SiO2 (dry-
load), gradient eluting with CH2Cl2 to MeOH in CH2Cl2 (10:90), gave the title compound (51 mg, 
36%) as a brown solid, mp 299.5 °C (dec.) (Found [ESI+]: 364.1327. C17H22N3O4S [MH] requires 
364.1326); IR (neat) νmax/cm-1: 3253 (N-H str), 1668 (C=O str), 1590 (N-H bend), 1420 (C-C str), 
1117 (C-N str), 1075 (C-O str); 1H NMR (600 MHz, DMSO-d6) δH/ppm: 10.06 (1H, s, NH), 8.30 (1H, 
s, 10’-CH), 7.76 (1H, d, J = 4 Hz, 4’-NH), 7.68 (1H, d, J = 9 Hz, 7’-CH), 7.47-7.43 (1H, m, 1’-NH), 
7.37 (1H, dd, J = 9, 1, Hz, 8’-CH), 4.82 (1H, t, J = 6 Hz, 3-CH), 3.58-3.52 (1H, m, 3’-CH), 3.35-3.33 
(2H, m, 2’-CH2), 3.29 (6H, s, OMe), 2.67 (2H, d,  J = 6 Hz, 2-CH2), 1.13 (3H, d, J = 6.5 Hz, Me); 13C 
NMR (151 MHz, DMSO-d6) δC/ppm: 167.2 (1-C), 164.7 (5’-C), 141.6 (C), 135.1 (9’-C), 133.9 (C), 
133.2 (C), 122.8 (7’-CH), 120.4 (8’-CH), 112.8 (10’-CH), 107.2 (C), 102.0 (3-CH), 53.1 (OMe), 50.9 
(2’-CH2), 47.7 (3’-CH), 40.9 (2-CH2), 18.6 (Me). 
6.2.26.2. COMU mediated microwave-assisted synthesis. 
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(R)-9-Amino-3-methyl-1,2,3,4-tetrahydro-5H-[1]benzothieno[3,2-e][1,4]diaepin-5-one (179) (93 
mg, 0.38 mmol) was added to a solution of 3,3-dimethoxypropanoic acid (172) (81 mg, 0.60 
mmol), COMU (270 mg, 0.62 mmol), EDCI.HCl (120 mg, 0.62 mmol) and DIEA (0.13 mL, 0.80 
mmol) in DMF (2.5 mL) under Ar and irradiated at 120 °C for 1 h in a pressure-rated glass vial (10 
mL) using a CEM Discover microwave synthesizer by modulating the initial power (120 W). After 
cooling in a flow of compressed air, the volatiles were removed in vacuo. Purification by SCX-2 
chromatography, gradient eluting with MeCN to MeOH, to give the title compound (110 mg, 
83%) as a brown solid, with identical spectroscopic data. LCMS purity: 84% (UV), Ret. Time = 
4.22 min. 
 
6.2.27. Methyl 7-(pyridin-3-yl)thieno[3,2-f]quinoline-2-
carboxylate (195A) 
 
Chemical Formula: C18H12N2O2S 
Mr: 320.65 
Methyl 5-aminobenzothiophenen-2-carboxylate (158) (120 mg, 0.58 mmol) and 3-
pyridinecarboxaldehyde (62 mg, 0.58 mmol) were stirred in MeCN (2 mL) for 1 h at RT. Iodine 
(62 mg, 0.24 mmol) and n-BVE (77 mg, 0.77 mmol) were then added and the solution irradiated 
at 100 °C for 3 h in a pressure-rated vial (10 mL) using a CEM Discover microwave synthesizer 
through modulation of the initial power (120 W). The solution was then diluted with EtOAc (30 
mL), washed with aqueous Na2S2O3 solution (1 M; 1 x 20 mL) and brine (1 x 20 mL), dried 
(Na2SO4), filtered and evaporated in vacuo. Purification by flash column chromatography on SiO2 
(dry-load), gradient eluting with hexanes-EtOAc (50:50) to (25:75) gave the title compound (49 
mg, 27%) as a brown solid, mp 224.2 °C (dec.) (Found [ESI+]: 321.0676. C21H9N2O2 [MH] requires 
321.0692); IR (neat) νmax/cm-1: 2922 (C-H str), 1718 (C=O str), 1569 (C-C str), 1266 (C-N str), 1018 
(C-O str); 1H NMR (500 MHz, CDCl3) δH/ppm: 9.41 (1H, s, 2’-CH), 8.74 (2H, m, 9-CH and 6’-CH), 
249 
 
8.70 (1H, s, 1-CH), 8.55 (1H, d, J = 8 Hz, 4’-CH), 8.20-8.16 (1H, m, 4-CH), 8.14-8.10 (1H, m, 5-CH), 
8.06 (1H, d, J = 9 Hz, 8-CH), 7.49 (1H, dd, J = 5, 2 Hz, 5’-CH), 4.02 (3H, s, Me); 13C NMR (100 MHz, 
CDCl3) δC/ppm: 162.9 (C), 154.1 (C), 150.3 (6’-CH), 148.7 (2’-CH), 147.2 (C), 141.2 (C), 134.8 (4’-
CH), 134.3 (C), 132.5 (9-CH), 129.5 (5-CH), 127.9 (1-CH), 124.6 (4-CH), 124.1 (C), 123.7 (5’-CH), 
119.1 (8-CH), one quaternary carbon not observed; m/z (EI+): 320 (M•+, 100), 289 (M-OMe, 26). 
Side product data: Methyl 6-methylthieno[2,3-g]quinoline-2-carboxylate (196) 
 
(Found [ESI+]: 258.0578. C14H12NO2S [MH] requires 258.0583); 1H NMR (500 MHz, CDCl3) 
δH/ppm: 8.63 (1H, s, 3-CH), 8.51 (1H, d, J = 8 Hz, 8-CH), 8.03 (2H, m, 4-CH and 9-CH), 7.44 (1H, 
d, J = 9 Hz, 7-CH), 4.00 (3H, s, OMe), 2.79 (3H, s, Me); 13C NMR (126 MHz, CDCl3) δC/ppm: 162.9 
(C), 158.4 (C), 146.5 (C), 140.3 (C), 134.9 (C), 133.8 (C), 131.6 (8-CH), 128.8 (4- or 9-CH), 127.9 
(4- or 9-CH), 123.8 (4- or 9-CH), 122.5 (7-CH), 52.5 (OMe), 25.1 (Me); m/z (EI+): 257 (M•+, 100), 
226 (M-OMe). 
 
6.2.28. 6-Methylpyridine-3-carboxaldehyde (190) 
 
Chemical Formula: C7H7NO 
Mr: 121.14 
DMSO (1.05 mL, 15.0 mmol) in dry CH2Cl2 (7 mL) was added drop-wise over 20 min to a solution 
of (COCl)2 (2 M in CH2Cl2; 3.5 mL, 7.0 mmol) in dry CH2Cl2 (12 mL), cooled to −78 °C under Ar, and 
the solution stirred for 20 min. To this solution, (6-methylpyridin-3-yl)methanol (197) (0.75 g, 
6.1 mmol) in dry CH2Cl2 (3 mL) was added drop-wise over 20 min and the reaction mixture stirred 
for 20 min. Then NEt3 (5 mL, 36 mmol) was added drop-wise over 10 min, and the solution 
allowed to warm to RT over 30 min. The solution as then poured into water (30 mL), extracted 
with CH2Cl2 (2 x 30 mL), the organic extracts were combined, washed with brine (1 x 30 mL), 
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dried (Na2SO4), filtered and evaporated in vacuo. Purification by flash column chromatography 
on SiO2 (dry-load), gradient eluting with EtOAc in hexanes (50:50) to (70:30), gave the title 
compound (0.55 g, 75%) as a brown oil, (Found [ESI+]: 122.0602. C7H8NO [MH] requires 
122.0600); 1H NMR (500 MHz, CDCl3) δH/ppm: 10.08 (1H, s, CHO), 8.97 (1H, d, J = 1 Hz, 2-CH), 
8.08 (1H, dd, J = 8, 1.5 Hz, 4-CH), 7.34 (1H, d, J = 8 Hz, 5-CH), 2.67 (3H, s, Me); 13C NMR (126 MHz, 
CDCl3) δC/ppm: 190.4 (CHO), 164.9 (6-C), 151.9 (2-CH), 135.9 (4-CH), 129.4 (3-C), 123.8 (5-CH), 
24.9 (Me); m/z (EI+): 137 (M+OH, 62), 121 (M•+, 100), 120 (90), 92 (84). Data matches literature 
values.367,368 
 
6.2.29. (R)-10-Methyl-3-(6-methylpyridin-3-yl)-9-10-11-12-
tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoline-8-
one. PF-3644022 (25) 
 
Chemical Formula: C21H18N4OS 
Mr: 374.12  
6-Methylpyridine-3-carboxaldehyde (190) (100 mg, 0.86 mmol) and (R)-9-amino-3-methyl-3,4-
dihydro-1H-benzo[4,5]thieno[3,2-e][1,4]diazepin-5(2H)-one (179) (150 mg, 0.61 mmol) were 
stirred in MeCN (2 mL) for 1 h at RT, and then n-BVE (100 mg, 1.0 mmol) and iodine (80 mg, 0.31 
mmol) were added and the solution irradiated at 100 °C for 3 h in a pressure-rated glass vial (10 
mL) using a CEM Discover microwave synthesizer through modulation of the initial power (120 
W). After cooling in a flow of compressed air, the reaction mixture was diluted with EtOAc (20 
mL) and then washed with aqueous Na2S2O3 solution (1M; 1 x 20 mL) and brine (1 x 20 mL), dried 
(Na2SO4), filtered and evaporated in vacuo. Purification by flash column chromatography on SiO2 
(dry-load), gradient eluting with MeOH (4-12%) in EtOAc, gave the title compound (13 mg, 6%) 
as a brown solid, (Found [ESI+]: 375.1282. C21H19N4OS [MH] requires 375.1274); [α]D24 + 32.0 (c 
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0.026, MeOH); IR (neat) νmax/cm-1: 2969 (C-H str), 1598 (broad, C=O str, N-H str), 1364 (C-N str), 
1199 (C-N str), 1033 (C-O str); 1H NMR (500 MHz, CDCl3) δH/ppm: 9.25 (1H, br. s, 2’-CH), 8.92 
(1H, d, J = 9 Hz, 1-CH), 8.48 (1H, dd, J = 8, 2 Hz, 4’-CH), 8.11 (1H, d, J = 9 Hz, 6-CH), 7.99 (1H, d, J 
= 9 Hz, 5-CH), 7.96 (1H, d, J = 9 Hz, 2-CH), 7.34 (1H, d, J = 8 Hz, 5’-CH), 6.40 (1H, br. s, 9-NH), 5.42 
(1H, br. s, 12-NH), 3.83 (1H, m, 10-CH), 3.75 (1H, m, 11-CHH), 3.68 (1H, m, 11-CHH), 2.66 (3H, s, 
Me), 1.41, (3H, d, J = 7 Hz, Me); 13C NMR (100 MHz, CDCl3) δC/ppm: 165.3 (C), 159.3 (C), 152.6 
(C), 147.7 (2’-CH), 145.0 (C), 140.4 (C), 135.1 (4’-CH), 131.8 (C), 129.8 (1-CH), 129.7 (6-CH), 125.6 
(C), 125.2 (5-CH), 124.3 (C), 123.4 (5’-CH), 117.9 (2-CH), 114.0 (C), 52.9 (11-CH2), 49.3 (10-CH), 
24.3 (Me), 19.4 (Me), one quaternary carbon not observed; m/z (EI+): 374 (M•+, 100), 331 (70), 
302 (38). 
 
6.2.30. Methyl 7-phenylthieno[3,2-f]quinoline-2-carboxylate 
(199) 
 
Chemical Formula: C19H13NO2S 
Mr: 319.38 
Benzaldehyde (55 mg, 0.52 mmol) and methyl 3-aminobenzothiophene-2-carboxylate (158) 
(106 mg, 0.51 mmol) were stirred in MeCN (2 mL) for 1 h at RT, and then n-BVE (76 mg, 0.76 
mmol) and iodine (71 mg, 0.28 mmol) were added and the solution irritated at 100 °C for 3 h in 
a pressure-rated glass vial (10 mL) using a CEM Discover microwave synthesizer by modulation 
of the initial power (120 W). After cooling in a flow of compressed air, the reaction mixture was 
diluted with EtOAc (20 mL) and washed with aqueous Na2S2O3 solution (1 M; 1 x 20 mL) and 
brine (1 x 20 mL), dried (Na2SO4), filtered and evaporated in vacuo. Purification by flash column 
chromatography on SiO2 (dry-load), gradient eluting with hexanes to EtOAc-hexanes (25:75), 
gave the title compound (49 mg, 30%) as a brown solid, mp 175.1-177.8 °C (Found [ESI+]: 
320.0750. C19H14NO2S [MH] requires 320.0740); IR (neat) νmax/cm-1: 3076 (C-H), 1713 (C=O str), 
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1570 (C-C str), 1244 (C-N str), 1068 (C-O str); 1H NMR (500 MHz, CDCl3) δH/ppm: 8.66-8.61 (2H, 
1-CH and 9-CH), 8.20 (2H, d, J = 7.5 Hz, 2’, 6’-CH), 8.16 (1H, d, J = 9 Hz, 4-CH), 8.06 (1H, d, J = 9 
Hz, 5-CH), 8.01 (1H, d, J = 8 Hz, 8-CH), 7.55 (2H, m, 3’, 5’-CH), 7.49 (1H, m, 4’-CH), 4.00 (3H, s, 
Me); 13C NMR (126 MHz, CDCl3) δC/ppm: 162.9 (C), 156.6 (C), 146.8 (C), 140.7 (C), 139.2 (C), 134.7 
(C), 133.9 (C), 132.0 (9-CH), 129.6 (4-CH), 129.3 (4’-CH), 128.8 (3’, 5’-CH), 127.9 (1-CH), 127.4 (2’, 
6’-CH), 124.0 (5-CH), 123.6 (C), 119.3 (8-CH), 52.5 (Me); m/z (EI+): 319 (M•+, 100), 288 (40), 260 
(19). 
 
6.2.31. Methyl 7-(6-methylpyridin-3-yl)thieno[3,2-f]quinoline-2-
carboxylate (200) 
 
Chemical Formula: C19H14N2O2S 
Mr: 334.39 
6-Methylpyridine-3-carboxaldehyde (190) (59 mg, 0.49 mmol) and methyl 5-
aminobenzo[b]thiophene-2-carboxylate (158) (99 mg, 0.48 mmol) were stirred in MeCN (2 mL) 
for 1 h at RT, and then n-BVE (72 mg, 72 mmol) and iodine (75 mg, 0.30 mmol) were then added 
and the solution irradiated at 100 °C for 3 h in a pressure-rated glass vial (10 mL) using a CEM 
Discover microwave synthesizer through modulation of the initial power (120 W). After cooling 
in a flow of compressed air, the solution was poured into EtOAc (20 mL), washed with aqueous 
Na2S2O3 solution (1 M; 1 x 10 mL) and brine (1 x 10 mL), dried (Na2SO4), filtered and evaporated 
in vacuo. Purification by flash column chromatography on SiO2 (dry-load), gradient eluting with 
EtOAc in hexanes (55:45) to (70:30), gave the title compound (7 mg, 4%) as a brown solid; (Found 
[ESI+]: 355.0855. C19H15N2O2S [MH] requires 335.0849); IR (neat) νmax/cm-1: 2921 (C-H str), 1721 
(C=O), 1570 (C-C str), 1258 (C-N str), 1070 (C-O str); 1H NMR (500 MHz, CDCl3) δH/ppm: 9.27 (1H, 
br. s, 2’-CH), 8.71 (1H, d, J = 8 Hz, 9-CH), 8.69 (1H, s, 1-CH), 8.45 (1H, dd, J = 8, 2 Hz, 4’-CH), 8.17 
(1H, d, J = 9 Hz, 4- or 5-CH), 8.10 (1H, d, J = 9 Hz, 4- or 5-CH), 8.03 (1H, d, J = 9 Hz, 8-CH), 7.34 
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(1H, d, J = 8 Hz, 5’-CH), 4.02 (3H, s, OMe), 2.67 (3H, s, Me); 13C NMR (126 MHz, CDCl3) δC/ppm: 
162.9 (C), 159.4 (C), 154.3 (C), 148.0 (2’-CH), 147.1 (C), 141.1 (C), 135.1 (4’-CH), 134.8 (C), 134.2 
(C), 132.4 (9-CH), 132.0 (C), 129.6 (4- or 5-CH), 128.0 (1-CH), 124.4 (4- or 5-CH), 124.0 (5’-CH), 
123.3 (C), 119.0 (8-CH), 52.6 (OMe), 24.4 (Me); m/z (EI): 334 (M•+, 100). 
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6.3. Chapter 4. 
6.3.1. 3-tert-Butyl-1-phenyl-1H-pyrazole-5-amine (215)  
 
Chemical Formula C13H17N3 
Mr: 215.29 
Phenyl hydrazine (0.43 mL, 4.4 mmol) was added to a solution of 4,4-dimethyl-3-
oxopentanenitrile (0.50 g, 4.0 mmol) in toluene:glacial AcOH solution ([5:1]; 1.5 mL) and 
irradiated at 120 °C for 40 min in a pressure-rated glass vial (10 mL) using a CEM Discover 
microwave synthesizer by moderating the initial power (100 W). After cooling in a flow of 
compressed air, the volatiles were removed in vacuo. Purification by flash column 
chromatography on SiO2 (dry-load), eluting with hexanes to EtOAc-hexanes (30:70) gave the title 
compound (0.78 g, 91%) as a crystalline brown solid, mp 63.6-64.6 °C (lit.52 64-66 °C) (Found 
[ESI+]: 216.1495. C13H18N3 [MH] requires 216.1495); IR (neat) νmax/cm-1: 2961 (C-H str), 1596 (N-
H bend), 1554 (C=C str), 1506 (C=C str), 1375 (C-H bend), 1241 (C-N str), 988 (N-H wag.); 1H NMR 
(500 MHz, DMSO-d6) δH/ppm: 7.57 (2H, d, J = 8 Hz, 2’-CH, 6’-CH), 7.44 (2H, t, J = 7 Hz, 3’-CH, 5’-
CH), 7.25 (1H, t, J = 7 Hz, 4’-CH), 5.39 (1H, s, 4-CH), 5.16 (2H, s, NH2), 1.22 (9H, s, CMe3); 13C NMR 
(126 MHz, DMSO-d6) δC/ppm: 160.7 (3-C), 146.9 (5-C), 139.6 (1’-C), 128.8 (3’-CH, 5’-CH), 125.4 
(4’-CH), 122.3 (2’-CH, 6’-CH), 86.9 (4-CH), 31.7 (3-CMe3), 30.1 (CMe3); m/z (EI+): 215 (M•+, 75), 
200 (M -Me, 100). 
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6.3.2. N-(3-(tert-Butyl)-1-phenyl-1H-pyrazol-5-yl)-N’-
(naphthalene-1-yl)urea (215A)  
 
Chemical Formula: C24H24N4O 
Mr: 384.47  
According to a modified procedure,52 1-naphthyl isocyanate (0.15 mL, 1.60 mmol) was added to 
a solution of 3-tert-butyl-1-phenyl-1H-pyrazole-5-amine (215) (0.20 g, 0.93 mmol) in CH2Cl2 (1.8 
mL) and stirred for 40 min at RT. Volatiles were removed in vacuo and the residue triturated 
with light petroleum. Purification by recrystallization from hot MeOH gave the title compound 
(0.23 g, 65%) as a colourless solid, mp 168.1-169.4 °C (MeOH) (Found [TOF MS EI+]: 385.2035. 
C24H25N4O [MH] requires 385.2028); IR (neat) νmax/cm-1: 3261 (N-H str), 2957 (C-H str), 1644 (C=O 
str), 1547 (N-H bend), 1502 (N-H bend), 1018 (C-N str); 1H NMR (500 MHz, DMSO-d6) δH/ppm: 
9.03 (1H, s, N’H), 8.79 (1H, s, NH), 8.01 (1H, d, J = 8 Hz, aryl-CH), 7.92 (2H, t, J = 7 Hz, aryl-CH), 
7.65 (1H, d, J = 8 Hz, aryl-CH), 7.56-7.51 (6H, aryl-CH), 7.45 (2H, aryl-CH), 6.43 (1H, s, 4-CH), 1.29 
(9H, s, CMe3); 13C NMR (126 MHz, DMSO-d6) δc/ppm: 160.7 (3-C), 152.1 (C), 138.61 (C), 137.2 
(C), 133.9 (C), 133.6 (C), 129.2 (3,4-PhCH), 128.2 (CH), 127.1 (CH), 126.2 (C), 125.8 (CH), 125.7 
(CH), 125.6 (CH), 124.2 (2, 6-PhCH), 123.3 (CH), 121.4 (CH), 118.0 (CH), 95.4 (4-CH), 31.9 (CMe3), 
30.1 (CMe3). 
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6.3.3. N-(3-(tert-Butyl)-1-phenyl-1H-pyrazol-5-yl)-N’-
(naphthalene-2-yl)urea (215B) 
Chemical Formula: 384.47 
Mr: C24H24N4O 
Following the procedure of Bagley et al., 2-naphthalene isocyanate (0.16 g, 0.93 mmol) was 
added to a solution of 3-tert-butyl-1-phenyl-1H-pyrazole-5-amine (215) (0.20 g, 0.92 mmol) in 
CH2Cl2 (1.8 mL) and stirred at RT for 20 min. The volatiles were removed in vacuo and the residue 
triturated with EtOAc-light petroleum to give the title compound (0.29 g, 81%) as a colourless 
solid, mp 200.7–206.3 °C, (Found [TOF MS EI+]: 385.2021. C24H25N4O [MH] requires 385.2028); 
IR (neat) νmax/cm-1: 3285 (N-H str), 2958 (C-H str), 1654 (C=O str), 1550 (N-H bend), 1500 (N-H 
bend), 1033 (C-N str);1H NMR (500 MHz, DMSO-d6) δH/ppm: 9.22 (1H, s, N’H), 8.48 (1H, s, NH), 
8.09 (1H, s, 1’-CH), 7.86-7.73 (3H, m, naphthyl-CH), 7.56 (4H, m, 2, 3, 5, 6-PhCH), 7.46-7.41 (3H, 
4-PhCH and naphthyl-CH), 7.38-7.32 (1H, m, naphthyl-CH), 6.43 (1H, s, 4-CH), 1.30 (9H, s, CMe3); 
13C NMR (126 MHz, DMSO-d6) δC/ppm: 160.7 (3-C), 151.6 (C), 138.5 (1-PhC), 137.1 (5-C), 136.9 
(2’-C), 133.6 (C), 129.2 (3, 5-PhCH), 129.1 (C), 128.3 (CH), 127.3 (CH), 127.1 (CH), 126.9 (CH) 126.3 
(CH), 124.2 (2, 6-PhCH), 124.0 (CH), 119.4 (3’-CH), 113.5 (1’-CH), 95.3 (4-CH), 31.9 (CMe3), 30.1 
(CMe3);  
 
6.3.4. N-(3-(tert-Butyl)-1-phenyl-1H-pyrazol-5-yl)-N’-(o-
tolyl)urea (215C)  
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Chemical Formula: C21H24N4O 
Mr: 348.44 
Following the procedure of Bagley et al.,52 o-tolyl isocyanate (0.12 mL, 0.97 mmol) was added to 
a solution of 3-tert-butyl-1-phenyl-1H-pyrazole-5-amine (A) (0.20 g, 0.93 mmol) in CH2Cl2 (1.8 
mL) and stirred at RT for 20 min. The volatiles were removed in vacuo and the residue triturated 
with EtOAc-light petroleum (1:1) to give the title compound (0.17 g, 53%) as a colourless solid, 
mp 166.6-168.0 °C (MeOH)  (Found [TOF MS EI+]: 349.2032. C21H25N4O [MH] requires 349.2028); 
IR (neat) νmax/cm-1: 3291 (N-H str), 2967 (C-H str), 1643 (C=O str), 1551 (N-H bend), 1502 (N-H 
bend), 1033 (C-N str); 1H NMR (500 MHz, DMSO-d6) δH/ppm: 8.71 (1H, s, NH), 8.19 (1H, s, N’H), 
7.69 (1H, d, J = 8 Hz, o-tolyl-CH), 7.54 (4H, m, 2, 3, 5, 6-PhCH), 7.40 (1H, m, 4-PhCH), 7.14 (2H, m, 
o-tolyl-CH), 6.96 (1H, t, J = 7 Hz, o-tolyl-CH), 6.36 (1H, s, 4-CH), 2.17 (3H, s, Me), 1.28 (9H, s, 
CMe3); 13C NMR (126 MHz, DMSO-d6) δc/ppm: 160.7 (3-C), 152.0 (C), 138.7 (1-PhC), 137.2 (5-C), 
136.9 (1’-C), 130.1 (CH), 129.2 (3, 5-PhCH), 128.3 (2’-C), 127.0 (4-PhCH), 126.0 (CH), 124.0 (2, 6-
PhCH), 123.2 (CH), 121.8 (CH), 95.8 (4-CH), 32.0 (CMe3), 30.1 (CMe3), 17.8 (Me). 
 
6.3.5. N-(3-(tert-Butyl)-1-phenyl-1H-pyrazol-5-yl)-N’-(4-
ethoxyphenyl)urea (215D) 
 
Chemical Formula: C22H26N4O2 
Mr: 378.47  
Following the procedure of Bagley et al., 4-ethoxyphenyl isocyanate (0.15 mL, 0.93 mmol) was 
added to a solution of 3-tert-butyl-1-phenyl-1H-pyrazole-5-amine (215) (0.20 g, 0.93 mmol) in 
CH2Cl2 (1.8 mL) and stirred at RT for 20 min. Volatiles were then removed in vacuo and the 
residue triturated with ethyl acetate: light petroleum (1:1) to give the title compound (0.30 g, 
86%) as a colourless solid, mp 215.7-219.3 °C (MeOH), (Found [TOF MS EI+]: 379.2130. [MH] 
requires 379.2134); IR (neat) νmax/cm-1: 3291 (N-H str), 2966 (C-H str), 1656 (C=O str), 1543 (N-H 
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bend), 1510 (N-H bend), 1445 (C-H bend), 1245 (C-N str), 1050 (C-N str), 1033 (C-N str); 1H NMR 
(500 MHz, DMSO-d6) δH/ppm: 8.78 (1H, s, NH), 8.27 (1H, s, N’H), 7.56-7.50 (4H, m, 2, 3, 5, 6-
PhCH), 7.41 (1H, m, 4-PhCH), 7.28 (2H, d, J = 9 Hz, 2’, 6’-CH), 6.83 (2H, d, J = 9 Hz, 3’, 5’-CH), 6.35 
(1H, s, 4-CH), 3.96 (2H, q, J = 7 Hz, CH2), 1.34-1.24 (12H, Me and CMe3); 13C NMR (126 MHz, 
DMSO-d6) δC/ppm: 160.6 (3-C), 153.8 (4’-C), 151.7 (C), 138.6 (1-PhC), 137.3 (5-C), 132.2 (1’-C), 
129.1 (3, 4-PhCH), 127.0 (4-PhCH), 124.1 (2, 6-PhCH), 119.9 (2’, 6’-CH), 114.5 (3’, 5’-CH), 95.3 (4-
CH), 63.0 (CH2), 31.9 (CMe3), 30.1 (CMe3), 14.6 (Me). 
 
6.3.6. N-(3-(tert-Butyl)-1-phenyl-1H-pyrazol-5-yl)-N’-(4-
fluorophenyl)urea (215E) 
 
Chemical Formula: C20H21FN4O 
Mr: 352.40  
Following the procedure of Bagley et al., 4-fluorophenyl isocyanate (0.15 mL, 1.30 mmol) was 
added to a solution of 3-tert-butyl-1-phenyl-1H-pyrazole-5-amine (215) (0.20 g, 0.93 mmol) in 
CH2Cl2 (1.8 mL) and stirred at 20 °C for 20 min. Volatiles were removed in vacuo and the residue 
triturated with EtOAc-light petroleum (1:5) to give the title compound (0.28 g, 87%) as a 
colourless solid, mp 194.0-201.0 °C (MeOH) (Found [TOF MS EI+]: 353.1772. C20H22FN4O [MH] 
requires 353.1778); IR (neat) νmax/cm-1: 3294 (N-H str), 2954 (C-H str), 1661 (C=O str), 1544 (N-H 
bend), 1509 (N-H bend), 1251 (C-N str), 1033 (C-N str); 1H NMR (500 MHz, DMSO-d6) δH/ppm: 
9.01 (1H, s, N’H), 8.36 (1H, s, NH), 7.53 (4H, m, 2, 3, 5, 6-PhCH), 7.41 (3H, 4-PhCH and 2’, 6’-CH), 
7.10 (2H, pt, 3JHH, 3JFH = 9 Hz, 3’, 5’-CH), 6.36 (1H, s, 4-CH), 1.28 (9H, s, CMe3); 13C NMR (126 MHz, 
DMSO-d6) δH/ppm: 160.7 (3-C), 157.4 (d, 1JFC = 238 Hz, 4’-CF), 151.7 (C), 138.5 (1-PhC), 137.0 (5-
CH), 135.6 (d, 4JFc = 2 Hz, 1’-C), 129.1 (3, 5-PhCH), 127.1 (4-PhCH), 124.1 (2, 6-PhCH), 119.9 (d, 
3JFc = 8 Hz, 2’, 6’-CH), 115.2 (d, 2JFc = 22 Hz, 3’, 5’-CH), 95.6 (4-CH), 31.9 (CMe3), 30.1 (CMe3). 
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6.3.7. N-(3,5-Bis(trifluoromethyl)phenyl)-N’-(3-(tert-butyl)-1-
phenyl-1H-pyrazol-5-yl)urea (215F) 
 
Chemical Formula: C22H20F6N4O 
Mr: 470.41 
Following the procedure of Bagley et al., 3,5-bis(trifluoromethyl)phenyl isocyanate (0.18 mL, 
1.04 mmol) was added to a solution of 3-tert-butyl-1-phenyl-1H-pyrazole-5-amine (215)  (0.20 
g, 0.93 mmol) in CH2Cl2 (1.8 mL) and stirred at 20 °C for 20 min. Volatiles were then removed in 
vacuo and the residue triturated with light petroleum to give the title compound (0.39 g, 88%) 
as a colourless solid, mp 175.7-177.8 °C (MeOH) (Found [TOF MS EI+]: 471.1617. C22H21N4OF6 
[MH] requires 471.1620); IR (neat) νmax/cm-1: 3287 (N-H str), 2967 (C-H str), 1662 (C=O str), 1549 
(N-H bend), 1502 (N-H bend), 1276 (C-N str), 1129 (C-F str), 1033 (C-N str); 1H NMR (500 MHz, 
DMSO-d6) δH/ppm: 9.70 (1H, s, NH), 8.67 (1H, s, N’H), 8.07 (2H, s, 2, 6-CH), 7.64 (1H, s, 4-CH), 
7.56-7.49 (4H, m, 2, 3, 5, 6-PhCH), 7.40 (1H, t, 3JHH = 6 Hz, 4-PhCH), 6.40 (1H, s, 4’-CH), 1.29 (9H, 
s, CMe3); 13C NMR (100 MHz, DMSO-d6) δH/ppm: 160.8 (3’-C), 151.9 (C), 141.5 (1-C), 138.5 (1-
PhC), 136.3 (5’-C), 130.7 (q, 2JFC = 37 Hz, 3, 5-C), 129.2 (3, 4-PhCH), 127.2 (4-PhCH), 124.0 (2, 6-
PhCH), 124.0 (q, 1JFC = 272 Hz, CF3), 117.9 (2, 6-CH), 114.6 (4-CH), 97.1 (4’-CH), 32.0 (CMe3), 30.1 
(CMe3); m/z (EI+): 471 (M•+, 100), 455 (M –Me, 45). 
 
6.3.8. N-(4-(Benzyloxy)phenyl)-N’-(3-(tert-butyl)-1-phenyl-1H-
pyrazol-5-yl)urea (215G) 
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Chemical Formula: C27H28N4O2 
Mr: 440.54  
Following the procedure of Bagley et al., 4-(benzyloxy)phenyl isocyanate (0.21 g, 0.94 mmol) 
was added to a solution of 3-tert-butyl-1-phenyl-1H-pyrazole-5-amine (215) (0.20 g, 0.92 mmol) 
in CH2Cl2 (1.8 mL) and stirred at RT for 20 min. Volatiles were then removed in vacuo and the 
residue triturated with EtOAc-light petroleum (1:5) to give the title product (0.33 g, 82%) as a 
colourless solid, mp 185.6-186.6 °C (MeOH) (Found [TOF MS EI+]: 441.2288. C27H29N4O2 [MH] 
requires 441.2291); IR (neat) νmax/cm-1: 3297 (N-H str), 2957 (C-H str), 1656 (C=O str), 1542 (N-H 
bend), 1509 (N-H bend), 1242 (C-N str), 1214 (C-O str), 1005 (C-N str); 1H NMR (500 MHz, DMSO-
d6) δH/ppm: 8.80 (1H, s, NH), 8.28 (1H, s, N’H), 7.54–7.49 (4H, m, 2, 3, 5, 6-PhCH), 7.35-7.44 (5H, 
m, Ar-CH), 7.31 (3H, m, Ar-CH), 6.92 (2H, d, J = 9 Hz, 3,5-CH), 6.35 (1H, s, 4’’-CH), 5.04 (2H, s, 
CH2), 1.27 (9H, s, CMe3); 13C NMR (126 MHz, DMSO-d6) δC/ppm: 160.7 (3’’-C), 153.6 (4-C), 151.7 
(C), 138.6 (1-PhC), 137.3 (5’’-C), 137.2 (1’’-C), 132.6 (1-C), 129.1 (3, 5-PhCH), 128.3 (3’, 5’-CH), 
127.6 (4’-CH), 127.5 (2’, 6’-CH), 127.1 (4-PhCH), 124.2 (2, 6-PhCH), 119.8 (2, 6-CH), 115.0 (3, 5-
CH), 95.3 (4’’-CH), 69.4 (CH2), 31.9 (CMe3), 30.1 (CMe3). 
 
6.3.9. N-(3-(tert-Butyl)-1-phenyl-1H-pyrazol-5-yl)-N’-(3,5-
dimethylphenyl) urea (215H) 
 
Chemical Formula: C22H26N4O 
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Mr: 362.47  
Following the procedure of Bagley et al., 3,5-dimethylphenyl isocyanate (0.13 mL, 0.93 mmol) 
was added to a solution of 3-tert-butyl-1-phenyl-1H-pyrazole-5-amine (215) (0.18 g, 0.84 mmol) 
in CH2Cl2 (1.8 mL) and stirred at 20 °C for 20 min. Volatiles were removed in vacuo and the 
residue triturated with EtOAc-light petroleum (1:1) to give the title compound (0.27 g, 89%) as a 
colourless solid, mp 196.7-199.5 °C (MeOH) (Found [TOF MS EI+]: 363.2193. C22H27N4O [MH] 
requires 363.2185); IR (neat) νmax/cm-1: 3001 (N-H str), 2957 (C-H str), 1657 (C=O str), 1543 (N-H 
bend), 1502 (N-H bend), 1372 (C-H bend), 1214 (C-N str), 1005 (C-N str); 1H NMR (500 MHz, 
DMSO-d6) δH/ppm: 8.84 (1H, s, N’H), 8.34 (1H, s, NH), 7.52 (4H, m, 2, 3, 5, 6-PhCH), 7.41 (1H, m, 
4-PhCH), 7.03 (2H, s, 2’, 6’-CH), 6.61 (1H, s, 4’-CH), 6.38 (1H, s, 4-CH), 2.21 (6H, s, Me), 1.28 (9H, 
s, CMe3); 13C NMR (126 MHz, DMSO-d6) δC/ppm: 160.7 (3-C), 151.4 (C), 139.1 (1’-C), 138.5 (1-
PhC), 137.7 (3’, 5’-C), 137.2 (5-C), 129.2 (3, 5-PhCH), 127.1 (4-PhCH), 124.2 (2, 6-PhCH), 123.6 
(4’-CH), 115.8 (2’, 6’-CH), 95.2 (4-CH), 31.9 (CMe3), 30.1 (CMe3), 21.0 (Me). 
 
6.3.10. N-(3-(tert-Butyl)-1-phenyl-1H-pyrazol-5-yl)-N’-(5-fluoro-
2-methylphenyl)urea (215I) 
 
Chemical Formula: C21H23FN4O 
Mr: 366.43  
Following the procedure of Bagley et al., 5-fluoro-2-methylphenyl isocyanate (0.12 mL, 0.93 
mmol) was added to a solution of 3-tert-butyl-1-phenyl-1H-pyrazole-5-amine (215) (0.20 g, 0.91 
mmol) in CH2Cl2 (1.8 mL) and stirred at 20 °C for 20 min. Volatiles were then removed in vacuo 
and the residue triturated with EtOAc-light petroleum (1:5) to give the title compound (0.22 g, 
67%) as a colourless solid, mp 164.9-166.4 °C (MeOH) (Found [TOF MS EI+]: 367.1937. 
C21H24N4OF [MH] requires 367.1934); IR (neat) νmax/cm-1: 3284 (N-H str), 2958 (C-H str), 1654 
(C=O str), 1546 (N-H bend), 1503 (N-H bend), 1236 (C-N str), 1004 (C-N bend); 1H NMR (500 MHz, 
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DMSO-d6) δH/ppm: 8.91 (1H, s, NH), 8.31 (1H, s, N’H), 7.73 (1H, dd, 3JFH = 12 Hz, 4JHH = 2 Hz, 6’-
CH), 7.54 (4H, m, 2, 3, 5, 6-PhCH), 7.42 (1H, m, 4-PhCH), 7.17 (1H, pt, 3JHH, 4JFH = 7 Hz, 3’-CH), 6.76 
(1H, ptd, 3JHH, 3JFH = 8, 4JHH = 2 Hz, 4’-CH), 6.38 (1H, s, 4-CH), 2.15 (3H, s, Me), 1.28 (9H, s, CMe3); 
13C NMR (126 MHz, DMSO-d6) δC/ppm: 161.0 (3-C), 160.5 (d, 1JFC = 240 Hz, 5’-CF), 151.9 (C), 138.7 
(1-PhC), 138.5 (d, 3JFC = 11 Hz, 1’-C), 137.0 (5-CH), 131.2 (d, 3JFC = 10 Hz, 3’-CH), 129.4 (3, 5-PhCH), 
127.3 (4-PhCH), 124.2 (2, 6-PhCH), 122.9 (d, 4JFC = 3 Hz, 2’-C), 109.0 (d, 2JFC = 21 Hz, 4’-CH), 107.3 
(d, 2JFC = 26 Hz, 6’-CH), 96.1 (4-CH), 32.1 (CMe3), 30.2 (CMe3), 17.2 (Me). 
 
6.3.11. N-(3-(tert-Butyl)-1-phenyl-1H-pyrazol-5-yl)-N’-(3,4-
difluorophenyl) urea (215J) 
 
Chemical Formula: C20H20F2N4O 
Mr: 370.39 
Following the procedure of Bagley et al., 3,4-difluorophenyl isocyanate (0.11 mL, 0.94 mmol) 
was added to a solution of 3-tert-butyl-1-phenyl-1H-pyrazole-5-amine (215) (0.20 g, 0.92 mmol) 
in CH2Cl2 (1.8 mL) and stirred at 20 °C for 20 min. Volatiles were then removed in vacuo and the 
residue triturated with EtOAc-light petroleum (1:5) to give the title compound (0.23 g, 67%) as a 
colourless solid, mp 154.1-156.4 °C (MeOH) (Found [TOF MS EI+]: 371.1681. C20H21N4OF2 [MH] 
requires 371.1683); IR (neat) νmax/cm-1: 3332 (N-H str), 2957 (C-H str), 1660 (C=O str), 1571 (N-H 
bend), 1513 (N-H bend), 1226 (C-N str), 1136 (C-N str); 1H NMR (500 MHz, DMSO-d6) δH/ppm: 
9.20 (1H, s, N’H), 8.44 (1H, s, NH), 7.61 (1H, pddd, 3JFH = 13, 4JHF = 7, 4JHH = 2 Hz, 2’CH), 7.52 (4H, 
m, 2, 3, 5, 6-PhCH), 7.41 (1H, m, 4-PhCH), 7.31 (1H, pq, 3JFH, 3JHH = 10 Hz, 5’-CH), 7.07 (1H, d, 3JHH 
= 9 Hz, 6’-CH), 6.37 (1H, s, 4-CH), 1.28 (9H, s, CMe3); 13C NMR (126 MHz, DMSO-d6) δC/ppm: 160.7 
(3-C), 151.6 (C), 149.0 (dd, 1JFC = 243, 2JFC = 13 Hz, 3’ or 4’-CF), 144.5 (dd, 1JFC = 240, 2JFC =12 Hz, 
4’ or 3’-CF), 138.5 (1-PhC), 136.7 (5-C), 136.4 (dd, 3JFC = 9, 4JFC = 2 Hz, 1’-C), 129.2 (3, 5-PhCH), 
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127.1 (4-PhCH), 124.1 (2, 6-PhCH), 117.3 (d, 2JFC =17 Hz, 5’-CH), 114.3 (dd, 3JFC = 6, 4JFC = 3 Hz, 6’-
CH), 107.1 (d, 2JFC = 22 Hz, 2’-CH), 96.0 (4-CH), 31.9 (CMe3), 30.1 (CMe3). 
 
6.3.12. N-(3-(tert-Butyl)-1-phenyl-1H-pyrazol-5-yl)-N’-
phenylurea (215K) 
 
Chemical Formula: C20H22N4O 
Mr: 334.41  
Following the procedure of Bagley et al., phenyl isocyanate (0.11 mL, 1.01 mmol) was added to 
a solution of 3-tert-butyl-1-phenyl-1H-pyrazole-5-amine (215) (0.20 g, 0.92 mmol) in CH2Cl2 (1.8 
mL) and stirred at 20 °C for 20 min. Volatiles were then removed in vacuo, and the residue 
triturated with EtOAc-light petroleum (1:5), and recrystallization with hot MeOH gave the title 
compound (0.26 g, 85%) as colourless crystals, mp 188.7-190.9 °C (Found [TOF MS EI+]: 
335.1875. C20H23N4O [MH] requires 335.1872); IR (neat) νmax/cm-1: 3276 (N-H str), 2957 (C-H str), 
1664 (C=O str), 1548 (N-H bend), 1498 (N-H bend), 1229 (C-N str), 1054 (C-N str); 1H NMR (500 
MHz, DMSO-d6) δH/ppm: 8.98 (1H, s, N’H), 8.37 (1H, s, NH), 7.56 - 7.51 (4H, m, 2, 3, 5, 6-PhCH), 
7.41 (3H, 4-PhCH and 2’, 6’-CH), 7.26 (2H, t, J = 8 Hz, 3’, 5’-CH), 6.97 (1H, t, J = 7 Hz, 4’-CH), 6.38 
(1H, s, 4-CH), 1.28 (9H, s, CMe3); 13C NMR (126 MHz, DMSO-d6) δC/ppm: 160.7 (3-C), 151.5 (C), 
139.3 (1’-C), 138.5 (1-PhC), 137.1 (5-C), 129.2 (3, 5-PhCH), 128.7 (3’, 5’-CH), 127.1 (4-PhCH), 
124.2 (2, 6-PhCH), 122.0 (4’-CH), 118.1 (2’, 6’-CH), 95.4 (4-CH), 31.9 (CMe3), 30.1 (CMe3). 
 
6.3.13. N-((3-(tert-Butyl)-1-phenyl-1H-pyrazol-5-yl)carbamoyl)-
4-methylbenzenesulfonamide (215L) 
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Chemical Formula: C21H24N4O3S 
Mr: 412.50  
Following the procedure of Bagley et al., p-tolylsulfonyl isocyanate (0.15 mL, 1.10 mmol) was 
added to a solution of 3-tert-butyl-1-phenyl-1H-pyrazole-5-amine (215) (0.20 g, 0.91 mmol) in 
CH2Cl2 (1.8 mL) and stirred at 20 °C for 20 min. Volatiles were then removed in vacuo and the 
residue triturated with EtOAc-light petroleum (1:1) to give the title compound (0.28 g, 75%) as a 
colourless solid, mp 166.3-170.6 °C (Found [TOF MS EI+]: 413.1655. C21H25N4O3S [MH] requires 
413.1647); IR (neat) νmax/cm-1: 3290 (N-H str), 2957 (C-H str), 1657 (C=O str), 1541 (N-H bend), 
1502 (N-H bend), 1212 (C-N str), 989 (S=O str); 1H NMR (500 MHz, DMSO-d6) δH/ppm: 11.09 (1H, 
br. s, NH), 8.55 (1H, s, N’H), 7.77 (2H, d, J = 8 Hz, 2, 6-CH), 7.47 - 7.35 (7H, 3, 5-CH and 2-6-PhCH), 
6.26 (1H, s, 4’-CH), 2.40 (3H, s, Me), 1.23 (9H, s, CMe3); 13C NMR (126 MHz, DMSO-d6) δC/ppm: 
160.7 (3’-C), 148.8 (C), 143.9 (4-C), 138.1 (1-PhC or 1-C), 136.7 (1-C or 1-PhC), 135.3 (5’-C), 129.4 
(3, 5-CH), 129.1 (3, 5-PhCH), 127.3 (2, 6-CH), 127.3 (4-PhCH), 124.0 (2, 6-PhCH), 96.8 (4’-CH), 
32.0 (CMe3), 30.0 (CMe3), 21.0 (Me). 
 
6.3.14. N-(3-(tert-Butyl)-1-phenyl-1H-pyrazol-5-yl)-N’-(3-
methoxyphenyl)urea (215M) 
 
Chemical Formula: C21H24N4O2 
Mr: 364.19  
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Following the procedure of Bagley et al., 3-methoxyphenyl isocyanate (0.13 mL, 1.00 mmol) was 
added to a solution of 3-tert-butyl-1-phenyl-1H-pyrazole-5-amine (215) (0.20 g, 0.93 mmol) in 
CH2Cl2 (1.8 mL) and stirred at 20 °C for 20 min. Volatiles were then removed in vacuo and the 
residue triturated with EtOAc-light petroleum (1:2) to give the title compound (0.22 g, 65%) as a 
colourless solid, mp 177.1-179.2 °C (MeOH) (Found [TOF MS EI+]: 365.1980. C21H25N4O2 [MH] 
requires 365.1978); IR (neat) νmax/cm-1: 3285 (N-H str), 2958 (C-H str), 1661 (C=O str), 1599 (N-H 
str), 1549 (N-H str), 1045 (C-O str); 1H NMR (500 MHz, DMSO-d6) δH/ppm: 9.00 (1H, s, N’H), 8.35 
(1H, s, NH), 7.56 - 7.49 (4H, m, 2, 3, 5, 6-PhCH), 7.41 (1H, m, 4-PhCH), 7.14 (2H, 2’, 5’-CH), 6.88 
(1H, d, J = 8 Hz, 6’-CH), 6.55 (1H, dd, J = 8, 2 Hz, 4’-CH), 6.38 (1H, s, 4-CH), 3.71 (3H, s, Me), 1.28 
(9H, s, CMe3); 13C NMR (126 MHz, DMSO-d6) δC/ppm: 160.7 (3-C), 159.6 (3’-C), 151.4 (C), 140.5 
(1’-C), 138.5 (1-PhC), 137.0 (5-C), 129.4 (5’-CH), 129.2 (3, 5-PhCH), 127.1 (4-PhCH), 124.2 (2, 6-
PhCH), 110.3 (6’-CH), 107.6 (4’-CH), 103.8 (2’-CH), 95.4 (4-CH), 54.8 (OMe), 31.9 (CMe3), 30.1 
(CMe3). 
 
6.3.15. N-(3-(tert-Butyl)-1-phenyl-1H-pyrazol-5-yl)-N’-(p-
tolyl)urea (215N) 
 
Chemical Formula: C21H24N4O  
Mr: 348.44  
Following the procedure of Bagley et al., p-tolyl isocyanate (0.13 mL, 1.03 mmol) was added to 
a solution of 3-tert-butyl-1-phenyl-1H-pyrazole-5-amine (215) (0.20 g, 0.92 mmol) in CH2Cl2 and 
stirred at 20 °C for 20 min. Volatiles were then removed in vacuo and the residue triturated with 
EtOAc-light petroleum (1:1) and recrystallization from hot MeOH gave the title compound (0.20 
g, 62%) as a colourless solid, mp 197.8-199.2 °C (Found [TOF MS EI+]: 349.2041. C21H25N4O [MH] 
requires 349.2028); IR (neat) νmax/cm-1: 3267 (N-H str), 2955 (C-H str), 1659 (C=O str), 1538 (N-H 
bend), 1362 (C-H rock), 1140 (C-N str); 1H NMR (500 MHz, DMSO-d6) δH/ppm: 8.88 (1H, s, N’H), 
266 
 
8.32 (1H, s, NH), 7.56 - 7.50 (4H, m, 2, 3, 5, 6-PhCH), 7.41 (1H, m, 4-PhCH), 7.28 (2H, d, J = 8 Hz, 
3’, 5’-CH), 7.06 (2H, d, J = 8 Hz, 2’, 6’-CH), 6.37 (1H, s, 4-CH), 2.23 (3H, s, CH3), 1.28 (9H, s, CMe3); 
13C NMR (126 MHz, DMSO-d6) δC/ppm: 160.7 (3-C), 151.5 (C), 138.5 (1-PhC), 137.2 (5-C), 136.7 
(1’-C), 130.8 (4’-C), 129.2 (3, 5-PhCH), 129.1 (3’, 4’-CH), 127.1 (4-PhCH), 124.2 (2, 6-PhCH), 118.2 
(2’, 6’-CH), 95.2 (4-CH), 31.9 (CMe3), 30.1 (CMe3), 20.1 (Me). 
 
6.3.16. 3-(tert-Butyl)-1-(p-tolyl)-1H-pyrazol-5-amine (217) 
 
Chemical Formula: C14H19N3 
Mr: 229.32 
According to a modified procedure,50 p-toylhydrazine hydrochloride (0.71 g, 0.44 mmol), 4,4-
dimethyl-3-oxopentanitrile (0.50 g, 0.40 mmol) and a catalytic amount of conc. HCl in EtOH (20 
mL) was irradiated at 130 °C for 20 min in a pressure-rated glass vial (35 mL) using a CEM 
Discover microwave synthesizer by modulating the initial power (200 W). After cooling in a flow 
of compressed air, the reaction mixture was basified with aqueous NaOH solution (10%) to pH 
12 and extracted with EtOAc (3 x 20 mL). The organic extracts were combined, washed with 
brine (1 x 30 mL), dried (MgSO4), filtered and evaporated in vacuo. Purification by flash column 
chromatography on SiO2 (dry-load), gradient eluting with hexanes to CH2Cl2, gave the title 
compound (0.77 g, 83%) as a light orange crystalline solid, mp 115.4-118.4 °C, (Found [ESI+]: 
230.1650. C14H20N3 [MH] requires 230.1652); IR (neat) νmax/cm-1: 3470 (N-H str), 2958 (C-H str), 
1633 (N-H bend), 1558 (C=N str), 1516 (C-C str), 1245 (C-N str), 819 (N-H wag); 1H NMR (500 
MHz, CDCl3) δH/ppm: 7.43 (2H, d, J = 8 Hz, 2’, 6’-CH), 7.25 (2H, d, J = 8 Hz, 3’, 5’-CH), 5.51 (1H, s, 
4-CH), 3.69 (2H, br. s, NH2), 2.38 (3H, s, Me), 1.32 (9H, s, CMe3); 13C NMR (126 MHz, CDCl3) 
δC/ppm: 162.1 (C), 144.6 (5-C), 136.8 (4’-C), 136.5 (1’-C), 129.9 (3’, 5’-CH), 124.0 (2’, 6’-CH), 87.4 
(4-CH), 32.2 (CMe3), 30.4 (CMe3), 21.0 (Me). 
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6.3.17. 3-(tert-Butyl)-1-methyl-1H-pyrazol-5-amine (226) 
 
Chemical Formula: C8H15N3 
Mr: 153.22  
Methyl hydrazine (0.09 mL, 1.70 mmol) and 4,4-dimethyl-3-oxopentanitrile (0.20 g, 1.60 mmol) 
in a toluene: glacial AcOH solution ([5:1]; 0.8 mL) was irradiated at 120 °C for 40 min in a 
pressure-rated glass vial (10 mL) using a CEM Discover microwave synthesizer by modulating the 
initial power (100 W). After cooling in a flow of compressed air the volatiles were removed in 
vacuo. Purification by flash column chromatography on SiO2, gradient eluting with CH2Cl2 to 
EtOAc, gave the title compound (0.24 g, 95%) as an off white crystalline solid, mp 151.4-155.0 °C 
(lit.52 156-157 (light petroleum)) (Found [ESI+]: 154.1339. C8H16N3 [MH] requires 154.1339); IR 
(neat) νmax/cm-1: 3392 (N-H str), 2956 (C-H str), 1627 (N-H bend), 1567 (C=N str), 1360 (C-H bend); 
1H NMR (500 MHz, CDCl3) δH/ppm: 5.42 (1H, br. s, 4-CH), 3.62 (3H, s, Me), 1.26 (9H, s, CMe3); 13C 
NMR (126 MHz, CDCl3) δC/ppm: 160.6 (3-C), 144.4 (5-C), 88.0 (4-CH), 33.9 (Me), 32.0 (CMe3), 
30.4 (CMe3). 
 
6.3.18. 3-(tert-Butyl)-1-(4-fluorophenyl)-1H-pyrazole-5-amine 
(227) 
 
Chemical Formula: C13H16FN3 
Mr: 233.28  
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According to a modified procedure,50 4-fluorophenylhydrazine hydrochloride (0.26 g, 1.60 
mmol), 4,4-dimethyl-3-oxopentanitrile (0.20 g, 1.57 mmol) and a catalytic amount of conc. HCl 
in EtOH (9 mL) was irradiated at 130 °C for 30 min in a pressure-rated glass vial (35 mL) using a 
CEM Discover microwave synthesizer by modulating the initial power (200 W). After cooling in 
a flow of compressed air, the reaction mixture was basified with aqueous NaOH solution (10%) 
to pH 12 and extracted with EtOAc (3 x 20 mL). The organic extracts were then combined, 
washed with brine (1 x 20 mL), dried (MgSO4), filtered and evaporated in vacuo. The residues 
were then triturated with light petroleum to give the title compound (0.32 g, 88%) as a red 
crystalline solid, mp 101.0-105.2 °C (Found [ESI+]: 234.1399. C13H17N3F [MH] requires 234.1401); 
IR (neat) νmax/cm-1: 3319 (N-H str), 2969 (C-H str), 1633 (N-H bend), 1510 (C=N str), 1216 (C-N 
str); 1H NMR (500 MHz, CDCl3) δH/ppm: 7.55 (2H, pdd, 3JHH = 9 Hz, 4JFH = 5 Hz 2’, 6’-CH), 7.14 (2H, 
pt, 3JFH, 3JHH = 9 Hz, 3’, 5’-CH), 5.53 (1H, s, 4-CH), 3.65 (2H, br. s, NH2), 1.32 (9H, s, CMe3); 13C NMR 
(126 MHz, CDCl3) δC/ppm: 162.4 (3-C), 161.4 (d, 1JFC = 246 Hz, 4’-C), 144.7 (5-C), 135.2 (1’-C), 
125.9 (d, 3JCF = 9 Hz, 2’, 6’-CH), 116.1 (d, 2JCF = 23 Hz, 3’, 5’-CH), 87.9 (4-CH), 32.2 (CMe3), 30.1 
(CMe3). 
 
6.3.19. 3-(tert-Butyl)-1-(4-nitrophenyl)-1H-pyrazol-5-amine 
(228) 
 
Chemical Formula: C13H16N4O2 
Mr: 260.29 
According to a modified procedure, 4-nitrophenyl hydrazine (0.25 g, 1.63 mmol) and 4,4-
dimethyl-3-oxopentanitrile (0.20 g, 1.63 mmol) in a toluene: glacial AcOH solution ([5:1]; 0.8 
mL) was irradiated at 120 °C for 40 min in a pressure-rated glass vial (10 mL) using a CEM 
Discover microwave synthesizer by modulating the initial power (100 W). After cooling in a flow 
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of compressed air the volatiles were removed in vacuo. Purification by flash column 
chromatography on SiO2 (dry-load), gradient eluting with CH2Cl2-hexanes (50:50) to CH2Cl2, gave 
the title compound (0.21 g, 48%) as an off white crystalline solid, mp 162.1-164.8 °C (lit.369 172) 
(Found [ESI+]: 261.1348. C13H17N4O2 [MH] requires 261.1346); IR (neat) νmax/cm-1: 3395 (N-H 
str), 2961 (C-H str), 1644 (N-H bend), 1592 (C=N str), 1504 (N-O str), 1331 (N-O str), 1241 (C-N 
str), 1108 (C-N str); 1H NMR (500 MHz, CDCl3) δH/ppm: 8.29 (2H, d, J = 9 Hz, 3’, 5’-CH), 7.90 (2H, 
d, J = 9 Hz, 2’, 6’-CH), 5.62 (1H, s, 4-CH), 3.82 (2H, br. s, NH2), 1.31 (9H, s, CMe3); 13C NMR (126 
MHz, CDCl3) δC/ppm: 164.0 (3-C), 145.4 (5-C), 145.0 (C), 144.8 (C), 124.9 (3’, 5’-CH), 122.1 (2’, 
6’-CH), 90.6 (4-CH), 32.4 (CMe3), 30.0 (CMe3). 
 
6.3.20. 1,3-Di-tert-butyl-1H-pyrazol-5-amine (229) 
 
Chemical Formula: C11H21N3 
Mr: 195.30  
4,4-Dimethyl-3-oxopentanitrile (0.50 g, 4.0 mmol) and tert-butyl hydrazine hydrochloride (0.66 
g, 5.3 mmol) were taken up in EtOH (10 mL), a catalytic amount of concentrated HCl was added, 
and the solution was heated to reflux for 18 h. Once cooled to RT, the solution was basified with 
aqueous NaOH solution (10 w%) to pH 12 and extracted with EtOAc (3 x 30 mL). The organic 
extracts were combined, washed with brine (1 x 40 mL), dried (Na2SO4), filtered and evaporated 
in vacuo. Purification by flash column chromatography on SiO2 (dry-load), gradient eluting with 
hexanes to EtOAc in hexanes (15:85), to give the title compound (0.47 g, 61%) as brown crystals, 
mp 68.7-70.4°C (lit.370 67-69 °C) (Found [ESI+]: 196.1800 C11H22N3 [MH] requires 196.1808); IR 
(neat) νmax/cm-1: 3355 (N-H str), 2962 (C-H str), 1629 (N-H bend), 1544 (C=N str), 1359 (C-H 
bend), 1232 (CH3 bend); 1H NMR (500 MHz, DMSO-d6) δH/ppm: 5.24 (1H, s, 4-CH), 4.60 (2H, br. 
s, NH2), 1.49 (9H, s, 1’-CMe3), 1.14 (9H, s, 3’-CMe3); 13C NMR (126 MHz, DMSO-d6) δC/ppm: 155.9 
(3-C), 146.1 (5-C), 88.2 (4-CH), 56.9 (1’-CMe3), 31.5 (3’-CMe3), 30.4 (3’-CMe3), 29.0 (1’-CMe3); 
m/z (EI+): 195 (M•⁺, 35), 139 (M-CMe3, 74), 124 (100). 
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6.3.21. 1-(4-Bromophenyl)-3-(tert-butyl)-1H-pyrazol-5-amine 
(230) 
 
Chemical Formula: C13H16BrN3 
Mr: 294.20 
4,4-Dimethyl-3-oxopentanitrile (0.20 g, 1.64 mmol) and 4-bromophenylhydrazine 
hydrochloride (0.35 g, 1.56 mmol) in a solution of EtOH (8 mL) and a catalytic amount of 
concentrated HCl was irradiated at 130 °C for 25 min in a pressure-rated glass vial (35 mL) using 
a CEM Discover microwave synthesizer by moderating the initial power (200 W). After cooling 
in a flow of compressed air, the solution was basified with aqueous NaOH solution (10 w%) to 
pH 12, partitioned between EtOAc (20 mL) and water (10 mL) and the aqueous layer extracted 
with EtOAc (2 x 20 mL). The organic extracts were combined, washed with brine (1 x 30 mL), 
dried (Na2SO4), filtered and evaporated in vacuo. Purification by flash column chromatography 
on SiO2 (dry-load), gradient eluting with hexanes to EtOAc in hexanes (25:75) gave the title 
compound (0.27 g, 58%) as a brown solid, mp 133.7-136.4 °C (Found [ESI+]: 294.0601. 
C13H17N379Br [MH] requires 294.0600); IR (neat) νmax/cm-1: 3437 (N-H str), 2957 (C-H str), 1635 
(N-H bend), 1557 (C=N str), 1500 (C-C str), 1244 (C-N str), 1065 (C-N str); 1H NMR (500 MHz, 
DMSO-d6) δH/ppm: 7.62 (2H, d, J = 9 Hz, 2’, 6’-CH), 7.56 (2H, d, J = 9 Hz, 3’, 5’-CH), 5.40 (1H, s, 4-
CH), 5.25 (2H, br. s, NH2), 1.21 (9H, s, CMe3); 13C NMR (126 MHz, DMSO-d6) δC/ppm: 161.2 (3-
C), 147.2 (5-C), 138.9 (1’-C), 131.7 (2’, 6’-CH), 124.0 (3’, 5’-CH), 117.6 (4’-C), 87.4 (4-CH), 31.7 
(CMe3), 30.0 (CMe3); m/z (EI+): 295 (M81Br •⁺, 45), 293 (M79Br •⁺, 48), 280 (M81Br – Me, 97), 278 
(M79Br-Me, 100). 
 
6.3.22. 1-Methyl-3-phenyl-1H-pyrazol-5-amine (231) 
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Chemical formula: C10H11N3 
Mr: 173.2  
Methyl hydrazine (0.27g, 5.82 mmol) and benzoylacetonitrile (0.35 g, 2.40 mmol) in a toluene-
glacial AcOH solution ([5:1]; 2 mL) was irradiated at 120 °C for 40 min in a pressure-rated glass 
vial (10 mL) using a CEM Discover microwave synthesizer by moderating the initial power (100 
W). After cooling in a flow of compressed air, the volatiles were removed in vacuo. Purification 
by flash column chromatography on SiO2, gradient eluting with CH2Cl2 to MeOH-CH2Cl2 (5:95), 
and recrystallization from hot EtOAc gave the title compound (0.21 g, 50%), as a purple 
crystalline solid, mp 124.1-128.1 °C (lit.371 124-126) (Found [ESI+]: 174.1021. C10H10N3 [MH] 
requires 174.1026); IR (neat) νmax/cm-1: 3425 (C-N str), 3145 (C-H str), 1623 (N-H bend), 1560 
(C=N str), 1511 (C-C str), 1271 (C-N str); 1H NMR (500 MHz, DMSO-d6) δH/ppm: 7.65 (1H, d, J = 8 
Hz, 2’, 6’-CH), 7.32 (2H, t, J = 7.5 Hz, 3’, 5’-CH), 7.21 (1H, t, J = 7.5 Hz, 4’-CH), 5.68 (1H, s, 4-CH), 
5.23 (2H, br. S, NH2), 3.56 (3H, s, Me); 13C NMR (126 MHz, DMSO-d6) δC/ppm: 148.0 (5-C), 147.7 
(3-C), 134.3 (1’-C), 128.2 (3’, 5’-CH), 126.7 (4’-CH), 124.5 (2’, 6’-CH), 85.2 (4-CH), 34.2 (Me); m/z 
(EI+): 173 (M•⁺, 100), 130 (14), 102 (10), 77 (10). 
 
6.3.23. 1,3-Diphenyl-1H-pyrazol-5-amine (232) 
 
Chemical Formula: C15H13N3 
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Mr: 235.28  
Benzoylacetonitrile (0.34 g, 2.37 mmol) and phenylhydrazine (0.26 g, 2.43 mmol) in a toluene-
glacial AcOH solution ([5:1]; 2 mL) was irradiated at 120 °C for 40 min in a pressure-rated glass 
vial (10 mL) using a CEM Discover microwave synthesizer, through modulation of the initial 
power (100 W). After cooling in a flow of compressed air, the volatiles were removed in vacuo. 
Purification by flash column chromatography on SiO2 (dry-load), gradient eluting with hexanes 
to EtOAc-hexanes (30:70), gave the title compound (0.51 g, 91%) as a yellow solid, mp 129.1-
130.2 °C (lit.372 129 -130 (CHCl3)) (Found [ESI+]: 236.1176. C15H14N3 [MH] requires 236.1182); IR 
(neat) νmax/cm-1: 3305 (N-H str), 1627 (N-H bend), 1598 (C=N str), 1505 (C-C str), 1377 (C-N str); 
1H NMR (500 MHz, DMSO-d6) δH/ppm: 7.74 (2H, d, J = 7.5 Hz, 2’’, 6’’-CH) 7.65 (2H, d, J = 8 Hz, 2’, 
6’-CH), 7.49 (2H, t, J = 8 Hz, 3’, 5’-CH), 7.37 (2H, t, J = 7.5 Hz, 3’’, 5’’-CH), 7.32 (1H, t, J = 7.5 Hz, 
4’-CH), 7.28 (1H, t, J = 7.5 Hz, 4’’-CH), 5.90 (1H, s, 4-CH), 5.40 (2H, br. s, NH2); 13C NMR (126 MHz, 
DMSO-d6) δC/ppm: 149.9 (3-C), 148.1 (5-C), 139.2 (1’-C), 133.6 (1’’-C), 129.0 (3’,5’-CH), 128.4 (3’’, 
5’’-CH), 127.4 (4’’-CH), 126.2 (4’-CH), 125.0 (2’’, 6’’-CH), 122.8 (2’, 6’-CH), 87.1 (4-CH); m/z (EI+): 
235 (M•⁺, 100), 234 (21), 207 (13). 
 
6.3.24. N-(3,5-Bis(trifluoromethyl)phenyl)-N’-(3-(tert-butyl)-1-
(p-tolyl)-1H-pyrazol-5-yl)urea (217F) 
 
Chemical Formula: C23H22F6N4O 
Mr: 484.44 
3-(tert-Butyl)-1-(p-tolyl)-1H-pyrazol-5-amine (217) (0.21 g, 0.90 mmol) was added to a solution 
of 3,3-bis(trifluoromethyl)phenyl isocyanate (0.19 g, 0.76 mmol) in CH2Cl2 (1 mL) and stirred at 
RT for 20 min. Volatiles were then removed in vacuo and residue triturated with light petroleum 
and recrystallized from hot MeOH to give the title compound (0.155 g, 42%) as colourless 
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crystals, mp 155.3-158.3 °C (MeOH) (Found [ESI+]: 485.1749 C23H23N4OF6 [MH] requires 
485.1771); IR (neat) νmax/cm-1: 3322 (N-H str), 2959 (C-H str), 1660 (C=O str), 1561 (N-H bend), 
1383 (C-H str), 1271 (C-N str), 1172 (C-O str), 1139 (C-F str); 1H NMR (500 MHz, DMSO-d6) 
δH/ppm: 9.70 (1H, br. s, NH), 8.60 (1H, br. s, N’H), 8.06 (2H, s, 2, 6-CH), 7.64 (1H, s, 4-CH), 7.40 
(2H, d, J = 8 Hz, 2’’, 6’’-CH), 7.32 (2H, d, J = 8 Hz, 3’’, 5’’-CH), 6.38 (1H, s, 4’-CH), 2.36 (3H, s, Me), 
1.28 (9H, s, CMe3); 13C NMR (100 MHz, DMSO-d6) δC/ppm: 160.5 (3’-C), 151.8 (C), 141.5 (1-C), 
136.7 (4’’-C), 136.2 (5’-C), 136.0 (1’’-C), 130.7 (q, 2JCF = 33 Hz, 3, 5-C), 129.6 (3’’, 5’’-CH), 124.1 
(2’’, 6’’-CH), 123.4 (q, 1JCF = 273 Hz, CF3), 117.9 (d, 3JCF = 3 Hz, 2, 6-CH), 114.6 (m, 3JCF = 3 Hz, 4-
CH), 96.5 (4’-CH), 32.0 (CMe3), 30.1 (CMe3), 20.5 (Me); m/z (EI+): 484 (M•⁺, 100), 469 (72), 240 
(64), 214 (76). 
 
6.3.25. N-(3,5-Bis(trifluoromethyl)phenyl)-N’-(3-tert-butyl-1-
methyl-1H-pyrazol-5-yl)urea (226F) 
 
Chemical Formula: C17H18F6N4O 
Mr: 408.34 
3,5-Bis(trifluoromethyl)phenyl isocyanate (0.15 mL, 0.87 mmol) was added to a solution of 3-
(tert-butyl)-1-methyl-1H-pyrazol-5-amine (226) (0.13 g, 0.84 mmol) in CH2Cl2 (1.7 mL) and stirred 
at RT for 20 min. Volatiles were then removed in vacuo and the residues triturated with light 
petroleum and recrystallized from hot MeOH to give the title compound (0.10 g, 30%)  as an off-
white powder, mp 155.7-159.7 °C (MeOH) (Found [ESI+]: 409.1454. C17H19N4OF6 [MH] requires 
409.1458); IR (neat) νmax/cm-1: 3307 (N-H str), 2968 (C-H str), 1706 (C=O str), 1573 (N-H bend), 
1386 (C-H str), 1276 (C-N str), 1166 (C-O str), 1130 (C-F str); 1H NMR (500 MHz, DMSO-d6) 
δH/ppm: 9.61 (1H, s, NH), 8.74 (1H, s, N’H), 8.14 (2H, s, 2, 6-CH), 7.64 (1H, s, 4-CH), 6.07 (1H, s, 
4’-CH), 3.61 (3H, s, Me), 1.22 (9H, s, CMe3); 13C NMR (100 MHz, DMSO-d6) δC/ppm: 158.6 (3’-C), 
152.1 (C), 141.7 (1’-C), 136.2 (5’-C), 130.7 (q, 2JCF = 33 Hz, 3, 5-C), 123.3 (app. d, 1JCF = 274 Hz, 
CF3), 118.0 (m, 2, 6-CH), 114.5 (4-C), 95.0 (4’-CH), 34.9 (Me), 31.8 (CMe3), 30.3 (CMe3). 
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6.3.26. N-(3,5-Bis(trifluoromethyl)phenyl)-N’-(3-tert-butyl-1-(4-
fluorophenyl)-1H-pyrazol-5-yl)urea (227F) 
 
Chemical Formula: C22H19F7N4O 
Mr: 488.40  
3,5-Bis(trifluoromethyl)phenyl isocyanate (0.15 mL, 0.87 mmol) was added to a solution of 3-
(tert-butyl)-1-(4-fluorophenyl)-1H-pyrazole-5-amine (227) (0.19 g, 0.82 mmol) in CH2Cl2 (1.7 mL) 
and stirred at RT for 20 min. Volatiles were then removed in vacuo and the residues triturated 
with light petroleum to give the title compound (0.30 g, 75%) as a yellow solid, mp 177.6-184.3 
°C (Found [ESI+]: 489.1499. C22H20N4OF7 [MH] requires 489.1520); IR (neat) νmax/cm-1: 3350 (N-H 
str), 2962 (C-H str), 1664 (C=O str), 1569 (N-H bend), 1510 (N-H bend), 1383 (C-H str), 1271 (C-N 
str), 1140 (C-F str);  1H NMR (500 MHz, DMSO-d6) δH/ppm: 9.70 (1H, s, NH), 8.66 (1H, s, N’H), 
8.07 (2H, s, 2, 6-CH), 7.63 (1H, s, 4-CH), 7.57 (2H, dd, 3JHH = 9, 4JHF = 5 Hz, 2’’, 6’’-CH), 7.35 (2H, pt, 
3JHF = 9, 3JHH = 9 Hz, 3’’, 5’’-CH), 6.39 (1H, s, 4’-CH), 1.29 (9H, s, CMe3); 13C NMR (100 MHz, DMSO-
d6) δC/ppm: 160.9 (d, 2JCF = 245 Hz, 4’’-C), 160.8 (3’-C), 151.9 (C), 141.5 (1-C), 136.4 (5’-C), 135.0 
(d, 4JCF = 3 Hz, 1’’-C), 130.7 (q, 2JCF = 32 Hz, 3, 5-C), 126.3 (d, 3JCF = 9 Hz, 2’’, 6’’-CH), 123.2 (q, 1JCF 
= 273 Hz, CF3), 117.9 (app. d, 3JCF = 3 Hz, 2, 6-CH), 115.9 (d, 2JCF = 23 Hz, 3’’, 5’’-CH), 114.6 (m, 3JCF 
= 4 Hz, 4-CH), 97.2 (4’-CH), 32.0 (CMe3), 30.1 (CMe3); m/z (EI): 488 (M•⁺, 100), 473 (55), 244 (60), 
218 (75). 
 
6.3.27. N-(3,5-Bis(trifluoromethyl)phenyl)-N’-(3-(tert-butyl)-1-
(4-nitrophenyl)-1H-pyrazol-5-yl)urea (228F) 
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Chemical Formula: C22H19F6H5O3 
Mr: 515.41  
3.5-Bis(trifluoromethyl)phenyl isocyanate (0.12g, 0.52 mmol) was added to a solution of 3-(tert-
butyl)-1-(4-nitrophenyl)-1H-pyrazol-5-amine (228) (0.15 g, 0.58 mmol) in CH2Cl2 (1.2 mL) and 
stirred at RT for 20 min. Volatiles were then removed in vacuo  and the residue triturated with 
light petroleum and recrystallized from hot MeOH to give the title compound (0.10 g, 35%) as 
orange crystals mp 215.1-217.8 °C (MeOH) (Found [ESI+]: 516.1442. C22H20N5O3F6 [MH] requires 
516.1465); IR (neat) νmax/cm-1: 3350 (N-H str), 2968 (C-H str), 1671 (C=O str), 1572 (N-H bend), 
1504 (N-O str), 1340 (N-O str), 1272 (C-N str), 1175 (C-O str), 1135 (C-F str); 1H NMR (500 MHz, 
DMSO-d6) δH/ppm: 9.79 (1H, br. s, NH), 8.92 (1H, br. s, N’H), 8.35 (2H, d, J = 9 Hz, 3’’, 5’’-CH), 
8.09 (2H, s, 2, 6-CH), 7.88 (2H, d, J = 9 Hz, 2’’, 6’’-CH), 7.64 (1H, s, 4-CH), 6.48 (1H, s, 4’-CH), 1.31 
(9H, s, CMe3); 13C NMR (100 MHz, DMSO-d6) δC/ppm: 162.4 (3’-C), 152.2 (C), 145.0 (1’’- or 4’’-
C), 143.9 (1’’- or 4’’-C), 141.5 (1-C), 137.1 (5’-C), 130.6 (q, 2JCF = 32 Hz, 3, 5-C), 124.7 (3’’, 5’’-CH), 
123.6 (q, 1JCF = 274 Hz, CF3), 123.0 (2’’, 6’’-CH), 118.1 (app. d, 3JCF = 3 Hz, 2, 6-CH), 114.7 (m, 3JCF 
= 4 Hz, 4-CH), 100.3 (4’-CH), 32.2 (CMe3), 29.8 (CMe3); m/z (EI+): 515 (M•⁺, 100), 286 (21), 271 
(100). 
 
6.3.28. N-(3,5-Bis(trifluoromethyl)phenyl)-N’-((1,3-di-tert-
butyl)-1H-pyrazol-5-yl)urea (229F) 
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Chemical Formula: C20H24F6N4O 
Mr: 450.43 
1,3-Di-tert-butyl-1H-pyrazol-5-amine (229) (0.095 g, 0.49 mmol) was added to a solution of 3,5-
bis(trifluoromethyl)phenyl isocyanate (0.11g, 0.43 mmol) in CH2Cl2 (1.5 mL) and stirred at RT for 
30 min. Volatiles were then removed in vacuo and the residue triturated with light petroleum 
to give the title compound (0.14 g, 72%) as a colourless powder, mp 202.2-203.3 °C (Found 
[ESI+]: 451.1923. C20H25N4OF6 [MH] requires 451.1927); IR (neat) νmax/cm-1: 3310 (N-H str), 2969 
(C-H str), 1655 (C=O str), 1576 (N-H bend), 1384 (C-H str), 1272 (C-N str), 1184 (C-O str), 1133 
(C-F str); 1H NMR (500 MHz, DMSO-d6) δH/ppm: 9.64 (1H, br. s, NH), 8.20 (1H, br. s, N’H), 8.15 
(2H, s, 2, 6-CH), 7.62 (1H, s, 4-CH), 6.05 (1H, s, 4’-CH), 1.54 (9H, s, 1’-NCMe3), 1.22 (9H, s, 3’-
CMe3); 13C NMR (100 MHz, DMSO-d6) δC/ppm: 156.6 (3’-C), 153.0 (C), 141.9 (1-C), 134.5 (5’-C), 
130.6 (q, 2JCF = 32 Hz, 3, 5-C), 123.2 (q, 1JCF = 273 Hz, CF3), 117.9 (app. d, 3JCF = 3 Hz, 2, 6-CH), 
114.4 (m, 3JCF = 4 Hz, 4-CH), 100.7 (4’-CH), 58.8 (1’-NCMe3), 31.8 (3’-CMe3), 30.3 (3’-CMe3), 29.6 
(1’-NCMe3); m/z (EI+):450 (M•⁺, 30), 379 (34), 139 (100). 
 
6.3.29. N-(3,5-Bis(trifluoromethyl)phenyl)-N’-(3-(tert-butyl)-1-
(4-bromophenyl)-1H-pyrazol-5-yl)urea (230F) 
 
Chemical Formula: C22H19BrF6N4O 
Mr: 549.06 
1-(4-Bromophenyl)-3-(tert-butyl)-1H-pyrazol-5-amine (230) (0.16 g, 0.54 mmol) was added to a 
solution of 3,5-bis(trifluoromethyl)phenyl isocyanate (0.13g, 0.50 mmol) in CH2Cl2 (1 mL) and 
stirred at RT for 20 min. Volatiles were then removed in vacuo and the residue triturated with 
light petroleum to give the title compound (0.16 g, 59%) as a colourless powder, mp 196.5-198.2 
°C (Found [ESI+]: 549.0715. C22H20N4O79BrF6 [MH] requires 549.0719); IR (neat) νmax/cm-1: 3286 
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(N-H str), 2962 (C-H str), 1664 (C=O str), 1564 (N-H bend), 1496 (C-C str), 1272 (C-N str), 1179 
(C-O str), 1137 (C-F str); 1H NMR (500 MHz, DMSO-d6) δH/ppm: 9.70 (1H, br. s, NH), 8.71 (1H, br. 
s, N’H), 8.07 (2H, s, 2, 6-CH), 7.70 (2H, d, J = 8 Hz, 2’’, 6’’-CH), 7.65 (1H, s, 4-CH), 7.51 (2H, d, J = 
8 Hz, 3’’, 5’’-CH), 6.40 (1H, br. s, 4’-CH), 1.29 (9H, s, CMe3); 13C NMR (100 MHz, DMSO-d6) 
δC/ppm: 161.7 (3’-C), 152.4 (C), 142.0 (1-C), 138.3 (1-PhC), 136.9 (5’-C), 132.6 (2, 6-PhCH), 131.2 
(q, 2JFC = 33 Hz, 3, 5-C), 126.2 (3, 5-PhCH), 124.2 (q, 1JFC = 273, CF3), 120.3 (4-PhCBr), 118.5 (m, 
3JFC = 3 Hz, 2, 6-CH), 115.1 (m, 3JFC = 4 Hz, 4-CH), 98.4 (4’-CH), 32.5 (CMe3), 30.5 (CMe3); m/z (EI+): 
548 (M79Br•⁺, 39), 535 (26), 306 (100), 278 (55), 228 (76). 
 
6.3.30. N-(3,5-Bis(trifluoromethyl)phenyl)-N’-(1-methyl-3-
phenyl-1H-pyrazol-5-yl)urea (231F) 
 
Chemical formula: C19H14F6N4O 
Mr: 428.11  
1-Methyl-3-phenyl-1H-pyrazol-5-amine (231) (0.15 g, 0.85 mmol) was added to a solution of 
3,5-bis(trifluoromethyl)phenyl isocyanate (0.18 g, 0.71 mmol) in CH2Cl2 (2 mL) and stirred at RT 
for 20 min. Volatiles were then removed in vacuo and the residue triturated with light 
petroleum to give the title compound (0.22 g, 73%) as a colourless solid, mp 195.3-198.9 °C 
(MeOH) (Found [ESI+]: 429.1146. C19H15N4OF6 [MH] requires 429.1144); IR (neat) νmax/cm-1: 
3378 (N-H str), 2966 (C-H str), 1674 (C=O str), 1561 (N-H bend), 1472 (C-C str), 1276 (C-N str), 
1125 (C-F str), 1054 (C-N str); 1H NMR (500 MHz, DMSO-d6) δH/ppm: 9.66 (1H, br. s, NH), 8.96 
(1H, br. s, N’H), 8.18 (2H, s, 2, 6-CH), 7.77 (2H, d, J = 8 Hz, 2’’, 6’’-CH), 7.67 (1H, s, 4-CH), 7.39 
(2H, t, J = 8 Hz, 3’’, 5’’-CH), 7.29 (1H, m, J = 8 Hz, 4’’-CH), 6.67 (1H, s, 4’-CH), 3.74 (3H, s, Me); 13C 
NMR (100 MHz, DMSO-d6) δC/ppm: 152.1 (C), 148.1 (3’-C), 141.6 (1-C), 137.6 (5’-C), 133.4 (1’’-
C), 130.7 (q, 2JCF = 33 Hz, 3,5-C), 128.5 (3’’,5’’-CH), 127.3 (4’’-CH), 124.7 (2’’,6’’-CH), 123.2.0 (app 
d, 1JCF = 273 Hz, CF3), 118.2 (d, 3JCF = 4 Hz, 2,6-CH), 114.7 (m, 3JCF = 5 Hz, 4-CH), 96.2 (4’-CH), 35.4 
(Me); m/z (EI+): 428 (M•⁺, 49), 173 (100). 
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6.3.31. N-(3,5-Bis(trifluoromethyl)phenyl)-N’-(1,3-diphenyl-1H-
pyrazol-5-yl)urea (232F) 
 
Chemical formula: C24H16F6N4O 
Mr: 490.12 
1,3-Diphenyl-1H-pyrazol-5-amine (232) (0.20 g, 0.86 mmol) was added to a solution of 3,5-
bis(trifluoromethyl)phenyl isocyanate (0.19 g, 0.73 mmol) in CH2Cl2 (2 mL) and stirred at RT for 
20 min. Volatiles were removed in vacuo and the residue triturated with light petroleum and 
recrystallized from hot MeOH to give the title compound (0.23 g, 65%) as colourless crystals, mp 
205.7-206.9 °C (MeOH) (Found [ESI+]: 491.1288. C24H17F6N4O [MH] requires 491.1301); IR (neat) 
νmax/cm-1: 3306 (N-H str), 2967 (C-H str), 1653 (C=O str), 1590 (N-H str), 1574 (N-H str), 1474 (C-
C str), 1274 (C-N str), 1126 (C-F str), 1055 (C-N str); 1H NMR (500 MHz, DMSO-d6) δH/ppm: 9.72 
(1H, br. s, NH), 8.86 (1H, br. s, N’H), 8.10 (2H, s, 2, 6-CH), 7.88 (2H, d, J = 7 Hz, 2’’’, 6’’’-CH), 7.65 
(3H, 4-CH and 2’’, 6’’-CH), 7.58 (2H, t, J = 8 Hz, 3’’, 5’’-CH), 7.49-7.41 (3H, 4’’-CH and 3’’’, 5’’’-CH), 
7.35 (1H, t, J = 7 Hz, 4’’’-CH), 6.99 (1H, s, 4’-CH); 13C NMR (100 MHz, DMSO-d6) δC/ppm: 151.9 
(C), 150.1 (3’-C), 141.4 (1-C), 138.3 (1’’-C), 137.6 (5’-C), 132.9 (1’’’-C), 130.7 (q, 2JCF = 32 Hz, 3, 5-
C), 129.3 (3’’, 5’’-CH), 128.6 (3’’’, 5’’’-CH), 127.9 (4’’ or 4’’’-CH), 127.8 (4’’ or 4’’’-CH), 125.1 (2’’’, 
6’’’-CH), 124.3 (2’’, 6’’-CH), 123.7 (q, 1JCF = 273 Hz, CF3), 118.1 (app d, 3JCF = 3 Hz, 2, 6-CH), 114.8 
(m, 4-CH), 98.0 (4’-CH); m/z (EI+): 490 (M•⁺, 45), 384 (30), 261 (37), 235 (100). 
 
6.3.32. N-(3,5-Difluorophenyl)-N’-(3-(tert-butyl)-1-(phenyl)-1H-
pyrazol-5-yl)urea (215O) 
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Chemical Formula: C20H20F2N4O 
Mr: 370.40  
3-(tert-Butyl)-1-phenyl-1H-pyrazol-5-amine (215) (0.16 g, 0.74 mmol) was added to 3,5-
difluorophenyl isocyanate (0.12 g, 0.74 mmol) in CH2Cl2 (2 mL) and stirred at RT for 20 min. 
Volatiles were then removed in vacuo  and the residue triturated with light petroleum to give 
the title compound (0.17 g, 61%) as a colourless solid, mp 171.0-173.0 °C (MeOH) (Found [ESI+]: 
371.1673. C20H21N4OF2 [MH] requires 371.1678); IR (neat) νmax/cm-1: 3322 (N-H str), 2956 (N-H 
str), 1670 (C=O str), 1554 (N-H str), 1500 (C-C str), 1231 (C-N str), 1117 (C-F str); 1H NMR (500 
MHz, DMSO-d6) δH/ppm: 9.38 (1H, br. s, NH), 8.54 (1H, br, s, N’H), 7.53 (4H, m, 2’’, 3’’, 5’’, 6’’-
CH), 7.44-7.36 (1H, m, 4’’-CH), 7.14 (2H, d, 3JHF = 8.5 Hz, 2, 6-CH), 6.78 (1H, t, 3JHF = 9.5 Hz, 4-CH), 
6.38 (1H, s, 4’-CH), 1.29 (9H, s, CMe3); 13C NMR (100 MHz, DMSO-d6) δC/ppm: 162.5 (dd, 1JCF = 
243, 3JCF = 15 Hz, 3, 5-CF), 160.7 (3’-C), 151.5 (C), 142.1 (t, 3JCF = 14 Hz, 1-C), 138.5 (1’’-C), 136.5 
(5’-C), 129.2 (3’’, 5’’-CH), 127.2 (4’’-CH), 124.1 (2’’, 6’’-CH), 100.9 (dd, 2JCF = 21, 4JCF = 8 Hz, 2, 6-
CH), 97.0 (t, 2JCF = 27 Hz, 4-CH), 96.3 (4’-CH), 32.0 (CMe3), 30.1 (CMe3); m/z (EI+): 370 (M•⁺, 47), 
350 (36), 226 (65), 200 (75), 139 (100). 
 
6.3.33. N-(3,5-Difluorophenyl)-N’-(3-(tert-butyl)-1-(p-tolyl)-1H-
pyrazol-5-yl)urea (217O) 
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Chemical Formula: C21H22F2N4O 
Mr: 384.18  
3-(tert-Butyl)-1-(p-tolyl)-1H-pyrazol-5-amine (B) (0.16 g, 0.70 mmol) was added to a solution of 
3,5-difluorophenyl isocyanate (0.11 g, 0.68 mmol) in CH2Cl2 (2 mL) and stirred at RT for 20 min. 
Volatiles were the removed in vacuo and the residue triturated with light petroleum to give the 
title compound  (0.17 g, 64%) as a colourless powder, mp 188.9-190.8 °C (MeOH) (Found [ESI+]: 
385.1829. C21H23N4OF2 requires 385.1834); IR (neat) νmax/cm-1: 3375 (N-H str), 2963 (C-H str), 
1720 (C=O str), 1619 (N-H str), 1542 (N-H str), 1478 (C-C str), 1196 (C-N str), 1114 (C-F str); 1H 
NMR (500 MHz, DMSO-d6) δH/ppm: 9.37 (1H, br. s, NH), 8.47 (1H, br. s, N’H), 7.38 (2H, d, 3JHH = 
8 Hz, 2’’, 6’’-CH), 7.32 (2H, d, 3JHH = 8 Hz, 3’’, 5’’-CH), 7.13 (2H, app d, 3JHF = 9 Hz, 2, 6-CH), 6.79 
(1H, t, 3JHF = 9 Hz, 4-CH), 6.35 (1H, s, 4’-CH), 2.37 (3H, s, Me), 1.27 (9H, s, CMe3); 13C NMR (100 
MHz, DMSO-d6) δC/ppm: 162.5 (dd, 1JCF = 243, 3JCF = 16 Hz, 3, 5-CF), 160.5 (3’-C), 151.4 (C), 142.1 
(t, 3JCF = 14 Hz, 1-C), 136.8 (4’’-C), 136.5 (5’-C), 136.0 (1’’-C), 129.6 (3’’, 5’’-CH), 124.2 (2’’, 6’’-
CH), 100.9 (dd, 2JCF = 29, 4JCF = 8 Hz, 2, 6-CH), 97.0 (app t, 2JCF = 26 Hz, 4-CH), 95.7 (4’-CH), 32.0 
(CMe3), 30.2 (CMe3), 20.5 (Me); m/z (EI+): 384 (M•⁺, 52), 240 (71), 229 (46), 214 (100). 
 
6.3.34. N-(3,5-Difluorophenyl)-N’-(3-tert-butyl-1-methyl-1H-
pyrazol-5-yl)urea (226O) 
 
Chemical Formula: C15H18F2N4O 
Mr: 308.33 
1-Methyl-3-phenyl-1H-pyrazol-5-amine (226) (0.16 g, 1.01 mmol) was added to a solution of 
3,5-difluorophenyl isocyanate (0.14 g, 0.93 mmol) in CH2Cl2 (2 mL) and stirred at RT for 20 min. 
Volatiles were then removed in vacuo and the residue triturated with light petroleum and 
recrystallized from hot MeOH to give the title compound (0.22 g, 78%) as colourless crystals, mp 
189.0-191.1 °C (MeOH) (Found [ESI+]: 309.1517. C15H19N4OF2 [MH] requires 309.1521); IR (neat) 
νmax/cm-1: 3322 (N-H str), 2964 (C-H str), 1711 (C=O str), 1610 (N-H bend), 1558 (N-H bend), 
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1478 (C-H bend), 1206 (C-N str), 1112 (C-F str); 1H NMR (500 MHz, DMSO-d6) δH/ppm: 9.27 (1H, 
br. s, NH), 8.61 (1H, br. s, N’H) 7.19 (2H, app d, 3JHF = 8 Hz, 2, 6-CH), 6.80 (1H, t, 3JHF = 9 Hz, 4-
CH), 6.04 (1H, s, 4’-CH), 3.59 (3H, s, Me), 1.21 (9H, s, CMe3); 13C NMR (100 MHz, DMSO-d6) 
δC/ppm: 162.5 (dd, 1JCF = 243, 3JCF = 15 Hz, 3, 5-CF), 158.5 (3’-CH), 151.7 (C), 142.2 (t, 3JCF = 14 Hz, 
1-C), 136.4 (5’-C), 101.0 (dd, 2JCF = 29, 4JCF = 8 Hz, 2, 6-CH), 96.9 (t, 2JCF = 26 Hz, 4-CH), 94.4 (4’-
CH), 34.9 (Me), 31.8 (CMe3), 30.3 (CMe3); m/z (EI+): 308 (M•⁺, 56), 164 (71), 138 (100). 
 
6.3.35. N-(3,5-Difluorophenyl)-N’-(3-(tert-butyl)-1-(4-
fluorophenyl)-1H-pyrazol-5-yl)urea (227O) 
 
Chemical Formula: C20H19F3N4O 
Mr: 388.15  
3-(tert-Butyl)-1-(4-fluorophenyl)-1H-pyrazole-5-amine (227) (128 mg, 0.55 mmol) was added to 
a solution of 3,5-difluorophenyl isocyanate (80 mg, 0.52 mmol) in CH2Cl2 (2 mL) and stirred at 
RT for 20 min. Volatiles were then removed in vacuo and the residue triturated with light 
petroleum and recrystallized from hot MeOH to give the title compound (80 mg, 40%) as 
colourless crystals, mp 165.3-169.3 °C (MeOH) (Found [ESI+]: 389.1582. C20H20N4OF3 [MH] 
requires 389.1584); IR (neat) νmax/cm-1: 2966 (C-H str), 1728 (C=O str), 1612 (N-H bend), 1553 
(N-H bend), 1226 (C-N str), 1113 (C-F str); 1H NMR (500 MHz, DMSO-d6) δH/ppm: 9.35 (1H, br. s, 
NH), 8.52 (1H, br. s, N’H), 7.55 (2H, dd, 3JHH = 8, 4JHF = 5 Hz, 2’’, 6’’-CH), 7.36 (2H, pt, 3JHH = 8.5, 
3JHF = 8.5 Hz, 3’’, 5’’-CH), 7.13 (2H, app. d, 3JHF = 8 Hz, 2, 6-CH), 6.79 (1H, t, 3JHF = 9 Hz, 4-CH), 6.36 
(1H, s, 4’-CH), 1.28 (9H, s, CMe3); 13C NMR (100 MHz, DMSO-d6) δC/ppm: 161.2 (dd, 1JCF = 243, 
3JCF = 16 Hz, 3, 5-CF), 160.9 (d, 1JCF = 245, 4’’-CF), 160.8 (3’-C), 151.5 (C), 142.0 (t, 3JCF = 14 Hz, 1-
C), 136.7 (5’-C), 134.9 (d, 4JCF = 3 Hz, 1’’-C), 126.5 (d, 3JHF = 8 Hz, 2’’, 6’’-CH), 116.0 (d, 2JCF = 23 
Hz, 3’’, 5’’-CH), 100.9 (dd, 2JCF = 21, 4JCF = 9 Hz, 2, 6-CH), 97.0 (t, 2JCF = 26 Hz, 4-CH), 96.4 (4’-CH), 
32.0 (CMe3), 30.1 (CMe3); m/z (EI+): 389 (MH+, 72), 244 (65), 218 (100). 
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6.3.36. N-3-(tert-Butyl)-1-(4-nitrophenyl)-1H-pyrazol-5-yl)-N’-
(3,5-difluorophenyl)urea (228O) 
 
Chemical Formula: C20H19F2N5O3 
Mr: 415.15  
3-(tert-Butyl)-1-(4-nitrophenyl)-1H-pyrazol-5-amine (228) (150 mg, 0.58 mmol) was added to a 
solution of 3,5-difluorophenylisocyanate (82 mg, 0.52 mmol) in CH2Cl2 (2 mL) and stirred at RT 
for 18 h. Volatiles were then removed in vacuo and the residue triturated with light petroleum 
and recrystallized from hot MeOH to give the title compound (54 mg, 25%) as yellow crystals, 
mp 178.6-182.0 °C (MeOH) (Found [ESI+]: 416.1534. C20H20N5O3F [MH] requires 416.1529); IR 
(neat) νmax/cm-1: 3298 (N-H str), 2963 (C-H str), 1662 (C=O str), 1610 (N-H bend), 1565 (N-H 
bend), 1503 (N-O str), 1334 (N-O str), 1234 (C-N str), 1116 (C-F str); 1H NMR (500 MHz, DMSO-
d6) δH/ppm: 9.45 (1H, br. s, N’H), 8.78 (1H, br. s, NH), 8.36 (2H, d, 3JHH = 9 Hz, 3’’, 5’’-CH), 7.87 
(2H, d, 3JHH = 9 Hz, 2’’, 6’’-CH), 7.14 (2H, d, 3JHF = 8 Hz, 2’, 6’-CH), 6.79 (1H, t, 3JHF = 9 Hz, 4’-CH), 
6.45 (1H, s, 4-CH), 1.30 (9H, s, CMe3); 13C NMR (100 MHz, DMSO-d6) δC/ppm: 162.5 (dd, 1JCF = 
243, 3JCF = 16 Hz, 3’, 5’-CF), 162.4 (3-C), 151.8 (C), 145.0 (1’’ or 4’’-C), 143.9 (1’’ or 4’’-C), 142.0 
(t, 3JCF = 14 Hz, 1’-C), 137.4 (5-C), 124.8 (3’’, 5’’-CH), 123.1 (2’’, 6’’-CH), 101.1 (dd, 2JCF = 21, 4JCF = 
9 Hz, 2’, 6’-CH), 99.5 (4-CH), 97.4 (t, 2JCF = 27 Hz, 4’-CH), 32.2 (CMe3), 29.9 (CMe3); m/z (EI+): 415 
(M•⁺, 30), 271 (100), 245 (88). 
 
6.3.37. N-(3,5-Difluorophenyl)-N’-(1,3-(tert-butyl)-1H-pyrazol-5-
yl)urea (229O) 
283 
 
 
Chemical Formula: C18H24F2N4O 
Mr: 350.19  
1,3-Di-tert-butyl-1H-pyrazol-5-amine (229) (0.14 g, 0.72 mmol) was added to a solution of 3,5-
difluorophenyl isocyanate (0.11 g, 0.68 mmol) in CH2Cl2 (2 mL) and stirred at RT for 20 min. 
Volatiles were then removed in vacuo and the residue triturated with light petroleum and 
recrystallized from hot MeOH to give the title compound (0.16 g, 69%) as colourless crystals, mp 
212.9-214.5 °C (MeOH) (Found [ESI+]: 351.1987. C18H25N4OF2 [MH] requires 351.1991); IR (neat) 
νmax/cm-1: 3366 (N-H str), 2957 (C-H str), 1663 (C=O str), 1612 (N-H bend), 1566 (N-H bend), 
1478 (C-H str), 1207 (C-N str), 1116 (C-F str); 1H NMR (500 MHz, DMSO-d6) δH/ppm: 9.31 (1H, 
br. s, NH), 8.01 (1H, br. s, N’H), 7.18 (2H, app d, 3JHF = 8 Hz, 2, 6-CH), 6.77 (1H, t, 3JHF = 9 Hz, 4-
CH), 6.02 (1H, s, 4’-CH), 1.53 (9H, s, 1’-CMe3), 1.21 (9H, s, 3’-CMe3); 13C NMR (100 MHz, DMSO-
d6) δC/ppm: 162.5 (dd, 1JCF = 243, 3JCF = 15 Hz, 3, 5-CF), 156.5 (3’-C), 152.6 (C), 142.5 (t, 3JCF = 15 
Hz, 1-C), 134.6 (5’-C), 100.9 (dd, 2JCF = 30, 4JCF = 9 Hz, 2, 6-CH), 100.4 (4’-CH), 96.7 (t, 2JCF = 27 Hz, 
4-CH), 58.7 (1’-CMe3), 31.8 (3’-CMe3), 30.3 (3’-CMe3), 29.5 (1’-CMe3); m/z (EI+): 350 (M•⁺, 39 ), 
150 (36), 139 (100). 
 
6.3.38. N-(3-(tert-Butyl)-1-(4-bromophenyl)-1H-pyrazol-5-yl)-N’-
(3,5-difluorophenyl)urea (230O) 
 
Chemical Formula: C20H19BrF2N4O 
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Mr: 448.07  
1-(4-Bromophenyl)-3-(tert-butyl)-1H-pyrazol-5-amine (230) (0.21 g, 0.71 mmol) was added to a 
3,5-difluorophenyl isocyanate (0.17 g, 1.01 mmol) in CH2Cl2 (2 mL) and stirred at RT for 20 min. 
Volatiles were then removed in vacuo and the residue triturated with light petroleum and 
recrystallized from hot MeOH to give the title compound (0.17 g, 54%) as colourless crystals, mp 
158.0-159.4 °C (Found [ESI+]: 449.0782. C20H20N4O79BrF2 [MH] requires 449.0783); IR (neat) 
νmax/cm-1: 3320 (N-H str), 2964 (C-H str), 1668 (C=O str), 1612 (N-H bend), 1552 (N-H bend), 
1478 (C-C str), 1228 (C-N str), 1116 (C-F str), 670 (C-Br str); 1H NMR (500 MHz, DMSO-d6) 
δH/ppm: 9.37 (1H, br. s, N’H), 8.58 (1H, br. s, NH), 7.71 (2H, d, 3JHH = 9 Hz, 3’’, 5’’-CH), 7.50 (2H, 
d, 3JHH = 9 Hz, 2’’, 6’’-CH), 7.14 (2H, d, 3JHF = 8 Hz, 2’, 6’-CH), 6.78 (1H, t, 3JHF = 9 Hz, 4’-CH), 6.38 
(1H, s, 4-CH), 1.28 (9H, s, CMe3); 13C NMR (100 MHz, DMSO-d6) δC/ppm: 163.8 (dd, 1JCF = 243, 
3JCF = 16 Hz, 3’, 6’-CF), 161.2 (3-C), 151.6 (C), 142.0 (t, 3JCF = 14 Hz, 1’-C), 137.8 (1’’-C), 136.7 (5-
C), 132.1 (2’’, 6’’-CH), 125.9 (3’’, 5’’-CH), 119.8 (4’’-C), 101.0 (dd, 2JCF = 21, 4JCF = 9 Hz, 2’, 6’-CH), 
97.0 (4’-CH and 4-CH), 32.0 (CMe3), 30.0 (CMe3); m/z (EI+): 449 (M79Br •⁺, 79), 305 (97), 279 
(100). 
 
6.3.39. N-(3,5-Difluorophenyl)-N’-(1-methyl-3-phenyl-1H-
pyrazol-5-yl)urea (231O) 
 
Chemical Formula: C17H14F2N4O 
Mr: 328.11 
1-Methyl-3-phenyl-1H-pyrazol-5-amine (231) (0.13 g, 0.73 mmol) was added to 3,5-
difluorophenyl isocyanate (0.10 g, 0.66 mmol) in CH2Cl2 (3 mL) and stirred at RT for 20 min. 
Volatiles were then removed in vacuo and the residue triturated with light petroleum and 
recrystallized from hot MeOH to give the title compound (0.18 g, 85%) as clear colourless 
crystals, mp 205.6-206.7 °C (MeOH) (Found [ESI+]: 329.1204. C17H15N4OF2 [MH] requires 
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329.1208); IR (neat) νmax/cm-1: 3284 (N-H str), 2973 (C-H str), 1711 (C=O str), 1609 (N-H bend), 
1558 (N-H bend), 1479 (C-H bend), 1235 (C-N str), 1114 (C-F str); 1H NMR (500 MHz, DMSO-d6) 
δH/ppm: 9.34 (1H, br. s, NH), 8.82 (1H, br. s, N’H), 7.76 (2H, d, 3JHH = 7.5 Hz, 2’’, 6’’-CH), 7.39 (2H, 
t, 3JHH = 7.5 Hz, 3’’, 5’’-CH), 7.28 (1H, t, 3JHH = 7.5 Hz, 4’’-CH), 7.22 (2H, app d, 3JHF = 8.5 Hz, 2, 6-
CH), 6.81 (1H, t, 3JHF = 9 Hz, 4-CH), 6.64 (1H, s, 4’-CH), 3.73 (3H, s, Me); 13C NMR (100 MHz, 
DMSO-d6) δC/ppm: 163 (dd, 1JCF = 243, 3JCF = 15 Hz, 3, 5-CF), 151.7 (C), 148.1 (3’-C), 142.1 (t, 3JCF 
= 14 Hz, 1-C), 137.8 (5’-C), 133.5 (1’’-C), 128.5 (3’’, 5’’-CH), 127.3 (4’’-CH), 124.7 (2’’, 6’’-CH), 
101.1 (dd, 2JCF = 21, 4JCF = 8 Hz, 2, 6-CH), 96.8 (t, 2JCF = 26 Hz, 4-CH), 95.5 (4’-CH), 35.4 (Me); m/z 
(EI+): 328 (M•⁺, 44), 199 (30), 173 (100). 
 
6.3.40. N-(3,5-Difluorophenyl)-N’-(1,3-diphenyl-1H-pyrazol-5-
yl)urea (232O) 
 
Chemical Formula: C22H16F2N4O 
Mr: 390.13  
1,3-Diphenyl-1H-pyrazol-5-amine (231) (0.20 g, 0.85 mmol) was added to 3,5-difluorophenyl 
isocyanate (0.12 g, 0.75 mmol) in CH2Cl2 (2 mL) and stirred at RT for 20 min. Volatiles were then 
removed in vacuo and the residue triturated with light petroleum and recrystallized from hot 
MeOH to give the title compound (0.21 mg, 70%) as colourless crystals, mp 195.4-200.4 °C 
(MeOH) (Found [ESI+]: 391.1365. C22H17N4OF2 [MH] requires 391.1365); IR (neat) νmax/cm-1: 
3324 (N-H str), 2945 (C-H str), 1726 (C=O str), 1615 (N-H bend), 1544 (N-H bend), 1480 (C=C str), 
1194 (C-N str), 1106 (C-F str); 1H NMR (500 MHz, DMSO-d6) δH/ppm: 9.42 (1H, br. s, NH), 8.71 
(1H, br. s, N’H), 7.86 (2H, d, 3JHH = 8 Hz, 2’’’, 6’’’-CH), 7.60 (4H, m, 2’’, 3’’, 5’’, 6’’-CH), 7.46 (3H, 
4’’-CH and 3’’’, 5’’’-CH), 7.35 (1H, t, 3JHH = 7.5 Hz, 4’’’-CH), 7.16 (2H, app d, 3JHF = 8.5 Hz, 2, 6-CH), 
6.95 (1H, s, 4’-CH), 6.81 (1H, t, 3JHF = 9 Hz, 4-CH); 13C NMR (100 MHz, DMSO-d6) δC/ppm: 163.0 
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(dd, 1JCF = 243, 3JCF = 17 Hz, 3, 5-CF), 152.0 (C), 150.6 (3’-C), 142.5 (t, 3JCF = 14 Hz, 1-C), 138.7 (1’’-
C), 138.4 (5’-C), 133.4 (1’’’-C), 129.8 (3’’, 5’’-CH), 129.1 (3’’’, 5’’’-CH), 128.4 (4’’ or 4’’’-CH), 128.3 
(4’ or 4’’’-CH), 125.6 (2’’’, 6’’’-CH), 124.9 (2’’, 6’’-CH), 101.5 (dd, 2JCF = 21, 4JCF = 8 Hz, 2, 6-CH), 
97.6 (4-CH and 4’-CH); m/z (EI+): 390 (M•⁺, 47), 261 (45), 235 (100). 
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Abstract: Microwave-assisted Suzuki-Miyaura cross-coupling reactions have been employed 
towards the synthesis of three different MAPKAPK2 (MK2) inhibitors to study accelerated 
aging in Werner syndrome (WS) cells, including the cross-coupling of a 2-chloroquinoline 
with a 3-pyridinylboronic acid, the coupling of an aryl bromide with an indolylboronic acid 
and the reaction of a 3-amino-4-bromopyrazole with 4-carbamoylphenylboronic acid. In all 
of these processes, the Suzuki-Miyaura reaction was fast and relatively efficient using a 
palladium catalyst under microwave irradiation. The process was incorporated into a rapid 
3-step microwave-assisted method for the synthesis of a MK2 inhibitor involving  
3-aminopyrazole formation, pyrazole C-4 bromination using N-bromosuccinimide (NBS), 
and Suzuki-Miyaura cross-coupling of the pyrazolyl bromide with 4-carbamoylphenylboronic 
acid to give the target 4-arylpyrazole in 35% overall yield, suitable for study in WS cells. 
Keywords: Suzuki-Miyaura; cross-coupling; MK2 inhibitor; Werner syndrome; cell aging; 
pyrazoles; heterocycles; microwave-assisted synthesis; boronic acid 
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1. Introduction 
Werner syndrome (WS) is an example of a monogenic segmental progeroid syndrome—a rare 
human autosomal recessive genetic instability syndrome that mimics many, but not all, of the 
polygenic features of physiological aging [1,2]. It was first characterized by Dr. Otto Werner [3] and 
its modern diagnosis often relies upon knowledge of previous family incidence and/or presentation 
with a series of clinical symptoms, including juvenile bilateral cataracts, scleroderma-like skin and 
premature graying of the hair [4]. Patients manifest a characteristic premature aging phenotype in their 
twenties or thirties and exhibit an increased predisposition to a number of pro-inflammatory  
age-related diseases [1], including type II diabetes mellitus, osteoporosis, and atherosclerosis, with 
premature death occurring typically from cancer or cardiovascular disease. Patients typically have high 
levels of inflammatory cytokines and intercellular adhesion molecule-1 (ICAM-1) and the same 
phenomenon can be observed in cell-based studies, with WS fibroblasts showing pronounced 
activation of inflammatory signaling pathways [5–7]. As a result, WS is often classified as an example 
of “inflamm-aging” [5,7] to highlight its association with, and patient pre-disposition to, age-related 
inflammatory disease pathologies [8]. The genetic basis of WS is known, with WS resulting from 
mutations in the RecQ3 DNA helicase-encoding gene WRN that give rise to a pathology attributed for the 
most part to the key role of RecQ3 in cellular responses to specific types of DNA damage. Lack of 
RecQ3 leads to frequent DNA replication fork stalling and subsequently genomic instability [9] and WS 
is classified as a chromosome instability syndrome [10]. The replication fork stalling and an increased 
pro-oxidant state [11] could provide the trigger for replication stress in WS leading to a decreased 
ability for WS cells to undergo division [5]. This is supported by the observation that young WS cells 
show a much reduced division capability compared to cells from normal individuals and resemble 
fibroblasts that have undergone stress-induced premature senescence [12], which is known from many 
different stimuli to be transduced by the mitogen activated protein kinase (MAPK) p38 [13–15]. This 
implicates the involvement of p38 signaling in the premature cell cycle arrest in WS and the short 
replicative life span observed in WS cell cultures. This in turn implicates a reduced ability of WS cells 
to divide as an underlying cause of accelerated aging in WS [2]. 
1.1. Studies of P38 Inhibitors in WS Cells 
The role of stress signaling in Werner syndrome cells has been investigated using a range of small 
molecule inhibitors (Figure 1) of p38 MAPK [16], including SB203580 [12,17,18], VX-745 [19–21], 
RO3201195 [22,23], UR-13756 [24], and BIRB 796 [25], to study the link between replicative 
senescence in vitro and in vivo pathophysiology. WS fibroblasts treated with a p38 inhibitor display an 
unexpected reversal of the accelerated aging phenotype [12] and, as such, this may provide a suitable 
model for future therapeutic interventions designed to combat the aging process itself [12,26]. 
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Figure 1. Inhibitors of p38 MAPK examined in WS cells. 
1.2. Synthesis and Properties of MK2 Inhibitors 
Although progress in the clinical development of successful p38 inhibitors for in vivo use is 
currently a considerable challenge [27], probably frustrated by toxicity issues, it may be possible to 
elicit a similar biological response by targeting the downstream kinase MAPKAPK2 (MK2) [16,28], 
which may itself be involved in the phenotypic characteristics seen in WS, including enlarged cellular 
morphology and prominent F-actin stress fibres [12]. MK2 activity up-regulates the expression of 
inflammatory pathways [29] and recent data suggest that MK2 acts as a checkpoint kinase that can 
lead to cell cycle arrest [30]. Furthermore MK2 knock-out mice exhibit normal, healthy phenotypes 
and are inflammation resistant [31], whereas p38 knock-out mice are lethal [32]. This could indicate 
that chemical inhibition of MK2 may be less problematic than inhibition of p38, whilst providing 
similar in vivo efficacy. 
As a consequence of these observations, there has been considerable recent activity in drug 
discovery programs to develop small molecule inhibitors of MK2 [33]. A number of different 
chemotypes have been investigated [34], including a series of pyrrolopyridines 1 [35], pyrazinoindolone 
2 [36], the benzo[4,5]thieno[3,2-e][1,4]diazepinone PF-3644022 [37] and recently tricyclic lactams 3 
as a non-ATP-competitive inhibitor scaffold [38], yet issues of selectivity, potency and/or toxicity 
remain [34,39]. Many, but not all, of these approaches used Suzuki-Miyaura reactions to introduce 
diversity to an advanced intermediate for scaffold optimization (Figure 2). Since its initial discovery as 
a Pd-catalyzed stereospecific cross-coupling reaction of 1-alkenylboranes [40], the Suzuki-Miyaura 
reaction has become one of the most efficient methods for C–C bond formation, in particular for  
aryl-aryl coupling [41]. It offers many advantages over other methods, in that it is largely unaffected 
by the presence of water, produces non-toxic inorganic by-products that are easily removed, tolerates  
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a broad range of functional groups and proceeds generally with regio- and stereocontrol [42]. In a 
recent analysis of reactions used in the pursuit of drug candidates taken from a 2008 data set [43], 
biaryl linkages were present in 40% of the compounds that were analyzed and the Suzuki-Miyaura 
reaction occurred in over 4% of all reactions and in 40% of all C–C bond forming reactions. Given the 
amenability of transition-metal mediated processes to be accelerated under microwave dielectric 
heating [44], and thus readily automated to probe SAR, it is perhaps not surprising to observe so many 
uses of this reaction in the development of MK2 inhibitors [28] and such a high occurrence of this 
reaction in drug discovery programs in general [44]. 
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Figure 2. Examples of MK2 inhibitors from different drug discovery programs, showing 
the use of Suzuki-Miyaura aryl-aryl coupling for late-stage scaffold optimization. 
Given the success of a p38 inhibitor in rescuing accelerated aging in WS cells, we carried out studies 
on a number of MK2 inhibitors (Figure 3) to establish their effect on cell aging phenotypes using 
fibroblasts from human WS [28,45,46]. Of these inhibitors, butyramide 4 was reported to act by blocking 
p38-MK2 docking, thus preventing the activation of MK2 by phospho-p38 [47] but in WS cells caused 
a stressed morphology and permanent cell cycle arrest [46] by a pathway that appeared not to involve 
MK2 inhibition [46]. A benzopyranopyridine inhibitor 5 [48] gave a similar cellular response at a 
concentration that inhibited MK2, but this was thought to be due to non-specific toxicity issues [46]. 
However, when primary WS fibroblasts were treated with a tetrahydropyrrolo[3,2-c]pyridin-4-one inhibitor 
6, the stressed cellular morphology and shortened replicative lifespan were both corrected, although 
the extension in life span was much smaller than the one seen upon treatment with SB203580 [45]. 
Given this promising indication, and the wide range of MK2 inhibitors investigated in other cellular 
models, a rapid route to another MK2 inhibitory chemotype was urgently required to provide added 
confirmation of the above findings. 
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Figure 3. MK2 inhibitor chemotypes and their effect on WS cells. 
2. Results and Discussion 
Our first approach aimed to take advantage of the Suzuki-Miyaura coupling in a rapid route to the 
Pfizer MK2 inhibitor PF-3644022 [37,49,50]. Although this compound exhibits single digit nanomolar 
potency against MK2 (IC50 5 nM), cellular activity below 500 nM (U937 TNFα release IC50 150 nM) [50], 
good selectivity across 200 human kinases and projected human pharmacokinetics sufficient for oral 
dosing, it was found to lead to acute hepatotoxicity in dogs, probably by disrupting hepatobiliary 
transporters [39]. Nevertheless, for study in WS cells, its activity and selectivity profile made it  
a compelling target, with preliminary data using this inhibitor showing extension of cellular replicative 
capacity in WS fibroblasts and correction of the stressed morphology (Figure 4), a result similar in 
magnitude to that seen using the tetrahydropyrrolo[3,2-c]pyridin-4-one inhibitor 6 [45]. 
 
Figure 4. Increased replicative lifespan (±SD; n = 3) and improvement cellular morphology 
in WS cells using PF-3644022. Cont = control, SB = SB203580 at 2.5 µM, PF1.0 and 
PF2.0 = PF-3644022 at 1.0 and 2.0 µM respectively. White bar = 100 µm (for methods see 
experimental section). 
The development of this inhibitor utilized a late-stage Suzuki-Miyaura coupling to introduce 
diversity at C-7 of a thieno[3,2-f]quinoline ring (see Figure 2) [49], following initial identification of 
promising SAR studies and cellular potency with a benzo[4,5]thieno[3,2-e][1,4]diazepin-5(2H)-one 
scaffold [50]. Given that our goal was the introduction of a 6-methyl-3-pyridyl substituent at C-7, we 
set out to incorporate the Suzuki-Miyaura coupling of the pyridinylboronic acid 10a and 2-chloroquinoline 
11 into an early stage of the synthesis (Figure 5). Elaboration of the target inhibitor should then 
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proceed in a similar fashion to Anderson’s route [49]: one-step formation of aminocyanoquinoline 8a 
from nitroquinoline 9a, followed by synthesis of aminobenzothiophene 7 by diazotization and subsequent 
reaction with methyl thioglycolate before the introduction of the diazepinone ring. 
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Figure 5. Disconnective approach to the synthesis of PF-3644022, utilizing an early-stage 
Suzuki-Miyaura cross-coupling reaction. 
2.1. Early-Stage Suzuki-Miyaura Cross-Coupling Reactions for the Synthesis of PF-3644022  
Starting with a known route to 11 [51], 3,4-dihydroquinolin-2(1H)-one (12) was nitrated using 
HNO3/H2SO4 and then treated with phosphorus oxychloride in DMF in the presence of DDQ as 
oxidant to give 2-chloro-6-nitroquinoline (11) in 90% isolated yield over the two steps (Figure 5). 
Suzuki-Miyaura cross-coupling with 6-methyl-3-pyridinylboronic acid (10a) using Na2CO3 base and 
PdCl2(PPh3)2 as catalyst in MeCN–H2O at 140 °C under microwave irradiation gave the cross-coupled 
product 9a in reasonable yield. However, use of the Yamazaki method for the synthesis of  
ortho-aminoaroylnitriles [52], namely treating nitroquinoline 9a with ethyl cyanoacetate and KOH in 
DMF at room temperature for up to 72 h, followed by hydrolysis using 5% NaOH (aq) at reflux for 3 h, 
in accordance with Anderson’s approach, gave only a trace of the 6-amino-5-cyanoquinoline 8a. Given 
the wide range of nitroquinolines compatible with this chemistry in Yamazaki’s original report [52], 
and its previous use in a route to PF-3644022 by Anderson [49], this was unexpected. To probe 
whether the acidity of the pyridine 6-methyl group had been responsible for this observation, the 
Suzuki-Miyaura cross-coupling reaction was repeated using 3-pyridinylboronic acid (10b), to give the 
2-pyridylquinoline 9b in 62% isolated yield (Figure 6). When this substrate was investigated in the 
Yamazaki cyanation reaction under identical conditions it behaved in a very similar fashion and only a 
trace of the cyanoquinoline product 8b was observed by 1H NMR spectroscopic analysis of a complex 
mixture. Efforts to introduce the Yamazaki cyanation at an earlier stage in the process were similarly 
unsuccessful. Dihydroquinolone 13 was inert to treatment with ethyl cyanoacetate and KOH in DMF, 
either at room temperature for 24 h followed by treatment with aqueous base or under more forcing 
conditions, when heated to 50 °C for 64 h. In both cases only unreacted starting material 13 was 
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obtained. Alternatively, when chloroquinoline 11 was reacted with ethyl cyanoacetate in the presence 
of base at RT for 64 h (Figure 6) a complex mixture of products was obtained, rather than 
cyanoquinoline 8c. It was apparent that either the lactam ring or an electrophilic chloroquinoline 
function interfered unfavorably with this cyanation reaction. For comparison, Yamazaki cyanation of 
6-nitroquinoline (14) under identical conditions gave the expected product, 6-amino-5-cyanoquinoline 
(15) in good yield (72%) after basic hydrolysis. Thus it was concluded that an early-stage  
Suzuki-Miyaura cross-coupling strategy was efficient for biaryl C-C bond formation but the  
2-pyridylquinoline products, as well as other quinoline-containing precursors, were incompatible with 
Yamazaki’s aminoaroylnitrile synthesis and so could not be used for the rapid synthesis of the MK2 
inhibitor, PF-3644022. 
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Figure 6. Synthesis of chloroquinoline 11 and subsequent Suzuki-Miyaura cross-coupling. 
2.2. Suzuki-Miyaura Cross-Coupling Reactions for the Synthesis of (Indolyl)phenylpyrazole MK2 
Inhibitor 18 
Given the success of pyrrolopyridinone 6 in correcting the WS phenotype, we next turned to the 
scaffold hopping strategy of Velcicky et al. [53] for rapid access to a MK2 inhibitor for study in WS 
cells. Velcicky found that replacing the pyrrolopyrimidinone pharmacophore 16, which overlays well 
with pyrrolopyridinone 6, with a series of benzamide derivatives 17 led to the development of a  
3-aminopyrazole 18 that inhibited intracellular phosphorylation of HSP27, as well as LPS-induced 
TNFα release in cells (Figure 7) [53]. The synthesis of this inhibitor employed two successive  
Suzuki-Miyaura cross-coupling reactions to establish the biaryl bonds. Given our recent report on the 
regiocontrolled synthesis of 3-aminopyrazoles [54], this was a compelling scaffold to study. 
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Figure 7. Scaffold-hopping strategy of Velcicky et al. [53], showing the use of  
Suzuki-Miyaura aryl-aryl coupling for scaffold optimization. 
The hydrochloride salt of 3-bromophenylhydrazine (19) was reacted with 3-methoxyacrylonitrile 
(20) (2 equiv.) in the presence of a large excess of sodium ethoxide in ethanol at reflux for 20 h (Figure 8) 
to give 3-aminopyrazole 21 in excellent yield (90%), or more rapidly under microwave irradiation at 
150 °C for 1 h in a sealed tube to give the same product in comparable yield (89%) [54]. Under the 
strongly basic conditions, no 5-aminopyrazole regioisomers were isolated or observed. Efforts to 
improve the microwave-assisted procedure, by switching to tert-butyl alcohol in the presence of  
tert-butoxide as base and irradiating at 150 °C for 2 h caused a significant reduction in yield (68%) and 
so the overnight conductive heating method was adopted as the procedure of choice as it could be 
readily carried out on gram scale. Suzuki-Miyaura cross-coupling of the arylbromide 21 with  
6-indolylboronic acid 22 under microwave irradiation at 150 °C for 2 h in DMF in the presence of 
cesium carbonate and tetrakis(triphenylphosphine)palladium(0) (10 mol%) gave the coupled product 
23 in 84% isolated yield. Unfortunately, bromination at C-4 of aminopyrazole 23 using NBS failed to 
provide 4-bromopyrazole 24 and instead gave a complex mixture of products, presumably due to 
competing bromination of the indolyl ring. It was possible to install the C-4 bromo group prior to 
Suzuki-Miyaura coupling by treating the N-(bromophenyl)pyrazole 21 with NBS in THF at RT for  
16 h to give dibromide 25 in 83% yield after purification by column chromatography. However, 
Suzuki-Miyaura cross-coupling of dibromide 25 with the 6-indolylboronic acid 22 under similar 
conditions did not provide the 4-bromopyrazole 24 and instead gave a complex mixture of products 
and could not differentiate between the two reactive sites. Although potentially this could be resolved 
through the use of different halogen moieties, given the difficulties or the need to use protecting group 
chemistries for the synthesis of the indole-containing inhibitor, we switched to a simpler pyrazole 
target, benzamide 26, reported to possess reasonable potency (IC50 2.0 µM), as a more accessible 
inhibitor for evaluation in WS cells. 
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Figure 8. Suzuki-Miyaura cross-coupling for the synthesis of 6-indolyl scaffolds. 
2.3. Suzuki-Miyaura Cross-Coupling Reactions for the Synthesis of Aminopyrazole MK2 Inhibitor 26 
Adopting a similar route, the hydrochloride salt of 4-methoxyphenylhydrazine (27) was reacted 
with 3-methoxyacrylonitrile (20) (2 equiv.) under basic conditions using sodium ethoxide in ethanol 
under microwave irradiation at 150 °C for 2 h to give 3-aminopyrazole 28 as the only observed 
regioisomer in 85% yield (Figure 9). Bromination using NBS in THF under microwave irradiation at 
150 °C for 2 h gave the C-4 brominated pyrazole 29 in 77% yield. This rapid microwave-assisted 
procedure was preferred over a method under ambient conditions, which required stirring with NBS in 
THF for 16 h but did give bromide 29 in slightly improved yield (82%). Suzuki-Miyaura coupling of 
the pyrazolylbromide 29 with 4-carbamoylphenylboronic acid (30) in iPrOH–H2O in the presence of 
potassium carbonate and bis(triphenylphosphine)palladium(II) chloride (10 mol%) under microwave 
irradiation at 150 °C for 2 h using similar conditions to Velcicky et al. [53] gave the coupled product 
26 in 54% yield after purification by column chromatography. This route to pyrazole 26 utilized three 
microwave-assisted steps, each of 2 h duration, starting from commercially-available materials and 
provided the target MK2 inhibitor in 35% overall yield, suitable for study in WS cells. 
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Figure 9. Microwave-assisted synthesis of the MK2 inhibitor 26 using  
a Suzuki-Miyaura cross-coupling. 
2.4. Biological Evaluation of Aminopyrazole MK2 Inhibitor 26 in WS Cells 
When WS fibroblasts were grown in the presence of inhibitor 26 at 25 µM a small lifespan 
extension was noted, although it was difficult to ascertain if this was significant, especially as little 
inhibition of MK2 activity was seen at this concentration [28]. Treatment with inhibitor 26 did, 
however, show improvement in the cellular morphology of the WS cells at 25 µM and 50 µM. These 
results were encouraging for the further development of MK2 inhibitors in this and other inflammatory 
therapeutic areas. 
2.5. The Role of MK2 in the WS Cell Phenotype and Its Modulation Using Chemical Inhibitors 
Effects of MK2 inhibitors on the growth and morphology of WS cells have been ambiguous: 
inhibitors 4 and 5 resulted in growth inhibition that was not related to MK2 inhibition [46]; inhibitor 6 
increased cellular replicative capacity at a concentration that maximally inhibited MK2 [45]; inhibitor 
26 showed a small increase in replicative capacity and alleviated the stressed morphology [28]; and 
finally, PF-3644022 had an effect similar in magnitude to inhibitor 6 at a dose that fully inhibited MK2 
(this work). Thus, three MK2 inhibitors with very different chemotypes gave similar results for WS 
fibroblasts on all cellular parameters tested. These data suggest a role for p38-activated MK2 in 
replicative senescence in WS fibroblasts, although this role appears to be much reduced compared to 
that of p38, as the p38 inhibitor SB203580 has much larger effects on the replicative capacity of WS 
fibroblasts [12]. Possible reasons for the reduced effects of MK2 inhibitors on replicative capacity are 
that MK2 may be only one of the downstream effectors of p38 responsible for cellular growth arrest [55], 
or that MK2 inhibitors have a narrow therapeutic window and become toxic to cell growth at levels 
close to the maximally effective dose [34]. This latter is seen with both PF-3644022 that is effective at 
2.0 µM but becomes toxic to cell growth at levels of 5.0 µM and above (unpublished data), and with 
inhibitor 6 that is maximally effective at 5.0 µM but toxic at 10.0 µM [45]. These data also suggest that 
MK2 inhibitors may not be as useful therapeutically as p38 inhibitors if the accelerated cell aging seen 
in WS does underlie the accelerated whole body aging, as suggested [2], but may prove useful in the 
alleviation of the associated inflammatory conditions that are thought to be MK2 dependent [29].  
Pharmaceuticals 2015, 8 267 
 
 
As inflammatory conditions that may be due to MK2 activation are an increasing issue during the 
normal human aging process [56], such inhibitors may be of wider therapeutic benefit in the general 
population. This then provides a good rationale for the continued efforts to find suitable MK2 
inhibitors for in vivo use. 
3. Experimental Section 
3.1. Synthetic Materials and Methods 
Commercially available reagents were used without further purification; solvents were dried by 
standard procedures. Light petroleum refers to the fraction with bp 40–60 °C and ether (Et2O) refers to 
diethyl ether. Column chromatography was carried out using Merck Kieselgel 60 H silica or Matrex 
silica 60. Analytical thin layer chromatography was carried out using aluminium-backed plates coated 
with Merck Kieselgel 60 GF254 that were visualised under UV light (at 254 and/or 360 nm). 
Microwave irradiation experiments were performed in a sealed Pyrex tube using a self-tunable CEM 
Discover or CEM Explorer focused monomodal microwave synthesizer at the given temperature using 
the instrument’s in-built IR temperature measuring device, by varying the irradiation power (initial 
power given in parentheses). 
Fully characterized compounds were chromatographically homogeneous. Melting points (mp) were 
determined on a Kofler hot stage apparatus or Stanford Research Systems Optimelt and are uncorrected. 
Infra–red (IR) spectra were recorded in the range 4000–600 cm−1 on a Perkin-Elmer 1600 series FTIR 
spectrometer using an ATR probe or as a KBr disk (KBr) and are reported in cm−1. Nuclear magnetic 
resonance (NMR) spectra were recorded in CDCl3 at 25 °C unless stated otherwise using a Varian 
VNMRS instrument operating at 400 or 500 MHz or a Bruker DPX 400 or 500 Avance instrument 
operating at 400 or 500 MHz for 1H spectra and 100 or 126 MHz for 13C spectra and were reported in 
ppm; J values were recorded in Hz and multiplicities were expressed by the usual conventions  
(s = singlet, d = doublet, t = triplet, app = apparent, m = multiplet, br = broad). Mass spectra (MS) 
were determined with a Fisons VG Platform II Quadrupole instrument using atmospheric pressure 
chemical ionization (APcI), a Waters Q-TOF Ultima using electrospray positive ionization (ES), a 
Waters LCT premier XE using atmospheric pressure chemical ionization (APcI), an Agilent 6130 
single quadrupole with an APcI/electrospray dual source, a Fisons Instrument VG Autospec using 
electron ionization (EI) at 70 eV (low resolution) or a ThermoQuest Finnigan LCQ DUO electrospray, 
unless otherwise stated. Some high-resolution mass spectra were obtained courtesy of the EPSRC 
Mass Spectrometry Service at Swansea, UK using the ionisation methods specified. In vacuo refers to 
evaporation at reduced pressure using a rotary evaporator and diaphragm pump, followed by the 
removal of trace volatiles using a vacuum (oil) pump. 
3.2. General Synthetic Procedures 
General Procedure for Suzuki-Miyaura Cross-Coupling 
A solution of 2-chloro-6-nitroquinoline, boronic acid (1.5–1.6 equiv.), aqueous Na2CO3 solution  
(2 equiv.) and PdCl2(PPh3)2 (10 mol%) in MeCN (0.2 M) was irradiated at 140 °C for 15 min in a 
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pressure-rated glass tube (35 mL) using a CEM Discover microwave synthesizer by moderating the 
initial power (200 W). After cooling in a flow of compressed air, the solvent was evaporated in vacuo 
and the residue was triturated with water. Purification by flash column chromatography on SiO2 gave 
the desired 2-pyridinyl-6-nitroquinoline. 
3.3. Synthetic Experimental Procedures 
3.3.1. 3,4-Dihydro-6-nitroquinolin-2(1H)-one (13) 
According to a known literature procedure [51], concentrated sulfuric acid (20 mL) was added to 
3,4-dihydro-2-(lH)-quinoline (12) (1.00 g, 6.79 mmol) in a 100 mL round-bottom flask. The reaction 
was placed into an ice-acetone bath (−10 °C approx.) and stirred to dissolve the solid. Nitric acid 
(69%; 0.50 mL, 11.3 mmol, 1.7 equiv.) was added dropwise and the orange-red solution was stirred at 
−10 to 0 °C for 30 min. The reaction was quenched by pouring onto a stirred ice-water slush (300 mL). 
The ice was allowed to melt and the precipitate was collected by vacuum filtration, washed with water 
and air dried under suction to give a beige-coloured solid (1.21 g, 93%), with identical physical and 
spectroscopic properties to literature data [51]. 
3.3.2. 2-Chloro-6-nitroquinoline (11) 
POCl3 (1.2 mL, 13.0 mmol) was added dropwise to a stirred solution of 13 (1.00 g, 5.2 mmol) and 
DDQ (1.30 g, 5.7 mmol) in DMF (20 mL) and the reaction mixture was stirred at RT for 1 h. The 
reaction mixture was then poured into iced water and the resultant precipitate was collected by vacuum 
filtration, washed with water and dried in air to give the title compound (1.05 g, 97%) as an orange 
solid, mp 226.8–227.9 °C (lit. [51] mp 235.5–236.5 °C) (Found [ES]: MH+, 209.0112. C9H6ClN2O2 
[MH] requires 209.0112); IR (neat) νmax/cm−1 3068 (C-H), 1619 (C=C), 1523 (NO2), 1485 (C=C), 1337 
(NO2), 1105 (C-N); 1H-NMR (500 MHz, d6-DMSO) δH/ppm 9.13 (1H, d, J 2.5, 5-CH), 8.78 (1H, d, J 
9, 4-CH), 8.52 (1H, dd, J 9, 2.5, 7-CH), 8.18 (1H, d, J 9, 8-CH), 7.84 (1H, d, J 9, 3-CH); 13C-NMR  
(126 MHz, d6-DMSO) δC/ppm 153.6 (C), 149.2 (C), 145.3 (C), 141.9 (4-CH), 129.7 (8-CH), 125.9 (C), 
125.0 (5-CH), 124.4 (3-CH), 124.1 (7-CH); m/z (EI) 208 (M•+, 100), 162 (48), 150 (49), 127 (81). 
3.3.3. 2-(6-Methylpyridin-3-yl)-6-nitroquinoline (9a) 
Biaryl 9a was prepared according to general synthetic procedure 3.2.1 using 2-chloro-6-
nitroquinoline (11) (0.45 g, 2.20 mmol), 6-methyl-3-pyridinylboronic acid (10a) (0.44 g, 3.20 mmol), 
aqueous Na2CO3 solution (1.5 M; 3 mL) and PdCl2(PPh3)2 (0.15 g, 0.21 mmol) in MeCN (12 mL). 
Purification by column chromatography on SiO2 gel, gradient eluting with CH2Cl2 to CH2Cl2–MeOH 
(9:1), gave the title compound (0.39 g, 69%) as an orange solid, mp 237.5–239.1 °C (Found [ES]: 
MH+, 266.0923. C15H12N3O2 [MH] requires 266.0924); IR (neat) νmax/cm−1 3070 (C-H), 2921 (C-H), 
1596 (C-C), 1534 (NO2), 1327 (NO2); 1H-NMR (500 MHz, CDCl3) δH/ppm 9.30 (1H, d, J 1, 2'-CH), 
8.82 (1H, d, J 2, 5-CH), 8.50 (2H, 4'-CH and 7-CH), 8.43 (1H, d, J 9, 4-CH), 8.28 (1H, d, J 9, 8-CH), 
8.05 (1H, d, J 9, 3-CH), 7.36 (1H, d, J 8, 5'-CH), 2.68 (3H, s, Me); 13C-NMR (126 MHz, CDCl3)  
δC/ppm 160.6 (C), 158.2 (C), 150.4 (C), 148.4 (2'-CH), 145.5 (C), 138.7 (4-CH), 135.4 (4'-CH), 131.4 
(8-CH), 131.3 (C), 126.0 (C), 124.3 (5-CH), 123.4 (7-CH), 123.4 (5'-CH), 120.0 (3-CH), 24.5 (Me). 
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3.3.4. 2-(Pyridin-3-yl)-6-nitroquinoline (9b) 
Biaryl 9b was prepared according to the general procedure 3.2.1 using 2-chloro-6-nitroquinoline 
(11) (0.15 g, 0.71 mmol), 3-pyridinylboronic acid (10b) (0.10 g, 1.14 mmol), aqueous Na2CO3 (1.4 M, 
1 mL) and PdCl2(PPh3)2 (0.05 g, 0.07 mmol) in MeCN (3.6 mL). Purification by column 
chromatography on SiO2 gel, eluting with EtOAc–CH2Cl2 (3:7), gave the title compound (0.11 g, 62%) 
as a yellow solid (Found [ES]: MH+, 252.0776. C14H10N3O2 [MH] requires 252.0767); IR (neat) νmax/cm−1 
3081 (C-H), 1607 (C=C), 1528 (NO2), 1337 (NO2); 1H-NMR (500 MHz, CDCl3) δH/ppm 9.43 (1H, br 
s, 2'-CH), 8.84 (1H, d, J 2, 5-CH), 8.78 (1H, d, J 3, 6'-CH), 8.58 (1H, d, J 8, 4'-CH), 8.53 (1H, dd, J 9, 
2, 7-CH), 8.48 (1H, d, J 8, 4-CH), 8.31 (1H, d, J 9, 8-CH), 8.08 (1H, d, J 9, 3-CH), 7.52 (1H, m,  
5'-CH); 13C-NMR (126 MHz, CDCl3) δC/ppm 158.0 (C), 151.2 (6'-CH), 150.4 (C), 149.0 (2'-CH), 
138.9 (4-CH), 135.2 (4'-CH), 131.6 (8-CH), 128.5 (C), 128.4 (C), 126.1 (C), 124.3 (5-CH), 123.8 (C), 
123.5 (7-CH), 120.2 (3-CH); m/z (EI) 251 (M•+, 100), 205 (35). 
3.3.5. 6-Amino-5-cyanoquinoline (15) 
6-Nitroquinoline (0.50 g, 2.85 mmol) was added to a solution of ethyl cyanoacetate (0.91 mL,  
8.61 mmol) and KOH (0.97 g, 17.0 mmol) in DMF (8.7 mL) and the mixture was stirred for 64 h. The 
solvent was evaporated in vacuo and the residue was dissolved in aqueous NaOH solution (5%; 12 mL) 
and heated at reflux for 3 h. The reaction mixture was allowed to cool and extracted with CHCl3  
(3 × 15 mL). The organic extracts were combined, dried (MgSO4) and evaporated in vacuo. Purification 
by flash column chromatography on SiO2 gel, gradient eluting with CH2Cl2 to CH2Cl2–MeOH (9:1), 
gave the title compound (0.35 g, 72%) as an orange solid, mp 181.2–182.8 °C (lit. [57] mp 181 °C) 
(Found [ES]: MH+, 170.0711. C10H8N3 [MH] requires 170.0713); IR (neat) νmax/cm−1 3391 (N-H), 
3337 (N-H), 3159 (C-H), 2199 (C≡N), 1635 (N-H), 1615 (C=C), 1337 (C-N); 1H-NMR (500 MHz, 
CDCl3) δH/ppm 8.74 (1H, d, J 3, 2-CH), 8.24 (1H, d, J 8, 4-CH), 8.06 (1H, d, J 9, 8-CH), 7.47 (1H, m, 
3-CH), 7.15 (1H, d, J 9, 7-CH), 4.93 (2H, br s, NH2); 13C-NMR (126 MHz, CDCl3) δC/ppm 150.3  
(6-C), 147.7 (2-CH), 142.4 (C), 136.0 (8-CH), 131.2 (4-CH), 128.9 (C), 123.4 (3-CH), 120.2 (7-CH), 
116.1 (CN), 86.9 (5-C). 
3.3.6. 3-Amino-1-(3-bromophenyl)-1H-pyrazole (21) 
A solution of 3-bromophenyl hydrazine hydrochloride (1.36 g, 6.00 mmol), 3-methoxyacrylonitrile 
(1.0 mL, 12.0 mmol) and NaOEt (1.77 g, 26.0 mmol) in dry EtOH (30 mL) was heated at reflux for  
20 h. After cooling the mixture to room temperature, water was added and the resultant precipitate was 
filtered, washed with water and finally dissolved in CH2Cl2. The organic extract was washed 
successively with water and brine, dried (MgSO4) and evaporated in vacuo to give the title compound 
(1.29 g, 90%) as a yellow solid, with identical physical and spectroscopic properties to literature data [54]. 
3.3.7. 3-Amino-1-[3-(1H-indol-6-yl)phenyl]-1H-pyrazole (23) 
A mixture of 3-amino-1-(3-bromophenyl)-1H-pyrazole (21) (0.20 g, 0.84 mmol), 6-indolylboronic 
acid (22) (0.13 g, 0.25 mmol), caesium carbonate (0.55 g, 1.68 mmol) and Pd(PPh3)4 (0.10 g, 0.08 mmol) 
in DMF (4 mL) was irradiated at 150 °C for 2 h in a sealed pressure-rated glass tube (10 mL) using  
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a CEM Discover microwave synthesizer by moderating the initial power (150 W). The mixture was 
cooled by passing a stream of compressed air through the microwave cavity and water was added  
(10 mL). The aqueous layer was extracted with EtOAc (3 × 20 mL) and the organic extracts were 
combined, washed with brine, dried (MgSO4) and evaporated in vacuo. Purification by column 
chromatography on silica gel, eluting with hexane–EtOAc (1:1 v/v) gave the title compound [53] (0.19 g, 
84%) as a colorless solid, mp 97–99 °C (Found: M•+, 274.1218. C17H14N2 [M] requires 274.1222); IR 
(KBr) νmax/cm−1 3411 (NH), 2922 (CH), 1626, 1604, 1586, 1479; 1H-NMR (400 MHz; d6-DMSO) 
δH/ppm 11.18 (1H, s, exch. D2O, NH), 8.26 (1H, d, J 2.6, H-5), 7.96 (1H, m, H-2'), 7.69 (1H, m, H-7''), 
7.63 (1H, d, J 8.3, H-6'), 7.58 (1H, m, H-5'), 7.46–7.41 (3H, H-4', H-2'' and H-4''), 7.35 (1H, dd, J 8.3, 
1.6, H-4''), 6.47 (1H, m, H-3''), 5.76 (1H, d, J 2.6, H-4), 5.17 (2H, s, exch. D2O, NH2); 13C-NMR (100 
MHz, d6-DMSO) δC/ppm 157.5 (C), 134.3 (C), 141.0 (C), 137.0 (C) 133.5 (C), 130.2 (C), 128.5 (CH), 
127.9 (CH), 126.8 (CH), 122.7 (CH), 120.9 (CH), 118.8 (CH), 115.2 (CH), 114.9 (CH), 110.0 (CH), 
101.5 (CH), 96.7 (CH); m/z (EI) 275 (MH+, 100%), 274 (M•+, 100), 273 (19), 246 (7), 205 (6), 191 (9), 
133 (14), 84 (21). 
3.3.8. 3-Amino-4-bromo-1-(3-bromophenyl)-1H-pyrazole (25) 
A solution of 3-amino-1-(3-bromophenyl)-1H-pyrazole (21) (0.16 g, 0.68 mmol) and NBS (0.120 g, 
0.68 mmol) in THF (10 mL) was stirred at room temperature for 16 h and then the solvent was 
vaporated in vacuo. The residue was dissolved in EtOAc, filtered through Celite and evaporated  
in vacuo. Purification by column chromatography on silica gel, eluting with hexane–EtOAC (3:1 v/v), 
gave the title compound (0.18 g, 83%) as a brown solid, mp 93–95 °C (Found: M•+, 314.9005. 
C9H779Br2N3 [M] requires 314.9007); IR (KBr) νmax/cm−1 3415, 3312, 3213, 1629, 1594, 1556; 1H-NMR 
(400 MHz; d6-DMSO) δH/ppm 8.55 (1H, s, H-5), 7.88 (1H, m, H-2'), 7.67 (1H, m, H-5'), 7.37–7.35 
(2H, m, H-4' and H-6'), 5.38 (2H, s, exch. D2O, NH2); 13C-NMR (100 MHz, d6-DMSO) δC/ppm 159.9 
(C), 142.5 (C), 131.8 (CH), 128.6 (CH), 127.5 (CH), 122.7 (C), 119.3 (CH), 115.1 (CH), 85.2 (C); m/z 
(EI) 275 (MH+, 100%); 319 (C9H781Br2N3•+, 61) 317 (C9H781Br79BrN3•+, 30), 315 (C9H779Br2N3•+, 17), 
220 (42), 205 (100), 189 (8), 177 (14), 145 (15), 105 (12). 
3.3.9. 3-Amino-1-(4-methoxyphenyl)-1H-pyrazole (28) 
The title compound was prepared as a yellow solid, exactly in accordance with our previously 
published microwave-assisted procedure [54]. 
3.3.10. 3-Amino-4-bromo-1-(4-methoxyphenyl)-1H-pyrazole (29) 
A solution of 3-amino-1-(4-methoxyphenyl)-1H-pyrazole (28) (0.13 g, 0.68 mmol) and NBS (0.12 g, 
0.68 mmol) in THF (4 mL) was irradiated at 150 °C for 2 h in a sealed pressure-rated glass tube  
(10 mL) using a CEM Discover microwave synthesizer by moderating the initial power (150 W). The 
mixture was cooled by passing a stream of compressed air through the microwave cavity and 
evaporated in vacuo. The residue was dissolved in EtOAc, filtered through Celite and the solvent was 
evaporated in vacuo. Purification by column chromatography on silica gel, eluting with hexane–EtOAc 
(3:1 v/v), gave the title compound (0.14 g, 77%) as a brown solid, mp 93–96 °C (Found: M•+, 
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267.0015. C10H1079BrN3O [M] requires 267.0007) IR (KBr) νmax/cm−1 3353 (NH), 1548, 1516, 1403, 
1245, 1084, 1041; 1H-NMR (400 MHz; d6-DMSO) δH/ppm 8.34 (1H, s, H-5), 7.57 (2H, d, J 9.0, H-2' 
and H-6'), 6.98 (2H, d, J 9.0, H-3' and H-5'), 5.15 (2H, s, exch. D2O, NH2), 3.76 (3H, s, OMe);  
13C-NMR (100 MHz, d6-DMSO) δC/ppm 157.0 (C), 155.5 (C), 134.2 (C), 127.8 (CH), 118.5 (CH), 
114.9 (CH), 95.3 (C), 55.8 (Me); m/z (EI) 269 (C10H1081BrN3O•+, 97), 267 (C10H1079BrN3O•+, 100). 
3.3.11. 3-Amino-4-(4-aminocarbonylphenyl)-1-(4-methoxyphenyl)-1H-pyrazole (26) 
A mixture of 3-amino-4-bromo-1-(4-methoxyphenyl)-1H-pyrazole (29) (0.15 g, 0.55 mmol),  
4-carbamoylphenylboronic acid (30) (90 mg, 0.54 mmol), K2CO3 (0.20 g, 1.44 mmol) and 
PdCl2(PPh3)2 (40 mg, 0.05 mmol) in iPrOH–H2O (1:1 v/v) (5 mL) was irradiated at 150 °C for 2 h in a 
sealed pressure-rated glass tube (10 mL) using a CEM Discover microwave synthesizer by moderating 
the initial power (150 W). The mixture was cooled by passing a stream of compressed air through the 
microwave cavity and water was added (10 mL). The aqueous layer was extracted with EtOAc  
(2 × 20 mL) and the organic extracts were combined, washed with brine, dried (MgSO4) and 
evaporated in vacuo. Purification by column chromatography on silica gel, eluting with hexane–EtOAc 
(1:3 v/v), gave the title compound (90 mg, 54%) as a cream solid, mp 251–253 °C (Found: M•+, 
308.1281. C17H16N4O2 [M] requires 308.1273); IR (KBr) νmax/cm−1 3389 (NH), 1653 (C=O), 1554, 
1522, 1399, 1106; 1H-NMR (400 MHz; d6-DMSO) δH/ppm 8.59 (1H, s, H-5), 7.96 (1H, br s, exch. 
D2O, NHH), 7.90 (2H, d, J 8.4, H-2' and H-6'), 7.69 (2H, d, J 7.6, H-3'' and H-5''), 7.67 (2H, d, J 7.6, 
H-2'' and H-6''), 7.31 (1H, br s, exch. D2O, NHH), 7.02 (2H, d, J 8.4, H-3' and H-5'), 5.18 (2H, s, exch. 
D2O, NH2), 3.51 (3H, s, OMe); 13C-NMR (100 MHz, d6-DMSO) δC/ppm 168.2 (C), 158.3 (C), 155.5 
(C), 135.1 (C), 133.6 (C), 132.1 (C), 128.9 (CH), 126.5 (CH), 125.5 (CH), 119.5 (CH), 116.7 (CH), 
56.0 (Me); m/z (EI) 308 (M•+, 100). 
3.4. Biological Procedures 
Werner syndrome fibroblast strains AG03141F, AG05229C and AG05229D were obtained from the 
Coriell Cell Repository (Camden, NJ, USA). All cells were cultured and treated with p38 and MK2 
inhibitors and grown to replicative senescence as described previously [45]. The replicative lifespan 
for inhibitor treated cells is measured as a percentage of the experimental lifespan seen in the 
respective control (non-inhibitor treated) cells for each cell strain. The results are plotted as mean ± 
standard deviation. The assay to detect F-actin stress fibres and cellular morphological changes using 
phalloidin-FITC is exactly as described previously [45]. 
4. Conclusions 
Suzuki-Miyaura cross-coupling reactions have been investigated for the synthesis of three different 
MK2 inhibitors for study in WS cells. Towards the synthesis of PF-3644022, cross-coupling of  
a 2-chloroquinoline with a 3-pyridinylboronic acid provided the desired biaryl target but the pyridine 
moiety and the chloroquinoline precursor both proved incompatible with the subsequent Yamazaki 
cyanation of a 6-nitroquinoline, en route to the benzothiophene ring. Thus, although a relatively  
early-stage Suzuki-Miyaura coupling would appear incompatible with this cyanation method, 
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alternative strategies for the incorporation of the 3-aminobenzo[b]thiophene moiety could be envisaged 
and thus incorporated with this transformation [58]. Towards the synthesis of a 3-aminopyrazole MK2 
inhibitor, bearing a 1-[(6-indolyl)phenyl] substituent, the Suzuki-Miyaura cross-coupling reaction 
established one biaryl linkage, but the unprotected indole group interfered with the subsequent NBS 
bromination required to set up the second Suzuki-Miyaura coupling. Use of a simpler 3-aminopyrazole 
circumvented this problem and provided an MK2 inhibitor for study in WS cells. In all cases with 
simple aryl bromides, the Suzuki-Miyaura cross-coupling reactions were reliable and relatively 
efficient. The synthesis of the 3-amino-1-(4-methoxyphenyl)pyrazole MK2 inhibitor proceeded in  
three steps and 35% overall yield from commercially-available materials, each step complete in 2 h 
under microwave irradiation. This constitutes an extremely rapid method for access to this chemical 
tool, of value in elucidating the role of MK2 in accelerated aging in this progeroid syndrome. Although 
MK2 inhibitors may not be as useful therapeutically as p38 inhibitors, if the accelerated cell aging seen 
in WS does underlie the accelerated whole body aging, they may prove useful in the alleviation of the 
associated inflammatory conditions that are thought to be MK2 dependent and have certainly helped to 
suggest a role for p38-activated MK2 in replicative senescence in WS fibroblasts. 
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Microwave-assisted synthesis of 3-aminobenzo[b]-
thiophene scaﬀolds for the preparation of kinase
inhibitors†
Mark C. Bagley,*a Jessica E. Dwyer,a Maria D. Beltran Molina,b Alexander W. Rand,a
Hayley L. Randa and Nicholas C. O. Tomkinsonb
Microwave irradiation of 2-halobenzonitriles and methyl thioglycolate in the presence of triethylamine in
DMSO at 130 °C provides rapid access to 3-aminobenzo[b]thiophenes in 58–96% yield. This transform-
ation has been applied in the synthesis of the thieno[2,3-b]pyridine core motif of LIMK1 inhibitors, the
benzo[4,5]thieno[3,2-e][1,4]diazepin-5(2H)-one scaﬀold of MK2 inhibitors and a benzo[4,5]thieno[3,2-d]-
pyrimidin-4-one inhibitor of the PIM kinases.
Introduction
Benzothiophenes are naturally-occurring heterocycles, found
in petroleum deposits in their simplest form but also discov-
ered recently as a motif in more complex glycosides isolated
from the roots of E. grijissii.1 Benzothiophenes are important
components of organic semiconductors due to their potential
for elongated and highly delocalised electronic structures.2,3
Substituted benzothiophenes have also found application in
drug discovery as highly-privileged structures and valuable
building blocks in medicinal chemistry, being incorporated
into tubulin polymerisation inhibitors,4,5 acetyl-CoA carboxy-
lase inhibitors,6 antidepressants,7 and as estrogen receptor
modulators.8,9 Benzothiophenes are present in a number of
clinical agents, including Raloxifene,10 a selective estrogen
receptor modulator, Zileuton,11 an inhibitor of 5-lipoxygenase
and leukotriene biosynthesis used for the treatment of
asthma, and the antifungal agent Sertaconazole, which inhi-
bits the synthesis of ergosterol.12
Scaﬀolds based upon 2- or 3-aminobenzo[b]thiophenes
have enormous potential for further derivatization and have
shown great promise in fragment-based drug discovery and in
hit identification or lead development, including approaches
towards antimitotic agents5,13 and in the development of
inhibitors of kinase targets, such as the LIMK protein family,14
PIM-kinases15 and MAPK-2 kinase (MK2) (Fig. 1).16,17 A
number of 3-aminothieno[2,3-b]pyridine-2-carboxamide hits,
such as 1, were identified from high throughput screening
(HTS) as inhibitors of LIMK1, leading to the development of
tricyclic derivatives such as 2a and the benzothieno[3,2-d]pyri-
Fig. 1 Aminobenzothiophene scaﬀolds in drug discovery.
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midine 2b as a LIMK1 inhibitor lead candidate, to disrupt
actin polymerisation and thus prevent the metastatic potential
of tumour cells where LIMK is over-expressed.14
Benzothienopyrimidinones have been investigated as PIM
kinase inhibitors.15 The PIM kinases (PIM1, PIM2 and PIM3)
have been implicated in tumourigenesis and simultaneous tar-
geting of all three isoforms has presented itself as a promising
approach in cancer therapy, with PIM triple knockout mice
found to be viable and fertile.18 The benzothiophene scaﬀold
was again identified from an initial HTS hit,15 leading to the
development of a range of potent and selective benzo[b]thio-
phene-derived inhibitors such as 3 with nM activity (Ki values
of 2, 3 and 0.5 nM against PIM1, PIM2 and PIM3, respectively)
with oral bioavailability in mouse models.
Examples of aminobenzothiophene derivatives are also
found amongst inhibitors of the mitogen activated protein
kinase (MAPK) family of enzymes. These enzymes are essential
for inflammatory cell signalling events and contain historically
popular drug targets for inflammatory diseases, including
rheumatoid arthritis and Crohn’s disease because of their
involvement in the production of pro-inflammatory cyto-
kines,19 as well as being implicated in accelerated cellular
ageing in Werner syndrome (WS) via p38.20–23 MAPK-activated
protein kinase (MK2) is a rate-limiting kinase downstream of
p38 in the MAPK pathway and has been the subject of many
studies in recent years,24 as MK2 knock-out mice possess
normal healthy phenotypes whereas p38 knock-out mice are
lethal.25 The aminobenzo[b]thiophene derivative PF-3644022
shows excellent kinase selectivity for MK2, in vivo potency on a
nanomolar scale and projected ADME characteristics that
suggested it was suitable for oral human dosing.17,26,27 However,
PF-3644022 was found to result in hepatotoxicity in dogs27 and
so the analogue PF029 was developed and exhibited an improved
toxicological profile with no loss of cellular potency. This was
rationalized through installation of a metabolic shunt onto the
reactive diazepinone ring and extension of the biaryl ring section
to increase the compound’s cationic character, thus reducing its
molecular aﬃnity for transporter proteins.
As part of our interest in the synthesis of MAPK inhibitors
for the study of cellular ageing in Werner syndrome,20,28–33 the
benzothiophene scaﬀold, and its selectivity and cellular activity
profile for MK2 exemplified by PF-3644022, made it an attractive
target for synthesis. We have shown that treating young WS cell
cultures with p38 MAPK inhibitors can bring about a complete
reversal of the ageing phenotype, giving increased replicative
life-span, growth rates comparable to normal young cells and a
reduction in levels of F-actin stress fibres.20,23 These findings
suggested that WS could be amenable to therapeutic interven-
tion, but with high toxicity and poor kinase selectivity exhibited
in vivo by many p38 inhibitors,34–36 an inhibitor scaﬀold that
targeted the downstream kinase MK2 would oﬀer a promising
alternative target.20,37
With such a range of biological properties, there is a conti-
nuing interest in the search for new methods to access substi-
tuted benzothiophenes.38 One approach, with the potential to
incorporate diversity into a target library, would be to employ
transition metal-mediated processes from the corresponding
3-halobenzo[b]thiophenes.39 However, methods for the syn-
thesis of 3-halobenzo[b]thiophenes are currently fairly limited.
In particular, routes can be problematic when using ring halo-
genation due to the low reactivity of the heteroaryl unit and its
functional group compatibility.40–43 The 5-endo-dig halocyclisa-
tion of ortho-alkynylaryl thiophenol derivatives oﬀers an
alternative approach,44–48 but this requires installation of an
alkyne by metal-catalyzed cross-coupling followed by cyclisa-
tion, mediated by a halogen-containing electrophile, so can
exhibit a number of inherent disadvantages.
Herein, we present an annulation-based method for the
rapid preparation of 3-halo and 3-amino-2-substituted benzo-
[b]thiophenes suitable for elaboration to a range of kinase
inhibitors.49 It employs microwave irradiation as a convenient
platform for fast reaction kinetics, and to improve reaction
eﬃciency, and avoids the need for metal-catalyzed processes to
establish the parent heterocycle. This method is shown to be
suitable to access the pharmacophore of a range of biologi-
cally-active scaﬀolds for application in medicinal chemistry
and drug discovery.
Results and discussion
The benzothiophene-containing chemotypes appearing in
recent drug discovery programmes (Fig. 1) feature, or could in
principle be derived from, electron-poor aminobenzothio-
phene intermediates or their 7-aza analogues (Scheme 1). For
Scheme 1 Benzothiophene precursors to kinase inhibitors.
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example, the PIM kinase inhibitor scaﬀold 4 has been
accessed from 5-bromobenzothiophene 5a, using the halogen
as a handle for library diversification in a late-stage Suzuki
coupling.15 Similarly, it could be hypothesized that inhibitors
of MK2 for study in WS cells, such as PF-3644022 (Fig. 1),
could be prepared from the same core motif 5, using 5-nitro-
benzothiophene 5b, rather than by the functionalization of
6-nitroquinoline as reported by Anderson et al.17 This
approach would enable the synthesis of a range of diverse
chemical tools from a single common template. The original
route to MK2 hit compound 6a, prior to the development of
PF-3644022,16 employed cinnamic acid 8a in reaction with
thionyl chloride in chlorobenzene at 120 °C to establish the
3-chlorobenzothiophene scaﬀold 7a (Scheme 1).50 Unfortu-
nately this route would be wholly inappropriate for the syn-
thesis of benzothiophene 7b for elaboration to the desired
intermediate 6b on route to PF-3644022, as altering the substi-
tuent-directing eﬀects to a nitro group results in poor yields
and inseparable mixtures of 7b and 7c in the benzothiophene
synthesis, as well as giving other side products, as reported by
Higa.51 Hence an alternative route had to be sought.
Our first approach towards scaﬀold 6b used an alternative
and established method to access 3-halobenzothiophenes by
halogenation of the corresponding benzothiophene.40 The
condensation of methyl thioglycolate with 2-chloro-5-nitrobenz-
aldehyde (9) under basic conditions gave methyl 5-nitrobenzo[b]-
thiophene-2-carboxylate (10) in high yield (Scheme 2). We have
shown in previous work how microwave dielectric heating can
be used to dramatically reduce reaction times in the synthesis
of inhibitor scaﬀolds.30,32,33,37,52 Given that elevated tempera-
ture has promoted this,53,54 and a closely-related process for
the synthesis of 2-acetylbenzothiophenes,55 we carried out this
transformation under microwave irradiation at 90 °C to give
the benzothiophene 10 in good yield, whilst shortening the
reaction time from 17 h to 15 min. Selective halogenation at
C-3 of 10 was facilitated in a convoluted sequence of reactions
via the carboxylic acid 11 to overcome poor heterocycle reactiv-
ity.40 Saponification, again conducted by microwave dielectric
heating, under basic conditions was complete in 3 min at
100 °C and gave the carboxylic acid 11 in excellent yield. Sub-
sequent heating with excess bromine and sodium acetate in
glacial acetic acid did give 3-bromobenzothiophene 13 in good
yield after esterification using methyl iodide on a number of
occasions. However, the bromination was found to be highly
variable and eﬀorts to develop an alternative process using
microwave heating were constantly frustrated56 and so a more
reliable and eﬃcient route was sought. The poor yield of this
bromination reaction is catalogued in a recent report.57
In an alternative approach, our success in the microwave-
assisted synthesis of 10 was adapted to incorporate an amino
group at C-3, amenable by diazotization chemistry to provide
eﬃcient access to 3-bromobenzothiophene 13. The cyclocon-
densation of methyl thioglycolate with 2-nitrobenzonitriles
under basic conditions has been established by Beck,58–60 and
adapted methods with halide displacement have also been
reported.61–64 By switching the base from NaOMe61 to Et3N63
and heating either 5-bromo-2-fluorobenzonitrile (14a) or
2-fluoro-5-nitrobenzonitrile (14b) and methyl thioglycolate
gave the corresponding 3-aminobenzothiophene 5a,b in very
high yield (Scheme 3), e.g. for 5b either at 100 °C in DMSO for
2 h using conductive heating (95% yield) or under microwave
irradiation at 130 °C for 11 min (94% yield), after simply
pouring the reaction mixture into ice-water and collecting the
product by filtration. Subsequent deaminative bromination60
of aminobenzo[b]thiophene 5b using tert-butyl nitrite in aceto-
nitrile in the presence of copper(II) bromide gave the target
bromobenzothiophene 13 in excellent yield by this much more
direct route.
The scope of this method was further explored by investi-
gating a number of substrates (Scheme 4, Table 1), suitable for
Scheme 2 Reagents and conditions: (i) K2CO3, DMF, RT, 17 h; (ii)
K2CO3, DMF, microwaves, 90 °C, 15 min; (iii) NaOH, MeOH–H2O, reﬂux,
3 h; (iv) NaOH, MeOH–H2O, microwaves, 100 °C, 3 min; (v) Br2, AcOH,
NaOAc, 55 °C, 48 h; (vi) MeI, K2CO3, DMF, RT, 3 h.
Scheme 3 Reagents and conditions: (i) Et3N, DMSO, 100 °C, 2 h; H2O;
(ii) Et3N, DMSO, microwaves, 130 °C, 11 min; H2O; (iii) tert-BuONO,
CuBr2, MeCN, 0 °C; RT, 2 h; HCl (aq.).
Scheme 4 Synthesis of benzothiophenes 5a–h and 7-aza–16.
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elaboration to a range of benzothiophene-containing scaﬀolds
found in drug discovery (Fig. 1).
It was found that the process was most eﬃcient for highly
electron-poor precursors, such as 14a–d (entries 1–4), and was
generally most eﬀective with 2-fluorides, but could also accom-
modate bromides and iodides albeit with reduced eﬃciency
(Table 1, entries 8 and 9). In most cases a very simple work up
procedure was eﬀective, providing benzothiophenes 5a–h in
65–96% yield in reaction times varying between 11 and
35 min, depending upon substrate. The eﬃciency compared
well to other available methods (cf. Table 1, entry 7, with Beck
synthesis of 5g,58 52% yield after 20 h), and so this method
was adopted as the route of choice to access the benzothio-
phene scaﬀold. Furthermore, it was possible to apply the pro-
cedure to the synthesis of 7-azabenzothiophene 16 using
2-halonicotinonitriles 15a–c. Interestingly, the choice of
halogen as substrate did not cause much variation in the yield
of azabenzothiophene product 16 (entries 11–13), which rep-
resents the core heterocyclic motif of the 3-aminothieno[2,3-b]-
pyridine-2-carboxamide inhibitors14 of LIMK1.
Having developed this rapid microwave-assisted method to
prepare benzothiophenes, the 5-nitro analogue 13 was further
elaborated to the benzo[4,5]thieno[3,2-e][1,4]diazepin-5(2H)-
one MK2 inhibitor scaﬀold 6b. Buchwald–Hartwig coupling of
(R)-tert-butyl (1-aminopropan-2-yl)carbamate (17) and bromo-
benzothiophene 13 gave a good yield of the N-arylated product
18 under microwave irradiation at 150 °C after 75 min
(Scheme 5). Subsequent Boc-deprotection using TFA and lacta-
mization by treatment with NaOMe using a modified pro-
cedure of Boschelli65 under conductive heating gave the MK2
inhibitor scaﬀold 6b, bearing suitable functionality for further
elaboration, in essentially quantitative yield.
Finally, an application of our microwave-assisted method to
access a pre-functionalized benzothiophene 5i for direct trans-
formation to a benzo[4,5]thieno[3,2-d]pyrimidin-4-one scaﬀold
21 as a chemical tool for PIM kinase inhibition15,66 was investi-
gated. This inhibitor exhibits subnanomolar to single-digit
nanomolar Ki values against all three PIM kinases and has
been co-crystallised with PIM1, guiding subsequent SAR
studies. It was postulated that rather than introducing the
cyclopropylvinyl group by a late-stage Suzuki coupling, in
accordance with the original diversification study, this group
could be incorporated from the start in order to access 20
directly. To that end, 2-fluorobenzonitrile 14i was prepared by
the Pd-catalyzed Suzuki–Miyaura coupling of 5-bromo-2-fluoro-
benzonitrile (14a) and the corresponding boronate ester at
80 °C,15 and heated with methyl thioglycolate in the presence
Table 1 Scope of the microwave-assisted synthesis of 3-amino ben-
zothiophenes 5a–h (Y = NH2) and the 7-aza analogue 16
Entry Substrate R X Z
Time/
mina Product
Yieldb
(%)
1 14a 5-Br F CH 11 5a 96
2 14b 5-NO2 F CH 11 5b 94
3 14c 5-Cl F CH 11 5c 92
4 14d 4-CF3 F CH 18 5d (R = 6-CF3) 80
5 14e 4-NO2 F CH 35 5e (R = 6-NO2) 67
6c 14f 5-Ph F CH 15 5f 85
7 14g H F CH 15 5g 65
8 14g H Br CH 15 5g 23
9 14g H I CH 15 5g 47
10 14h 5-CF3 F CH 20 5h 88
11 15a H F N 15 16 66
12 15b H Cl N 15 16 69
13 15c H Br N 15 16 51
aHold time at the given temperature, as measured by the in-built IR
sensor, by modulation of the initial microwave power. b Isolated yield
of product 5 or 16 after reaction according to Scheme 4, cooling in a
stream of compressed air and pouring the reaction mixture into iced
water. c Product was isolated by aqueous work up, followed by
purification by column chromatography on silica gel.
Scheme 5 Reagents and conditions: (i) Pd(OAc)2 (5 mol%), Cs2CO3,
(±)-BINAP (13 mol%), PhMe, microwaves, 150 °C, 75 min; (ii) TFA, CH2Cl2,
RT, 4.5 h; (iii) NaOMe, MeOH, 50 °C, 2 h; reﬂux, 2 h; HCl (aq.).
Scheme 6 Reagents and conditions: (i) trans-2-cyclopropyl-
vinylboronic acid pinacol ester, Pd(Ph3)2Cl2 (10 mol%), 1 M Na2CO3,
DME/EtOH/H2O, 80 °C, 16 h; (ii) Et3N, DMSO, microwaves, 130 °C,
35 min; (iii) 2-chloroacetonitrile, HCl, dioxane, RT, 16 h; (iv) Me2NH,
EtOH, RT, 16 h; SCX column, MeOH/CH2Cl2; NH3, MeOH.
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of Et3N in DMSO at 130 °C for 35 min under microwave
irradiation to give the corresponding benzothiophene 5i in
reasonable yield after purification by column chromatography
(Scheme 6). The cyclopropylvinyl group was found to be com-
patible with the subsequent chemistry: reaction of 5i with
chloroacetonitrile in 4 N HCl in dioxane gave chloromethyl
derivative 19 which, on reaction with dimethylamine, under-
went further cyclization to give the thienopyrimidinone scaﬀold
20 after purification by immobilization on an acidic resin. Thus
the method delivered this known PIM kinase inhibitor by an
extremely rapid route, suitable for biological study.
Experimental
Materials and methods
Commercially available reagents were used without further
purification; solvents were dried by standard procedures. Light
petroleum refers to the fraction with bp 40–60 °C and ether
refers to diethyl ether. Unless otherwise stated, reactions were
performed under an atmosphere of air. Flash chromato-
graphy was carried out using Merck Kieselgel 60 H silica or
Matrex silica 60. Analytical thin layer chromatography was
carried out using aluminium-backed plates coated with Merck
Kieselgel 60 GF254 that were visualised under UV light (at 254
and/or 360 nm). Microwave irradiation experiments were per-
formed in a sealed Pyrex tube using a self-tunable CEM Discover,
CEM Explorer or Biotage Initiator 2.5 EXP EU focused monomo-
dal microwave synthesizer at the given temperature using the
instrument’s in-built IR temperature measuring device, by
varying the irradiation power (initial power given in parentheses).
Fully characterized compounds were chromatographically
homogeneous. Melting points were determined on a Kofler
hot stage apparatus or Stanford Research Systems Optimelt
and are uncorrected. Specific rotations were measured at the
indicated temperature (in °C) using a ADP440 polarimeter (Bel-
lingham + Stanley) at the sodium D line and are given in deg
cm−3 g−1 dm−1 with concentration c in 10−2 g cm−3. Infra-red
spectra were recorded in the range 4000–600 cm−1 on a Perkin-
Elmer 1600 series FTIR spectrometer using an ATR probe or a
Shimadzu IRAﬃnity-1 equipped with an ATR accessory and are
reported in cm−1. NMR spectra were recorded using a Varian
VNMRS instrument operating at 400 or 500 MHz or a Bruker
Avance III 400 MHz or Bruker Avance DRX 500 MHz for 1H
spectra and 100 or 126 MHz for 13C spectra; J values were
recorded in Hz and multiplicities were expressed by the usual
conventions. Low resolution mass spectra were determined
using a Waters Q-TOF Ultima using electrospray positive
ionization, A Waters LCT premier XE using atmospheric
pressure chemical ionization (APcI), an Agilent 6130 single
quadrupole with an APcI/electrospray dual source, a Fisons
Instrument VG Autospec using electron ionization at 70 eV
(low resolution) or a ThermoQuest Finnigan LCQ DUO electro-
spray, unless otherwise stated. TOFMS refers to time-of-flight
mass spectrometry, ES refers to electrospray ionization, CI refers
to chemical ionization (ammonia), FTMS refers to Fourier trans-
form mass spectrometry, NSI refers to nano-electrospray ioniza-
tion and EI refers to electron ionization. A number of high
resolution mass spectra were obtained courtesy of the EPSRC
Mass Spectrometry Service at University College of Wales,
Swansea, UK using the ionization methods specified.
Synthetic procedures
General procedure for synthesis of 3-aminobenzo[b]thio-
phenes 5 from benzonitriles 14. A mixture of the benzonitrile
14 (1.0 equiv.), methyl thioglycolate (1.05 equiv.) and triethyl-
amine (3.1 equiv.) in dry DMSO (2 M) was irradiated in a
Biotage Initiator 2.5 EXP EU or CEM Discover microwave
synthesizer at 130 °C for the time specified (hold time) by
modulating the initial microwave power. After cooling to room
temperature in a stream of compressed air, the reaction
mixture was poured into ice-water and the resulting solid col-
lected, washed with water and dried in vacuo to give the
desired product.
Methyl 3-amino-5-bromobenzo[b]thiophene-2-carboxylate
(5a). 5-Bromo-2-fluorobenzonitrile (14a) (0.50 g, 2.50 mmol),
methyl thioglycolate (0.22 mL, 2.60 mmol) and triethylamine
(1.10 mL, 7.75 mmol) were reacted according to the above
general procedure for 11 min to give the title compound
(700 mg, 96%) as a brown solid, mp 170–171 °C (Found [ES+]:
285.9535. C10H979BrNO2S [MH] requires 285.9532); IR (neat)
νmax/cm−1 3477 (N–H), 3363 (N–H), 2954 (C–H), 1681 (CvO);
1H NMR (400 MHz, d6-DMSO) δH/ppm 8.44 (1H, d, J = 1.9 Hz,
4-CH), 7.82 (1H, d, J = 8.6 Hz, 7-CH), 7.64 (1H, dd, J = 8.6, 1.9
Hz, 6-CH), 7.17 (2H, bs, NH2), 3.79 (3H, s, Me); 13C NMR
(101 MHz, d6-DMSO) δC/ppm 164.6 (C), 148.6 (C), 137.7 (C),
133.2 (C), 131.0 (C), 125.7 (CH), 125.2 (CH), 117.1 (CH), 96.1
(C), 51.4 (Me); m/z (ES) 286 (M[79Br]H+, 100%).
Methyl 3-amino-5-nitrobenzo[b]thiophene-2-carboxylate
(5b). 2-Fluoro-5-nitrobenzonitrile (14b) (0.50 g, 3.0 mmol),
methyl thioglycolate (0.30 mL, 3.3 mmol) and triethylamine
(1.3 mL, 9.3 mmol) were reacted according to the above general
procedure for 11 min to give the title compound (0.71 g, 94%) as an
orange solid, mp 243.4–244.1 °C (acetone) (lit.,67 mp 244–246 °C)
(Found [FTMS]: 253.0280. C10H9N2O4S [MH] requires 253.0278); IR
(neat) νmax/cm−1 3445 (N–H), 3342 (N–H), 1681 (CvO), 1572
(NO2), 1432 (C–C), 1328 (NO2), 1276 (C–O), 1093 (C–O); 1H NMR
(500 MHz, d6-DMSO) δH/ppm 9.24 (1H, d, J = 2 Hz, 4-CH), 8.29
(1H, dd, J = 9, 2 Hz, 6-CH), 8.12 (1H, d, J = 9 Hz, 7-CH), 7.47 (2H,
bs, NH2), 3.82 (3H, s, Me); 13C NMR (100 MHz, d6-DMSO) δC/ppm
164.2 (C), 149.6 (C), 144.9 (C), 144.5 (C), 131.4 (C), 124.3 (CH),
122.0 (CH), 119.4 (CH), 96.8 (C), 51.4 (Me); m/z (EI) 252 (M•+,
100%), 219 (72). 1H and 13C NMR spectroscopic analyses were in
good agreement with literature data.67
Methyl 3-amino-5-chlorobenzo[b]thiophene-2-carboxylate
(5c). 5-Chloro-2-fluorobenzonitrile (14c) (0.50 g, 3.2 mmol),
methyl thioglycolate (0.30 mL, 3.36 mmol) and triethylamine
(1.38 mL, 9.92 mmol) were reacted according to the above
general procedure for 11 min to give the title compound
(710 mg, 92%) as a colourless solid, mp 170–172 °C (Found
[ES+]: 242.0039. C10H935ClNO2S [MH] requires 242.0037); IR
(neat) νmax/cm−1 3477 (N–H), 3365 (N–H), 1681 (CvO), 1278
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(C–O); 1H NMR (500 MHz, d6-DMSO) δH/ppm 8.30 (1H, d, J =
2.1 Hz, 4-CH), 7.88 (1H, d, J = 8.6 Hz, 7-CH), 7.53 (1H, dd, J =
8.6, 2.1 Hz, 6-CH), 7.17 (2H, bs, NH2), 3.79 (3H, s, Me); 13C NMR
(126 MHz, d6-DMSO) δC/ppm 164.6 (C), 148.7 (C), 137.3 (C),
132.7 (C), 129.1 (C), 128.4 (CH), 125.0 (CH), 122.7 (CH), 96.2 (C),
51.4 (Me); m/z (ES) 242 (M[35Cl]H+, 100%). 1H NMR spectro-
scopic analyses were in good agreement with literature data.15
Methyl 3-amino-6-(trifluoromethyl)benzo[b]thiophene-2-car-
boxylate (5d). 2-Fluoro-4-(trifluoromethyl)benzonitrile (14d)
(0.50 g, 2.64 mmol), methyl thioglycolate (0.24 mL,
2.73 mmol) and triethylamine (1.14 mL, 8.20 mmol) were
reacted according to the above general procedure for 20 min
to give the title compound (580 mg, 80%) as a colourless
solid, mp 159–161 °C (Found [ES+]: 298.0120. C11H8F3NNaO2S
[MNa] requires 298.0124); IR (neat) νmax/cm−1 3471 (N–H),
3344 (N–H), 2964 (C–H), 1664 (CvO); 1H NMR (400 MHz,
d6-DMSO) δH/ppm 8.38–8.32 (2H, 5-CH and 7-CH), 7.72 (1H, d,
J = 8.7 Hz, 4-CH), 7.26 (2H, bs, NH2), 3.82 (3H, s, Me); 13C NMR
(126 MHz, d6-DMSO) δC/ppm 164.5 (C), 148.8 (C), 138.9 (C),
134.1 (C), 128.4 (q, 2JC–F = 31.8 Hz, C), 124.2 (q, 1JC–F = 272.7 Hz,
C), 124.1 (CH), 121.0–120.7 (m, CH), 120.3–120.0 (m, CH), 97.4
(C), 51.5 (Me); m/z (ES) 276 (MH+, 100%).
Methyl 3-amino-6-nitrobenzo[b]thiophene-2-carboxylate (5e).
2-Fluoro-4-nitrobenzonitrile (14e) (0.50 g, 3.00 mmol), methyl
thioglycolate (0.28 mL, 3.15 mmol) and triethylamine
(1.29 mL, 9.30 mmol) were reacted according to the above
general procedure for 35 min to give the title compound
(510 mg, 67%) as a colourless solid, mp 228–231 °C (lit.,58 mp
229–231 °C) (Found [ES+]: 275.0101. C10H8N2NaO4S [MNa]
requires 275.0097); IR (neat) νmax/cm−1 3489 (N–H), 3367 (N–
H), 1697 (CvO), 1624 (C–O); 1H NMR (400 MHz, d6-DMSO) δH/
ppm 8.90 (1H, d, J = 2.1 Hz, 7-CH), 8.37 (1H, d, J = 8.7 Hz,
4-CH), 8.19 (1H, dd, J = 8.7, 2.1 Hz, 5-CH), 7.30 (2H, bs, NH2),
3.83 (3H, s, Me); 13C NMR (101 MHz, d6-DMSO) δC/ppm 164.3
(C), 148.4 (C), 147.0 (C), 138.8 (C), 135.6 (C), 124.2 (CH), 119.8
(CH), 118.5 (CH), 99.8 (C), 51.7 (Me); m/z (ES) 253 (MH+, 20%),
252 (M•+, 100). 1H NMR spectroscopic analyses were in good
agreement with literature data.63
Methyl 3-amino-5-phenylbenzo[b]thiophene-2-carboxylate
(5f). 4-Fluoro-[1,1′-biphenyl]-3-carbonitrile (14f ) (0.30 g,
1.52 mmol), methyl thioglycolate (0.14 mL, 1.59 mmol) and
triethylamine (0.65 mL, 4.74 mmol) were reacted according to
a modified general procedure for 15 min. After cooling in
a stream of compressed air, EtOAc (25 mL) was added and the
solution was washed sequentially with water (3 × 25 mL) and
brine (3 × 25 mL), dried over MgSO4 and evaporated in vacuo.
Purification by flash chromatography on silica gel, eluting
with light petroleum–EtOAc (4 : 1), gave the title compound
(380 mg, 85%) as a colourless solid, mp 96–97 °C (Found [ES+]:
284.0741. C16H14NO2S [MH] requires 284.0740); IR (neat) νmax/
cm−1 3439 (N–H), 3338 (N–H), 2949 (C–H), 1658 (CvO); 1H
NMR (400 MHz, d6-DMSO) δH/ppm 8.54 (1H, s, 4-CH), 7.91
(1H, d, J = 8.5 Hz, 7-CH), 7.84 (1H, d, J = 8.5 Hz, 6-CH), 7.78
(2H, d, J = 7.5 Hz, 2′,6′-PhH), 7.51 (2H, app t, J = 7.5 Hz, 3′,5′-
PhH), 7.39 (1H, t, J = 7.5 Hz, 4′-PhH), 7.26 (2H, bs, NH2), 3.80
(3H, s, Me); 13C NMR (101 MHz, d6-DMSO) δC/ppm 164.8 (C),
149.9 (C), 139.6 (C), 138.0 (C), 136.2 (C), 132.2 (C), 129.0 (CH),
127.5 (CH), 127.2 (CH), 126.7 (CH), 123.6 (CH), 121.0 (CH),
95.0 (C), 51.2 (Me); m/z (ES) 284 (MH+, 100%).
Methyl 3-aminobenzo[b]thiophene-2-carboxylate (5g).
2-Fluorobenzonitrile (14g) (0.16 mL, 1.5 mmol), methyl thio-
glycolate (0.135 mL, 1.5 mmol) and triethylamine (0.63 mL,
4.5 mmol) were reacted according to the above general pro-
cedure for 15 min to give the title compound (203 mg, 65%) as
a purple solid, mp 107.6–107.8 °C (MeOH–H2O) (lit.,58 mp
110–111 °C) (Found [ES+]: 208.0434. C10H10NO2S [MH] requires
208.0432); IR (neat) νmax/cm−1 3434 (N–H), 3337 (N–H), 1659
(CvO), 1520, 1289 (C–O); 1H NMR (500 MHz, d6-DMSO)
δH/ppm 8.13 (1H, d, J = 8.1 Hz, 4-CH), 7.82 (1H, d, J = 8.1 Hz,
7-CH), 7.50 (1H, m, 6-CH), 7.39 (1H, m, 5-CH), 7.15 (2H, bs,
NH2), 3.78 (3H, s, Me); 13C NMR (101 MHz, d6-DMSO) δC/ppm
164.8 (CvO), 149.8 (3-C), 138.8 (7α-C), 131.4 (3α-C), 128.5
(6-CH), 123.8 (5-CH), 123.1 (4-CH), 123.1 (7-CH), 94.4 (2-C),
51.2 (Me); m/z (ES) 207 (M•+, 93%), 176 (30), 175 (100),
147 (34), 146 (37). NMR spectroscopic analyses were in good
agreement with literature data.59,68
Methyl 3-amino-5-(trifluoromethyl)benzo[b]thiophene-2-car-
boxylate (5h). 2-Fluoro-5-(trifluoromethyl)benzonitrile (14h)
(0.50 g, 2.6 mmol), methyl thioglycolate (0.24 mL, 2.73 mmol)
and triethylamine (1.14 mL, 8.20 mmol) were reacted accord-
ing to the above general procedure for 20 min to give the
title compound (640 mg, 88%) as a colourless solid, mp
140–141 °C (Found [ES+]: 298.0121. C11H8F3NNaO2S [MNa]
requires 298.0120); IR (neat) νmax/cm−1 3468 (N–H), 3335
(N–H), 1664 (CvO); 1H NMR (400 MHz, d6-DMSO) δH/ppm
8.67 (1H, bs, 4-CH), 8.09 (1H, d, J = 8.5 Hz, 7-CH), 7.79 (1H,
dd, J = 8.5, 1.5 Hz, 6-CH), 7.34 (2H, s, NH2), 3.82 (3H, s, Me);
13C NMR (101 MHz, d6-DMSO) δC/ppm 164.5 (C), 149.3 (C),
142.5 (C), 131.3 (C), 124.9 (q, 2JC–F = 32.7 Hz, C), 124.5 (q, 1JC–F
= 272.1 Hz, C), 124.4 (C–H), 124.1 (m, C–H), 120.7 (m, C–H),
96.2 (C), 51.4 (Me); m/z (ES) 276 (MH+, 100%).
Methyl (E)-3-amino-5-(2-cyclopropylvinyl)benzo[b]thiophene-
2-carboxylate (5i). (E)-5-(2-Cyclopropylvinyl)-2-fluorobenzoni-
trile (14i) (0.25 g, 1.33 mmol), methyl thioglycolate (0.12 mL,
1.39 mmol) and triethylamine (0.57 mL, 4.12 mmol) were
reacted according to a modified general procedure for
35 min. After cooling in a stream of compressed air, EtOAc
(25 mL) was added and the solution was washed sequentially
with water (3 × 25 mL) and brine (3 × 25 mL), dried over
MgSO4 and evaporated in vacuo. Purification by flash chrom-
atography on silica gel, eluting with light petroleum–EtOAc
(4 : 1), gave the title compound (210 mg, 58%) as a colourless
solid, mp 131–132 °C (Found [ES+]: 274.0899. C15H16NO2S [M]
requires 274.0896); IR (neat) νmax/cm−1 3481 (N–H), 3365 (N–
H), 1672 (CvO); 1H NMR (400 MHz, d6-DMSO) δH/ppm 8.12
(1H, d, J = 1.6 Hz, 4-CH), 7.71 (1H, d, J = 8.5 Hz, 7-CH), 7.50
(1H, dd, J = 8.5, 1.6 Hz, 6-CH), 7.12 (2H, bs, NH2), 6.53 (1H, d,
J = 15.8 Hz, CH), 5.93 (1H, dd, J = 15.8, 9.1 Hz, CH), 3.78
(3H, s, Me), 1.69–1.55 (1H, m, CH), 0.86–0.80 (2H, m,
CHH), 0.56–0.49 (2H, m, CHH); 13C NMR (101 MHz, d6-
DMSO) δC/ppm 164.8 (C), 149.7 (C), 136.9 (C), 135.2 (C), 133.7
(CH), 131.9 (C), 126.4 (CH), 126.4 (CH), 123.1 (CH), 119.4 (CH),
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94.9 (C), 51.2 (Me), 14.4 (CH), 7.1 (CH2); m/z (ES) 274 (MH+,
100%).
(3R)-3-Methyl-9-nitro-1,2,3,4-tetrahydro-5H-[1]benzothieno-
[3,2-e][1,4]diazepin-5-one (6b). A solution of (R)-methyl 3-
((2-((tert-butoxycarbonyl)amino)propyl)amino)-5-nitrobenzo[b]-
thiophene-2-carboxylate (18) (0.30 g, 0.73 mmol) in TFA (10%
v/v in CH2Cl2) (5.7 mL, 7.3 mmol) was stirred at room tempera-
ture for 4.5 h. When salt formation was confirmed by TLC ana-
lysis [Rf 0.3 in MeOH–CH2Cl2 (1 : 9)] the mixture was
evaporated in vacuo. The residue was dissolved in a mixture of
MeOH (5 mL) and NaOMe (25 wt% in MeOH; 1 mL, 4.4 mmol)
and warmed to 50 °C for 2 h before heating at reflux for 2 h.
The reaction mixture was then allowed to cool to room tem-
perature, cooled in an ice bath, neutralized by the addition of
hydrochloric acid (1 M) and stirred at 0 °C for 30 min. The
resulting solid was isolated by filtration under reduced
pressure, washed with water and dried in air to give the title
compound (0.18 g, 100%) as a red powder, mp 337.4–342.4 °C
(dec.) (Found [ES+]: 278.0590. C12H1sN3O3S [MH] requires
278.0594); [α]24D +110.6 (c 0.04, MeOH); IR (neat) νmax/cm−1
3307 (N–H), 1598 (CvO), 1501 (NO2), 1438 (C–C), 1318 (NO2),
1102 (C–N), 736 (N–H); 1H NMR (500 MHz, d6-DMSO) δH/ppm
9.03 (1H, d, J = 2 Hz, 10-CH), 8.22 (1H, dd, J = 9, 2 Hz, 8-CH),
8.05 (1H, d, J = 9 Hz, 7-CH), 8.02 (1H, m, 1-NH), 7.95 (1H, d, J =
3 Hz, 4-NH), 3.60 (1H, m, 3-CH), 3.39 (2H, m, 2-CH2), 1.16 (3H,
d, J = 7 Hz, Me); 13C NMR (125 MHz, d6-DMSO) δC/ppm 164.2
(5-C), 145.3 (C), 144.2 (C), 141.8 (C), 132.9 (C), 123.8 (7-CH),
120.8 (8-CH), 118.6 (10-CH), 108.6 (C), 50.6 (2-CH2), 47.6 (3-CH),
18.6 (Me); m/z (ES) 277 (M•+, 87%), 262 (24), 234 (29), 206 (30).
Methyl 5-nitrobenzo[b]thiophene-2-carboxylate (10), pre-
pared under ambient conditions. Methyl thioglycolate
(0.48 mL, 5.4 mmol) and K2CO3 (0.89 g, 6.5 mmol) were added
sequentially to a solution of 2-chloro-5-nitrobenzaldehyde
(1.01 g, 5.4 mmol) in DMF (6.5 mL) and the mixture was
stirred at room temperature for 17 h. The reaction was then
quenched in ice-water and the resulting solid collected,
washed with water and dried in vacuo to give the title compound
(1.22 g, 95%) as an oﬀ-white solid, mp 213.3–217.6 °C (lit.,69
mp 213–215 °C) (Found [FTMS + p NSI]: 255.0435.
C10H11N2O4S [MNH4] requires 255.0434); IR (neat) νmax/cm−1
3093 (C–H), 1701 (CvO), 1528 (NO2), 1439 (C–C), 1342 (NO2),
1302 (C–O); 1H NMR (500 MHz, CDCl3) δH/ppm 8.80 (1H, d, J =
2 Hz, 4-CH), 8.32 (1H, dd, J = 9, 2 Hz, 6-CH), 8.20 (1H, s,
3-CH), 8.01 (1H, d, J = 9 Hz, 7-CH), 4.00 (3H, s, Me); 13C NMR
(125 MHz, CDCl3) δC/ppm 162.2 (C), 147.4 (C), 145.9 (C), 138.3
(C), 137.2 (C), 130.7 (3-CH), 123.6 (7-CH), 121.2 (9-CH), 120.9
(7-CH), 52.9 (Me); m/z (EI) 237 (M•+, 100%), 206 (63), 160 (25).
1H NMR spectroscopic analyses were in good agreement with
literature data.53,70
Methyl 5-nitrobenzo[b]thiophene-2-carboxylate (10), using
microwave-assisted conditions. A mixture of 2-chloro-5-nitro-
benzaldehyde (0.75 g, 4.0 mmol), methyl thioglycolate (0.45 mL,
5 mmol) and K2CO3 (0.67 g, 4.8 mmol) in DMF (4.5 mL) was
irradiated at 90 °C for 15 min (hold time) in a pressure-rated
glass tube (35 mL) using a CEM Discover microwave synthesizer
by moderating the initial power (100 W). After cooling in a flow
of compressed air, the reaction mixture was poured into water
and the resulting solid filtered under reduced pressure, washed
with water and dried in air to give the title compound (0.84 g,
88%) as an oﬀ-white solid, mp 216.8–218.5 °C (lit.,69 mp
213–215 °C), with identical spectroscopic properties.
5-Nitrobenzo[b]thiophene-2-carboxylic acid (11), using con-
ductive heating. A solution of aqueous NaOH (1 M; 5 mL,
5 mmol) was added to a solution of methyl 5-nitrobenzo[b]-
thiophene-2-carboxylate (10) (0.40 g, 1.7 mmol) in MeOH
(5.5 mL) and the mixture was heated at reflux for 3 h. After
cooling to room temperature, the solution was acidified with
1 M HCl (aq.) and the resulting solid filtered under reduced
pressure and dried in air to give the title compound (0.36 g,
95%) as an oﬀ-white powder, mp 241.4–242.7 °C (lit.,71 mp
239–241 °C) (Found [TOFMS]: 224.0020. C9H6NO4S [MH]
requires 224.0018); IR (neat) νmax/cm−1 2844 (br, O–H), 1670
(CvO), 1600 (C–C), 1511 (NO2), 1344 (NO2), 1313 (C–O); 1H
NMR (500 MHz, CD3OD) δH/ppm 8.87 (1H, d, J = 2 Hz, 4-CH),
8.30 (1H, dd, J = 9, 2 Hz, 6-CH), 8.24 (1H, s, 3-CH), 8.15 (1H, d,
J = 9 Hz, 7-CH); 13C NMR (125 MHz, CD3OD) δC/ppm 164.8 (C),
148.9 (5-C), 147.5 (C), 140.3 (C), 140.0 (C), 132.0 (3-CH), 125.1
(7-CH), 122.3 (4-CH), 121.9 (6-CH); m/z (EI) 223 (M•+, 100%),
195 (38), 149 (37). 1H NMR spectroscopic analyses were in
good agreement with literature data.53
5-Nitrobenzo[b]thiophene-2-carboxylic acid (11), using
microwave-assisted heating. A mixture of methyl 5-nitrobenzo-
[b]thiophene-2-carboxylate (10) (0.20 g, 0.84 mmol), aqueous
NaOH solution (1 M; 2.5 mL) and MeOH (3.5 mL) was irra-
diated at 100 °C for 3 min (hold time) in a pressure-rated glass
tube (10 mL) using a CEM Discover microwave synthesizer by
moderating the initial power (100 W). After cooling in a flow of
compressed air, the reaction mixture was diluted with water,
acidified with 1 M HCl and the resulting solid was filtered
under reduced pressure, washed with water and dried in air to
give the title compound (0.16 g, 94%) as an oﬀ-white powder,
mp 241.3–242.1 °C (lit.,71 mp 239–241 °C), with identical spec-
troscopic properties.
3-Bromo-5-nitrobenzo[b]thiophene-2-carboxylic acid (12).
According to a modified literature procedure,57 bromine
(1.4 mL, 27 mmol) was added portion-wise to a solution of
5-nitrobenzo[b]thiophene-2-carboxylic acid (11) (1.0 g,
4.5 mmol) and anhydrous sodium acetate (1.13 g, 13 mmol) in
glacial acetic acid (28 mL) under N2. A reflux condenser was
fitted and the solution heated at 55 °C for 27 h. After cooling
to room temperature, the solution was poured into ice-water
and the resulting solid isolated by vacuum filtration and dried
in air to give the title compound (1.02 g, 75%) as a yellow
powder, mp 309.5–316.8 °C (lit.,40 mp 307–309 °C) (Found
[TOF MS]: 301.9126. C9H579BrNO4S [MH] requires 301.9123);
IR (neat) νmax/cm−1 2961 (br, O–H), 1701 (CvO), 1600 (C–C),
1511 (NO2), 1347 (NO2), 1270 (C–O), 620 (C–Br); 1H NMR
(500 MHz, CD3OD) δH/ppm 8.83 (1H, d, J = 2 Hz, 4-CH), 8.39
(1H, dd, J = 9, 2 Hz, 6-CH), 8.21 (1H, d, J = 9 Hz, 7-CH); m/z (EI)
303 (M[81Br]•+, 98%), 301 (M[79Br]•+, 96), 293 (17), 291 (13).
Methyl 3-bromo-5-nitrobenzo[b]thiophene-2-carboxylate
(13), from acid 12. According to a modified literature pro-
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cedure,57 iodomethane (0.46 mL, 7.4 mmol) was added to a
solution of 3-bromo-5-nitrobenzo[b]thiophene-2-carboxylic
acid (12) (1.12 g, 3.7 mmol) and K2CO3 (1.28 g, 9.2 mmol) in
DMF (15 mL). After stirring at room temperature for 3 h, the
reaction mixture was quenched with saturated aqueous NH4Cl
solution, poured into excess water and filtered under reduced
pressure. The collected solid was washed with water and dried
in air to give the title compound (1.09 g, 93%) as an oﬀ-white
powder, mp 211.5–212.5 °C (lit.,40 mp 211–212 °C) (Found
[TOF MS]: 315.9279. C10H779BrNO4S [MH] requires 315.9279);
IR (neat) νmax/cm−1 3101 (C–H), 1691 (CvO), 1600 (C–C), 1514
(NO2), 1347 (NO2), 1089 (C–O), 1052 (C–O), 617 (C–Br); 1H
NMR (500 MHz, CDCl3) δH/ppm 8.90 (1H, d, J = 2 Hz, 4-CH),
8.38 (1H, dd, J = 9, 2 Hz, 6-CH), 8.00 (1H, d, J = 9 Hz, 7-CH),
4.02 (3H, s, Me); 13C NMR (125 MHz, CDCl3) δc/ppm 161.0 (C),
146.5 (5-C), 144.6 (C), 138.9 (C), 131.0 (3α-C), 123.8 (7-CH),
122.2 (6-CH), 121.3 (4-CH), 115.6 (3-CH), 53.0 (Me); m/z (EI)
317 (M[81Br]•+, 100%), 315 (M[79Br]•+, 94), 286 (58), 284 (55).
Methyl 3-bromo-5-nitrobenzo[b]thiophene-2-carboxylate
(13), from 3-aminobenzothiophene 5b. Following the pro-
cedure of Iaroshenko et al.,60 CuBr2 (0.94 g, 4.2 mmol) was
added to a solution of tert-butyl nitrite (0.45 mL, 3.8 mmol) in
dry MeCN (11 mL) at 0 °C under argon. Methyl 3-amino-4-
nitrobenzo[b]thiophene-2-carboxylate (5b) (0.69 g, 2.7 mmol)
was then added portion-wise and the solution kept at 0 °C
until nitrogen evolution ceased. The reaction mixture was
allowed to warm to room temperature, stirred for 2 h and then
poured into dilute hydrochloric acid (10%; 25 mL). The
aqueous mixture was extracted with EtOAc (3 × 30 mL) and the
organic extracts were combined, dried (Na2SO4) and evapor-
ated in vacuo to give the title compound (0.86 g, 99%) as an
orange solid, mp 212.3–213.0 °C (acetone) (lit.,40 mp 211–212 °C),
with identical spectroscopic and spectrometric properties.
(E)-5-(2-Cyclopropylvinyl)-2-fluorobenzonitrile (14i). To a
solution containing 5-bromo-2-fluorobenzonitrile (14a) (3.0 g,
15.0 mmol), Pd(PPh3)2Cl2 (1.0 g, 1.5 mmol) and trans-2-cyclo-
propylvinylboronic acid pinacol ester (3.7 mL, 18 mmol) in
DME/EtOH/H2O (7 : 2 : 3) (50 mL) was added aqueous Na2CO3
solution (1 M; 27 mL). The resulting mixture was placed under
an atmosphere of nitrogen and heated at 80 °C for 16 h after
which time the reaction was cooled to room temperature and
filtered through Celite. Purification by flash column chromato-
graphy on silica gel, eluting with light petroleum–EtOAc (9 : 1),
gave the title compound (2.4 g, 86%) as a yellow oil (Found [ES+]:
188.0868. C12H11NF [MH] requires 188.0870); IR (neat) νmax/cm−1
3007 (C–H), 2496 (CN), 1672 (CvC); 1H NMR (400 MHz, CDCl3)
δH/ppm 7.53–7.46 (2H, m), 7.16–7.08 (1H, m), 6.39 (1H, d, J =
15.7 Hz), 5.71 (1H, dd, J = 15.7, 9.0 Hz), 1.65–1.53 (1H, m),
0.92–0.84 (2H, m), 0.59–0.52 (2H, m); 13C NMR (101 MHz,
CDCl3) δC/ppm 161.7 (d, J = 258.2 Hz), 137.9, 135.3 (d, J = 3.5 Hz),
131.8 (d, J = 7.9 Hz), 130.0, 124.2, 116.5 (d, J = 20.3 Hz), 101.5 (d,
J = 15.7 Hz), 77.2, 14.7, 7.6; m/z (ES) 188 (MH+, 100%).
Methyl 3-aminothieno[2,3-b]pyridine-2-carboxylate (16).
2-Chloro-3-pyridinecarbonitrile (15b) (35 mg, 0.25 mmol),
methyl thioglycolate (0.22 mL, 0.25 mmol) and triethylamine
(0.10 mL, 0.72 mmol) were reacted according to the above
general procedure for 15 min to give the title compound
(36 mg, 69%) as a yellow solid, mp 191 °C (dec.) (lit.,13 mp
194–196 °C) (Found [ES+]: 209.0380. C9H9N2O2S [MH] requires
209.0385); IR (neat) νmax/cm−1 3417 (N–H), 3314, 3202, 2943,
1679 (CvO), 1291 (C–O), 1127 (C–O); 1H NMR (500 MHz, d6-
DMSO) δH/ppm 8.68 (1H, dd, J = 4.6, 1.6 Hz, 6-CH), 8.54 (1H,
dd, J = 8.1, 1.6 Hz, 4-CH), 7.46 (1H, dd, J = 8.1, 4.6 Hz, 5-CH),
7.30 (2H, bs, NH2), 3.80 (3H, s, Me); 13C NMR (101 MHz,
d6-DMSO) δC/ppm 164.7 (CvO), 159.7 (7α-C), 150.7 (6-CH),
147.7 (3-C), 131.4 (4-CH), 125.5 (3α-C), 119.4 (5-CH), 93.2 (2-C),
51.4 (Me); m/z (EI) 208 (M•+, 100%), 177 (28), 176 (93), 148 (60).
1H NMR spectroscopic analyses were in good agreement with
literature data.13
tert-Butyl [(2R)-1-aminopropan-2-yl]carbamate (17). Accord-
ing to a modified literature procedure,72 a solution of Boc-D-
Ala-OH (0.50 g, 2.64 mmol) and HOBt·H2O (0.41 g, 3.0 mmol)
in CH2Cl2 (20 mL) was cooled to 0 °C and EDCI·HCl (0.58 g,
3.0 mmol) was added. The solution was allowed to warm to
room temperature and stirred for 30 min. The solution was
then cooled to 0 °C, aqueous NH3 (18.1 M; 0.6 mL) was added
drop-wise and the mixture was stirred at room temperature for
30 min. Any solid residue was removed by filtration and the fil-
trate was washed sequentially with water (20 mL) and brine
(2 × 20 mL), dried (MgSO4) and evaporated in vacuo. Purifi-
cation by flash column chromatography on SiO2, gradient
eluting with MeOH–CH2Cl2 (from 3–7% MeOH), gave Boc-D-
Ala-NH2 (0.37 g, 75%) as colourless crystals, mp
127.5–128.2 °C (lit.,73 mp 120–121 °C). According to a modi-
fied literature procedure,74 BH3·SMe2 (2 M in THF; 13.5 mL,
27 mmol) was added portion-wise to a solution Boc-D-Ala-NH2
(0.5 g, 2.7 mmol) in dry THF (9 mL) under N2 at 0 °C. The reac-
tion mixture was allowed to warm to room temperature, stirred
for 18 h, evaporated in vacuo and treated with MeOH (3 ×
15 mL), stirring and evaporating in vacuo each time. Purifi-
cation by ion exchange chromatography using an Isolute SPE
SCX-2 flash column, eluting first with MeOH and then with a
solution of NH3 in MeOH (2 M), gave the title compound
(0.39 g, 84%) as a colourless oil [Rf 0.3 in MeOH–CH2Cl2 (1 : 9)]
(Found [ES+]: 175.1443. C8H19N2O2 [MH] requires 175.1441);
[α]24D −5.7 (c 1.1, MeOH); IR (neat) νmax/cm−1 2973 (C–H), 1685
(CvO), 1521 (N–H), 1364 (CH3 deformation), 1247 (C–O), 1165
(C–N), 1045 (C–O), 872 (N–H); 1H NMR (500 MHz, CDCl3) δH/
ppm 4.78 (1H, m, NHBoc), 3.60 (1H, m, 2-CH), 2.70 (1H, m, 1-
CHH), 2.59 (1H, m, 1-CHH), 1.40 (9H, s, CMe3), 1.08 (3H, d, J =
7 Hz, 3-Me); 13C NMR (125 MHz, CDCl3) δC/ppm 155.7 (C),
79.1 (C), 48.6 (2-CH), 47.4 (4-CH2), 28.4 (CMe3), 18.5 (Me).
1H NMR spectroscopic analyses were in good agreement with
literature data.75
(R)-Methyl 3-((2-((tert-butoxycarbonyl)amino)propyl)amino)-
5-nitrobenzo[b]thiophene-2-carboxylate (18). According to a
modified literature procedure,76 (R)-tert-butyl (1-aminopropan-
2-yl)carbamate (17) (35 mg, 0.20 mmol) was added to a stirred
mixture of methyl 3-bromo-5-nitrobenzo[b]thiophene-2-carboxy-
late (13) (50 mg, 0.16 mmol), Cs2CO3 (73 mg, 0.22 mmol),
(±)-BINAP (13 mg, 0.02 mmol) and Pd(OAc)2 (2.0 mg, 8.0 μmol)
in dry toluene (1.0 mL) under N2 and the mixture was irra-
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diated at 150 °C for 75 min (hold time) in a pressure-rated
glass tube (10 mL) using a CEM Discover microwave synthesi-
zer by moderating the initial power (200 W). After cooling in a
flow of compressed air, the reaction mixture was partitioned
between water (20 mL) and EtOAc (30 mL). The aqueous layer
was further extracted with EtOAc (2 × 30 mL) and the organic
extracts were combined, washed with brine (30 mL), dried
(Na2SO4) and evaporated. Purification by flash column chrom-
atography on SiO2 (dry load), gradient eluting with light pet-
roleum to Et2O–light petroleum (1 : 1), gave the title compound
(50 mg, 76%) as a red solid, mp 182.9–184.0 °C (Found [ES+]:
410.1378. C18H24N3O6S [MH] requires 410.1380); [α]24D +55.3 (c
0.1, MeOH); IR (neat) νmax/cm−1 3355 (N–H), 2954 (C–H), 1672
(CvO), 1588 (NO2) 1508 (C–C), 1325 (NO2), 1230 (C–O), 1060
(C–N); 1H NMR (500 MHz, d6-DMSO) δH/ppm 8.94 (1H, m, 4-
CH), 8.27 (1H, d, J = 9 Hz, 6-CH), 8.15 (1H, d, J = 9 Hz, 7-CH),
7.54 (1H, m, 3-NH), 6.87 (1H, d, J = 6 Hz, 2′-NH), 3.81 (4H, m,
1′-CHH and OMe), 3.76 (1H, m, 2′-CH), 3.57 (1H, m, 1′-CHH),
1.32 (9H, s, CMe3), 1.12 (1H, d, J = 6 Hz, 3′-Me); 13C NMR
(125 MHz, d6-DMSO) δC/ppm 164.0 (C), 155.1 (C), 150.3 (3-C),
145.2 (C), 144.3 (C), 131.1 (3α-C), 124.7 (7-CH), 121.6 (6-CH),
120.5 (4-CH), 99.5 (2-C), 77.6 (CMe3), 51.7 (OMe), 50.5 (1′-CH2),
46.2 (2′-CH), 28.1 (CMe3), 18.3 (3′-Me); m/z (EI) 410 (MH+,
100%), 409 (M•+, 70).
Methyl 3-((1-amino-2-chloroethylidene)amino)-5-((E)-2-cyclo-
propylvinyl)benzo[b]thiophene-2-carboxylate hydrochloride (19).
Methyl (E)-3-amino-5-(2-cyclopropylvinyl)benzo[b]thiophene-
2-carboxylate (5i) (200 mg, 0.73 mmol) was suspended in a
solution of HCl in 1,4-dioxane (4 M; 3 mL) and chloro-
acetonitrile (91 μL, 1.43 mmol) was added drop-wise. The
reaction mixture was stirred at room temperature for 16 h
and the suspension was filtered under reduced pressure,
washed with light petroleum (60 mL) and dried in vacuo for
6 h to give the title compound (110 mg, 39%) as a colourless
solid, mp 195–197 °C (dec.) (Found [ES+]: 317.0512.
C16H1435ClN2OS [MH − MeOH] requires 317.0515); IR (neat)
νmax/cm−1 3332 (br, N–H), 3001 (C–H), 2675 (C–H), 1676
(CvO), 1620 (CvC); 1H NMR (400 MHz, CD3OD) δH/ppm 7.91
(1H, d, J = 8.6 Hz, 7-CH), 7.72 (1H, d, J = 1.5 Hz, 4-CH), 7.67
(1H, dd, J = 8.6, 1.5 Hz, 6-CH), 6.60 (1H, d, J = 15.8 Hz, CH),
5.96 (1H, dd, J = 15.8, 9.1 Hz, CH), 4.73 (2H, s, CH2), 3.94 (3H,
s, Me), 1.65–1.55 (1H, m, CH), 0.87–0.79 (2H, m, CHH),
0.59–0.48 (2H, m, CHH); 13C NMR (101 MHz, CD3OD) δC/ppm
166.3 (C), 162.4 (C), 138.9 (C), 138.3 (CH), 138.0 (C), 135.8 (C),
130.5 (C), 130.4 (C), 127.7 (CH), 127.3 (CH), 124.6 (CH), 119.6
(CH), 53.4 (Me), 40.1 (CH), 15.5 (CH), 7.8 (CH2, CH2); m/z (ES)
349 (M[35Cl]H+, 100%).
(E)-8-(2-Cyclopropylvinyl)-2-((dimethylamino)methyl)benzo-
[4,5]thieno[3,2-d]pyrimidin-4(3H)-one (20). Compound 19
(70 mg, 0.18 mmol) was added to a solution of dimethylamine
in ethanol (33%; 3 mL) and the reaction mixture was stirred at
room temperature for 16 h. The solvent was evaporated
in vacuo and the resulting colourless solid was dissolved in
MeOH–CH2Cl2 (1 : 1; 5 mL) and loaded onto an SCX cartridge
(1 g). The cartridge was flushed with MeOH (3 × 5 mL) and
then eluted with a solution of NH3 in MeOH (2 M; 8 mL) to
give the title compound as a colourless solid (55 mg, 94%), mp
202–203 °C (dec.) (Found [ES+]: 326.1324 C18H20N3OS [MH]
requires 326.1322); IR (neat) νmax/cm−1 2873 (br, C–H), 1672
(CvO), 1587 (CvC); 1H NMR (400 MHz, d6-DMSO) δH/ppm
12.41 (1H, bs, NH), 8.09 (1H, d, J = 1.5 Hz, 4-CH), 8.03 (1H, d,
J = 8.5 Hz, 7-CH), 7.69 (1H, dd, J = 8.5, 1.5 Hz, 6-CH), 6.68 (1H,
d, J = 15.8 Hz, CH), 6.01 (1H, dd, J = 15.8, 9.2 Hz, CH), 3.52
(2H, s, CH2), 2.29 (6H, s, Me), 1.66–1.56 (1H, m, CH), 0.85–0.78
(2H, m, CHH), 0.61–0.54 (2H, m, CHH); 13C NMR (101 MHz,
d6-DMSO) δC/ppm 158.5 (C), 157.2 (C), 152.7 (C), 138.3 (C),
136.2 (CH), 135.2 (CH), 134.6 (C), 126.5 (C), 126.2 (CH), 123.9
(CH), 122.0 (C), 119.7 (CH), 61.3 (CH2), 45.1 (Me, Me), 14.7
(CH), 7.2 (CH2, CH2); m/z (ES) 326 (MH+, 100%). 1H NMR spec-
troscopic analyses were in good agreement with literature data
for the corresponding HCl salt.15
Conclusions
This method for the microwave-assisted synthesis of 3-amino-
benzo[b]thiophenes is rapid, simple to carry out and generally
high yielding. It has been applied in the synthesis of a range
of functional benzothiophenes and their 7-aza analogues and
constitutes a very eﬃcient route to the corresponding 3-halo-
benzothiophenes using diazonium chemistry. Applications of
this process have been shown in the synthesis of the thieno-
[2,3-b]pyridine core motif of LIMK1 inhibitors using 2-halopyr-
idine-3-carbonitriles, the benzo[4,5]thieno[3,2-e][1,4]diazepin-
5(2H)-one scaﬀold of MK2 inhibitors with functionality suit-
able for subsequent modification using Buchwald–Hartwig
chemistry, and a benzo[4,5]thieno[3,2-d]pyrimidin-4-one target
as a chemical tool for inhibition of PIM kinases. In the case of
inhibitors of MK2, the use of this approach has been shown to
be superior to traditional bromination chemistry using the
parent benzothiophene heterocycle. Given the speed, eﬃciency
and reliability of these methods, and their ability to incorpor-
ate a wide range of functionality, these approaches are likely to
find application in providing chemical tools, rapidly, reliably
and eﬃciently, for advancing studies in chemical biology, as
well as to access targets in medicinal chemistry.
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The eﬀect of RO3201195 and a pyrazolyl ketone
P38 MAPK inhibitor library on the proliferation of
Werner syndrome cells†
Mark C. Bagley,*a Jessica E. Dwyer,a Mohammed Baashen,‡a Matthew C. Dix,b
Paola G. S. Murziani,b Michal J. Rokicki,c David Kiplingc and Terence Davis*c
Microwave-assisted synthesis of the pyrazolyl ketone p38 MAPK inhibitor RO3201195 in 7 steps and 15%
overall yield, and the comparison of its eﬀect upon the proliferation of Werner Syndrome cells with a
library of pyrazolyl ketones, strengthens the evidence that p38 MAPK inhibition plays a critical role in
modulating premature cellular senescence in this progeroid syndrome and the reversal of accelerated
ageing observed in vitro on treatment with SB203580.
Introduction
P38α is one isoform of the mitogen-activated protein kinase
(MAPK) intracellular enzymes which are central to the
regulation of cytokine biosynthesis and inflammatory cell sig-
nalling.1,2 The reduction of pro-inflammatory cytokine levels
oﬀers a means for the treatment of inflammatory disorders
such as rheumatoid arthritis and atherosclerosis.3,4 In
addition to inflammatory disorders, p38α is known to play a
role in the resistance of various cancers to chemotherapy,
cancer proliferation and metastasis.5,6 This makes p38α a com-
pelling therapeutic target for the design of safe and eﬃcacious
inhibitors suitable for clinical investigation.2,7 Following the
discovery that pyridinylimidazole p38α inhibitors such as
SB203580 mediate multiple cellular responses,1 including the
production of inflammatory cytokines, a wide variety of struc-
turally-distinct chemotypes8,9 have been discovered to inhibit
this enzyme with notable diﬀerences in binding motif.10 Many
of these have been used in stage II or III clinical trials.11
Werner syndrome (WS) is a rare autosomal recessive dis-
order.12 The mutated gene (WRN) encodes for a RecQ helicase
involved in DNA replication, recombination and repair. Indi-
viduals living with the syndrome display the premature onset
of many of the clinical features of old age, show early suscepti-
bility to a number of major age-related diseases and have an
abbreviated median life expectancy (47 years). Consequently,
WS is widely used as a model disease to investigate the mecha-
nisms underlying normal human ageing. Associated with
these aged features, fibroblasts from WS individuals have a
much-reduced replicative capacity when compared with fibro-
blasts from normal individuals, and have a stressed, aged,
morphology and high levels of activated p38α.13–15 This accel-
erated cellular senescence is thought to underlie whole body
ageing in this syndrome. As part of our interest in mechanisms
of premature cell senescence, we showed that administering
the p38α inhibitor SB203580 to WS cells rescues all of the fea-
tures of accelerated replicative decline.13 This observation
suggested that the abbreviated life span of WS cells is due to
stress-induced growth arrest mediated by p38α MAPK, which
we speculate is transduced from the frequently stalled DNA
replication forks observed in these cells.16 It also oﬀers a
means to clinically regulate this process and, by therapeutic
means, intervene in a premature ageing syndrome.16
However, it has been shown that SB203580 is not specific
for p38α, but also inhibits the related N-terminal c-Jun kinases
(JNKs) that may play a role in cellular senescence.17–19 Thus
more work is needed using inhibitors that do not target the
JNKs to verify the role played by p38α in WS cells. In addition,
SB203580 is not suitable for possible in vivo use.11
This manuscript describes a rapid route to one such inhibi-
tor, RO3201195 (1),20 the study of this inhibitor in WS cells,
and its comparison with the canonical p38α inhibitor
SB203580 to investigate the role of p38α MAPK signal trans-
duction in replicative senescence. This pyrazolyl ketone p38α
MAPK inhibitor progressed to clinical trials, is orally bio-
available, exhibits high kinase selectivity, and inhibited the
†Electronic supplementary information (ESI) available. See DOI: 10.1039/
c5ob02229k
‡Current address: Department of Chemistry, College of Science and Humanities,
Shaqra University, Kingdom of Saudi Arabia.
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CF10 3AT, UK
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production of the cytokines IL-6 and TNFα upon lipopolysac-
charide (LPS) challenge in rats.20 Thus, RO3201195 could be a
valuable chemical tool in dissecting the accelerated ageing
pathophysiology seen in WS cells and its rescue in vitro using
small molecule inhibitors of this stress signalling pathway.13,21
Our rapid approach to the inhibitor employs microwave
irradiation to accelerate a number of steps, preparing the
central pyrazole motif through cyclocondensation of hydrazine
3 and a suitably protected benzoylnitrile 2, derivatized by
homologation prior to heterocycle formation (Fig. 1). This
approach had been successful for the synthesis of a pyrazolyl
ketone library (4)22 and so should be suitable for rapid pro-
duction of the target inhibitor under microwave-assisted
conditions.
Results and discussion
The synthesis of a suitably functionalized β-ketonitrile deriva-
tive 2, as a precursor for pyrazole formation, was first investi-
gated using the Pd-catalyzed Heck reaction23,24 of
3-iodoanisole and 3-methoxyacrylonitrile (5). This approach
had the advantage that, potentially, it could access 3-methoxy-
benzoylacetonitrile (6) directly from commercially-available
materials, upon acid hydrolysis of the coupled product, methyl
vinyl ether 7 (Scheme 1, top), providing a very rapid route into
the pyrazole skeleton. Heck reactions of α- or β-substituted
enol ethers are known and have been shown to provide
eﬃcient access to 1-arylpropanone derivatives.25 However,
although there are numerous examples of Heck reactions of
α,β-disubstituted alkenes such as methylacrylates,26 3-ethoxy-
acrylates,27 cinnamates,28 crotonates29 and alkoxypropenes,30
there are very few examples of β-alkoxyacrylonitriles in these
and related processes. Enol ethers are less reactive than
electron-poor alkenes in Heck transformations and so these
slow reactions often require high catalyst loadings, more reac-
tive aryl iodides as substrates and the use of certain additives,
particularly when performed under solid–liquid phase transfer
conditions.31 Furthermore, α,β-disubstituted alkenes may
suﬀer from steric constraints and so, although direct, this
approach for the synthesis of benzoylacetonitriles was
untested. Ortar et al.32 did describe the arylation of an α-meth-
oxyacrylate back in 1987 using aryl iodides, palladium acetate
(3 mol%), NaHCO3 base and tetrabutylammonium chloride as
additive. Using Jeﬀery’s conditions for Heck-type processes as
a starting point,33 methods related to the conditions for aryla-
tion of acrylonitrile with aryl iodides34 were investigated in the
Heck reaction of 3-iodoanisole and 3-methoxyacrylonitrile (5).
The use of Pd(OAc)2 (10 mol%) as catalyst in MeCN–H2O (3 : 1)
(Table 1) under microwave-assisted heating at 130 °C for 1.5 h
(entry 4) with K2CO3 as base and tetrabutylammonium
bromide (TBAB) as additive gave, following aqueous work up,
the α-aryl enol ether 7 as a mixture of (E)- and (Z)-diastereo-
isomers, in a 2 : 1 ratio, as determined by 1H NMR spectro-
scopic analysis. The diastereoisomers could be separated by
column chromatography, albeit in variable and poor yield. Low
conversions and poor diastereocontrol has been observed
before in Heck reactions of β-alkoxyacrylonitriles25 but, in our
case, separation would not be required if the mixture could be
converted directly to the target benzoylacetonitrile 6.
Surprisingly the hydrolysis of the enol ether diastereoiso-
meric mixture 7 required very forcing conditions. Simple treat-
ment of the Heck reaction mixture with acid under ambient
conditions failed to provide β-ketonitrile 6. The hydrolysis of
related alkoxyacrylonitriles were notable, by their absence,
Scheme 1 Synthesis of 3-methoxybenzoylacetonitrile (6) by Heck
coupling (top) or Claisen ester condensation (bottom). Reagents and
conditions: (i) see Table 1; (ii) cHCl–MeOH (1 : 4), microwaves, 110 °C,
30 min; (iii) MeOH, H2SO4, reﬂux, 2.5 h (90%); or MeOH, H2SO4, micro-
waves, 110 °C, 10 min (94%); (iv) see Table 2; HCl (aq).
Fig. 1 P38 MAPK inhibitors SB203580 and RO3201195 (1), a pyrazolyl
ketone library 4 and disconnective approach to 1.
Paper Organic & Biomolecular Chemistry
948 | Org. Biomol. Chem., 2016, 14, 947–956 This journal is © The Royal Society of Chemistry 2016
Op
en
 A
cc
ess
 A
rti
cle
. P
ub
lis
he
d o
n 1
2 N
ov
em
be
r 2
01
5. 
Do
wn
loa
de
d o
n 2
1/0
1/2
01
6 1
2:5
3:0
9. 
 T
his
 ar
tic
le 
is 
lic
en
sed
 un
de
r a
 C
rea
tiv
e C
om
mo
ns
 A
ttr
ibu
tio
n 3
.0 
Un
po
rte
d L
ice
nc
e.
View Article Online
from the study of Doucet and Santelli following Heck reaction
of 3-ethoxyacrylonitrile, catalyzed by a tetraphosphane/palla-
dium complex.25 However, by resorting to more forcing con-
ditions, gratifyingly, microwave irradiation of the isolated
diastereoisomeric mixture 7 in cHCl–MeOH (1 : 4) at 110 °C for
30 min finally provided benzoylacetonitrile 6 after purification
by column chromatography but only in modest isolated yield
over the two steps (Table 1, entry 1, 36%).
Eﬀorts to improve the overall yield of this process by chan-
ging the base from K2CO3 to NaHCO3, in accordance with
Heck methods for the synthesis of cinnamonitriles,34 carrying
out the hydrolysis in cHCl–MeOH (1 : 4) under microwave
irradiation as before (Table 1, entry 2), gave no improvement
in yield (34%). Similarly, carrying out the Heck reaction in a
sealed tube under microwave irradiation using K2CO3 at
130 °C for 1 h (entry 3) or 1.5 h (entry 4) was poorly eﬃcient.
The microwave-assisted reaction using NaHCO3 at 130 °C for
1.5 h (entry 5) did give a modest yield of product (37%),
similar to the longer conductive heating processes, but this
was not improved further by raising the temperature of reac-
tion to 140 °C (entry 6) or to 150 °C in the presence of an
alternative additive DPPP (10 mol%) (entry 7). Although the
route had been successful for the preparation of ketonitrile 6,
the need to isolate enol ether 7, in order to carry out the hydro-
lysis under high-temperature conditions, and the modest yield
for the overall process (entry 5 gave the best yield, at 37%)
meant that an alternative route had to be sought.
Considering the original approach to RO3201195 (1) by
Roche,20 eﬀorts were made to access ketonitrile 6 by a more
traditional Claisen ester approach. Fischer esterification of
3-methoxybenzoic acid (8) in methanol using sulfuric acid as
catalyst at reflux for 3 h gave methyl ester 9 in good yield
(90%). This was improved further by carrying out the process
in a sealed tube under microwave irradiation at 110 °C for
10 min to give methyl ester 9 in 94% yield (Scheme 1, bottom).
A well-established method35 for Claisen condensation using
sodium ethoxide or sodium methoxide as base was frustrated
by the almost immediate formation of a homogenous gelati-
nous mass and so a range of conditions were investigated
(Table 2). Heating this mixture in acetonitrile at reflux for 24 h
gave only a very low yield (9% in both cases) of the benzoylace-
tonitrile 6 (entries 1 and 2) and significant return of unreacted
ester and so alternative methods were employed. Carrying out
the reaction using NaH in THF at reflux for 1.5 h gave an
immediate improvement in eﬃciency and provided the con-
densation product 6 in 15% yield (entry 3), 35% yield if heated
at 150 °C for 1 h in a sealed tube under microwave irradiation
(entry 4). Changing the solvent to toluene and heating the
mixture at 90 °C for 16 h gave a similar yield (entry 5, 34%).
However, the use of freshly-prepared LDA as base at −50 °C in
THF (entry 7) gave the Claisen condensation product 6 in good
yield (70%), whereas at lower temperatures was ineﬃcient
(entry 6). Given the high yield and speed of the microwave-
assisted esterification, this route now represented the quickest
and most eﬃcient means to access this key intermediate.
Considering our previous success in the use of microwave
irradiation in cyclocondensation reactions for the preparation
of pyrazoles,17,36,37 the aminopyrazole core motif of BIRB
796,38 and pyrazolyl ketone libraries,22,39 benzoylacetonitrile 6
was homologated in a microwave-assisted Knoevenagel con-
densation using N,N′-diphenylformamidine (10) in xylenes at
180 °C for 20 min to give enaminone 11 in good yield (74%)
(Scheme 2). Cyclocondensation by microwave irradiation with
the hydrochloride salt of 4-fluorophenylhydrazine (3) in the
presence of Et3N in EtOH at 140 °C for 1 h gave 5-aminopyra-
zole 12 in superior yield (86%) to a range of other methods,39
after purification by column chromatography. Protodemethyl-
ation using BBr3 in CH2Cl2 (1 M) at RT overnight gave the
corresponding phenol 13 in quantitative yield, which was
reacted in a SN2 displacement reaction with ketal-protected
tosyl glycerate 14 under basic conditions. The reaction in DMF
in the presence of K2CO3 at 80 °C for 24 h gave only a very low
yield of product 15 (9%)39 but switching to DMSO and carrying
Table 1 Investigating conditions for Heck reaction of 3-iodoanisole
and 3-methoxyacrylonitrile (5) to give benzoylacetonitrile 6
Entry Base Additive Conditionsa
Yieldb
(%)
1 K2CO3 TBAB Conductive heating, 90 °C, 24 h 36
2 NaHCO3 TBAB Conductive heating, 90 °C, 24 h 34
3 K2CO3 TBAB Microwaves,c 130 °C, 1 h 26
4 K2CO3 TBAB Microwaves,
c 130 °C, 1.5 h 20
5 NaHCO3 TBAB Microwaves,c 130 °C, 1.5 h 37
6 NaHCO3 TBAB Microwaves,c 140 °C, 1 h 19
7 K2CO3 DPPP Microwaves,c 150 °C, 1.5 h 31
a Isolated yield of benzoylacetonitrile 6. b Reaction of 3-iodoanisole
(1 equiv.), 3-methoxyacrylonitrile (5) (4 equiv.), Pd(OAc)2 (10 mol%),
base (2 equiv.) and additive (10 mol%) in MeCN–H2O (3 : 1) under the
given conditions, followed by aqueous work up, microwave irradiation
in cHCl–MeOH (1 : 4) at 110 °C (hold time) for 30 min (by moderation
of initial power, 150 W) and aqueous work up, followed by purification
by column chromatography on silica. cMicrowave irradiation in a
sealed tube at the given temperature, as measured by the instrument’s
in-built IR sensor, for the given time (hold time) by moderation of the
initial power (150 W).
Table 2 Investigating conditions for base-mediated Claisen con-
densation of methyl benzoate 9 and acetonitrile to give benzoylaceto-
nitrile 6
Entry Base Conditions Yielda (%)
1 NaOEt MeCN, RT; reflux, 24 h 9
2 NaOMe MeCN, RT; reflux, 24 h 9
3 NaH THF, reflux, 1 h 15
4b NaH THF, microwaves, 150 °C, 1 h 35
5 NaH PhMe, 90 °C, 16 h 34
6 LDA THF, −78 °C, 1.5 h 18
7 LDA THF, −50 °C, 3 h 70
a Isolated yield of benzoylacetonitrile 6 from methyl benzoate 9 after
purification by column chromatography on silica. bMicrowave
irradiation in a sealed tube at the given temperature, as measured by
the instrument’s in-built IR sensor, for the given time (hold time) by
moderation of the initial power.
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out the SN2 displacement at a slightly higher temperature
(100 °C) for prolonged period (40 h) gave phenyl ether 15 in
improved yield (42%) after purification by column chromato-
graphy, followed by recrystallization. Submitting the product
of tosylate displacement 15 to ketal deprotection directly, prior
to recrystallization, under acid-catalyzed aqueous conditions at
50 °C for 18 h gave RO3201195 (1) in 37% yield over the two
steps, after purification by column chromatography and recrys-
tallization. The target inhibitor exhibited spectroscopic data
that matched literature values.22,39 It was prepared in 15%
overall yield in 7 separate steps from commercially-available
material, three of them employing microwave irradiation, to
provide rapid access to material suitable for examination in
WS cells.
Due to limited supplies of primary WS fibroblasts, initial
experiments to determine the eﬀects of novel kinase inhibitors
on cellular proliferation were performed using WStert cells (see
materials and methods for a description of these cells).
Despite being immortal, these telomerized cells retain the
slow proliferation rate typical of primary WS cells and show a
similar response to SB203580 treatment.14 Thus, these cells
can be used to test the eﬀects of modulators of the p38-signal-
ling pathway prior to their use on primary cells.
WStert cells were grown in standard medium supplemented
with SB203580 at a final concentration ranging from 10 nM to
50 µM (Fig. 2a). SB203580 inhibited p38α even at the lowest
doses used of 10 nM with maximum inhibition seen at 1.0 µM
and above (Fig. 2c), and has an IC50 for p38α of approximately
30 nM as measured by us, and others.40,41 SB203580 treatment
resulted in an increased proliferation rate of the WStert cells
compared to DMSO-treated control cells even at the lowest con-
Scheme 2 Microwave-assisted synthesis of RO3201195. Reagents and
conditions: (i) xylenes, microwaves, 180 °C, 20 min; (ii) Et3N, EtOH,
140 °C, 1 h; (iii) BBr3in CH2Cl2 (1 M), 0 °C-RT, 18 h; (iv) K2CO3, DMSO,
100 °C, 40 h; (v) TsOH, MeOH–H2O, 50 °C, 18 h.
Fig. 2 Eﬀects of p38α inhibitors on Werner syndrome cells. Eﬀects of
SB203580 (a) and RO3201195 (b) on the proliferation rate of WStert cells,
with 100% representing the DMSO control. Titration curves for inhibition
of p38α activity for SB203580 (c) and RO3201195 (d) measured as the
ratio of phosphorylated HSP27 to total HSP27 (measured by ELISA). For
(a) to (d) DMSO are control cells, ‘An’ are cells treated with anisomycin
to activate p38α, 10 to 50 000 are cells treated with p38 inhibitors at the
indicated concentration. (e) Plot of % p38α activity versus % increase in
WStert cell proliferation rate for both SB203580 and RO3201195. (f ) Pro-
liferation of Werner syndrome AG05229 primary ﬁbroblasts in the pres-
ence of SB203580 (2.5 µM) or RO3201195 (10 µM) measured as
population doublings versus days. (g) Plot of % increase in proliferation
rate of WStert cells against % p38α activity using pyrazolyl ketone library
4. See Table 3 for compound identities. (h) Immunoblot showing that
neither SB203580 nor RO3201195 inhibit JNK at the optimal concen-
trations for their eﬀects on cellular proliferation rates. C = DMSO
control, A = cells treated with anisomycin to activate p38α and JNK, and
the other three lanes show the eﬀect of the given inhibitor concen-
trations in anisomycin-treated cells.
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centration used, with the eﬀect on proliferation rate increasing
steadily with increasing SB203580 concentration and reaching
a maximum between 2.5 µM and 10 µM. When the level of
p38α activity was plotted against the eﬀects upon proliferation
rate a sigmoid curve was found (Fig. 2e). At 2.5 µM SB203580
resulted in an increase in proliferation rate of approximately
22% compared to DMSO controls (Fig. 2a and e).
RO3201195 has an IC50 of approximately 190 nM with
maximal inhibition between 2.5 and 10 µM.39 In this work,
RO3201195 inhibited p38α at a minimum concentration of
25 nM, with the maximal eﬀect seen at 10.0 µM (Fig. 2d).
RO3201195 had an increasing eﬀect on the proliferation rate
of WStert cells up to 10.0 µM concentration, thereafter becom-
ing inhibitory (Fig. 2b). As seen for SB203580, when the level
of p38α activity was plotted against the eﬀects of RO3201195
upon proliferation rate a sigmoid curve was found (Fig. 2e):
indeed the curve was essentially identical with the curve
obtained using SB203580. The maximal increase seen in
the proliferation rate of WStert cells was 19% at 10.0 µM
(Fig. 2b and e).
The above data show that the optimal concentration of
these inhibitors for the maximal eﬀects on WStert cells are
2.5 µM for SB203580 and 10.0 µM for RO3201195. The inhibi-
tors completely inhibited p38α but did not inhibit total JNK
activity in WStert cells at these concentrations as measured by
analyzing the phosphorylation of their downstream targets
HSP27 and c-Jun by immunoblot (Fig. 2h). WStert cells are
stimulated with anisomycin that activates p38α and JNKs as
shown by the increased presence of the band in the A lane
of the p-HSP27 panel, and the apperance of the doublet in the
p-c-Jun and c-Jun panels (Fig. 2h). RO3201195 at 10.0 µM
and SB203580 at 2.5 µM concentration reduced the p-HSP27
band to the level seen in the unstimulated control
(C lane), but had no eﬀect on the doublet seen in p-c-Jun and
c-Jun.
We next used the p38α inhibitors on the primary Werner
syndrome fibroblast strain WAG05229 that was close to replica-
tive senescence to determine their eﬀects on cellular senes-
cence. For SB203580 a concentration of 2.5 µM was used,
whereas for RO3201195 10.0 µM concentration was employed,
as these were the lowest concentrations that resulted in
maximal proliferation rate and 100% p38α inhibition (see
Fig. 2). The cells were re-fed with DMEM containing the inhibi-
tors as described previously.15 DMSO-treated fibroblasts proli-
ferated very slowly and only achieved a single population
doubling in the 88 days of the experiment (Fig. 2f). Inhibitor
treated cells, however, had a much elevated proliferation rate,
and managed approximately 7.5 population doublings prior to
growth arrest (Fig. 2f). There was essentially no diﬀerence
whichever inhibitor was used. Thus, as the eﬀects of these
inhibitors on WS cells are essentially identical and yet they
show very diﬀerent kinase specificity profiles at the concen-
trations used (the only common denominator being p38), the
conclusion is that the eﬀects on proliferation seen in both
WStert cells and primary WS fibroblasts result from the inhi-
bition of p38α.
Finally, we used a pyrazolyl ketone library 4 (Table 3) of
compounds related to RO320119522 for their eﬀects on the pro-
liferation of WStert cells (Fig. 2g). These were used at a concen-
tration of 1.5 µM that resulted in a varied degree of p38α
inhibition from approximately 5% to greater than 95% (Fig. 2g
and ref. 22). When the eﬀect on the proliferation rate of WStert
cells by this pyrazolyl ketone library were plotted against the %
p38α activity (as assessed by ELISA22), a linear response was
seen (Fig. 2g), providing further support that these eﬀects on
cellular proliferation are due to p38α inhibition.
The data presented in this paper showing that
RO3201195 has essentially identical eﬀects on the proliferation
of WS cells as SB203580, and that the proliferation rate is
dependent on p38 activity, provide very strong support that the
prevention of premature senescence seen in WS fibroblasts by
SB203580 reported previously13 is via p38α signalling. If pre-
mature cellular senescence does underlie the accelerated
ageing seen in WS individuals, these data also provide further
support that the use of p38 inhibitors in vivo may alleviate
this accelerated ageing.16 Finally, RO3201195 is shown to be a
useful tool for the dissection of signalling pathways in human
cells, as it is eﬃcacious, relatively potent and is more kinase
selective than SB203580.20 In addition, it has shown thera-
peutic eﬃcacy in vivo in rats in regulating cytokine production
upon LPS challenge,20 so may prove useful for future in vivo
use.
Experimental
Materials and methods
Commercially available reagents were used without further
purification; solvents were dried by standard procedures. Light
petroleum refers to the fraction with bp 40–60 °C and ether
refers to diethyl ether. Unless otherwise stated, reactions were
performed under an atmosphere of air. Flash chromatography
was carried out using Merck Kieselgel 60 H silica or Matrex
silica 60. Analytical thin layer chromatography was carried out
using aluminium-backed plates coated with Merck Kieselgel
Table 3 Pyrazolyl ketone library 4 studied in WStert cellsa
4 R1 R2
A OMe 4-Iodophenyl
Bb OMe 4-Fluorophenyl
C H 4-Fluorophenyl
D H 4-Bromophenyl
E H 2,6-Dichlorophenyl
F H 2,4-Difluorophenyl
H H Phenyl
I OMe 4-Tolyl
J OMe Methyl
K H 4-Chloromethyl
L OMe 4-Chloromethyl
a See ref. 22 for preparation. b Corresponds with compound 12 from
Scheme 2.
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60 GF254 that were visualised under UV light (at 254 and/or
360 nm). Microwave irradiation experiments were performed
in a sealed Pyrex tube using a self-tunable CEM Discover or
CEM Explorer focused monomodal microwave synthesizer at
the given temperature using the instrument’s in-built IR tem-
perature measuring device, by varying the irradiation power
(initial power given in parentheses).
Fully characterized compounds were chromatographically
homogeneous. Melting points were determined on a Kofler
hot stage apparatus or Stanford Research Systems Optimelt
and are uncorrected. Specific rotations were measured at the
indicated temperature (in °C) using a ADP440 polarimeter
(Bellingham + Stanley) at the sodium D line and are given in
deg cm3 g−1 dm−1 with concentration c in 10−2 g cm−3. Infra-
red spectra were recorded in the range 4000–600 cm−1 on a
Perkin-Elmer 1600 series FTIR spectrometer using an ATR
probe or using KBr disks or as a nujol mull for solid samples
and thin films between NaCl plates for liquid samples and are
reported in cm−1. NMR spectra were recorded using a Varian
VNMRS instrument operating at 400 or 500 MHz or a Bruker
Avance III 400 MHz for 1H spectra and 101 or 126 MHz for 13C
spectra; J values were recorded in Hz and multiplicities were
expressed by the usual conventions. Low resolution mass
spectra were determined using a Waters Q-TOF Ultima using
electrospray positive ionization, A Waters LCT premier XE
using atmospheric pressure chemical ionization (APcI), an
Agilent 6130 single quadrupole with an APcI/electrospray dual
source, a Fisons Instrument VG Autospec using electron
ionization at 70 eV (low resolution) or a ThermoQuest Finni-
gan LCQ DUO electrospray, unless otherwise stated. TOFMS
refers to time-of-flight mass spectrometry, ES refers to electro-
spray ionization, CI refers to chemical ionization (ammonia),
FTMS refers to Fourier transform mass spectrometry, NSI
refers to nano-electrospray ionization and EI refers to electron
ionization. A number of high resolution mass spectra were
obtained courtesy of the EPSRC Mass Spectrometry Service at
University College of Wales, Swansea, UK using the ionization
methods specified.
Synthetic procedures
3-Methoxybenzoylacetonitrile (6) by Claisen ester conden-
sation using LDA as base (Table 2, entry 6). n-BuLi (2.5 M in
hexanes; 5.3 mL, 13.2 mmol) was added dropwise to a stirred
solution of DIPA (1.9 mL, 13.6 mmol) in dry THF (2 mL) at
0 °C under Ar, and the mixture was stirred at 0 °C for 10 min.
In a separate flask, a solution of methyl 3-methoxybenzoate (9)
(1.1 g, 6.6 mmol) and dry acetonitrile (0.5 mL, 9.5 mmol) in
dry THF (5 mL) was cooled to −50 °C. The cold LDA solution
was added dropwise and the reaction mixture was stirred at
−50 °C for 3 h. Saturated aqueous NH4Cl solution (10 mL) was
then added. The solution was allowed to warm to room tem-
perature, extracted with EtOAc (3 × 20 mL), washed with
aqueous HCl solution (1 M; 20 mL) and brine (20 mL), dried
(MgSO4) and evaporated in vacuo. Purification by column
chromatography on silica gel (dry load), gradient eluting with
hexanes to EtOAc–hexanes (2 : 3), gave the title compound
(0.82 g, 70%) as a yellow solid, mp 86.3–87.4 °C (MeOH) (lit.,42
mp 87–88 °C) (Found [ES]: 198.0523. C10H9NO2Na [MNa]
requires 198.0525); IR (neat) νmax/cm−1 2948 (CH str.), 2252
(CuN str.), 1694 (CvO str.), 1580 (CC), 1451 (CH), 1258 (C–O),
1012 (C–O); 1H NMR (500 MHz, CDCl3) δH/ppm 7.49–7.41 (3H,
2-, 5- and 6-CH), 7.21 (1H, d, J = 8, 4-CH), 4.07 (2H, s, CH2),
3.88 (3H, s, Me); 13C NMR (126 MHz, CDCl3) δC/ppm 186.9 (C),
160.2 (3-C), 135.7 (1-C), 130.1 (5-CH), 121.2 (4-CH), 120.9
(6-CH), 113.6 (CN), 112.8 (2-CH), 55.6 (Me), 29.4 (CH2); m/z (EI)
175 (M•+, 36%), 135 ([M − CH2CN]+, 100).
3-Methoxybenzoylacetonitrile (6) by Claisen ester conden-
sation using NaH as base (Table 2, entry 5). NaH (60% dis-
persion in mineral oil; 0.49 g, 12.0 mmol) was added portion-
wise to a stirred solution of dry MeCN (0.65 mL, 20.3 mmol) in
dry toluene (5 mL) at 0 °C under Ar, and the mixture was
warmed to room temperature and stirred for 2 h. The reaction
mixture was then cooled to 0 °C before dropwise addition of a
solution of methyl 3-methoxybenzoate (9) (1.05 g, 6.3 mmol)
in dry toluene (5 mL). Once complete, the solution was
allowed to warm to room temperature and stirred at 90 °C for
16 h. After cooling, the reaction mixture was filtered and the
filtrate was extracted with water (20 mL). The isolated solids
were then dissolved in the aqueous extract, acidified to pH 3–4
using aqueous HCl solution (1 M), extracted with EtOAc (3 ×
20 mL), dried (Na2SO4) and evaporated in vacuo. Purification
by column chromatography on silica gel (dry load), gradient
eluting with hexanes to EtOAc–hexanes (2 : 3), and recrystalliza-
tion (EtOAc–hexanes) gave the title compound (0.36 g, 34%) as
a colourless solid, mp 87.3–88.2 °C (EtOAc) (lit.,42 mp
87–88 °C), with identical spectroscopic properties.
3-Methoxybenzoylacetonitrile (6) by Heck coupling, followed
by enol ether hydrolysis (Table 1). 3-Methoxyacrylonitrile (5)
(0.28 g, 3.40 mmol) was added to a stirred solution of 3-iodo-
anisole (0.20 g, 0.86 mmol), base (1.71 mmol), tetrabutyl-
ammonium bromide (27 mg, 86 µmol) and Pd(OAc)2 (19 mg,
86 µmol) in water–MeCN (3 : 1) (3 mL) under Ar and the
mixture was heated at 90 °C for 20 h (entries 1 and 2) or irra-
diated at 130 °C or 140 °C for 1–1.5 h in a pressure-rated glass
vial (10 mL) using a CEM Discover microwave synthesizer
(entries 3–6) by moderating the initial power (150 W). After
cooling, the solution was partitioned between water and EtOAc
and the aqueous layer was further extracted with EtOAc (2 ×
10 mL). The organic extracts were combined, washed with
brine (20 mL), dried (Na2SO4) and evaporated in vacuo. The
crude residue was dissolved in MeOH (2 mL) in air and con-
centrated HCl was added (10.2 M; 0.5 mL). The mixture was
irradiated at 110 °C for 1 h in a pressure-rated glass vial
(10 mL) using a CEM Discover microwave synthesiser by mod-
erating the initial power (150 W). After cooling in a flow of
compressed air, the solution was partitioned between water
and EtOAc, and the aqueous layer was further extracted with
EtOAc (2 × 10 mL). The organic extracts were combined,
washed with brine (20 mL), dried and evaporated in vacuo.
Purification by column chromatography on silica gel (dry
load), gradient eluting with hexanes to EtOAc–hexanes (2 : 3),
gave the title compound as a yellow solid, mp 87.0–87.6 °C
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(MeOH) (lit.,42 mp 87–88 °C), with identical spectroscopic
properties.
(E)- and (Z)-3-Methoxy-3-(3-methoxyphenyl)prop-2-enenitrile
(7) by Heck coupling. 3-Methoxyacrylonitrile (5) (0.72 g,
8.7 mmol) was added to a stirred solution of potassium
carbonate (0.63 g, 4.5 mmol), tetrabutylammonium bromide
(80 mg, 0.24 mmol), 3-iodoanisole (0.47 g, 2.0 mmol) and
palladium acetate (50 mg, 0.20 mmol) in water–MeCN (4 : 1)
(12 mL) under Ar and the solution was stirred at 90 °C for
24 h. After cooling, the solution was partitioned between water
and EtOAc and the aqueous layer was further extracted with
EtOAc (2 × 20 mL). The organic extracts were combined,
washed with brine (20 mL), dried (Na2SO4) and evaporated in
vacuo. Purification by column chromatography on silica gel
(dry load), gradient eluting with hexanes to EtOAc–hexanes
(15 : 85), gave the title compounds (0.26 g, 68%; Z : E (1 : 2)) as
yellow oils [Rf 0.5 (Z)-7 and 0.3 (E)-7 in EtOAc–light petroleum
(1 : 4)] (Found [ES]: 212.0679. C11H11NO2Na [MNa] requires
212.0682); IR (neat) νmax/cm−1 3069 (C–H str.), 2950 (C–H str.),
2198 (CuN str.), 1605 (CvC str.), 1579 (C–C str.), 1437 (C–H
bend), 1215 (C–O str.), 1117 (C–O str.), 1047 (C–O str.);
1H NMR (500 MHz, CDCl3) δH/ppm [(Z)-7] 7.31 (1H, t, J = 8,
5′-CH), 7.11 (1H, d, J = 8, 6′-CH), 7.06 (1H, s, 2′-CH), 7.00 (1H,
d, J = 8, 3′-CH), 4.96 (1H, s, 2-CH), 4.24 (3H, s, 3-OMe), 3.84
(3H, s, 3′-OMe); δH/ppm [(E)-7] 7.40–7.33 (2H, 5′,6′-CH), 7.30
(1H, s, 2′-CH), 7.03 (1H, d, J = 7, 4′-CH), 4.65 (1H, s, 2-CH),
3.85 (6H, app s, 3- and 3′-OMe); 13C NMR (126 MHz, CDCl3)
δC/ppm [(Z)-7] 170.9 (3-C), 159.7 (3′-C), 135.3 (1′-C), 129.7 (5′-
CH), 118.9 (6′-CH), 117.3 (CN), 116.7 (4′-CH), 112.2 (2′-CH),
71.2 (2-CH), 59.6 (3-OMe), 55.4 (3′-OMe); δC/ppm [(E)-7] 173.0
(3-C), 159.4 (3′-C), 134.1 (1′-C), 129.5 (5′-CH), 120.3 (6′-CH),
118.4 (CN), 117.4 (4′-CH), 112.9 (2′-CH), 69.9 (2-CH), 56.8
(3-OMe), 55.4 (3′-OMe); m/z (EI) 189 (M•+, 100%), 132 (29),
69 (39).
Methyl 3-methoxybenzoate (9) using conductive heating. A
catalytic amount of concentrated H2SO4 (0.01 mL, 0.20 mmol)
was added to a stirred solution of 3-methoxybenzoic acid (8)
(1.48 g, 9.7 mmol) in MeOH (10 mL) and the mixture was
stirred at reflux for 3 h. After cooling to room temperature, the
solvent was evaporated in vacuo and the residue was parti-
tioned between water and Et2O. The ethereal solution was
washed with saturated aqueous NaHCO3 solution, dried
(Na2SO4) and evaporated in vacuo to give the title compound
(1.45 g, 90%) as a colourless oil (Found [ES]: 189.0520.
C9H10O3Na [MNa] requires 189.0522); IR (neat) νmax/cm−1 2953
(C–H str.), 1718 (CvO str.), 1601 (CC str.), 1276 (C–O str.),
1221 (C–O str.); 1H NMR (500 MHz, CDCl3) δH/ppm 7.64 (1H,
d, J = 8, 6-CH), 7.57 (1H, br. s, 2-CH), 7.35 (1H, t, J = 8, 5-CH),
7.11 (1H, dd, J = 8, 2, 4-CH), 3.92 (3H, s, CO2Me), 3.86 (3H, s,
OMe); 13C NMR (126 MHz, CDCl3) δC/ppm 166.9 (C), 159.6
(3-C), 131.5 (1-C), 129.3 (5-CH), 122.0 (6-CH), 199.5 (4-CH),
144.0 (2-CH), 55.4 (OMe), 52.1 (CO2Me); m/z (EI): 166
(M•+, 14%), 135 ([M − OMe]+, 39), 93 (100).
Methyl 3-methoxybenzoate (9) using microwave irradiation.
A catalytic amount of concentrated H2SO4 (0.01 mL,
0.20 mmol) was added to a stirred solution of 3-methoxy-
benzoic acid (8) (1.48 g, 9.7 mmol) in MeOH (10 mL) and the
mixture was irradiated at 110 °C for 10 min in a pressure-rated
glass tube (35 mL) using a CEM Discover microwave synthe-
sizer by moderating the initial power (200 W). After cooling in
a flow of compressed air, the solvent was evaporated in vacuo
and the residue was partitioned between water and Et2O. The
ethereal solution was washed with saturated aqueous NaHCO3
solution, dried (Na2SO4) and evaporated in vacuo to give the
title compound (1.52 g, 94%) as a colourless oil, with identical
physical and spectroscopic properties.
2-(3-Methoxybenzoyl)-3-(phenylamino)acrylonitrile (11). A
solution of 3-methoxybenzoylacetonitrile (6) (0.20 g, 1.1 mmol)
and N,N′-diphenylformamidine (10) (0.24 g, 1.2 mmol) in dry
xylenes (7.5 mL) was irradiated at 180 °C under Ar for 20 min
in a pressure-rated glass tube (35 mL) using a CEM Discover
microwave synthesizer by moderating the initial power (200 W).
After cooling in a stream of compressed air, the solution
was diluted with hexanes to give a precipitate. Isolation by
gravity filtration gave the title compound (0.23 g, 74%) as a col-
ourless solid, mp 107.4–108.8 °C (lit.,22 mp 105 °C) (Found
[ES]: 279.1126. C17H15N2O2 [MH] requires 279.1128); IR (neat)
νmax/cm−1 3062 (C–H str.), 2921 (C–H str.), 2204 (CuN str.),
1634 (CvO str.), 1596 (N–H bend), 1571 (C–C str.), 1392 (C–C
str.), 1313 (C–N str.), 1225 (C–O str.), 1044 (C–O str.), 990 (C–H
bend), 867 (N–H wag); 1H NMR (500 MHz, CDCl3) δH/ppm
12.76 (1H, d, J = 12, NH), 8.06 (1H, d, J = 12, 3-CH), 7.57 (1H,
d, J = 8, 6′-CH), 7.46 (3H, m, 2′-, 3″, and 5″-CH), 7.40 (1H, t, J =
8, 5′-CH), 7.30 (1H, m, 4″-CH), 7.23 (2H, d, J = 8, 2″- and
6″-CH), 7.11 (1H, d, J = 8, 6′-CH), 3.89 (3H, s, Me); 13C NMR
(126 MHz, CDCl3) δC/ppm 192.1 (C), 159.6 (3′-C), 154.1 (3-CH),
139.2 (1′-C), 138.1 (1″-C), 130.2 (3″, 5″-CH), 129.4 (5′-CH), 126.6
(4″-CH), 120.5 (6′-CH), 120.3 (1-CN), 118.9 (4′-CH), 117.9
(2″, 6″-CH), 112.7 (2′-CH), 83.5 (2-C), 55.5 (Me); m/z (EI): 278
(M•+, 49%), 277 ([M − H]+, 100), 135 (52).
[5-Amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-3-methoxyphenyl
ketone (12). A mixture of 2-(3-methoxybenzoyl)-3-(phenyl-
amino)acrylonitrile (11) (0.13 g, 0.46 mmol), 4-fluorophenylhy-
drazine hydrochlororide (3·HCl) (73 mg, 0.47 mmol) and
triethylamine (20 µL, 140 µmol) in ethanol (3 mL) was irra-
diated at 140 °C for 1 h in a pressure-rated glass vial (10 mL)
using a CEM Discover microwave synthesizer by moderating
the initial power (150 W). After cooling in a stream of com-
pressed air, the solvent was evaporated in vacuo. Purification
by column chromatography on silica gel (dry load), gradient
eluting with hexanes to EtOAc–hexanes (3 : 7), gave the title
compound (0.11 g, 86%) as a pink solid, mp 130.1–132.0 °C
(Found [ES]: 312.1138. C17H15FN3O2 [MH] requires 312.1143);
IR (neat) νmax/cm−1 3318 (N–H str.), 2925 (C–H str.), 1610
(CvO str.), 1595 (N–H bend), 1539 (C–C str.), 1286 (C–N str.),
1223 (C–O str.), 1051 (C–O str.), 838 (N–H wag); 1H NMR
(400 MHz, CDCl3) δH/ppm 7.81 (1H, s, 3-CH), 7.56 (2H, m, 2′,
6′-CH), 7.42 (2H, m, 5″, 6″-CH), 7.35 (1H, s, 2″-CH), 7.25 (2H,
m, 3′, 5′-CH), 7.11 (1H, m, 4″-CH), 6.04 (2H, bs, exch. D2O,
NH2), 3.89 (3H, s, Me); 13C NMR (101 MHz, CDCl3) δC/ppm
189.4 (C), 162.2 (d, 1JCF = 250, 4′-CF), 159.8 (3″-C), 150.6 (5-C),
142.0 (3-CH), 141.1 (1″-C), 133.3 (d, 4JCF = 4, 1′-C), 129.5
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(5″-CH), 126.1 (d, 3JCF = 9, 2′, 6′-CH), 120.7 (6″-CH), 117.8 (4″-
CH), 116.9 (d, 2JCF = 23, 3′, 5′-CH), 113.0 (2″-CH), 104.8 (4-C),
55.4 (OMe); m/z (APcI) 312 (MH+, 100%).
[5-Amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-3-hydroxyphenyl
ketone (13). Boron tribromide solution (1 M in CH2Cl2;
1.7 mL, 1.70 mmol) was added dropwise to a solution of
[5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-3-methoxyphenyl
ketone (12) (0.10 g, 0.34 mmol) in dry CH2Cl2 (1 mL) at 0 °C
under Ar. The mixture was allowed to warm to room tempera-
ture and stirred for 20 h. Water (15 mL) was then added cau-
tiously and the mixture was extracted with EtOAc (3 × 15 mL).
The organic extracts were combined, washed with brine, dried
(MgSO4) and evaporated in vacuo to give the title compound
(0.10 g, quant.) as a brown solid, mp 192.2–194.9 °C (Found
[ES]: 298.0984. C16H13FN3O2 [MH] requires 298.0986); IR (neat)
νmax/cm−1 3320 (N–H str.), 3204 (br. O–H), 3072 (C–H str.),
1610 (CvO str.), 1592 (N–H bend), 1538 (C–C str.), 1310 (C–N
str.), 1126 (C–O str.), 841 (N–H wag); 1H NMR (500 MHz,
CD3OD) δH/ppm 7.78 (1H, s, 3-CH), 7.59 (2H, m, 2′, 6′-CH),
7.37–7.29 (3H, 3′, 5′- and 5″-CH), 7.23 (1H, d, J = 7, 6″-CH),
7.18 (1H, s, 2″-CH), 7.00 (1H, dd, J = 7, 1, 4″-CH); 13C NMR
(100 MHz, CD3OD) δC/ppm 191.6 (C), 164.1 (d, 1JCF = 247, 4′-
CF), 159.2 (3″-C), 153.4 (5-C), 143.6 (3-CH), 142.7 (1″-C), 135.0
(d, 4JCF = 3, 1′-C), 131.1 (5″-CH), 128.5 (d, 3JCF = 9, 2′, 6′-CH),
120.6 (6″-CH), 120.1 (4″-CH), 118.0 (d, 3JCF = 24, 3′, 5′-CH),
116.0 (2″-CH), 105.7 (4-C); m/z (EI) 297 (M•+, 91%), 296
([M − H]+, 100), 204 (31).
5-Amino-1-(4-fluorophenyl)-4-{3-[2(S)-3-dihydroxypropoxy]-
benzoyl}pyrazole (RO3201195) (1). (S)-2,2-Dimethyl-1,3-dioxo-
lan-4-ylmethyl p-toluenesulfonate (14) (0.60 mL, 2.5 mmol)
and anhydrous K2CO3 (0.59 g, 4.25 mmol) were added to a
solution of [5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-3-
hydroxyphenyl ketone (13) (0.48 g, 1.61 mmol) in dry DMSO
(15 mL) under argon and the mixture was heated at 100 °C for
40 h. After cooling, the solution was diluted with water
(25 mL) and extracted with EtOAc (3 × 20 mL). The organic
extracts were combined, washed with brine, dried (MgSO4) and
evaporated in vacuo. Purification by column chromatography
on silica gel (dry load), gradient eluting with light petroleum
to EtOAc–light petroleum (2 : 3), gave [5-amino-1-(4-fluoro-
phenyl)-1H-pyrazol-4-yl] {3-[(R)-2,2-dimethyl-1,3-dioxolan-4-yl)-
methoxy]phenyl} ketone (15), which was dissolved in MeOH–
water (4 : 1) (4 mL). p-Toluene sulfonic acid monohydrate
(40 mg, 0.21 mmol) was added and the solution was heated at
50 °C for 18 h. After cooling, the solvent was evaporated in
vacuo. The residue was dissolved in EtOAc, washed with satu-
rated aqueous NaHCO3 solution, dried (MgSO4) and evapor-
ated in vacuo. Purification by column chromatography on
silica gel (dry load), gradient eluting with light petroleum to
EtOAc, followed by recrystallization (EtOAc–hexanes) gave the
title compound (0.22 g, 37%) as a colourless solid, mp
154.1–154.6 °C (EtOAc) (Found [ES]: 372.1353. C19H19FN3O4
[MH] requires 372.1354); [α]21D −28 (c 0.2, EtOAc); [α]22D + 6.5
(c 0.6, MeOH); IR (neat) νmax/cm−1 3440 (N–H str.), 3330 (O–H
str.), 3229 (O–H str.), 2896 (C–H str.), 1633 (CvO str.), 1597
(NH2 str.), 1540 (CvN str.), 1498 (C–C str.), 1292 (C–O str.),
1222 (C–F str.), 1053 (C–O str.), 839 (NH2 wag.); 1H NMR
(500 MHz, d6-DMSO) δH/ppm 7.80 (1H, s, 3H), 7.61 (2H, m, 2′,
6′-CH), 7.47–7.37 (3H, 3′, 4′- and 5″-CH), 7.33 (1H, d, J = 7,
6″-CH), 7.25 (1H, m, 2″-CH), 7.14 (3H, 4″-CH and NH2), 4.95
(1H, bs, CHOH), 4.65 (1H, bs, CH2OH), 4.09 (1H, m, OCHH),
3.95 (1H, m, OCHH), 3.82 (1H, m, CHOH), 3.47 (2H, d, J = 5,
CH2OH); 13C NMR (126 MHz, d6-DMSO) δC/ppm 187.5 (C),
161.1 (d, 1JCF = 244, 4′-C), 158.7 (3″-C), 151.2 (5-C), 141.4
(3-CH), 140.9 (1″-C), 133.7 (d, 4JCF = 3, 1′-C), 129.6 (5″-CH),
126.4 (d, 3JCF = 9, 2′, 6′-CH), 120.1 (6″-CH), 117.8 (4″-CH), 116.3
(d, 2JCF = 23, 3′, 5′-CH), 113.3 (2″-CH), 103.5 (4-C), 69.9
(CHOH), 69.8 (CH2O), 62.6 (CH2OH); m/z (EI) 371 (M•+, 10%),
325 (33), 160 (100).
Cells and cell growth
Human adult dermal primary Werner syndrome AG05229 and
AG03141 fibroblasts were obtained from the Coriell Cell Re-
positories (Camden, NJ, USA). WStert cells are AG03141 fibro-
blasts that have been immortalised by the ectopic expression
of human enzyme telomerase and have been described
previously.14
Cells were grown in DMEM growth medium as previously
described.15 Cell proliferation rates for the WStert cells were
measured as cumulated population doublings (CPDs) divided
by the number of days of the experiment concerned and
expressed as a percentage of the proliferation rate of control
cells (with the control being 100%). The number of CPDs
achieved at each passage of the cells was calculated according
to the formula: PDs = log(Nt/No)/log2, where Nt is number of
cells counted and No is number of cells seeded. For primary
cells the CPDs were plotted versus days in culture. For asses-
sing the eﬀects of the various kinase inhibitors the culture
medium was supplemented with the inhibitor dissolved in
DMSO, with the medium being replaced daily. For controls an
equivalent volume of the inhibitor solvent (DMSO) was added
to the medium.
P38 inhibitor assay
The ability of SB203580 and RO3201195 to inhibit the p38α
signalling pathway was tested in human immortalised HCA2
cells using an ELISA system (obtained from Cell Signalling,
NEB, UK) as previously described.39 Kinase activity was
detected using antibodies specific for HSP27 and its phos-
phorylated form, the degree of activation being measured as
the ratio of phospho-protein/total protein (Fig. 2d and e). In
this system activation of p38α by anisomycin activates the
kinase MK2 that then phosphorylates the small heat shock
protein HSP27. As MK2 is the major HSP27 kinase,43 the
activity of p38α can be assessed by the phosphorylation status
of HSP27.
Immunoblot assays for stress kinase activity in WS cells
The ability of SB203580 and RO3201195 to inhibit the p38α
and JNK signalling pathways in WStert cells was tested by
immunoblot detection of the phosphorylated versions of their
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downstream targets HSP27 (pHSP27) and c-Jun (p-c-Jun) as
previously described.15,44
Conclusions
This manuscript describes the chemical synthesis and biologi-
cal evaluation of a p38α MAPK inhibitor, RO3201195 (1), in
WS cells. Two complementary routes for the chemical syn-
thesis of a key intermediate, benzoylacetonitrile 6, are
described, both of them involving the use of microwave dielec-
tric heating for rapid reaction kinetics. Of these two routes, a
classical approach based upon a Claisen ester condensation
was found to be the most eﬃcient. The benzoylacetonitrile
intermediate 6 was transformed by Knoevenagel condensation,
followed by cyclocondensation with a hydrazine, both under
microwave irradiation, to give the core pyrazole motif. Phenox-
ide alkylation by SN2 displacement of tosylate, followed by
ketal deprotection, gave the target inhibitor in a sequence of
7 steps and 15% overall yield.
The eﬀects of RO3201195 (1) on cellular proliferation were
first examined using WStert cells, where it was found that the
inhibitor elicited a very similar response to the prototypical
p38 MAPK inhibitor SB203580. The maximal increase seen in
the proliferation rate of WStert cells was 19% at 10.0 µM con-
centration of RO3201195 (1). At this concentration, the inhibi-
tor completely inhibited p38α but did not inhibit total JNK
activity in WStert cells, as determined by immunoblot assay.
Following these findings, the cellular senescence of primary
Werner syndrome fibroblast strain WAG05229 was investigated
on treatment with SB203580 or RO3201195 (1). Despite the
fact that these inhibitors showed very diﬀerent kinase speci-
ficity profiles at the concentrations used, the eﬀects on WS
cells were essentially identical. Thus, we concluded that the
eﬀects on proliferation of treating WStert cells or primary WS
fibroblasts with SB203580 or RO3201195 (1) resulted from
inhibition of p38α. This was further supported by studying the
eﬀects of a pyrazolyl ketone library on WStert cells at a given
concentration, which showed a linear relationship between the
proliferation rate and % p38α activity. Thus, we conclude
RO3201195 (1) is a useful chemical tool for dissecting signal-
ling pathways in human cells in order to understand the eﬀect
of p38 MAPK signalling upon cell proliferation in this human
progeroid syndrome.
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Chapter 2: 1H NMR, 13C NMR, IR and Mass 
spectra 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Methyl 3-methoxybenzoate (123) 
  
 1
H 
NM
R 
Sp
ec
tr
um
 (5
00
 M
Hz
, C
DC
l 3)
 fo
r m
et
hy
l 3
-m
et
ho
xy
be
nz
oa
te
  
 B0
4J
D
03
1B
 P
ro
to
n 
fo
r C
ar
bo
n.
es
p
9.
5
9.
0
8.
5
8.
0
7.
5
7.
0
6.
5
6.
0
5.
5
5.
0
4.
5
4.
0
3.
5
3.
0
2.
5
2.
0
1.
5
1.
0
0.
5
Ch
em
ic
al
 S
hi
ft 
(p
pm
)
3.
13
3.
00
0.
86
0.
91
0.
82
0.
83
M
06
(s
)
M
02
(s
)
M
05
(s
)
M
01
(d
)
M
04
(d
d)
M
03
(t)
3.86
3.92
7.10
7.10
7.11
7.12
7.27
7.33
7.35
7.36
7.57
7.63
7.65
13
C 
NM
R 
sp
ec
tr
um
 (1
26
 M
Hz
, C
DC
l 3)
 fo
r m
et
hy
l 3
-m
et
ho
xy
be
nz
oa
te
 
B
04
JD
03
1B
 C
A
R
B
O
N
_0
1.
es
p
19
2
18
4
17
6
16
8
16
0
15
2
14
4
13
6
12
8
12
0
11
2
10
4
96
88
80
72
64
56
48
40
32
24
16
8
0
Ch
em
ic
al
 S
hi
ft 
(p
pm
)
52.09
55.41
77.00
114.04
119.48
121.98
129.34
131.51
159.61
166.93



3-Methoxybenzoylacetonitrile (107) 
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(E)-3-Methoxy-3-(3-methoxyphenyl)prop-2-enenitrile (129-E) 
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(Z)-3-Methoxy-3-(3-methoxyphenyl)prop-2-enenitrile (129-Z) 
 
  
1 H
 N
M
R 
Sp
ec
tr
um
 (5
00
 M
Hz
, C
DC
l 3)
 fo
r (
Z)
-3
-m
et
ho
xy
-3
-(3
-m
et
ho
xy
ph
en
yl
)p
ro
p-
2-
en
en
itr
ile
 
B
04
JD
05
9_
F1
 .e
sp
9.
5
9.
0
8.
5
8.
0
7.
5
7.
0
6.
5
6.
0
5.
5
5.
0
4.
5
4.
0
3.
5
3.
0
2.
5
2.
0
1.
5
1.
0
0.
5
0
Ch
em
ic
al
 S
hi
ft 
(p
pm
)
3.
30
3.
00
0.
88
0.
91
0.
91
0.
96
1.
04
M
03
(s
)
M
05
(s
)
M
07
(s
)
M
04
(d
)
M
06
(s
)
M
02
(d
)
M
01
(m
)
7.33
7.32
7.30
7.27
7.13
7.11
7.06
7.01
7.00
4.96
4.25
3.84
13
C 
NM
R 
Sp
ec
tr
um
 (1
26
 M
Hz
, C
DC
l 3)
 fo
r (
Z)
-3
-m
et
ho
xy
-3
-(3
-m
et
ho
xy
ph
en
yl
)p
ro
p-
2-
en
en
itr
ile
 
B
04
JD
05
9_
F1
 c
ar
bo
n.
es
p
19
2
18
4
17
6
16
8
16
0
15
2
14
4
13
6
12
8
12
0
11
2
10
4
96
88
80
72
64
56
48
40
32
24
16
8
0
Ch
em
ic
al
 S
hi
ft 
(p
pm
)
170.89
159.74
135.32
129.69
118.94
117.28
116.69
112.18
77.00
71.25
59.58
55.38


2-(3-Methoxybenzoyl)-3-(phenylamino)prop-2-enenitrile (124) 
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[5-Amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-3-methoxyphenyl 
ketone (125) 
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[5-Amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-3-hydroxyphenyl 
ketone (126) 
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[5-Amino-1-(4-fluorophenyl)-1H-pyrazo-4-yl]{3-[(R)-2,2-dimethyl-1,3-
dioxolan-4-yl)methoxy]phenyl} ketone (136) 
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5-Amino-1-(4-fluorophenyl)-4-{3-[2(S)-3-
dihydroxypropoxy]benzoyl} pyrazole (RO3201195) (10) 
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Chapter 3: 1H NMR, 13C NMR, IR and Mass 
spectra 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2-Chloro-6-nitroquinoline (151) 
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2-(6-Methylpyridin-3-yl)-6-nitroquinoline (153) 
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6-Nitro-2-(pyridin-3-yl)quinoline (152) 
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6-Amino-5-cyanoquinoline (144) 
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Methyl 5-nitrobenzo[b]thiophene-2-carboxylate (162)  
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5-Nitrobenzo[b]thiophene-2-carboxylic acid (167)  
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3-Bromo-5-nitrobenzo[b]thiophene-2-carboxylic acid (168) 
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Methyl 3-bromo-5-nitrobenzo[b]thiophene-2-carboxylate (164)  
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Methyl 3-amino-5-nitrobenzothiophene-2-carboxylate (170) 
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Methyl 5-aminobenzo[b]thiophene-2-carboxylate (158)  
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Methyl 5-amino-3-bromobenzo[b]thiophene-2-carboxylate (165)  
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(2E)-3-Ethoxyprop-2-enoyl chloride 
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Methyl 3-bromo-5-{[(2E)-3-ethoxyprop-2-enoyl]amino} 
benzo[b]thiophene-2-carboxylate (171) 
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3,3-Dimethoxypropanoic acid (172) 
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Methyl 5-(3,3-dimethoxypropanamido)benzo[b]thiophene-2-
carboxylate (174)  
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Methyl 3-bromo-5-(3,3-dimethoxypropanamido)benzo[b] 
thiophene-2-carboxylate (175) 
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Methyl 7-oxo-6,7-dihydrothieno[3,2-f]quinoline-2-carboxylate 
(160A and 160B)  
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Methyl 1-bromo-7-oxo-6,7-dihydrothieno[3,2-f]quinoline-2-
carboxylate (176A and 176B)  
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Methyl 1-bromo-7-chlorothieno[3,2-f]quinoline-2-carboxylate (166)  
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Methyl 7-chloro-1-(6-methylpyridin-3-yl)thieno[3,2-f]quinoline-2-
carboxylate (177) 
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(R)-tert-Butyl-(1-amino-1-oxopropan-2-yl)carbamate (182)   
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tert-Butyl ([2R]-1-aminopropan-2-yl)carbamate (137)  
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(R)-Methyl 3-((2-((tert-butoxycarbonyl)amino)propyl)amino)-
benzo[b]thiophene-2-carboxylate (184) 
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(R)-Methyl 3-((2-((tert-butoxycarbonyl)amino)propyl)amino)-5-
nitrobenzo[b]thiophene-2-carboxylate (185)  
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(3R)-3-Methyl-9-nitro-1,2,3,4-tetrahydro-5H-[1]benzothieno[3,2-
e][1,4]diazepin-5-one (178)  
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(3R)-9-Amino-3-methyl-1,2,3,4-tetrahydro-5H-[1]benzothieno[3,2-
e][1,4]diaepin-5-one (179) 
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3,3-Dimethoxy-N-((3R)-3-methyl-5-oxo-2,3,4,5-tetrahydro-1H-
[1]benzo[4,5]thieno[3,2-e][1,4]diazepin-9-yl)propanamide (186) 
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Methyl 7-(pyridin-3-yl)thieno[3,2-f]quinoline-2-carboxylate (195A) 
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Methyl 6-methylthieno[2,3-g]quinoline-2-carboxylate (196) 
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6-Methylpyridine-3-carboxaldehyde (190) 
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(R)-10-Methyl-3-(6-methylpyridin-3-yl)-9-10-11-12-tetrahydro-8H-
[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoline-8-one. PF-3644022 
(25) 
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Methyl 7-phenylthieno[3,2-f]quinoline-2-carboxylate (199) 
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Methyl 7-(6-methylpyridin-3-yl)thieno[3,2-f]quinoline-2-
carboxylate (200) 
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Chapter 4: 1H NMR, 13C NMR, IR and Mass 
spectra and DSF results 
 
3-tert-Butyl-1-phenyl-1H-pyrazole-5-amine (215)  
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N-(3-(tert-Butyl)-1-phenyl-1H-pyrazol-5-yl)-N’-(naphthalene-1-
yl)urea (215A)  
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N-(3-(tert-Butyl)-1-phenyl-1H-pyrazol-5-yl)-N’-(naphthalene-2-
yl)urea (215B) 
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N-(3-(tert-Butyl)-1-phenyl-1H-pyrazol-5-yl)-N’-(o-tolyl)urea (215C)  
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N-(3-(tert-Butyl)-1-phenyl-1H-pyrazol-5-yl)-N’-(4-ethoxyphenyl)urea 
(215D) 
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N-(3-(tert-Butyl)-1-phenyl-1H-pyrazol-5-yl)-N’-(4-fluorophenyl)urea 
(215E) 
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N-(3,5-Bis(trifluoromethyl)phenyl)-N’-(3-(tert-butyl)-1-phenyl-1H-
pyrazol-5-yl)urea (215F) 
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Table 1 Crystal data and structure refinement for BIRB_libhit1.
Identification code BIRB_libhit1
Empirical formula C22H20F6N4O
Formula weight 470.42
Temperature/K 173.0
Crystal system monoclinic
Space group P21/c
a/Å 14.621(4)
b/Å 16.734(6)
c/Å 8.879(3)
α/° 90
β/° 100.61(3)
γ/° 90
Volume/Å3 2135.4(12)
Z 4
ρcalcg/cm
3 1.463
BIRB_libhit1
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μ/mm‑1 1.119
F(000) 968.0
Crystal size/mm3 0.2 × 0.04 × 0.02
Radiation CuKα (λ = 1.54184)
2Θ range for data collection/° 8.11 to 79.926
Index ranges ­12 ≤ h ≤ 12, ­13 ≤ k ≤ 13, ­7 ≤ l ≤ 5
Reflections collected 2308
Independent reflections 1271 [Rint = 0.0540, Rsigma = 0.1074]
Data/restraints/parameters 1271/267/302
Goodness­of­fit on F2 1.056
Final R indexes [I>=2σ (I)] R1 = 0.0848, wR2 = 0.2201
Final R indexes [all data] R1 = 0.1342, wR2 = 0.2902
Largest diff. peak/hole / e Å­3 0.27/­0.30
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Table 2 Fractional Atomic Coordinates (×104) and Equivalent Isotropic
Displacement Parameters (Å2×103) for BIRB_libhit1. Ueq is defined as
1/3 of of the trace of the orthogonalised UIJ tensor.
Atom x y z U(eq)
F1 9182(6) 615(7) 4684(11) 106(4)
F2 9676(6) 1788(7) 5096(11) 103(3)
F3 10234(6) 877(7) 6629(10) 103(4)
F4 7556(6) 1271(6) 11324(10) 92(3)
F5 8692(6) 500(5) 11145(9) 84(3)
F6 8918(6) 1741(5) 11492(10) 87(3)
O1 5687(6) 2615(5) 7743(10) 61(3)
N1 2990(8) 3912(7) 5520(13) 55(3)
N2 3804(8) 3679(7) 5005(13) 57(3)
N3 4836(7) 2560(7) 5355(12) 56(4)
N4 6304(7) 2001(7) 5873(12) 54(3)
C1 2814(10) 3372(9) 6517(17) 59(4)
C2 3490(10) 2760(9) 6659(16) 57(4)
C3 4059(10) 2966(9) 5733(16) 52(4)
C4 5640(10) 2401(8) 6399(17) 44(4)
C5 7169(10) 1751(8) 6694(17) 54(4)
C6 7867(10) 1570(8) 5946(17) 55(4)
C7 8738(10) 1297(9) 6687(18) 58(4)
C8 8876(11) 1180(9) 8248(18) 67(4)
C9 8172(11) 1343(9) 9053(17) 63(4)
C10 7302(10) 1604(8) 8255(16) 58(4)
C11 9451(13) 1127(13) 5820(20) 84(4)
C12 8315(13) 1217(11) 10695(19) 73(4)
C13 2016(10) 3470(9) 7334(16) 61(4)
C14 1196(10) 3854(10) 6277(17) 75(5)
C15 1720(10) 2666(9) 7862(18) 76(5)
C16 2322(10) 3996(10) 8758(17) 78(5)
C17 4102(12) 4168(9) 3875(18) 64(4)
C18 3491(11) 4556(9) 2833(16) 68(5)
C19 3811(12) 5064(10) 1812(17) 73(5)
C20 4763(13) 5123(10) 1890(18) 81(5)
C21 5350(12) 4719(9) 2946(18) 71(4)
C22 5051(11) 4217(9) 3995(18) 69(4)
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Table 3 Anisotropic Displacement Parameters (Å2×103) for BIRB_libhit1. The
Anisotropic displacement factor exponent takes the form:
­2π2[h2a*2U11+2hka*b*U12+…].
Atom U11 U22 U33 U23 U13 U12
F1 84(7) 129(8) 101(7) ­36(6) 9(5) 22(6)
F2 91(7) 122(8) 104(7) 5(6) 41(6) 15(6)
F3 75(6) 140(9) 92(7) ­4(6) 8(5) 25(6)
F4 86(6) 117(8) 70(6) 22(5) 9(5) 7(5)
F5 106(7) 67(6) 71(6) 9(4) ­6(5) 9(5)
F6 95(7) 81(7) 76(6) ­6(5) ­4(5) ­5(5)
O1 70(7) 68(7) 41(6) ­5(5) 2(5) 2(5)
N1 51(6) 57(7) 53(7) ­4(5) ­3(5) ­5(5)
N2 49(6) 55(7) 60(7) ­3(5) ­3(5) ­7(5)
N3 50(6) 74(8) 41(7) ­9(6) 0(5) 6(5)
N4 53(6) 57(8) 51(7) ­5(6) 6(5) 7(5)
C1 58(7) 54(8) 64(8) 0(6) 5(6) 1(5)
C2 60(8) 56(8) 51(8) 0(6) 3(6) 0(6)
C3 51(7) 56(7) 47(8) ­4(5) 1(5) 2(6)
C4 41(7) 48(9) 41(7) 0(6) 2(5) ­7(6)
C5 52(7) 49(9) 55(7) 3(6) ­2(5) ­2(6)
C6 53(7) 47(10) 62(8) 3(7) 1(5) 2(6)
C7 55(7) 53(9) 61(7) 1(6) ­4(5) 6(6)
C8 75(8) 54(11) 65(7) 2(6) ­3(6) 2(7)
C9 72(7) 56(9) 55(6) 2(5) ­7(5) ­5(7)
C10 64(7) 49(9) 57(7) 2(6) 0(5) ­12(6)
C11 71(8) 104(9) 74(8) ­6(6) 9(6) 12(6)
C12 85(8) 71(8) 57(7) 8(5) ­4(6) 5(6)
C13 58(7) 64(8) 60(7) 5(6) 5(5) 3(6)
C14 62(8) 83(11) 80(9) 15(8) 12(7) 6(7)
C15 78(11) 76(8) 72(10) 10(7) 13(8) 2(7)
C16 63(10) 91(11) 81(9) ­13(7) 16(7) 3(8)
C17 80(7) 52(9) 55(8) ­3(6) ­1(6) ­7(7)
C18 81(8) 66(10) 53(8) ­1(7) 2(6) 7(7)
C19 104(9) 62(10) 55(9) ­1(7) 20(7) 20(8)
C20 104(9) 62(11) 79(11) ­8(8) 27(8) 19(8)
C21 94(9) 35(10) 85(10) ­16(7) 19(7) 9(7)
C22 79(8) 49(10) 73(9) ­9(7) 0(7) ­2(7)
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Table 4 Bond Lengths for BIRB_libhit1.
AtomAtom Length/Å   AtomAtom Length/Å
F1 C11 1.327(19)   C5 C6 1.351(18)
F2 C11 1.35(2)   C5 C10 1.386(18)
F3 C11 1.303(18)   C6 C7 1.399(18)
F4 C12 1.333(19)   C7 C8 1.377(19)
F5 C12 1.350(17)   C7 C11 1.43(2)
F6 C12 1.349(17)   C8 C9 1.38(2)
O1 C4 1.236(14)   C9 C10 1.407(19)
N1 N2 1.406(15)   C9 C12 1.45(2)
N1 C1 1.323(17)   C13 C14 1.523(19)
N2 C3 1.376(17)   C13 C15 1.51(2)
N2 C17 1.424(19)   C13 C16 1.539(19)
N3 C3 1.416(17)   C17 C18 1.332(19)
N3 C4 1.382(16)   C17 C22 1.37(2)
N4 C4 1.334(16)   C18 C19 1.39(2)
N4 C5 1.401(16)   C19 C20 1.39(2)
C1 C2 1.412(19)   C20 C21 1.333(19)
C1 C13 1.49(2)   C21 C22 1.38(2)
C2 C3 1.319(18)        
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Table 5 Bond Angles for BIRB_libhit1.
AtomAtomAtom Angle/˚   AtomAtom Atom Angle/˚
C1 N1 N2 107.9(12)   C5 C10 C9 120.5(15)
N1 N2 C17 117.2(12)   F1 C11 F2 103.4(15)
C3 N2 N1 105.1(12)   F1 C11 C7 113.2(16)
C3 N2 C17 137.5(14)   F2 C11 C7 111.0(16)
C4 N3 C3 123.6(12)   F3 C11 F1 108.6(16)
C4 N4 C5 127.8(12)   F3 C11 F2 105.1(16)
N1 C1 C2 109.7(14)   F3 C11 C7 114.8(16)
N1 C1 C13 121.1(14)   F4 C12 F5 105.2(14)
C2 C1 C13 129.2(15)   F4 C12 F6 104.5(14)
C3 C2 C1 105.5(15)   F4 C12 C9 115.8(14)
N2 C3 N3 117.7(14)   F5 C12 C9 113.7(14)
C2 C3 N2 111.8(15)   F6 C12 F5 103.3(13)
C2 C3 N3 130.5(15)   F6 C12 C9 113.1(15)
O1 C4 N3 118.8(14)   C1 C13 C14 110.1(12)
O1 C4 N4 124.7(14)   C1 C13 C15 110.3(13)
N4 C4 N3 116.5(13)   C1 C13 C16 109.1(12)
C6 C5 N4 120.2(13)   C14 C13 C16 110.0(13)
C6 C5 C10 118.1(14)   C15 C13 C14 109.2(12)
C10 C5 N4 121.4(14)   C15 C13 C16 108.1(13)
C5 C6 C7 123.2(14)   C18 C17 N2 121.1(15)
C6 C7 C11 120.1(15)   C18 C17 C22 124.3(16)
C8 C7 C6 118.1(15)   C22 C17 N2 114.6(15)
C8 C7 C11 121.8(15)   C17 C18 C19 119.4(16)
C7 C8 C9 120.5(15)   C18 C19 C20 117.9(16)
C8 C9 C10 119.3(15)   C21 C20 C19 120.7(18)
C8 C9 C12 120.6(15)   C20 C21 C22 122.6(17)
C10 C9 C12 120.1(16)   C17 C22 C21 115.1(16)
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Table 6 Torsion Angles for BIRB_libhit1.
A B C D Angle/˚   A B C D Angle/˚
N1N2 C3 N3 176.2(11)   C5 C6 C7 C8 2(2)
N1N2 C3 C2 ­1.4(15)   C5 C6 C7 C11 ­179.1(16)
N1N2 C17C18 ­32.1(19)   C6 C5 C10C9 6(2)
N1N2 C17C22 146.0(12)   C6 C7 C8 C9 ­1(2)
N1C1 C2 C3 0.5(16)   C6 C7 C11 F1 ­55(2)
N1C1 C13C14 36.0(19)   C6 C7 C11 F2 61(2)
N1C1 C13C15 156.6(13)   C6 C7 C11 F3 180.0(15)
N1C1 C13C16 ­84.8(16)   C7 C8 C9 C10 2(2)
N2N1 C1 C2 ­1.4(15)   C7 C8 C9 C12 179.8(14)
N2N1 C1 C13 177.0(11)   C8 C7 C11 F1 123.7(17)
N2C17C18C19 176.1(13)   C8 C7 C11 F2 ­120.6(16)
N2C17C22C21­177.2(12)   C8 C7 C11 F3 ­2(3)
N4C5 C6 C7 ­178.2(13)   C8 C9 C10C5 ­4(2)
N4C5 C10C9 179.0(13)   C8 C9 C12F4 ­170.0(14)
C1 N1 N2 C3 1.7(14)   C8 C9 C12F5 ­48(2)
C1 N1 N2 C17 177.9(11)   C8 C9 C12F6 69(2)
C1 C2 C3 N2 0.6(16)   C10C5 C6 C7 ­5(2)
C1 C2 C3 N3 ­176.6(13)   C10C9 C12F4 8(2)
C2 C1 C13C14­145.9(15)   C10C9 C12F5 129.8(15)
C2 C1 C13C15 ­25(2)   C10C9 C12F6 ­112.8(17)
C2 C1 C13C16 93.3(18)   C11 C7 C8 C9 ­179.4(16)
C3 N2 C17C18 142.5(16)   C12C9 C10C5 177.8(14)
C3 N2 C17C22 ­39(2)   C13C1 C2 C3 ­177.7(14)
C3 N3 C4 O1 1(2)   C17N2 C3 N3 1(2)
C3 N3 C4 N4 178.8(13)   C17N2 C3 C2 ­176.4(15)
C4 N3 C3 N2 118.2(14)   C17C18C19C20 2(2)
C4 N3 C3 C2 ­65(2)   C18C17C22C21 1(2)
C4 N4 C5 C6 ­160.1(14)   C18C19C20C21 ­2(2)
C4 N4 C5 C10 27(2)   C19C20C21C22 1(2)
C5 N4 C4 O1 ­1(2)   C20C21C22C17 0(2)
C5 N4 C4 N3 ­178.5(12)   C22C17C18C19 ­2(2)
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Experimental
Single  crystals  of  C22H20F6N4O  [BIRB_libhit1] were  []. A  suitable  crystal  was  selected  and  []  on  a Xcalibur,  Eos,
Gemini ultra diffractometer. The crystal was kept at 173.0 K during data collection. Using Olex2 [1], the structure was solved
with the ShelXT [2] structure solution program using Direct Methods and refined with the ShelXL [3] refinement package using
Least Squares minimisation.
1. Dolomanov, O.V., Bourhis, L.J., Gildea, R.J, Howard, J.A.K. & Puschmann, H. (2009), J. Appl. Cryst. 42, 339­341.
2. Sheldrick, G.M. (2008). Acta Cryst. A64, 112­122.
3. Sheldrick, G.M. (2008). Acta Cryst. A64, 112­122.
Crystal structure determination of [BIRB_libhit1]
Crystal Data  for  C22H20F6N4O  (M =470.42  g/mol):  monoclinic,  space  group  P21/c  (no.  14),  a  =  14.621(4)  Å,  b  =
16.734(6)  Å,  c  =  8.879(3)  Å,  β  =  100.61(3)°, V  =  2135.4(12)  Å3,  Z  =  4,  T  =  173.0  K,  μ(CuKα)  =  1.119  mm­1, Dcalc  =
1.463 g/cm3, 2308 reflections measured (8.11° ≤ 2Θ ≤ 79.926°), 1271 unique (Rint = 0.0540, Rsigma = 0.1074) which were used in
all calculations. The final R1 was 0.0848 (I > 2σ(I)) and wR2 was 0.2902 (all data).
Refinement model description
Number of restraints ­ 267, number of constraints ­ unknown.
Details:
1. Fixed Uiso
 At 1.2 times of:
  All C(H) groups, All N(H) groups
 At 1.5 times of:
  All C(H,H,H) groups
2. Rigid body (RIGU) restrains
 C4, F5, C12, F6, F4, C9, C10, C8, C5, C7, N4, C6, C11, F3, F2, F1, O1, N3, C3,
  N2, C2, N1, C17, C1, C22, C18, C13, C21, C19, C14, C15, C16, C20
 with sigma for 1‐2 distances of 0.004 and sigma for 1‐3 distances of 0.004
3.a Aromatic/amide H refined with riding coordinates:
 N3(H3), N4(H4), C2(H2), C6(H6), C8(H8), C10(H10), C18(H18), C19(H19),
 C20(H20), C21(H21), C22(H22)
3.b Idealised Me refined as rotating group:
 C14(H14A,H14B,H14C), C15(H15A,H15B,H15C), C16(H16A,H16B,H16C)
This report has been created with Olex2, compiled on 2014.09.19 svn.r3010 for OlexSys. Please let us know if there are any errors or if you would like to have additional
features.
Table 7 Hydrogen Atom Coordinates (Å×104) and
Isotropic Displacement Parameters (Å2×103) for
BIRB_libhit1.
Atom x y z U(eq)
H3 4805 2400 4403 67
H4 6186 1878 4893 65
H2 3526 2298 7289 68
H6 7761 1631 4864 66
H8 9458 987 8775 80
H10 6803 1681 8791 70
H14A 1382 4378 5943 113
H14B 678 3920 6828 113
H14C 999 3511 5381 113
H15A 1505 2326 6968 113
H15B 1215 2741 8435 113
H15C 2250 2411 8524 113
H16A 2859 3751 9421 117
H16B 1808 4045 9322 117
H16C 2494 4528 8440 117
H18 2842 4486 2790 82
H19 3390 5363 1081 87
H20 5001 5455 1184 97
H21 6000 4778 2980 85
H22 5471 3928 4743 83
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N-(3-(tert-Butyl)-1-phenyl-1H-pyrazol-5-yl)-N’-(3,5-dimethylphenyl) 
urea (215H) 
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N-(3-(tert-Butyl)-1-phenyl-1H-pyrazol-5-yl)-N’-(5-fluoro-2-
methylphenyl)urea (215I) 
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N-(3-(tert-Butyl)-1-phenyl-1H-pyrazol-5-yl)-N’-(3,4-difluorophenyl) 
urea (215J) 
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N-(3-(tert-Butyl)-1-phenyl-1H-pyrazol-5-yl)-N’-phenylurea (215K) 
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N-((3-(tert-Butyl)-1-phenyl-1H-pyrazol-5-yl)carbamoyl)-4-
methylbenzenesulfonamide (215L) 
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N-(3-(tert-Butyl)-1-phenyl-1H-pyrazol-5-yl)-N’-(3-
methoxyphenyl)urea (215M) 
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N-(3-(tert-Butyl)-1-phenyl-1H-pyrazol-5-yl)-N’-(p-tolyl)urea (215N) 
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3-(tert-Butyl)-1-(p-tolyl)-1H-pyrazol-5-amine (217) 
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3-(tert-Butyl)-1-methyl-1H-pyrazol-5-amine (226) 
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3-(tert-Butyl)-1-(4-fluorophenyl)-1H-pyrazole-5-amine (227) 
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3-(tert-Butyl)-1-(4-nitrophenyl)-1H-pyrazol-5-amine (228) 
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1,3-Di-tert-butyl-1H-pyrazol-5-amine (229) 
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1-(4-Bromophenyl)-3-(tert-butyl)-1H-pyrazol-5-amine (230) 
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1-Methyl-3-phenyl-1H-pyrazol-5-amine (231) 
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1,3-Diphenyl-1H-pyrazol-5-amine (232) 
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N-(3,5-Bis(trifluoromethyl)phenyl)-N’-(3-(tert-butyl)-1-(p-tolyl)-1H-
pyrazol-5-yl)urea (217F) 
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N-(3,5-Bis(trifluoromethyl)phenyl)-N’-(3-tert-butyl-1-methyl-1H-
pyrazol-5-yl)urea (226F) 
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N-(3,5-Bis(trifluoromethyl)phenyl)-N’-(3-tert-butyl-1-(4-
fluorophenyl)-1H-pyrazol-5-yl)urea (227F) 
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N-(3,5-Bis(trifluoromethyl)phenyl)-N’-(3-(tert-butyl)-1-(4-
nitrophenyl)-1H-pyrazol-5-yl)urea (228F) 
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N-(3,5-Bis(trifluoromethyl)phenyl)-N’-((1,3-di-tert-butyl)-1H-
pyrazol-5-yl)urea (229F) 
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N-(3,5-Bis(trifluoromethyl)phenyl)-N’-(3-(tert-butyl)-1-(4-
bromophenyl)-1H-pyrazol-5-yl)urea (230F) 
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N-(3,5-Bis(trifluoromethyl)phenyl)-N’-(1-methyl-3-phenyl-1H-
pyrazol-5-yl)urea (231F) 
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N-(3,5-Bis(trifluoromethyl)phenyl)-N’-(1,3-diphenyl-1H-pyrazol-5-
yl)urea (232F) 
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N-(3,5-Difluorophenyl)-N’-(3-(tert-butyl)-1-(phenyl)-1H-pyrazol-5-
yl)urea (215O) 
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N-(3,5-Difluorophenyl)-N’-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-
yl)urea (217O) 
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N-(3,5-Difluorophenyl)-N’-(3-tert-butyl-1-methyl-1H-pyrazol-5-
yl)urea (226O) 
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N-(3,5-Difluorophenyl)-N’-(3-(tert-butyl)-1-(4-fluorophenyl)-1H-
pyrazol-5-yl)urea (227O) 
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N-3-(tert-Butyl)-1-(4-nitrophenyl)-1H-pyrazol-5-yl)-N’-(3,5-
difluorophenyl)urea (228O) 
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N-(3,5-Difluorophenyl)-N’-(1,3-(tert-butyl)-1H-pyrazol-5-yl)urea 
(229O) 
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N-(3-(tert-Butyl)-1-(4-bromophenyl)-1H-pyrazol-5-yl)-N’-(3,5-
difluorophenyl)urea (230O) 
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N-(3,5-Difluorophenyl)-N’-(1-methyl-3-phenyl-1H-pyrazol-5-yl)urea 
(231O) 
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Table 1 Crystal data and structure refinement for BIRB_xtal3.
Identification code BIRB_xtal3
Empirical formula C17H16F2N4O2
Formula weight 346.34
Temperature/K 173.0
Crystal system triclinic
Space group P­1
a/Å 7.3053(6)
b/Å 19.0191(15)
c/Å 19.5624(16)
α/° 61.876(8)
β/° 85.618(7)
γ/° 86.500(7)
Volume/Å3 2389.1(4)
Z 6
ρcalcg/cm
3 1.444
μ/mm‑1 0.963
F(000) 1080.0
Crystal size/mm3 0.6 × 0.1 × 0.1
Radiation CuKα (λ = 1.54184)
2Θ range for data collection/° 8.92 to 142.83
Index ranges ­8 ≤ h ≤ 8, ­23 ≤ k ≤ 23, ­23 ≤ l ≤ 19
BIRB_xtal3
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Reflections collected 17105
Independent reflections 9017 [Rint = 0.0700, Rsigma = 0.1049]
Data/restraints/parameters 9017/0/688
Goodness­of­fit on F2 1.101
Final R indexes [I>=2σ (I)] R1 = 0.0997, wR2 = 0.2767
Final R indexes [all data] R1 = 0.1383, wR2 = 0.3044
Largest diff. peak/hole / e Å­3 0.40/­0.36
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Table 2 Fractional Atomic Coordinates (×104) and Equivalent Isotropic
Displacement Parameters (Å2×103) for BIRB_xtal3. Ueq is defined as
1/3 of of the trace of the orthogonalised UIJ tensor.
Atom x y z U(eq)
F1 8281(6) 7075(3) 1496(2) 64.5(12)
F2 10705(6) 4462(2) 2725(2) 53.4(10)
O1 8073(6) 4293(2) 5112(2) 41.7(10)
N1 7570(7) 5615(3) 4231(3) 36.5(11)
N2 6760(7) 5169(3) 5511(3) 35.9(11)
N3 5832(7) 4880(3) 6805(2) 32.6(10)
N4 5813(6) 4281(3) 7551(2) 32.8(10)
C1 8237(8) 5628(3) 3535(3) 34.0(12)
C2 7948(8) 6342(3) 2851(3) 38.8(13)
C3 8576(9) 6385(4) 2151(3) 43.5(14)
C4 9499(9) 5762(4) 2077(4) 44.8(14)
C5 9777(8) 5087(4) 2758(4) 39.1(13)
C6 9180(8) 4988(3) 3487(3) 34.4(11)
C7 7517(8) 4973(3) 4956(3) 33.3(11)
C8 6592(7) 4635(3) 6300(3) 29.5(11)
C9 7095(8) 3837(3) 6720(3) 33.8(12)
C10 6589(7) 3647(3) 7500(3) 31.3(11)
C11 6846(8) 2872(3) 8189(3) 33.4(11)
C12 7955(9) 2285(4) 8121(3) 41.8(14)
C13 8181(10) 1542(4) 8753(4) 49.3(16)
C14 7336(12) 1374(4) 9470(4) 58.0(19)
C15 6242(12) 1965(4) 9544(4) 59(2)
C16 6009(10) 2704(4) 8918(3) 46.7(15)
C17 5145(9) 5673(3) 6644(3) 42.1(14)
F3 5513(6) 1664(2) 11568(2) 53.6(10)
F4 2541(7) 2822(2) 13018(2) 64.3(13)
O2 1868(6) 5201(2) 10624(2) 41.9(10)
N5 3167(7) 4304(3) 10237(2) 33.1(10)
N6 2331(6) 5558(3) 9334(2) 32.5(10)
N7 1603(6) 6805(3) 8278(2) 32.2(10)
N8 881(6) 7553(3) 8108(2) 32.4(10)
C18 3408(7) 3626(3) 10952(3) 31.3(11)
C19 4332(8) 2972(3) 10924(3) 34.7(12)
C20 4607(8) 2293(3) 11602(4) 38.4(13)
C21 4031(9) 2208(3) 12327(3) 41.9(14)
C22 3141(9) 2866(3) 12326(3) 40.2(13)
C23 2806(8) 3577(3) 11667(3) 35.2(12)
C24 2401(7) 5032(3) 10112(3) 31.0(11)
C25 1646(7) 6337(3) 9052(3) 30.1(11)
C26 928(8) 6773(3) 9407(3) 31.9(11)
C27 458(7) 7527(3) 8792(3) 29.6(11)
C28 ­431(7) 8208(3) 8862(3) 31.4(11)
C29 ­800(10) 8160(4) 9584(4) 48.1(16)
C30 ­1746(12) 8769(4) 9668(4) 59(2)
C31 ­2313(10) 9451(4) 9019(4) 51.9(17)
C32 ­1925(9) 9507(4) 8299(4) 47.8(15)
C33 ­1002(9) 8903(3) 8208(3) 40.7(13)
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C34 2147(9) 6612(3) 7661(3) 40.6(13)
F5 ­886(7) 11585(3) 6958(2) 64.5(12)
F6 1380(8) 13205(2) 4413(3) 70.9(14)
O3 2746(6) 10821(2) 4208(2) 40(1)
N9 1574(7) 10359(3) 5460(2) 32.4(10)
N10 2859(7) 9489(3) 5062(2) 32.7(10)
N11 3846(7) 8439(3) 4785(2) 33.3(10)
N12 4611(7) 8297(3) 4195(3) 35(1)
C35 1117(7) 11069(3) 5506(3) 30.1(11)
C36 321(8) 10994(3) 6200(3) 34.9(12)
C37 ­99(9) 11678(4) 6270(3) 42.5(14)
C38 222(9) 12430(4) 5681(4) 46.6(15)
C39 1016(9) 12469(3) 5014(4) 42.7(14)
C40 1476(8) 11824(3) 4883(3) 37.0(13)
C41 2422(7) 10275(3) 4864(3) 29.2(11)
C42 3636(7) 9237(3) 4546(3) 29.9(11)
C43 4256(8) 9631(3) 3777(3) 32.1(11)
C44 4851(7) 9023(3) 3584(3) 30.6(11)
C45 5663(8) 9114(3) 2840(3) 31.6(11)
C46 6580(8) 9810(3) 2343(3) 36.1(12)
C47 7332(9) 9929(4) 1618(3) 41.8(14)
C48 7180(9) 9351(4) 1396(3) 44.3(14)
C49 6269(10) 8653(4) 1882(4) 45.5(15)
C50 5506(9) 8538(3) 2596(3) 40.2(13)
C51 3507(10) 7792(3) 5554(3) 46.7(16)
O4 5128(7) 6695(2) 4552(3) 44.6(10)
O5 4792(6) 4691(3) 8725(2) 44.4(10)
O6 765(6) 8694(3) 6532(2) 44.5(10)
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Table 3 Anisotropic Displacement Parameters (Å2×103) for BIRB_xtal3. The
Anisotropic displacement factor exponent takes the form:
­2π2[h2a*2U11+2hka*b*U12+…].
Atom U11 U22 U33 U23 U13 U12
F1 68(3) 64(3) 31.1(17) 0.0(17) 1.3(17) 22(2)
F2 61(2) 51(2) 54(2) ­32.6(18) 5.3(17) 11.3(18)
O1 59(3) 24.5(19) 32.3(19) ­8.3(15) 4.5(17) 15.2(17)
N1 49(3) 23(2) 31(2) ­8.8(18) 1.6(19) 11.1(19)
N2 48(3) 22(2) 31(2) ­9.7(17) ­0.4(19) 15.1(19)
N3 40(3) 23(2) 30(2) ­11.3(17) ­1.1(18) 12.0(18)
N4 38(3) 27(2) 30(2) ­10.8(17) ­1.5(18) 10.2(18)
C1 31(3) 34(3) 33(3) ­15(2) 4(2) 6(2)
C2 36(3) 35(3) 37(3) ­11(2) ­1(2) 10(2)
C3 40(3) 47(3) 28(3) ­6(2) ­2(2) 8(3)
C4 40(3) 55(4) 38(3) ­22(3) ­2(2) 4(3)
C5 33(3) 40(3) 48(3) ­25(3) 4(2) 7(2)
C6 33(3) 31(3) 38(3) ­16(2) 1(2) 6(2)
C7 36(3) 28(3) 33(3) ­12(2) 1(2) 8(2)
C8 30(3) 25(2) 28(2) ­9(2) ­0.3(19) 9(2)
C9 41(3) 26(3) 30(2) ­11(2) ­3(2) 13(2)
C10 33(3) 24(2) 35(3) ­13(2) ­4(2) 8(2)
C11 42(3) 26(3) 31(2) ­13(2) ­8(2) 9(2)
C12 48(4) 33(3) 36(3) ­11(2) ­1(2) 10(2)
C13 58(4) 31(3) 50(3) ­13(3) ­9(3) 16(3)
C14 86(6) 33(3) 38(3) ­3(3) ­9(3) 11(3)
C15 92(6) 42(4) 31(3) ­11(3) 6(3) 6(4)
C16 71(5) 31(3) 35(3) ­15(2) 3(3) 9(3)
C17 54(4) 28(3) 40(3) ­14(2) 0(2) 18(2)
F3 59(2) 25.5(17) 68(2) ­16.6(16) ­5.2(18) 20.2(16)
F4 100(3) 42(2) 30.4(17) ­4.1(15) 8.6(19) 16(2)
O2 54(3) 31(2) 32.7(19) ­11.3(16) 0.9(17) 19.7(18)
N5 43(3) 22(2) 29(2) ­9.4(17) ­1.5(18) 15.8(18)
N6 38(2) 26(2) 29(2) ­10.5(17) ­3.3(17) 14.8(18)
N7 40(3) 24(2) 27(2) ­8.5(17) ­3.6(17) 14.5(18)
N8 36(2) 23(2) 32(2) ­9.3(17) ­4.3(18) 14.3(18)
C18 32(3) 21(2) 32(2) ­6(2) ­3(2) 7.3(19)
C19 32(3) 25(3) 42(3) ­14(2) 2(2) 12(2)
C20 36(3) 23(3) 53(3) ­16(2) ­3(2) 10(2)
C21 46(3) 22(3) 44(3) ­5(2) ­3(3) 7(2)
C22 51(4) 28(3) 31(3) ­6(2) 1(2) 4(2)
C23 38(3) 25(3) 34(3) ­8(2) ­1(2) 10(2)
C24 31(3) 26(2) 31(2) ­10(2) ­5(2) 12(2)
C25 29(3) 25(2) 30(2) ­9(2) ­1.5(19) 10.9(19)
C26 36(3) 27(3) 28(2) ­9(2) ­3(2) 10(2)
C27 28(3) 25(2) 31(2) ­11(2) ­2.2(19) 8.9(19)
C28 28(3) 26(3) 37(3) ­13(2) ­1(2) 9(2)
C29 62(4) 33(3) 42(3) ­14(2) 2(3) 16(3)
C30 79(5) 44(4) 54(4) ­27(3) 10(3) 17(3)
C31 45(4) 40(3) 70(4) ­28(3) 4(3) 16(3)
C32 42(3) 31(3) 65(4) ­19(3) ­6(3) 17(3)
C33 49(4) 28(3) 38(3) ­11(2) ­4(2) 14(2)
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C34 52(4) 36(3) 32(3) ­16(2) ­5(2) 15(3)
F5 86(3) 60(2) 54(2) ­37(2) 20(2) 6(2)
F6 111(4) 23.2(18) 62(2) ­10.9(17) 20(2) 4(2)
O3 57(3) 24.8(18) 27.7(18) ­6.0(15) 4.3(16) 14.2(17)
N9 40(3) 22(2) 29(2) ­8.9(17) ­0.2(17) 10.8(18)
N10 42(3) 25(2) 24.6(19) ­8.2(16) 0.0(17) 14.7(18)
N11 42(3) 25(2) 29(2) ­10.7(17) ­0.2(18) 12.5(18)
N12 44(3) 25(2) 33(2) ­12.6(18) ­0.8(19) 14.7(19)
C35 33(3) 23(2) 31(2) ­12(2) ­3(2) 11(2)
C36 42(3) 29(3) 31(2) ­13(2) 0(2) 11(2)
C37 47(4) 45(3) 40(3) ­26(3) 5(2) 10(3)
C38 50(4) 35(3) 64(4) ­33(3) 0(3) 13(3)
C39 52(4) 22(3) 45(3) ­10(2) 4(3) 6(2)
C40 44(3) 25(3) 33(3) ­9(2) 0(2) 12(2)
C41 27(2) 24(2) 34(2) ­12(2) ­2.8(19) 11.3(19)
C42 32(3) 21(2) 32(2) ­10.8(19) ­1(2) 11.9(19)
C43 40(3) 24(2) 27(2) ­9.8(19) ­2(2) 12(2)
C44 32(3) 24(2) 31(2) ­11(2) ­3(2) 13(2)
C45 35(3) 26(2) 32(2) ­14(2) ­4(2) 16(2)
C46 38(3) 29(3) 37(3) ­13(2) ­4(2) 11(2)
C47 44(3) 37(3) 38(3) ­14(2) 4(2) 7(2)
C48 55(4) 38(3) 33(3) ­14(2) 4(2) 11(3)
C49 63(4) 38(3) 40(3) ­23(3) ­1(3) 11(3)
C50 49(3) 30(3) 39(3) ­16(2) 2(2) 7(2)
C51 67(4) 28(3) 33(3) ­7(2) 3(3) 14(3)
O4 57(3) 26(2) 46(2) ­13.9(17) ­6(2) 12.3(18)
O5 57(3) 43(2) 39(2) ­26.2(18) 1.6(18) 11(2)
O6 52(3) 36(2) 30.4(19) ­4.6(16) 1.3(17) 8.0(19)
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Table 4 Bond Lengths for BIRB_xtal3.
AtomAtom Length/Å   AtomAtom Length/Å
F1 C3 1.354(7)   C19 C20 1.364(8)
F2 C5 1.357(7)   C20 C21 1.385(9)
O1 C7 1.231(7)   C21 C22 1.374(8)
N1 C1 1.401(7)   C22 C23 1.382(7)
N1 C7 1.366(7)   C25 C26 1.372(7)
N2 C7 1.374(7)   C26 C27 1.414(7)
N2 C8 1.391(7)   C27 C28 1.471(7)
N3 N4 1.365(6)   C28 C29 1.378(8)
N3 C8 1.349(7)   C28 C33 1.407(7)
N3 C17 1.452(6)   C29 C30 1.382(9)
N4 C10 1.344(7)   C30 C31 1.389(10)
C1 C2 1.404(8)   C31 C32 1.371(10)
C1 C6 1.400(7)   C32 C33 1.374(8)
C2 C3 1.376(8)   F5 C37 1.357(7)
C3 C4 1.389(9)   F6 C39 1.362(7)
C4 C5 1.366(9)   O3 C41 1.229(6)
C5 C6 1.386(8)   N9 C35 1.414(7)
C8 C9 1.385(7)   N9 C41 1.349(7)
C9 C10 1.415(7)   N10 C41 1.379(7)
C10 C11 1.469(7)   N10 C42 1.382(7)
C11 C12 1.390(8)   N11 N12 1.377(6)
C11 C16 1.404(8)   N11 C42 1.363(7)
C12 C13 1.382(8)   N11 C51 1.441(7)
C13 C14 1.385(10)   N12 C44 1.345(7)
C14 C15 1.397(10)   C35 C36 1.381(7)
C15 C16 1.372(9)   C35 C40 1.402(7)
F3 C20 1.359(6)   C36 C37 1.386(8)
F4 C22 1.356(7)   C37 C38 1.369(9)
O2 C24 1.218(7)   C38 C39 1.357(9)
N5 C18 1.400(6)   C39 C40 1.386(8)
N5 C24 1.379(6)   C42 C43 1.379(7)
N6 C24 1.374(7)   C43 C44 1.411(7)
N6 C25 1.390(6)   C44 C45 1.464(7)
N7 N8 1.378(6)   C45 C46 1.394(8)
N7 C25 1.348(7)   C45 C50 1.399(8)
N7 C34 1.442(7)   C46 C47 1.399(8)
N8 C27 1.330(7)   C47 C48 1.372(9)
C18 C19 1.401(7)   C48 C49 1.389(9)
C18 C23 1.395(8)   C49 C50 1.384(8)
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Table 5 Bond Angles for BIRB_xtal3.
AtomAtomAtom Angle/˚   AtomAtom Atom Angle/˚
C7 N1 C1 127.2(5)   O2 C24 N5 124.7(5)
C7 N2 C8 124.2(4)   O2 C24 N6 123.5(5)
N4 N3 C17 119.8(4)   N6 C24 N5 111.8(4)
C8 N3 N4 111.8(4)   N7 C25 N6 119.2(5)
C8 N3 C17 128.3(4)   N7 C25 C26 107.9(4)
C10 N4 N3 104.8(4)   C26 C25 N6 132.9(5)
N1 C1 C2 116.5(5)   C25 C26 C27 104.9(4)
C6 C1 N1 124.3(5)   N8 C27 C26 111.0(5)
C6 C1 C2 119.2(5)   N8 C27 C28 122.1(4)
C3 C2 C1 118.8(5)   C26 C27 C28 126.8(5)
F1 C3 C2 118.2(6)   C29 C28 C27 120.0(5)
F1 C3 C4 117.9(5)   C29 C28 C33 118.2(5)
C2 C3 C4 123.9(5)   C33 C28 C27 121.7(5)
C5 C4 C3 115.1(6)   C28 C29 C30 121.2(6)
F2 C5 C4 117.9(5)   C29 C30 C31 120.2(7)
F2 C5 C6 117.2(5)   C32 C31 C30 118.9(6)
C4 C5 C6 124.9(6)   C31 C32 C33 121.5(6)
C5 C6 C1 118.1(5)   C32 C33 C28 120.0(6)
O1 C7 N1 125.3(5)   C41 N9 C35 128.5(4)
O1 C7 N2 122.5(5)   C41 N10 C42 123.9(4)
N1 C7 N2 112.2(5)   N12 N11 C51 120.9(4)
N3 C8 N2 120.1(4)   C42 N11 N12 111.0(4)
N3 C8 C9 107.8(4)   C42 N11 C51 127.9(5)
C9 C8 N2 132.1(5)   C44 N12 N11 105.1(4)
C8 C9 C10 104.2(4)   C36 C35 N9 117.3(5)
N4 C10 C9 111.4(4)   C36 C35 C40 120.6(5)
N4 C10 C11 121.9(5)   C40 C35 N9 122.1(5)
C9 C10 C11 126.7(5)   C35 C36 C37 118.8(5)
C12 C11 C10 119.2(5)   F5 C37 C36 117.4(5)
C12 C11 C16 118.8(5)   F5 C37 C38 119.5(5)
C16 C11 C10 122.0(5)   C38 C37 C36 123.1(5)
C13 C12 C11 120.6(6)   C39 C38 C37 115.6(5)
C12 C13 C14 120.5(6)   F6 C39 C40 116.4(5)
C13 C14 C15 119.0(6)   C38 C39 F6 117.8(5)
C16 C15 C14 120.7(6)   C38 C39 C40 125.7(5)
C15 C16 C11 120.3(6)   C39 C40 C35 116.1(5)
C24 N5 C18 127.2(5)   O3 C41 N9 125.3(5)
C24 N6 C25 123.3(4)   O3 C41 N10 122.3(5)
N8 N7 C34 120.1(4)   N9 C41 N10 112.4(4)
C25 N7 N8 111.0(4)   N11 C42 N10 118.9(5)
C25 N7 C34 128.9(4)   N11 C42 C43 107.5(4)
C27 N8 N7 105.2(4)   C43 C42 N10 133.5(5)
N5 C18 C19 116.0(5)   C42 C43 C44 105.2(4)
C23 C18 N5 124.2(5)   N12 C44 C43 111.1(5)
C23 C18 C19 119.8(5)   N12 C44 C45 121.0(5)
C20 C19 C18 118.9(5)   C43 C44 C45 127.9(5)
F3 C20 C19 118.4(5)   C46 C45 C44 119.0(5)
F3 C20 C21 117.8(5)   C46 C45 C50 118.4(5)
C19 C20 C21 123.8(5)   C50 C45 C44 122.5(5)
C22 C21 C20 115.2(5)   C45 C46 C47 120.8(6)
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F4 C22 C21 118.1(5)   C48 C47 C46 119.6(6)
F4 C22 C23 117.2(5)   C47 C48 C49 120.5(5)
C21 C22 C23 124.8(6)   C50 C49 C48 120.0(6)
C22 C23 C18 117.5(5)   C49 C50 C45 120.7(6)
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Table 6 Torsion Angles for BIRB_xtal3.
A B C D Angle/˚   A B C D Angle/˚
F1 C3 C4 C5 179.1(6)   C24 N5 C18 C19 ­176.1(6)
F2 C5 C6 C1 179.3(5)   C24 N5 C18 C23 3.4(10)
N1 C1 C2 C3 ­179.9(6)   C24 N6 C25 N7 ­178.9(5)
N1 C1 C6 C5 ­179.5(6)   C24 N6 C25 C26 0.4(10)
N2 C8 C9 C10 178.7(6)   C25 N6 C24 O2 0.1(9)
N3 N4 C10C9 ­0.4(7)   C25 N6 C24 N5 ­179.1(5)
N3 N4 C10C11 179.4(5)   C25 N7 N8 C27 ­0.9(6)
N3 C8 C9 C10 ­0.7(7)   C25 C26 C27 N8 ­0.7(7)
N4 N3 C8 N2 ­179.0(5)   C25 C26 C27 C28 177.6(5)
N4 N3 C8 C9 0.5(7)   C26 C27 C28 C29 3.5(10)
N4 C10C11 C12 ­168.0(6)   C26 C27 C28 C33 ­173.4(6)
N4 C10C11 C16 11.9(9)   C27 C28 C29 C30 ­175.5(7)
C1 N1 C7 O1 0.6(10)   C27 C28 C33 C32 176.1(6)
C1 N1 C7 N2 ­179.5(6)   C28 C29 C30 C31 ­1.4(13)
C1 C2 C3 F1 179.7(6)   C29 C28 C33 C32 ­0.9(10)
C1 C2 C3 C4 ­0.4(11)   C29 C30 C31 C32 0.3(13)
C2 C1 C6 C5 ­0.6(9)   C30 C31 C32 C33 0.4(12)
C2 C3 C4 C5 ­0.8(10)   C31 C32 C33 C28 ­0.1(11)
C3 C4 C5 F2 ­178.7(6)   C33 C28 C29 C30 1.6(11)
C3 C4 C5 C6 1.4(10)   C34 N7 N8 C27 177.5(5)
C4 C5 C6 C1 ­0.7(10)   C34 N7 C25 N6 1.7(9)
C6 C1 C2 C3 1.1(9)   C34 N7 C25 C26 ­177.7(6)
C7 N1 C1 C2 172.8(6)   F5 C37 C38 C39 179.9(6)
C7 N1 C1 C6 ­8.3(10)   F6 C39 C40 C35 179.3(6)
C7 N2 C8 N3 179.9(6)   N9 C35 C36 C37 178.3(5)
C7 N2 C8 C9 0.6(11)   N9 C35 C40 C39 ­177.8(6)
C8 N2 C7 O1 2.0(10)   N10C42 C43 C44 ­178.5(6)
C8 N2 C7 N1 ­177.9(5)   N11 N12C44 C43 0.3(6)
C8 N3 N4 C10 0.0(6)   N11 N12C44 C45 179.4(5)
C8 C9 C10N4 0.7(7)   N11 C42 C43 C44 ­0.5(6)
C8 C9 C10C11 ­179.1(6)   N12N11 C42 N10 179.0(5)
C9 C10C11 C12 11.7(10)   N12N11 C42 C43 0.7(7)
C9 C10C11 C16 ­168.4(6)   N12C44 C45 C46 ­153.5(5)
C10C11 C12C13 ­178.1(6)   N12C44 C45 C50 28.5(9)
C10C11 C16C15 178.2(7)   C35 N9 C41 O3 ­9.8(10)
C11 C12C13C14 ­1.3(11)   C35 N9 C41 N10 172.0(5)
C12C11 C16C15 ­1.9(11)   C35 C36 C37 F5 179.7(6)
C12C13C14C15 0.4(13)   C35 C36 C37 C38 0.6(10)
C13C14C15C16 ­0.3(13)   C36 C35 C40 C39 1.0(9)
C14C15C16C11 1.0(13)   C36 C37 C38 C39 ­1.0(11)
C16C11 C12C13 2.1(10)   C37 C38 C39 F6 ­179.4(6)
C17N3 N4 C10 ­177.8(5)   C37 C38 C39 C40 1.5(11)
C17N3 C8 N2 ­1.4(10)   C38 C39 C40 C35 ­1.5(11)
C17N3 C8 C9 178.0(6)   C40 C35 C36 C37 ­0.6(9)
F3 C20C21C22 179.3(6)   C41 N9 C35 C36 ­177.0(6)
F4 C22C23C18 ­179.6(6)   C41 N9 C35 C40 1.8(9)
N5 C18C19C20 ­179.8(6)   C41 N10C42 N11 ­173.7(5)
N5 C18C23C22 179.9(6)   C41 N10C42 C43 4.1(10)
N6 C25C26C27 ­179.2(6)   C42 N10C41 O3 ­2.2(9)
N7 N8 C27C26 1.0(6)   C42 N10C41 N9 176.1(5)
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N7 N8 C27C28 ­177.4(5)   C42 N11 N12C44 ­0.6(6)
N7 C25C26C27 0.2(7)   C42 C43 C44 N12 0.1(7)
N8 N7 C25N6 179.9(5)   C42 C43 C44 C45 ­179.0(6)
N8 N7 C25C26 0.4(7)   C43 C44 C45 C46 25.4(9)
N8 C27C28C29 ­178.3(6)   C43 C44 C45 C50 ­152.5(6)
N8 C27C28C33 4.7(9)   C44 C45 C46 C47 ­178.3(5)
C18N5 C24O2 2.7(10)   C44 C45 C50 C49 178.9(6)
C18N5 C24N6 ­178.2(5)   C45 C46 C47 C48 ­0.6(9)
C18C19C20F3 ­179.7(5)   C46 C45 C50 C49 1.0(9)
C18C19C20C21 ­0.4(10)   C46 C47 C48 C49 0.7(10)
C19C18C23C22 ­0.7(9)   C47 C48 C49 C50 0.1(10)
C19C20C21C22 0.0(10)   C48 C49 C50 C45 ­0.9(10)
C20C21C22F4 179.9(6)   C50 C45 C46 C47 ­0.2(8)
C20C21C22C23 0.0(10)   C51 N11 N12C44 ­175.8(6)
C21C22C23C18 0.3(10)   C51 N11 C42 N10 ­6.2(9)
C23C18C19C20 0.7(9)   C51 N11 C42 C43 175.5(6)
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Table 7 Hydrogen Atom Coordinates (Å×104) and
Isotropic Displacement Parameters (Å2×103) for
BIRB_xtal3.
Atom x y z U(eq)
H1 7136 6072 4199 44
H2 6355 5663 5358 43
H2A 7331 6786 2872 47
H4 9907 5803 1587 54
H6 9405 4501 3941 41
H9 7652 3495 6529 41
H12 8563 2396 7635 50
H13 8922 1143 8696 59
H14 7499 864 9905 70
H15 5653 1855 10032 70
H16 5278 3104 8979 56
H17A 3903 5638 6884 63
H17B 5114 6013 6082 63
H17C 5955 5902 6860 63
H5 3546 4259 9821 40
H6A 2742 5392 8998 39
H19 4761 3001 10441 42
H21 4237 1729 12792 50
H23 2188 4015 11701 42
H26 780 6605 9949 38
H29 ­396 7701 10031 58
H30 ­2010 8720 10172 71
H31 ­2958 9873 9074 62
H32 ­2303 9974 7853 57
H33 ­750 8955 7703 49
H34A 1285 6869 7247 61
H34B 2139 6032 7863 61
H34C 3386 6802 7455 61
H9A 1266 9913 5875 39
H10 2630 9127 5546 39
H36 67 10482 6621 42
H38 ­91 12894 5735 56
H40 2005 11890 4398 44
H43 4278 10191 3448 39
H46 6696 10208 2498 43
H47 7945 10408 1281 50
H48 7701 9428 907 53
H49 6171 8255 1725 55
H50 4868 8064 2923 48
H51A 3492 7290 5530 70
H51B 2317 7884 5771 70
H51C 4480 7762 5886 70
H4A 4001 6556 4578 67
H4B 5140 7198 4431 67
H5A 5063 4552 8364 67
H5B 5797 4720 8921 67
H6B ­393 8799 6438 67
H6C 871 8341 7015 67
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Experimental
Single crystals of C17H16F2N4O2 [BIRB_xtal3] were []. A suitable crystal was selected and [] on a Xcalibur, Eos, Gemini
ultra diffractometer. The crystal was kept at 173.0 K during data collection. Using Olex2 [1], the structure was solved with the
ShelXT [2] structure solution program using Direct Methods and refined with the ShelXL [3]  refinement  package using Least
Squares minimisation.
1. Dolomanov, O.V., Bourhis, L.J., Gildea, R.J, Howard, J.A.K. & Puschmann, H. (2009), J. Appl. Cryst. 42, 339­341.
2. Sheldrick, G.M. (2008). Acta Cryst. A64, 112­122.
3. Sheldrick, G.M. (2008). Acta Cryst. A64, 112­122.
Crystal structure determination of [BIRB_xtal3]
Crystal  Data  for  C17H16F2N4O2  (M  =346.34  g/mol):  triclinic,  space  group  P­1  (no.  2),  a  =  7.3053(6)  Å,  b  =
19.0191(15) Å, c  =  19.5624(16) Å, α  =  61.876(8)°, β  =  85.618(7)°,  γ  =  86.500(7)°, V = 2389.1(4) Å3, Z  =  6,  T  =  173.0  K,
μ(CuKα) = 0.963 mm­1, Dcalc = 1.444 g/cm3, 17105 reflections measured (8.92° ≤ 2Θ ≤ 142.83°), 9017 unique (Rint = 0.0700,
Rsigma = 0.1049) which were used in all calculations. The final R1 was 0.0997 (I > 2σ(I)) and wR2 was 0.3044 (all data).
Refinement model description
Number of restraints ­ 0, number of constraints ­ unknown.
Details:
1. Fixed Uiso
 At 1.2 times of:
  All C(H) groups, All N(H) groups
 At 1.5 times of:
  All C(H,H,H) groups, All O(H,H) groups
2.a Free rotating group:
 O4(H4A,H4B), O5(H5A,H5B), O6(H6B,H6C)
2.b Aromatic/amide H refined with riding coordinates:
 N1(H1), N2(H2), C2(H2A), C4(H4), C6(H6), C9(H9), C12(H12), C13(H13), C14(H14),
  C15(H15), C16(H16), N5(H5), N6(H6A), C19(H19), C21(H21), C23(H23), C26(H26),
 C29(H29), C30(H30), C31(H31), C32(H32), C33(H33), N9(H9A), N10(H10), C36(H36),
 C38(H38), C40(H40), C43(H43), C46(H46), C47(H47), C48(H48), C49(H49), C50(H50)
2.c Idealised Me refined as rotating group:
 C17(H17A,H17B,H17C), C34(H34A,H34B,H34C), C51(H51A,H51B,H51C)
This report has been created with Olex2, compiled on 2014.09.19 svn.r3010 for OlexSys. Please let us know if there are any errors or if you would like to have additional
features.
N-(3,5-Difluorophenyl)-N’-(1,3-diphenyl-1H-pyrazol-5-yl)urea 
(232O) 
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SRPK1A SRPK2A MAPK14A CLK1A DYRK1AA PIM1A R1 R2 R3
COMPOUND AVG AVG AVG AVG AVG AVG phenyl tert-butyl
B03JD133A 2.92 0.57 15.8 1.6 2.67 1.94 phenyl tert-butyl 1-Napthyl
B03JD137B 1.34 0.17 13.08 0.4 0.16 0.24 phenyl tert-butyl o-tolyl
B03JD138 A 8.55 1.58 10.64 3.17 4.19 3.08 phenyl tert-butyl 2-naphthyl
B03JD139C 8.02 1.04 7.59 2.21 1.79 2.28 phenyl tert-butyl 4-ethoxyphenyl
B03JD140B 7.13 0.82 12.25 1.82 0.96 1.46 phenyl tert-butyl 4-fluorophenyl
B03JD141B 9.19 1.45 2.03 3.07 3.87 2.8 phenyl tert-butyl bis-(3,5-CF3)Phenyl
B03JD143B 5.75 0 4.56 4.4 0 1.82 phenyl tert-butyl 3-benzyloxyphenyl
B03JD144B 4.39 0.44 7.88 1.5 1.31 1.64 phenyl tert-butyl 3,5-dimethylphenyl
B03JD145C 2.82 0.54 12.09 1.4 1.19 1.2 phenyl tert-butyl 5-fluoro-2-methylphenyl
B03JD146B 11.69 2.36 12.43 3.98 3.15 3.03 phenyl tert-butyl 3,4-difluorophenyl
B03JD147A 3.91 0.41 12.3 1.25 0.87 0.92 phenyl tert-butyl phenyl
B03JD152 0 0 0 0.13 0.06 0.45 phenyl tert-butyl p-tosylate
B03JD151B 4.38 0.3 9.6 1.21 0.63 1.12 phenyl tert-butyl 3-methoxyphenyl
B03JD160A 4.71 0.39 11.4 1.21 0.77 1.16 phenyl tert-butyl p-tolyl
BIRB796 12.53 1.16 20.56 1.69 0.4 0.48 R1 R2 R3
B04JD088B 9.95 1.34 1.17 2.79 2.97 2.41 p-tolyl tert-butyl bis-(3,5-CF3)Phenyl
B03JD190A 11.8 1.52 1.24 2.08 2.13 2.03 methyl tert-butyl bis-(3,5-CF3)Phenyl
B04JD001A 11.81 1.35 0.82 2.65 2.12 2.76 4-fluorophenyl tert-butyl bis-(3,5-CF3)Phenyl
B04JD004B -0.61 1.32 1.54 2.14 2.36 1.98 4-nitrophenyl tert-butyl bis-(3,5-CF3)Phenyl
B04JD010A 1.15 0.75 0.49 1.25 2.63 2.21 tert-butyl tert-butyl bis-(3,5-CF3)Phenyl
B04JD012A 12.25 1.34 0.7 19.53 3.24 11.48 4-bromophenyl tert-butyl bis-(3,5-CF3)Phenyl
B04JD086B 2.57 1.58 1.86 2.7 4.34 4.5 methyl phenyl bis-(3,5-CF3)Phenyl
B04JD89B 1.72 1.09 0.81 2.2 2.52 2.76 phenyl phenyl bis-(3,5-CF3)Phenyl
B04JD096A 13.72 1.46 5.18 3.17 2.25 2.01 phenyl tert-butyl 3,5-difluorophenyl
B04JD087B 14.82 2.33 6.48 4.51 1.96 2.6 p-tolyl tert-butyl 3,5-difluorophenyl
B04JD090B 6.37 0.42 2.84 0.55 0.61 -0.15 methyl tert-butyl 3,5-difluorophenyl
B04JD083A 12.62 1.51 5.33 2.83 1.98 1.93 4-fluorophenyl tert-butyl 3,5-difluorophenyl
B04JD109B 14.15 2.14 7.51 3.87 1.69 1.56 4-nitrophenyl tert-butyl 3,5-difluorophenyl
B04JD092A 0.14 0.13 0.1 -0.01 0.45 -0.04 tert-butyl tert-butyl 3,5-difluorophenyl
B04JD108C 12.72 1.94 5.1 3.18 2.71 2.35 4-bromophenyl tert-butyl 3,5-difluorophenyl
B04JD097A 1.34 0.37 0.22 1.41 1.74 1.2 methyl phenyl 3,5-difluorophenyl
B04JD103B 2.27 1.23 2.59 2.07 3.48 2.87 phenyl phenyl 3,5-difluorophenyl
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5-fluoro-2-methylphenyl
 - two nitro models very differnet results!!
LOSS OF ACTIVITY WITH BULK @ 1-N
LOSS OF ACTIVITY WITH 3-PHENYL
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